<SEC-DOCUMENT>0000950123-18-012230.txt : 20181221
<SEC-HEADER>0000950123-18-012230.hdr.sgml : 20181221
<ACCEPTANCE-DATETIME>20181129165912
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-18-012230
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		13
FILED AS OF DATE:		20181129
<PUBLIC-REL-DATE>20181221
DATE AS OF CHANGE:		20181214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gossamer Bio, Inc.
		CENTRAL INDEX KEY:			0001728117
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				475461709
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02311
		FILM NUMBER:		181209038

	BUSINESS ADDRESS:	
		STREET 1:		3013 SCIENCE PARK
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 922-0718

	MAIL ADDRESS:	
		STREET 1:		3013 SCIENCE PARK
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on November 29,
2018 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>as Amendment No.&nbsp;1 to the draft Registration Statement </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>GOSSAMER BIO, INC. </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">47-5461709</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3013 Science Park Road, Suite 200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92121 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">684-1300</FONT> </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>area code, of registrant&#146;s principal executive offices) </B></P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sheila Gujrathi,
M.D. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Gossamer Bio, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3013
Science Park Road, Suite 200 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92121 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">684-1300</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>area code, of agent for service) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to:
</I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Matthew T. Bush</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cheston J. Larson</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kevin C.
Reyes</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>12670 High Bluff Drive</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San
Diego, California 92130</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">523-5400</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Christian Waage</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Executive Vice President</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and General Counsel</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Gossamer Bio, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>3013
Science Park Road, Suite 200</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92121</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">684-1300</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Charles S. Kim</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Sean Clayton</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>David
Peinsipp</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Kristin VanderPas</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Cooley LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>4401 Eastgate
Mall</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92121</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(858)&nbsp;550-6000</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As soon as practicable after this Registration Statement is declared effective. </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b)&nbsp;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148;
and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities To Be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed Maximum<BR>Aggregate Offering<BR>Price<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration Fee<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, $0.0001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.
Includes shares of common stock that the underwriters have the option to purchase. </P></TD></TR></TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:7%; font-size:8pt; font-family:Times New Roman"><B>The Registrant
hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become
effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#c21128">The information in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these
securities in any state or other jurisdiction where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Subject to Completion </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Preliminary Prospectus dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g59i87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This is an initial
public offering of shares of common stock of Gossamer Bio, Inc. All of the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock are being sold by the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common stock. It is currently estimated that the initial public offering price
will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. We have applied to list our common stock on the Nasdaq Global Select
Market under the symbol &#147;GOSS.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined under the federal securities laws
and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and may elect to do so in future filings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves risks that are described in the &#147;<A HREF="#toc626950_2">Risk&nbsp;Factors</A>&#148; section
beginning on page 11 of this prospectus. </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">See the section titled &#147;Underwriting&#148; for additional information regarding compensation payable to the
underwriters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To the extent that the underwriters sell more than
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, the underwriters have the option to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock from us at the initial public offering price less the underwriting discount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any other state securities commission has approved or disapproved of these securities or passed on the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares of common stock to purchasers on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top"><B>BofA&nbsp;Merrill&nbsp;Lynch</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Leerink&nbsp;Partners</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Barclays&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Prospectus dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018
</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_4">MARKET AND INDUSTRY DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_9">SELECTED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_10">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_11">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_12">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_13">EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_14">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_15">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_16">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_17">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_18">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_19">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_21">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_22">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_23">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc626950_24">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:19%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus or any
free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We
and the underwriters are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or any free writing prospectus is accurate only as of its
date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our common stock. You should read this entire prospectus carefully, especially the section in this prospectus titled &#147;Risk Factors&#148; and our financial statements and the related notes thereto included at the end
of this prospectus, before making an investment decision. As used in this prospectus, unless the context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;the Company&#148; and &#147;Gossamer Bio&#148; refer to
Gossamer Bio, Inc. and its subsidiaries on a consolidated basis. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the
disease areas of immunology, inflammation and oncology. Our goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases. To accomplish this goal, we have assembled
a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. Our collective
immunology and translational discovery and development expertise serves as the foundation of our company. We intend to maintain a scientifically rigorous and inclusive corporate culture where employees strive to bring improved therapeutic options to
patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Development Programs </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are pursuing product candidates with strong scientific rationale to address indications where there is both a high unmet need and an
opportunity to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics. We currently have
six programs: three clinical-stage product candidates and three preclinical programs. We commenced a Phase 2b clinical trial for our most advanced product candidate, GB001, in October 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our current programs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g05u28.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GB001 (DP2 Antagonist) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB001 is an oral antagonist of prostaglandin D<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB> receptor 2, or DP2, in development for
the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma and other allergic conditions. Eosinophilic asthma is caused by high levels of white blood cells known as
eosinophils and is associated with more severe symptoms, late-onset disease and resistance to steroid treatment. We estimate that approximately 50% of severe asthma patients in the United&nbsp;States have eosinophilic asthma. Despite the
availability of new biologic therapies for these patients, asthma exacerbations remain a significant healthcare problem and unmet medical need. As of July&nbsp;31, 2018, GB001 had been studied in 359 subjects in total and was generally well
tolerated. In a Phase 2 clinical trial conducted in Japan, GB001 showed a statistically significant improvement in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-first</FONT></FONT> asthma exacerbation compared to placebo.
In a separate 248 subject Phase 2 clinical trial, neither treatment group, GB001 nor montelukast, achieved the primary endpoint of improvement in forced expiratory volume in one second, or
FEV<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>, as compared to placebo, which we believe was primarily related to study design and execution issues related to patient selection, including adherence to inhaled corticosteroid therapy,
eosinophilic phenotype thresholds and disease severity. We commenced a Phase 2b clinical trial in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma in October&nbsp;2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Furthermore, we believe that there are a number of indications along the allergic spectrum for which GB001 may provide benefit. Accordingly,
we plan to pursue the parallel development of GB001 in chronic rhinosinusitis with nasal polyps, or CRSwNP, and chronic spontaneous urticaria, or CSU. We expect to initiate
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase 2 clinical trials for these indications in 2019. We retain worldwide rights to GB001, excluding Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GB002 (PDGF Receptor Kinase Inhibitor) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB002 is an orally inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor in development for
the treatment of pulmonary arterial hypertension, or PAH, an orphan disease with high unmet medical need. PAH is characterized by abnormally high pressure in the blood vessels transporting blood from the right side of the heart to the lungs and is a
progressive and often fatal disease. In contrast to the three classes of marketed vasodilatory therapies for PAH, GB002 has the potential to be the first treatment with disease-modifying effects. Modulation of the PDGF pathway has been shown to be
therapeutically relevant in PAH. In 2013, Novartis Pharmaceutical Corporation announced results from a Phase&nbsp;3 clinical trial in PAH of imatinib (Gleevec), a tyrosine kinase inhibitor with known activity against PDGF and marketed for oncology
indications. These results were notable for not only achievement of statistically significant improvement in the study&#146;s primary efficacy endpoint, but also for systemic toxicities. To our knowledge, no further development of the drug has
occurred in PAH. To date, these toxicities have not been observed with GB002 in our ongoing Phase&nbsp;1 studies in healthy volunteers. We plan to commence a Phase&nbsp;1b clinical trial in PAH in the first half of 2019 and a Phase&nbsp;2/3 clinical
trial in PAH in the second half of 2019. We retain worldwide rights to GB002. The U.S. Food and Drug Administration, or FDA, has granted GB002 orphan drug designation for the treatment of patients with PAH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GB004 <FONT STYLE="white-space:nowrap">(HIF-1</FONT></I></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><B><I></I></B><B><I> Stabilizer) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB004 is a novel, <FONT STYLE="white-space:nowrap">gut-targeted,</FONT> oral small molecule in development for the treatment of inflammatory
bowel disease, or IBD, including ulcerative colitis, or UC, and Crohn&#146;s disease, or CD. GB004 stabilizes hypoxia inducible <FONT STYLE="white-space:nowrap">factor-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, or <FONT
STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, through the inhibition of prolyl hydroxylase domain proteins, or PHDs, key enzymes involved in HIF degradation. Preclinical data from animal models of IBD
demonstrated that <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> stabilization restores intestinal epithelial barrier integrity and function and results in immunomodulatory effects that we believe are
important in reducing inflammation and enhancing mucosal healing in IBD patients. We have completed a Phase 1 single-ascending-dose, or SAD, study in healthy volunteers and are dosing healthy </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
volunteers in a Phase 1 multiple-ascending-dose, or MAD, study. We plan to pursue clinical development in both UC and CD patients and, following submission of an Investigational New Drug, or IND,
application with the FDA, initiate a Phase 1b clinical trial in UC in the first half of 2019. We also plan to initiate a Phase&nbsp;2 clinical trial in UC in the first half of 2020. We retain worldwide rights to GB004. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Research Capabilities and Preclinical Programs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently have three programs in preclinical development. GB1275 is an oral small molecule, CD11b agonist in preclinical development for
the treatment of oncology indications for which we plan to submit an IND application in 2019. We are also currently evaluating a portfolio of novel BTK inhibitors for the treatment of autoimmune indications and small molecule cancer metabolism
modulators for the treatment of solid tumors. We are continuing to build our research capabilities, specifically focusing on our areas of expertise within immunology, inflammation and oncology, in order to advance new programs into the clinic, as
well as to optimize our existing programs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our founders and management team have held senior positions at leading biopharmaceutical companies, including Receptos, Inc., Genentech USA,
Inc. (Roche), or Genentech, Bristol-Myers Squibb Company, GlaxoSmithKline LLC and Celgene Corporation, among others, and possess substantial experience and expertise across the spectrum of drug discovery, development and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Sheila Gujrathi, M.D., our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and President and Chief Executive Officer, was previously Chief
Medical Officer of Receptos until its acquisition by Celgene in 2015, and has also served in senior leadership roles at Bristol-Myers Squibb and Genentech. Faheem Hasnain, our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Executive Chairman
and former Chief Executive Officer, previously served as Chief Executive Officer at Receptos, and has over 30 years of senior leadership experience at both large and small biopharmaceutical companies. Luisa
<FONT STYLE="white-space:nowrap">Salter-Cid,</FONT> Ph.D., our Chief Scientific Officer, was previously the Head of Immunology Discovery at Bristol-Myers Squibb, having overseen immunology and immuno-oncology discovery efforts since 2005. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The development and operational expertise of our executive and senior scientific team will be essential as we execute on our strategy of
building a large, diversified biopharmaceutical company to deliver significant value to both patients and shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our goal is to be an industry leader in the disease areas of immunology, inflammation and oncology and to enhance and extend the lives of
patients suffering from such diseases. Critical components of our business strategy include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Create deep therapeutic centers of excellence by leveraging our immunology and translational discovery and
development expertise. </P></TD></TR></TABLE>   <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maximize the impact of our product candidates by expanding development across multiple indications.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expeditiously generate
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data from our preclinical programs to facilitate value creation and efficient capital deployment. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage the drug discovery, development and commercialization expertise of our world-class team.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our ability to execute our business strategy is subject to numerous risks, as more fully described in the section titled &#147;Risk
Factors&#148; immediately following this Prospectus Summary. These risks include, among others: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history, have incurred significant operating losses since our inception and expect to
incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary
capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend heavily on the success of GB001, GB002 and GB004, which are in either Phase 1 or Phase 2 clinical
development. If we are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially
harmed. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of
preclinical studies and early clinical trials are not necessarily predictive of future results. In addition, our assumptions about why our product candidates are worthy of future development and potential approval are based on data primarily
collected by other companies. Our product candidates may not have favorable results in later clinical trials, if any, or receive regulatory approval on a timely basis, or at all. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any difficulties or delays in the commencement or completion, or termination or suspension, of our current or
planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face significant competition, and if our competitors develop technologies or product candidates more rapidly
than we do or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct many of our preclinical studies and clinical trials and to manufacture our
product candidates, and these third parties may not perform satisfactorily. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have recently substantially increased the size of our organization, and we may encounter difficulties in
managing our growth and expanding our operations successfully. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we fail to comply with our obligations in the agreements under which we license intellectual property rights
from third parties, including for GB002 and GB004, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. Additionally, several of our license agreements
include sublicenses from a third party, including for GB002, and we must rely on the direct licensor&#146;s compliance with its obligations under its original license agreement. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">After this offering, our executive officers, directors and principal stockholders, if they choose to act
together, will continue to have the ability to control or significantly influence all matters submitted to stockholders for approval. Furthermore, many of our current directors were appointed by our principal stockholders, and one such principal
stockholder, HH Goss Holdings LLC, has the right to designate one member to our board of directors and have such member appointed to any board committee that it requests effective as of the closing of this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We were
incorporated under the laws of the state of Delaware on October&nbsp;26, 2015 under the name FSG, Bio, Inc. and changed our name to Gossamer Bio, Inc. in 2017. Our principal executive offices are located at 3013 Science Park Road, Suite 200, San
Diego, California 92121, and our telephone number is <FONT STYLE="white-space:nowrap">(858)&nbsp;684-1300.</FONT> Our website address is www.gossamerbio.com<I>.</I> The information contained in, or accessible through, our website does not constitute
part of this prospectus. We have included our website address as an inactive textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus includes trademarks,
tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this prospectus appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and &#153;
symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the Jumpstart Our Business Startups Act, or the JOBS Act, enacted in April 2012. An emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include,
but are not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to present only two years of audited financial statements and only two years of related
Management&#146;s Discussion&nbsp;&amp; Analysis of Financial Condition and Results of Operations in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended, or Sarbanes-Oxley; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports,
proxy statements and registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until the
last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended, or the Securities Act, which such
fifth anniversary will occur in 2023. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the
Securities Exchange Act of 1934, or the Exchange Act, our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease
to be an emerging growth company prior to the end of such five-year period. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have elected to take advantage of certain of the reduced disclosure obligations in the
registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might
receive from other public reporting companies in which you hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging
growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or
revised accounting standards as other public companies that are not emerging growth companies. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option to purchase additional shares of
common stock in full) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares </P></TD>
<TD>We have granted the underwriters an option exercisable for a period of 30 days to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We intend to use the net proceeds of this offering to fund research and development of our product candidates and development programs and for working capital and general corporate purposes. See &#147;Use of Proceeds&#148; for a more complete
description of the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus and the other information in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Directed shares </P></TD>
<TD>At our request, the underwriters have reserved for sale, at the initial public offering price, up to 5% of the shares offered hereby for our directors, officers, employees, business associates and related persons who have expressed an interest
in purchasing common stock in the offering. See &#147;Underwriting&#148; for more information. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Select Market Symbol </P></TD>
<TD>&#147;GOSS&#148; </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering set forth above is
based on 207,121,355 shares of our common stock outstanding as of September&nbsp;30, 2018, including 35,098,238&nbsp;shares subject to forfeiture, after giving effect to the automatic conversion of all outstanding shares of our convertible preferred
stock into 137,220,799&nbsp;shares of our common stock immediately prior to the closing of this offering, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9,469,500 shares of common stock issuable upon exercise of stock options outstanding as of September&nbsp;30,
2018, at a weighted-average exercise price of $0.65 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for
future issuance under our 2019 equity incentive plan, or the 2019 Plan, which will become effective in connection with this offering (which number
includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares remaining available for issuance under our 2017 equity incentive plan, or the 2017 Plan, as of September&nbsp;30, 2018, which will become
available for issuance under the 2019 Plan upon its effectiveness, but does not include any potential evergreen increases pursuant to the terms of the 2019 Plan); and </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for
future issuance under our 2019 employee stock purchase plan, or the ESPP, which will become effective in connection with this offering (which number does not include any potential evergreen increases pursuant to the terms of the ESPP).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, this prospectus assumes or gives effect to the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our
amended and restated bylaws, each of which will occur immediately prior to the closing of this offering; </P></TD></TR></TABLE>   <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our convertible preferred stock into 137,220,799 shares of
our common stock immediately prior to the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">20,612-for-one</FONT></FONT> stock split of
our common stock effected in January 2018; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">one-for-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> reverse stock
split of our common stock to be effected before the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of the outstanding options described above; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Consolidated Financial Data </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following tables set forth a summary of our historical consolidated financial data as of, and for the periods ended on, the dates
indicated. We have derived the summary consolidated statements of operations data for the years ended December&nbsp;31, 2016 and 2017 from our audited consolidated financial statements included elsewhere in this prospectus. We have derived the
summary consolidated statements of operations data for the nine months ended September&nbsp;30, 2017 and 2018 and the summary consolidated balance sheet data as of September&nbsp;30, 2018 from our unaudited consolidated financial statements included
elsewhere in this prospectus. The unaudited consolidated financial statements have been prepared on a basis consistent with our audited consolidated financial statements included in this prospectus and, in the opinion of management, reflect all
adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position as of September&nbsp;30, 2018 and results of operations for the nine months ended September&nbsp;30, 2017 and 2018. You should read this
data together with our consolidated financial statements and related notes included elsewhere in this prospectus and the sections titled &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not necessarily indicative of our future results. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In process research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(109,186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock outstanding, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,602,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares of common stock outstanding, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,740,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">See Note 2 to our consolidated financial statements included elsewhere in this prospectus for an explanation of
the method used to calculate the historical and pro forma net loss per share, basic and diluted, and the number of shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">In connection with the issuance of the Series A convertible preferred stock in January 2018, certain of our
founders entered into stock restriction agreements, whereby 20,612,000 of previously unrestricted shares of common stock became subject to forfeiture to us upon the founders&#146; termination of employment or service, which obligation lapses as the
shares vest. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro&nbsp;Forma&nbsp;As</B><br><B>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">256,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">256,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Gives effect to&nbsp;the automatic conversion of all of our outstanding shares of convertible preferred stock
into an aggregate of 137,220,799 shares of common stock and the related reclassification of the carrying value of the convertible preferred stock to permanent equity immediately prior to the closing of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Gives effect to (i)&nbsp;the pro forma adjustments set forth in footnote (1)&nbsp;above and (ii)&nbsp;the
issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share
would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents and marketable securities, working capital, total assets and total stockholders&#146; equity by approximately $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) the pro forma as adjusted amounts of each of cash, cash equivalents and marketable securities, working capital,
total assets and total stockholders&#146; equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us. The pro forma information discussed above is illustrative only and will be adjusted based on the actual initial public offering price and other terms of our initial public offering determined at pricing.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements
included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below,
together with all of the other information in this prospectus, including our consolidated financial statements and related notes included elsewhere in this prospectus and &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations,&#148; before making an investment decision. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the
trading price of our common stock could decline and you could lose part or all of your investment. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Limited Operating History,
Financial Position and Capital Requirements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history, have incurred significant operating losses since our inception
and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical-stage
biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We commenced operations in 2017, and to date, we have focused primarily on organizing and staffing our company, business planning,
raising capital, identifying, acquiring and <FONT STYLE="white-space:nowrap">in-licensing</FONT> our product candidates and conducting preclinical studies and early clinical trials. GB001, GB002 and GB004 are in clinical development, while our other
development programs remain in the preclinical or research stage. We have not yet demonstrated an ability to successfully complete any clinical trials, obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party
to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a
history of successfully developing and commercializing biopharmaceutical products. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses
since our inception. If our product candidates are not successfully developed and approved, we may never generate any revenue. Our net losses were $6.8&nbsp;million and $108.2&nbsp;million for the year ended December&nbsp;31, 2017 and the nine
months ended September&nbsp;30, 2018, respectively. As of September&nbsp;30, 2018, we had an accumulated deficit of $115.1&nbsp;million. Substantially all of our losses have resulted from expenses incurred in connection with our research and
development programs and from general and administrative costs associated with our operations. All of our product candidates will require substantial additional development time and resources before we would be able to apply for or receive
regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory
approval for and potentially commercialize any of our product candidates and seek to identify, assess, acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or develop additional product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This
will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing
and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant
enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the
biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to
achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product
candidates or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs,
commercialization efforts or other operations. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The development of biopharmaceutical product candidates is capital-intensive. We
expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned clinical trials of GB001, GB002 and GB004, continue research and development and initiate clinical trials of our other
development programs and seek regulatory approval for our current product candidates and any future product candidates we may develop. In addition, as our product candidates progress through development and toward commercialization, we will need to
make milestone payments to the licensors and other third parties from whom we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> or acquired our product candidates, including GB002 and GB004. Furthermore, if and to the extent we seek to
acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates in the future, we may be required to make significant upfront payments, milestone payments, and/or licensing payments. If we obtain regulatory approval for
any of our product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any clinical trial or preclinical study is highly uncertain, we
cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Furthermore, following the completion of this offering, we expect to incur additional costs associated
with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay,
reduce or eliminate our research and development programs or any future commercialization efforts. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that the net proceeds
from this offering, together with our existing cash, cash equivalents and marketable securities, will enable us to fund our operations for at least the next 12&nbsp;months. In particular, we expect that the net proceeds from this offering and our
existing cash, cash equivalents and marketable securities will allow us to complete our ongoing Phase 2b clinical trial for GB001, our planned Phase 1b clinical trial in PAH for GB002 and our planned Phase 1b clinical trial in UC for GB004. We have
based these estimates on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently
unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. In addition, we
may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management
from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the type, number, scope, progress, expansions, results, costs and timing of, our clinical trials and preclinical
studies of our product candidates which we are pursuing or may choose to pursue in the future; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of manufacturing for our product candidates, including commercial manufacturing if any
product candidate is approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public
company, including enhanced internal controls over financial reporting; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with hiring additional personnel and consultants as our clinical activities increase;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of the milestone or other payments we must make to the licensors and other third parties
from whom we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> our acquired our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is
approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors
and adequate market share and revenue for any approved products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with any products or technologies that we may <FONT STYLE="white-space:nowrap">in-license</FONT>
or acquire. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Conducting clinical trials and preclinical studies is a time consuming, expensive and uncertain process
that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our
commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may
not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations
or require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate
substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. To the extent that we raise
additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common
stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or
declaring dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we raise funds through future collaborations, licenses and other similar arrangements, we may have to relinquish
valuable rights to our future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend heavily on the success of GB001, GB002 and GB004, which are in either Phase 1 or Phase 2 clinical development. If we are unable to advance our
product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our three clinical-stage product candidates are in Phase 1 or Phase 2 clinical development. We commenced a Phase 2b clinical trial of GB001 in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma in October 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
GB002 is currently undergoing Phase&nbsp;1 clinical studies in healthy volunteers, and we plan to commence a Phase&nbsp;1b clinical trial in PAH in the first half of 2019 and a Phase&nbsp;2/3
clinical trial in PAH in the second half of 2019. Our third clinical-stage product candidate, GB004, is currently undergoing a Phase&nbsp;1 clinical trial in healthy volunteers, and, following submission of an IND with the FDA, we expect to initiate
a Phase&nbsp;1b clinical trial in UC in the first half of 2019. Our assumptions about why these product candidates are worthy of future development and potential approval in these, or any, indications are based on data primarily collected by other
companies. We also have preclinical product candidates that will need to progress through <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies prior to clinical development. None of our product candidates have advanced into a pivotal study
for the indications for which we are studying. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product
candidates. The success of our product candidates will depend on several factors, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment in clinical trials and completion of clinical trials and preclinical studies with favorable
results; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of INDs by the FDA or similar regulatory filing by comparable foreign regulatory authorities for the
conduct of clinical trials of GB004 and our preclinical product candidates and our proposed design of future clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrating safety and efficacy to the satisfaction of applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receipt of marketing approvals from applicable regulatory authorities, including new drug applications, or NDAs,
from the FDA and maintaining such approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making arrangements with our third-party manufacturers for, or establishing, commercial manufacturing
capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if
and when approved, whether alone or in collaboration with others; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment and maintenance of patent and trade secret protection or regulatory exclusivity for our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining an acceptable safety profile of our products following approval; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining and growing an organization of people who can develop our products and technology.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain of our product candidates are subject to regulation as combination products, which means that they are composed
of both a drug product and device product. If marketed individually, each component would be subject to different regulatory pathways and reviewed by different centers within the FDA. Our product candidates that are considered to be drug-device
combination products will require review and coordination by FDA&#146;s drug and device centers prior to approval, which may delay approval. Under FDA regulations, combination products are subject to current good manufacturing practice, or cGMP,
requirements applicable to both drugs and devices, including the Quality System, or QS, regulations applicable to medical devices. Combination products are also subject to the Medical Device Directives and Standards in Europe. Problems associated
with the device component of the combination product candidate may delay or prevent approval. If the manufacturer of the device products make modifications, or if we elect to change a device component or develop our own proprietary device component,
we will need to perform validation testing and obtain FDA and other regulatory approval prior to using the modified device component. If the FDA or any other regulatory body fails to approve use of those modified devices or take significant
enforcement action against the manufacturer, we would not be able to market or may have to suspend marketing our products in certain jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The success of our business, including our ability to finance our company and generate any
revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates, which may never occur. We have not yet succeeded and may not succeed in demonstrating efficacy and
safety for any product candidates in clinical trials or in obtaining marketing approval thereafter. Given our early stage of development, it may be several years, if at all, before we have demonstrated the safety and efficacy of a treatment
sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue
our business. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical
studies and early clinical trials are not necessarily predictive of future results. In addition, our assumptions about why our product candidates are worthy of future development and potential approval are based on data primarily collected by other
companies. Our product candidates may not have favorable results in later clinical trials, if any, or receive regulatory approval on a timely basis, if at all. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that
any clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate
can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The results from preclinical studies or clinical trials of a product candidate may not predict the results of later clinical trials of the
product candidate, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having
progressed through preclinical studies and initial clinical trials. In particular, while two Phase&nbsp;2 clinical trials of GB001 have been conducted prior to our acquisition of GB001, we do not know how GB001 will perform in future clinical
trials, including as a result of any differences from targeting a population of more severe asthma subjects with elevated eosinophil counts, as well as other differences in our planned trial design. Further, GB001 did not meet its primary efficacy
endpoint of improvement in FEV<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> over 10&nbsp;weeks in the first Phase&nbsp;2 clinical trial conducted by Pulmagen Therapeutics (Asthma) Limited, or Pulmagen, and the second Phase&nbsp;2
clinical trial conducted by Pulmagen and its partner, Teijin Pharma Limited, or Teijin, was limited to only Japanese patients. While we have designed our ongoing Phase&nbsp;2b trial in a manner intended to address what we believe to be the
shortcomings of the first Pulmagen Phase&nbsp;2 clinical trial, we cannot be certain that such failure was not due to GB001 itself or that the results of our ongoing Phase&nbsp;2b trial will otherwise be successful in a broader patient population.
It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. For example, our decision
to advance GB002 as a potential treatment for PAH is based in part on the efficacy of imatinib (Gleevec), a tyrosine kinase inhibitor with known activity against PDGF and marketed for oncology indications, observed by Novartis Pharmaceutical
Corporation, or Novartis, in a Phase&nbsp;3 clinical trial; however, we may not observe similar efficacy in our clinical trials of GB002. Moreover, this and any future preclinical and clinical data may be susceptible to varying interpretations and
analyses. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Furthermore, we cannot assure you that our
preclinical programs will be able to progress from candidate identification to Phase&nbsp;1 clinical development. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition,
Teijin, a third party over which we have no control, has the right to develop and commercialize GB001 in Japan. If serious adverse events or other problems occur during any clinical trials of GB001 conducted by Teijin, the FDA or other regulatory
authorities may delay, limit or deny approval of GB001 or require us to conduct additional clinical trials as a condition to marketing approval, which would increase our costs. If we receive FDA approval for GB001 and a new and serious safety issue
is identified in clinical trials conducted by Teijin, regulatory authorities may withdraw their approval of the product or otherwise restrict our ability to market and sell GB001. In addition, treating physicians may be less willing to prescribe our
product due to concerns over such adverse events, which would limit our ability to commercialize GB001. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the foregoing reasons, we cannot be certain that our ongoing and planned clinical trials
and preclinical studies will be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which
could have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any difficulties or delays in the commencement
or completion, or termination or suspension, of our current or planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical
studies to demonstrate the safety and efficacy of the product candidates in humans. We are currently conducting a Phase 2b clinical trial of GB001 in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT>
eosinophilic asthma, and we plan to commence a Phase 1b clinical trial of GB002 in PAH patients in the first half of 2019 and a Phase&nbsp;2/3 clinical trial of GB002 in PAH in the second half of 2019, among other planned trials. In addition, before
we can initiate our planned Phase 1b clinical trial of GB004 in UC patients, currently planned for the first half of 2019, we must submit the results of preclinical studies to the FDA along with other information, including information about product
candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND application. We will have to follow the same procedure for our other preclinical product candidates which we plan to advance to clinical
development, and we may also be required to submit regulatory filings to foreign regulatory authorities to the extent we initiate clinical trials outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of
clinical trials can be delayed for a number of reasons, including delays related to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our
clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on
trial design; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any failure or delay in reaching an agreement with contract research organizations, or CROs, and clinical trial
sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining approval from one or more institutional review boards, or IRBs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment
of additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of product candidate or obtaining sufficient quantities of combination
therapies for use in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post- treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects choosing an alternative treatment for the indication for which we are developing our product candidates,
or participating in competing clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects experiencing severe or unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the
resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a facility manufacturing our product candidates or any of their components, including the device component of
orally inhaled GB002, being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements, or infections or cross-contaminations of
product candidates in the manufacturing process; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any changes to our manufacturing process that may be necessary or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not
performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements; third-party contractors not performing data collection or analysis in a
timely or accurate manner; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or
regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in
which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition
of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In
addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which
may impact the costs, timing or successful completion of a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Further, conducting clinical trials in foreign countries, as
we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in
healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive
compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may
conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the
integrity of the data </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing
applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our
product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate
development and approval process and jeopardize our ability to commence product sales and generate revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, many of the
factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. We may make formulation or
manufacturing changes to our product candidates, in which case we may need to conduct additional preclinical studies to bridge our modified product candidates to earlier versions. Any delays to our clinical trials that occur as a result could
shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be
significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may find it difficult to
enroll patients in our clinical trials. If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to identify and enroll a sufficient
number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors
including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a
clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies and experience, competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of the
product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating as well as any drugs under development. We will be required to identify and enroll a
sufficient number of subjects for each of our clinical trials. Potential subjects for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such
trials. For example, a limited number of patients are affected by PAH, which is our target indication for GB002. We also may encounter difficulties in identifying and enrolling subjects with a stage of disease appropriate for our planned clinical
trials and monitoring such subjects adequately during and after treatment. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible subjects to participate in the clinical trials required
by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and diagnosing subjects may prove costly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as
completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. For certain of our product candidates, including GB002, the conditions which we currently plan to evaluate are orphan or rare diseases with limited patient pools from
which to draw for clinical trials. The eligibility criteria of our clinical trials, once established, will further limit the pool of available trial participants. If patients are unwilling to participate in our trials for any reason, including the
existence of concurrent clinical trials for similar patient populations, if they are unwilling to enroll in a clinical trial with a placebo-controlled design or the availability of approved therapies, or we otherwise have difficulty enrolling a
sufficient number of patients, the timeline for recruiting subjects, conducting studies and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a sufficient number of subjects for any of our future
clinical trials would result in significant delays or may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require us to abandon one or more clinical trials altogether. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials
and, while we intend to enter into agreements governing their services, we will have limited influence over their actual performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
cannot assure you that our assumptions used in determining expected clinical trial timelines are correct or that we will not experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or
preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business,
prospects, operating results and financial condition. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As is the case with pharmaceuticals generally, it is likely that there may
be side effects and adverse events associated with our product candidates&#146; use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects
caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign
regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business,
financial condition and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, if our product candidates are associated with undesirable side effects in
clinical trials or have characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less
prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate if approved. We may also be required to modify our study plans based on findings in our ongoing clinical
trials. GB001 was generally well tolerated with a treatment-emergent adverse event rate similar to placebo in completed Phase 2 clinical trials. In Phase&nbsp;1 studies conducted by Pulmagen and Teijin, a single serious adverse event deemed by the
investigator likely to be related to GB001 was observed in a Japanese patient who had received a 160mg dose. The patient experienced intrahepatic cholestasis, a liver disorder, which resolved after treatment discontinuation. We are also currently
conducting Phase&nbsp;1a SAD and MAD double-blind, placebo-controlled, randomized trials of orally inhaled GB002 in healthy adult volunteers, and no treatment related safety issues have been reported to date. However, further analysis may reveal
adverse events inconsistent with the safety profile observed to date. Additionally, while we have not yet completed clinical trials for GB002 and have only completed a Phase&nbsp;1 SAD study in healthy volunteers for GB004, and it is likely that
there may be side effects associated with their use. For example, in 2013, results from a Phase&nbsp;3 clinical trial in PAH of imatinib (Gleevec) showed statistically significant improvement in its primary efficacy endpoint, but systemic toxicities
were also observed. We cannot be certain that GB002 will not exhibit similar toxicities. Many compounds that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the
compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as the use of these product
candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials,
will be reported by subjects. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, if one or more of our product candidates receives marketing approval, and we or
others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw, suspend or limit approvals of such product; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to recall a product or change the way such product is administered to patients;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label, such as a &#147;black box&#148; warning or a
contraindication; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide
outlining the risks of such side effects for distribution to patients; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way a product is distributed or administered, conduct additional clinical trials
or change the labeling of a product or be required to conduct additional post-marketing studies or surveillance; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of the product may decrease significantly or the product could become less competitive; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and
could significantly harm our business, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As an organization, we are in the process of completing our first Phase
1 clinical trials, have never conducted later-stage clinical trials or submitted an NDA, and may be unable to do so for any of our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are early in our development efforts for our product candidates, and we will need to successfully complete later-stage and pivotal clinical
trials in order to obtain FDA or comparable foreign regulatory approval to market GB001, GB002, GB004 or any future product candidates. Carrying out later-stage clinical trials and the submission of a successful NDA is a complicated process. As an
organization, we are in the process of completing Phase&nbsp;1 clinical trials for GB001, GB002 and GB004 and conducting a Phase 2b clinical trial for GB001. We have not yet conducted any clinical trials for our other product candidates. We have not
previously conducted any later stage or pivotal clinical trials, have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not previously submitted an IND or an NDA or other comparable foreign
regulatory submission for any product candidate. We also plan to conduct a number of clinical trials for multiple product candidates in parallel over the next several years, which may be a difficult process to manage with our limited resources and
which may divert the attention of management. In addition, we have had limited interactions with the FDA and cannot be certain how many additional clinical trials of GB001, GB002, GB004 or any other product candidates will be required or how such
trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our product candidates. We may require more
time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay
us in submitting NDAs for and commercializing our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates are subject to extensive regulation and compliance, which is costly and time
consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution
of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. In the United States, we are not permitted to market our product candidates until we
receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the
product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny
approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. We are not permitted to market any of our product candidates in the
United States until we receive approval of an NDA from the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to obtaining approval to commercialize a product candidate in the
United States or abroad, we must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and
effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be
sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for
our product candidates either prior to or post-approval, or may object to elements of our clinical development program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA or
comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree with the design or implementation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or ambiguous results from our clinical trials or results may not meet the level of statistical
significance required by the FDA or comparable foreign regulatory agencies for approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by
individuals using drugs similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in
the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in
countries where the standard of care is potentially different from that of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety
risks; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may not agree that the data collected from clinical trials of our product candidates are
acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may disagree regarding the formulation, labeling and/or the specifications of our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or
with other significant restrictions on distribution and use; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may find deficiencies in the manufacturing processes or facilities of our third-party
manufacturers with which we contract for clinical and commercial supplies; or the approval policies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulations of such authorities may significantly change in a manner rendering our or any of our potential future
collaborators&#146; clinical data insufficient for approval; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may not accept a submission due to, among other reasons, the content or formatting of the
submission. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing
risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by
the FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to
obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes
and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we eventually complete clinical trials and receive approval
of an NDA or foreign marketing application for our product candidates, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including Phase 4 clinical trials,
and/or the implementation of a REMS, which may be required to ensure safe use of the drug after approval. The FDA or the comparable foreign regulatory authority also may approve a product candidate for a more limited indication or patient population
than we originally requested, and the FDA or comparable foreign regulatory authority may not approve the labeling that we believe is necessary or desirable for the successful commercialization of a product. Any delay in obtaining, or inability to
obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we have multiple product candidates in our clinical pipeline and are considering a variety of target indications, we may expend our limited
resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. &nbsp;&nbsp;&nbsp;&nbsp; </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on specific product candidates, indications and development programs. We
also plan to conduct several clinical trials for multiple product candidates in parallel over the next several years, which may make our decision as to which product candidates to focus on more difficult. As a result, we may forgo or delay pursuit
of opportunities with other product candidates that could have had greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on
current and future research and development programs and product candidates for specific indications may not yield any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product
candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Additionally, we may pursue additional <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of development-stage assets or
programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or
license of a particular product candidate, potentially resulting in a diversion of our management&#146;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result
in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to obtain or maintain orphan drug designations for certain of our product candidates, and we may be unable to maintain the benefits
associated with orphan drug designation, including the potential for market exclusivity. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in some
jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan product if it is intended to treat a
rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population of greater than 200,000 individuals in the United States, but for which there is no
reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the European Medicines Agency&#146;s, or the EMA&#146;s, Committee for Orphan Medicinal Products grants orphan drug
designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. We have
received orphan drug designation in the United States for GB002 for patients with PAH, and we may seek orphan drug designation in the European Union for GB002 for patients with PAH, as well as seek orphan drug designation for certain of our other
product candidates. There can be no assurance that the FDA or the EMA&#146;s Committee for Orphan Medicinal Products will grant orphan designation for any indication for which we apply, or that we will be able to maintain such designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States, orphan designation entitles a party to financial incentives such as opportunities for grant funding toward clinical
trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. In addition, if a product candidate that has orphan designation subsequently receives the first FDA approval for the disease for which it has such designation,
the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a
showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity. The applicable exclusivity period is ten years in Europe, but such exclusivity period can be
reduced to six years if a product no longer meets the criteria for orphan designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because
different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve the same drug for the same condition if such regulatory authority concludes
that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug
any advantage in the regulatory review or approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are currently conducting, and may in the future conduct, certain of our clinical trials for our
product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are currently conducting, and may in the future conduct one or more of our clinical trials for our product candidates outside the United
States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the FDA requires the clinical trial to have been conducted
in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. In addition, when studies are conducted only at sites outside of the United States,
the FDA generally does not provide advance comment on the clinical protocols for the studies, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> clinical trial was inadequate, which would likely require us to conduct additional clinical trials. There can be no assurance the FDA will accept data from clinical trials conducted outside of the
United States. If the FDA does not accept data from our clinical trials of our product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our
development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Conducting clinical trials outside the United States also exposes us to additional risks,
including risks associated with: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional foreign regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign exchange fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with foreign manufacturing, customs, shipment and storage requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cultural differences in medical practice and clinical research; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diminished protection of intellectual property in some countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">From
time to time, we may publicly disclose preliminary or topline or data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a
more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and
carefully evaluate all data.&nbsp;As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and
fully evaluated.&nbsp;Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed
with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes
may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. For example, we commenced a Phase
2b clinical trial in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma in October 2018 and expect to conduct an interim analysis in the first half of 2020. If the interim analysis
is positive, we plan on initiating a Phase 3 clinical trial thereafter. However, if the final data from the Phase 2b </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trial materially differs in an adverse manner from the interim analysis, we may have unnecessarily expended or committed substantial resources to the Phase 3 clinical trial, which costs
we may never be able to recover. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates,
calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our
company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the
material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding
a particular drug, drug candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and
commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related
to Our Reliance on Third Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct many of our preclinical studies and clinical trials. Any failure by a
third party to conduct the clinical trials according to GCPs and other requirements and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are dependent on third parties to conduct our clinical trials and preclinical studies, including our ongoing clinical trials for GB001,
GB002 and GB004 and preclinical studies for our other development programs. Specifically, we have used and relied on, and intend to continue to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our
clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of
data. While we have agreements governing the activities of our third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in
accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP
requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of
trial sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign
regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with
these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There is no guarantee that
any such CROs, investigators or other third parties will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet
regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial
entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as
scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the
FDA concludes that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA we submit by the FDA. Any such delay or rejection could prevent us from commercializing our
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with
alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires management time and focus. In addition, there is a natural
transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, investigators and
other third parties, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties for the manufacture of our product candidates for clinical and preclinical development and expect to continue to do so for the
foreseeable future. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or
commercialization efforts. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not own or operate manufacturing facilities and have no plans to build our own clinical or
commercial scale manufacturing capabilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates and related raw materials for clinical and preclinical development, as well as for commercial
manufacture if any of our product candidates receive marketing approval. The facilities used by third-party manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we
submit an NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with cGMP requirements for manufacture of drug products. If these third-party manufacturers cannot
successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, including requirements related to the manufacturing of high potency compounds, they will not be able to secure and/or
maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a
comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would
significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions
being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which
could significantly and adversely affect supplies of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our or a third party&#146;s failure to execute on our manufacturing
requirements, to do so on commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to initiate or continue clinical trials of GB001, GB002, GB004 or any future product candidates
under development; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by
regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements to cease development or to recall batches of our product candidates; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the event of approval to market and commercialize our product candidates, an inability to meet commercial
demands for our product candidates or any other future product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we may be unable to establish
any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture our product according to our specifications; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to manufacture our product according to our schedule or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">misappropriation of our proprietary information, including our trade secrets and
<FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our product candidates and any products that we may develop may compete with other product candidates and products for
access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval, and any
related remedial measures may be costly or time consuming to implement. We do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of our product candidates. If our
current third-party manufacturers cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them on a timely basis or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our
future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance
on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because we currently rely on other third parties to manufacture our product candidates and to perform quality testing, we must, at times,
share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, consulting agreements or other similar agreements
with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual
provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into
the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets and despite our efforts to protect
our trade secrets, a competitor&#146;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business,
financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to enter into collaborations, licenses and other similar arrangements and may not be
successful in doing so, and even if we are, we may not realize the benefits of such relationships. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may seek to enter into
collaborations, joint ventures, licenses and other similar arrangements for the development or commercialization of our product candidates, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints.
We may not be successful in our efforts to establish such collaborations for our product candidates because our research and development pipeline may be insufficient, our product candidates may be deemed to be at too early of a stage of development
for collaborative effort or third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking
appropriate strategic partners, and the negotiation process can be time consuming and complex. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. We cannot be certain
that, following a strategic transaction or license, we will achieve an economic benefit that justifies such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if we are
successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed,
the safety of a product candidate is questioned or sales of an approved product candidate are unsatisfactory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, any potential
future collaborations may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the
development and commercialization of our product candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into collaborations
related to our product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition
and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review,
which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to
comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Following potential approval of any our product candidates, the FDA may impose significant restrictions on a product&#146;s indicated uses or
marketing or impose ongoing requirements for potentially costly and time consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy of the product. The FDA may also require a REMS as a condition
of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk
minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion,
import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued
compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our products, including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among
other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or
voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or
suspension or revocation of approvals; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of our products; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
and could require us to expend significant time and resources in response and could generate negative publicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, if any of
our product candidates is approved, our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products.
In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#146;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their
patients in a manner that is inconsistent with the approved label. If we are found to have promoted such <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The FDA and other agencies actively
enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to
significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion.
The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we
may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We also cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact
our business and industry. Namely, the current U.S. administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s
ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions,
including the Executive Orders, will be implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#146;s ability to engage in oversight
and implementation activities in the normal course, our business may be negatively impacted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects,
financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The commercial success of our product candidates will depend upon the degree of market acceptance of
such product candidates by physicians, patients, healthcare payors and others in the medical community. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our product candidates
may not be commercially successful. Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our
current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our products will depend on a number of
factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstration of clinical efficacy and safety compared to other more-established products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the indications for which our product candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the limitation of our targeted patient population and other limitations or warnings contained in any <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> labeling; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance of a new drug for the relevant indication by healthcare providers and their patients;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in
relation to alternative treatments and therapies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government
healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay all, or a portion of, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on the use of our products, and the prevalence and severity of any adverse effects;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential product liability claims; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of our products as well as competitive drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our or any of our potential future collaborators&#146; sales and marketing strategies; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unfavorable publicity relating to the product. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or
patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources
and may never be successful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the
promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. If we are found or alleged to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, as our product
candidates would be, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s approved labeling. If we are found to have promoted such <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies
from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we
cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of our product candidates, if approved, will depend in part on the extent to which governmental authorities and health
insurers establish coverage, adequate reimbursement levels and favorable pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability
to generate revenue. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs such as
Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve coverage and acceptable
levels of reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement
payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will
be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may
refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to
reimburse patients for the less expensive product. Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for
our products. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product
development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States,
third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require <FONT
STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will
decide with respect to the coverage and reimbursement for our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining reimbursement status is time consuming,
costly and uncertain. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the
coverage determination process is often a time consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate
reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are
likely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to extensive governmental price controls and other
market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the prices of medical
products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or
other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may
be insufficient to generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and third-party
payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment
for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative
changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new
products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their
technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or
may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in
the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In particular,
there is intense competition in the fields of immunology, inflammation and oncology. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with
universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development
personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and <FONT
STYLE="white-space:nowrap">in-licensing</FONT> new product candidates. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect to face competition from existing products and products in development for each of our product candidates. GB001, currently in
development for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma, is an oral DP2 antagonist, a class of medicines with no currently-approved agents. However,
other DP2 antagonists are currently in development by Novartis, Chiesi Farmaceutici S.p.A., Merck&nbsp;&amp; Company, Inc. and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sunshine Lake Pharma Co., Ltd. If approved, we will also face branded competition from existing biologics, including Xolair (omalizumab/anti-immunoglobulin E, or
<FONT STYLE="white-space:nowrap">anti-IgE,</FONT> marketed by Genentech and Novartis) and Dupixent <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(dupilumab/anti-IL-4/IL-13,</FONT></FONT></FONT>
marketed by Regeneron Pharmaceuticals, Inc., or Regeneron, and Sanofi S.A.), for moderate to severe asthma, and Nucala <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(mepolizumab/anti-IL-5,</FONT></FONT> marketed by
GlaxoSmithKline), Cinqair <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(reslizumab/anti-IL-5,</FONT></FONT> marketed by Teva Pharmaceutical Industries Ltd.), and Fasenra <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(benralizumab/anti-IL-5,</FONT></FONT> marketed by AstraZeneca Pharmaceuticals LP) for severe eosinophilic asthma. We will also face competition from generic montelukast, which is utilized in mild to moderate patients.
Several other agents are advancing in clinical trials for asthma, including tezepelumab (anti-TSLP; Amgen/AstraZeneca), REGN3500 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-IL-33;</FONT></FONT> Regeneron), etokimab <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-IL-33;</FONT></FONT> AnaptysBio, Inc.), GSK3772847 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-IL-33;</FONT></FONT> GlaxoSmithKline) and RG6149 <FONT
STYLE="white-space:nowrap">(anti-ST2;</FONT> Genentech). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Additionally, while there are no agents currently approved beyond
corticosteroids for CRSwNP, several agents approved for or in development for asthma are currently in development for CRSwNP, including Xolair, Fasenra, Dupixent and etokimab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Xolair is currently <FONT STYLE="white-space:nowrap">FDA-approved</FONT> for the treatment of CSU. We may also face competition from agents
currently in development for the indication, including ligelizumab <FONT STYLE="white-space:nowrap">(anti-IgE;</FONT> Novartis) and AK002 <FONT STYLE="white-space:nowrap">(anti-Siglec-8;</FONT> Allakos Inc.). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB002 is a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> PDGF receptor kinase
inhibitor initially targeted for intermediate and high-risk PAH patients. While potentially unique in our class, we expect our primary competition in this patient set will include prostanoids, available in oral form as Orenitram (United Therapeutics
Corporation, or United Therapeutics) and Uptravi (Janssen Pharmaceuticals, Inc., or Janssen), by inhalation as Tyvaso (United Therapeutics), and by infusion as Remodulin (United Therapeutics). While we may face some competition from products used in
class&nbsp;I and II patients, such as the oral PDE5 inhibitors, including Revatio (Pfizer Inc.) and Adcirca (United Therapeutics); the sGC stimulator Adempas (Bayer AG); and oral ERAs, including Tracleer (Janssen), Letairis (Gilead Sciences, Inc.)
and Opsumit (Janssen), we believe that, if approved, GB002 would be used along with these background therapies. PAH is also an active indication for investigational drugs, and we may face competition in the future from ralinepag (Arena
Pharmaceuticals, Inc.), sotatercept (Acceleron Pharma, Inc.) and bardoxolone methyl (Reata Pharmaceuticals, Inc.). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB004 is potentially a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> stabilizer with the potential to restore epithelial barrier
function in patients with IBD. Patients with mild to moderate UC can initially be maintained in remission using a <FONT STYLE="white-space:nowrap">5-aminosalucylic</FONT> acid, or <FONT STYLE="white-space:nowrap">5-ASA.</FONT> For those patients who
do not respond to <FONT STYLE="white-space:nowrap">5-ASA,</FONT> or those with more severe and/or extensive disease at diagnosis, corticosteroids are generally the next line of treatment. Patients who have become nonresponsive or intolerant to
corticosteroids may move to azathioprine and <FONT STYLE="white-space:nowrap">6-mercaptopurine.</FONT> The treatment of severe patients is dominated by <FONT STYLE="white-space:nowrap">anti-TNF</FONT> biologics, though the paradigm is shifting
because of the approval of agents in other classes, such as anti-integrin, <FONT STYLE="white-space:nowrap">IL-12</FONT> / <FONT STYLE="white-space:nowrap">IL-23,</FONT> and Janus kinase, or JAK, inhibitors. Further disruption is expected in the
coming years through the introduction of oral S1P1 inhibitors and additional oral JAK inhibitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many of our competitors have
significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors,
including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these
products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer,
more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing
our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the market opportunities for our products are smaller than we believe they are, our revenue may be
adversely affected, and our business may suffer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The precise incidence and prevalence for all the conditions we aim to address
with our product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are
based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new trials may
change the estimated incidence or prevalence of these diseases. The total addressable market across all of our product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of our
product candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of our product candidates relative to such alternative treatments, acceptance by the medical
community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our
products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Further, even if we obtain significant market share for our product candidates,
because some of our potential target populations are very small, we may never achieve profitability despite obtaining such significant market share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest
significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product
candidates ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and
time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have
no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize
qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal
sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and
distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any
products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in
commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and
other risks and uncertainties. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our future growth may depend, in part, on our ability to develop and commercialize our product
candidates in foreign markets. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory
approvals for any of our product candidates. To obtain separate regulatory approval in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
many other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing
and distribution of our product candidates. If we obtain regulatory approval of our product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">different regulatory requirements for approval of drugs in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the existence of additional third-party patent rights of potential relevance to our business;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers and regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign reimbursement, pricing and insurance regimes; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is common; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters
including earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business Operations and Industry </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results
to fall below expectations or any guidance we may provide. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our quarterly and annual operating results may fluctuate
significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and cost of, and level of investment in, research, development, regulatory approval and
commercialization activities relating to our product candidates, which may change from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">coverage and reimbursement policies with respect to our product candidates, if approved, and potential future
drugs that compete with our products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing our product candidates, which may vary depending on the quantity of production and the
terms of our agreements with third-party manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of the milestone or other payments we must make to the licensors and other third parties
from whom we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> our acquired our product candidates, including payments due upon a change in control of our subsidiaries; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenditures that we may incur to acquire, develop or commercialize additional product candidates and
technologies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of demand for any approved products, which may vary significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future accounting pronouncements or changes in our accounting policies; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and success or failure of preclinical studies or clinical trials for our product candidates or
competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results.
As a result, comparing our operating results on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results as an indication of our
future performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This variability and unpredictability could also result in our failing to meet the expectations of industry or
financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the
expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or
recruit additional management or clinical and scientific personnel, our business will suffer. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our
continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We are highly dependent upon our senior management, particularly our Chief Executive Officer and our Executive Chairman, as well as our
senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned clinical trials or
the commercialization of our product candidates. Although we have executed employment agreements or offer letters with each member of our senior management team, these agreements are terminable at will with or without notice and, therefore, we may
not be able to retain their services as expected. We do not currently maintain &#147;key person&#148; life insurance on the lives of our executives or any of our employees, except for our Chief Executive Officer and Executive Chairman. This lack of
insurance means that we may not have adequate compensation for the loss of the services of these individuals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will need to expand and
effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company culture and continuing
to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses, particularly in the San Diego area. Our
industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that
will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have recently substantially increased the size of our organization, and we may encounter difficulties in managing our growth and expanding our
operations successfully. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have substantially increased our organization from 11 employees in January 2018 to 72 full-time
employees and 1 part-time employee as of October&nbsp;1, 2018. As we continue development and pursue the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potential commercialization of our product candidates, as well as function as a public company, we will need to continue to expand our financial, development, regulatory, manufacturing, marketing
and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties.
Our future financial performance and our ability to develop and commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage our recent substantial growth and any future growth effectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to various foreign, federal, and state healthcare and privacy laws and regulations, and our failure to comply with these laws and
regulations could harm our results of operations and financial condition. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our business operations and current and future
arrangements with investigators, healthcare professionals, consultants, third-party payors and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare and privacy laws and regulations. These laws may
constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and
willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, in return for, either the referral of an individual or the
purchase, lease, or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A
person or entity does not need to have actual knowledge of the federal Anti- Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services
resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal false claims and civil monetary penalties laws, including the civil False Claims Act, which
prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or
used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and
civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or
specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH,
and their implementing regulations, also impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization
by covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers as well as their business associates that perform certain services for or on their behalf involving the use or disclosure of
individually identifiable health information; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics
and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare and Medicaid Services, or CMS, information related
to payments and other &#147;transfers of value&#148; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians
described above and their immediate family members; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-</FONT> governmental
third-party payors, including private insurers, or by the patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and
marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales
representatives; state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA; state and foreign governments that
have enacted or proposed requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals (including the EU General Data Protection Regulation 2016/679, or
GDPR, and the California Consumer Protection Act, or CCPA), and federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use, and dissemination of data, thus complicating compliance
efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of May 25, 2018, the GDPR replaced the Data Protection Directive with respect to the processing of personal
data in the European Union. The GDPR imposes many requirements for controllers and processors of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures
to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention and secondary use of information, increased requirements pertaining to health data and pseudonymised (i.e.,
key-coded) data and additional obligations when we contract third-party processors in connection with the processing of the personal data. The GDPR allows EU member states to make additional laws and regulations further limiting the processing of
genetic, biometric or health data. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#128;20,000,000 or up to 4% of the total worldwide annual
turnover of the preceding financial year, whichever is higher, and other administrative penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Ensuring that our internal operations
and business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our consulting and
advisory board arrangements with physicians and other healthcare providers, some of whom received stock options as compensation for services provided, do not comply with current or future statutes, regulations, agency guidance or case law involving
applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to
significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions,
disgorgement, individual imprisonment, contractual damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws, diminished profits and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time consuming and may require significant financial and personnel resources.
Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be
in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability
to operate our business and our results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently enacted legislation, future legislation and healthcare reform measures may increase
the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and
regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain
marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act,
collectively the Affordable Care Act, was enacted in the United States. Among the provisions of the Affordable Care Act of importance to our potential product candidates, the Affordable Care Act: establishes an annual, nondeductible fee on any
entity that manufactures or imports specified branded prescription drugs and biologic agents; extends manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;
expands eligibility criteria for Medicaid programs; expands the entities eligible for discounts under the Public Health program; increases the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; creates a new
Medicare Part D coverage gap discount program; establishes a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and
establishes a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At this time, we are unsure of the full impact that the Affordable Care Act will have on our business. There have been judicial and political
challenges to certain aspects of the Affordable Care Act. For example, since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements of the Affordable Care Act.
Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes
under the Affordable Care Act have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by
the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate.&#148; Additionally, on January&nbsp;22, 2018, President Trump
signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care <FONT STYLE="white-space:nowrap">Act-mandated</FONT> fees, including the
<FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share. Further, the Bipartisan Budget
Act of 2018, or the BBA, among other things, amends the Affordable Care Act, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole,&#148; by increasing from
50&nbsp;percent to 70&nbsp;percent the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. More recently, in July
2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome
of federal district court litigation regarding the method CMS uses to determine this risk adjustment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Congress may consider other legislation to repeal or repeal and replace other elements of the Affordable Care Act. It remains unclear the extent to which any such change may impact our business
or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted.
On August&nbsp;2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to
subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2027 unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which,
among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost
of prescription drugs. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At the federal
level, the Trump administration&#146;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit
Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT>
patients. Additionally, the Trump administration released a &#147;Blueprint&#148; to lower drug prices through proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize
manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services has begun the process of soliciting feedback on some of these measures
and, at the same time, is implementing others under its existing authority. Although some of these, and other, proposals will require authorization through additional legislation to become effective, Congress and the Trump administration have each
indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At the state level,
legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions
could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which
suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business,
results of operations, financial condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Additionally, on May&nbsp;30, 2018, the Trickett Wendler, Frank Mongiello,
Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients with life-threatening diseases or conditions to access certain
investigational new drug products that have completed a Phase 1 clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access
program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect that the Affordable Care Act, these new laws and other healthcare reform measures that may be adopted in the future may result in
additional reductions in Medicare and other healthcare funding, more </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other
government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or
commercialize our product candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and any of our third-party manufacturers or suppliers may use potent chemical agents and
hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We and any of our third-party manufacturers or suppliers will use biological materials, potent chemical agents and may use hazardous
materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste
products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and
current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or
hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of
contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we maintain workers&#146; compensation insurance for certain costs and expenses we may incur due to injuries to our employees
resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in
connection with our storage or disposal of biologic, hazardous or radioactive materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs in
order to comply with current or future environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production
efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit
commercialization of our products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability as a result of the clinical trials of our
product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing,
manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of
warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer protection acts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or
cease the commercialization of our products. Even a successful defense would </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation and significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant negative financial impact; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decline in our stock price. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently hold approximately $10&nbsp;million in product liability insurance coverage in the aggregate. We may need to increase our
insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an
acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we maintain such insurance, any claim that may be brought against us could result in a court
judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product
liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain,
sufficient capital to pay such amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We and any of our potential future collaborators will be required to report to regulatory authorities if
any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we and any of our potential future collaborators are successful in commercializing our products, the FDA and foreign regulatory authorities
would require that we and any of our potential future collaborators report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be
triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our potential future collaborators or CROs may fail to report adverse events within the prescribed timeframe. If we or any of our potential
future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in
approval or clearance of future products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or
consultants or potential future collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The United States federal and various state and foreign governments have adopted or proposed requirements regarding the collection,
distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use,
and dissemination of data. Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer
viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations or result in the unauthorized disclosure
of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as GDPR), it could result in a material disruption of our development programs and our business operations,
whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally
identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Even though we may have contractual protections with such vendors,
contractors, or other organizations, notifications and <FONT STYLE="white-space:nowrap">follow-up</FONT> actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses, harm customer
confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our
regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material
adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur
liability, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons,
fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third- party manufacturers to produce our product candidates. Our ability
to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. In addition, our
corporate headquarters is located in San Diego, California near major earthquake faults and fire zones, and the ultimate impact on us of being located near major earthquake faults and fire zones and being consolidated in a certain geographical area
is unknown. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees and
independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of
unauthorized activities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to us that violate: (1)&nbsp;the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate
information to such authorities, (2)&nbsp;manufacturing standards, including cGMP requirements, (3)&nbsp;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or
(4)&nbsp;laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the
creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and
deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or
other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such
actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of
significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages,
reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and
regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs
regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls, and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign
Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in
which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, clinical research organizations, contractors and other collaborators and partners from authorizing, promising, offering,
providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products
abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or
government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, clinical research organizations, contractors and other collaborators and partners,
even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or
import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may engage
in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and <FONT
STYLE="white-space:nowrap">out-licensing</FONT> or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of intellectual property, products or technologies, similar to our approach in <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquiring
our current product candidates. Any future transactions could increase our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization
expenses or acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Additional potential transactions that we may consider
in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future acquisitions may also require us to obtain additional
financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the
future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although there can be no assurance that we will undertake or successfully
complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
success depends on our ability to protect our intellectual property and our proprietary technologies. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our commercial success
depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights
of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed. We generally seek to protect our
proprietary position by filing patent applications in the United States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent applications cannot be enforced against
third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our patent applications
will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around or invalidated
by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our
proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the
intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we own issued patents in the United States and foreign countries, we cannot be certain that the claims in our other U.S. pending
patent applications, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the
patent offices and courts in foreign countries, nor can we be certain that the claims in our issued patents will not be found invalid or unenforceable if challenged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential
future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise
may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made
significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope
of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S.
courts, allowing foreign competitors a better opportunity to create, develop and market competing products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The patent
prosecution process is also expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be
commercially advantageous. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to
control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of our licensor in order to enforce the licensed
patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and
maintenance activities by our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they
fail to do so, this could cause us to lose rights in any applicable intellectual property that we <FONT STYLE="white-space:nowrap">in-license,</FONT> and as a result our ability to develop and commercialize products or product candidates may be
adversely affected and we may be unable to prevent competitors from making, using and selling competing products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, although
we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators,
CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent
protection. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties,
including our GB002 and GB004, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. Additionally, several of our license agreements include sublicenses
from a third party, including for GB002, and we must rely on the direct licensor&#146;s compliance with its obligations under its original license agreement. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a party to a number of license agreements under which we are granted rights to intellectual property that are important to our business
and we may enter into additional license agreements in the future. For example, in October 2017, we entered into an exclusive license agreement with Pulmokine, Inc. to obtain an exclusive license to certain intellectual property rights to develop
and commercialize GB002. In June 2018, we entered into an exclusive license agreement with Aerpio Pharmaceuticals, Inc., or Aerpio, to obtain an exclusive license to certain intellectual property rights to develop, manufacture and commercialize
GB004. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These and our other existing license agreements impose, and we expect that any future license agreements where we <FONT
STYLE="white-space:nowrap">in-license</FONT> intellectual property, will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
comply with our obligations under these agreements, or we are subject to bankruptcy-related proceedings, the licensor may have the right to terminate the license, in which event we would not be
able to market products covered by the license. Additionally, several of our existing license agreements include sublicenses from a third party who is not the original licensor of the intellectual property at issue, including for GB002. Under these
agreements, we must rely on our direct licensor to comply with its obligations under the primary license agreements under which such licensor obtained rights in the applicable intellectual property, where we may have no relationship with the
original licensor of such rights. If our licensors fail to comply with their obligations under these upstream license agreements, the original third-party licensor may have the right to terminate the original license, which may terminate our
sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms,
or at all, which may impact our ability to continue to develop and commercialize our product candidates incorporating the relevant intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we cannot
provide any assurances that third-party patents do not exist which might be enforced against our product candidates in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we
are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources
to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property
rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business
and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor
that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patents and other rights to third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidates, and what activities satisfy those diligence obligations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to transfer or assign the license; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual
property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a
material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, certain of our agreements may limit or delay our ability to consummate certain
transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, if we choose to sublicense or assign to any third parties our rights under our existing license agreements with Aerpio or
Pulmokine with respect to any licensed product, we may be required to pay to Pulmokine or Aerpio, as applicable, a specified percentage of all revenue to be received in connection with such transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our
patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been
the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being
issued which protect our product candidates or which effectively prevent others from commercializing competitive product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be
reinterpreted after issuance. Even if patent applications we own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing
with us, or otherwise provide us with any competitive advantage. Any patents that we own may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know
whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a <FONT
STYLE="white-space:nowrap">non-infringing</FONT> manner which could materially adversely affect our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may not cover our
product candidates or may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party <FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the USPTO, or become involved
in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and <I>inter partes</I> review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal
assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our predecessors and the patent examiner were unaware
during prosecution. There is no assurance that all potentially relevant prior art relating to our patents and patent applications or those of our licensors has been found. There is also no assurance that there is not prior art of which we, our
predecessors or licensors are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications or those of our licensors, which may, nonetheless, ultimately be found to affect the validity
or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates
and compete directly with us, without payment to us. Such loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar
or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the
eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license,
develop or commercialize current or future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The patent protection and patent prosecution for some of our product candidates may
be dependent on third parties. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We or our licensors may fail to identify patentable aspects of inventions made in the course of
development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or
filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are
not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our
patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which
may have an adverse impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a licensee of third parties, we rely on third parties to file and prosecute patent
applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our patents or patent applications
and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other
intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these
patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such
patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual
property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our
ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from
third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often retain
certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary
scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our
rights to our licensed technology in the event of misuse. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If we are limited in our ability to utilize acquired or licensed technologies,
or if we lose our rights to critical <FONT STYLE="white-space:nowrap">in-licensed</FONT> technology, we may be unable to successfully develop, <FONT STYLE="white-space:nowrap">out-license,</FONT> market and sell our products, which could prevent or
delay new product introductions. Our business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our
ability to develop, <FONT STYLE="white-space:nowrap">out-license</FONT> or market and sell our product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Some of our intellectual property
has been discovered through government funded programs and thus may be subject to federal regulations such as <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain reporting requirements and a preference for U.S.-based
companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some of the intellectual property rights we have acquired or licensed or may acquire or license in the future may have been generated through
the use of U.S. government funding and may therefore be subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain federal regulations. For example, some of the research and development work on GB002 was funded by government research grants. As a result, the U.S. government may have certain rights to
intellectual property embodied in our product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act. These U.S. government rights include a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
<FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant
exclusive, partially exclusive, or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any of these inventions to a third party if it determines that: (i)&nbsp;adequate steps have not been taken to commercialize the invention;
(ii)&nbsp;government action is necessary to meet public health or safety needs; or (iii)&nbsp;government action is necessary to meet requirements for public use under federal regulations (also referred to as
<FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;). The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application
to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial
resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may
be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be
likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> product manufacturers for products covered by such intellectual property. To the extent any of our future intellectual property is also generated through the use of U.S. government funding, the
provisions of the Bayh-Dole Act may similarly apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to our
competitive advantage. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because
intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to develop products that are similar to our product candidates but that are not covered by the
claims of the patents that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or predecessors might not have been the first to make the inventions covered by the issued
patents or patent application that we own or license; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or predecessors might not have been the first to file patent applications covering certain of
our inventions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by
our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, it could significantly harm our business, results of
operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our commercial success depends significantly on our ability to operate without infringing the patents and other
proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research,
development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary
rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and
outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or
foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to
materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As
the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as
confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that we were the
first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our
product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases
and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third
parties would be time consuming and could: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">result in costly litigation that may cause negative publicity; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">divert the time and attention of our technical personnel and management; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cause development delays; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevent us from commercializing any of our product candidates until the asserted patent expires or is held
finally invalid or not infringed in a court of law; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be
possible on a cost-effective basis; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject us to significant liability to third parties; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable
terms, or at all, or which might be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors gaining access to the same technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although no third party has asserted a claim of patent infringement against us as of the date of this prospectus, others may hold proprietary
rights that could prevent our product candidates from being marketed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for damages,
including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation
expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially
acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we
cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could
prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and operating results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could
be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect
on our business, results of operations, financial condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce our patents or the
patents of our licensors, which could be expensive, time consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we and/or
our licensors may be required to file infringement claims, which can be expensive and time consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not
infringed. If we or any of our licensors or potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is
invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness, written description or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the
patent withheld relevant information from the USPTO or made a misleading statement during prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If a defendant were to prevail on
a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent
applications or those of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse
impact on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights
may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources
available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to
sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise
our ability to compete in the marketplace. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other
proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common
shares to decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the course of any intellectual property litigation, there could be public announcements of the
initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing
products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a
material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivation or interference proceedings may be necessary to determine priority of inventions, and an
unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Derivation or interference proceedings provoked by third parties or brought by us or declared by the USPTO or similar proceedings in foreign
patent offices may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the
prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our
management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license
necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement
or defense of our issued patents. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed
into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the
Leahy-Smith Act, the United States transitioned in March 2013 to a &#147;first inventor to file&#148; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the
patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a patent covering an invention of ours even if
we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable
patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of
time after filing or until issuance, we cannot be certain that we were the first to either (1)&nbsp;file any patent application related to our product candidates or (2)&nbsp;invent any of the inventions claimed in our patents or patent applications.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may
affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR,
IPR, and derivation proceedings. An </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts
necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first
presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court
action. Thus, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material
adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law, or laws in other countries,
could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As is the case
with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity.
Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the
value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or
enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection
available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty
with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in
unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual
property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights.
Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is
generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our
product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates, patents protecting our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with
sufficient rights to exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain patent term extension for our
product candidates, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA marketing
approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch- Waxman
Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation
for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug
product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension
because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent
protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our
patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their
product earlier than might otherwise be the case. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we have issued patents pending patent applications in the United States and certain other countries, filing, prosecuting and
defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws
of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries
outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to
develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates,
and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many companies
have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection,
which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert
claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may
be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Many countries have
compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license
to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed
by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the
USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the
USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us
comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in
abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, we rely on the protection of our trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology
and other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> including entering into confidentiality agreements
with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the
agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is
difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no
right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive
position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent
protection or to protect our trade secret information may be jeopardized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we have wrongfully hired an employee
from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As is common in the biopharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the
development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biopharmaceutical companies
including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their
former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against
these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our
Common Stock and This Offering </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active, liquid and orderly market for our common stock may not develop, and you may not be able to resell
your common stock at or above the public offering price. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our common
stock. Although we expect to list our common stock on the Nasdaq Global Select Market, or Nasdaq, an active trading market for our common stock may never develop or be sustained following this offering. We and the representatives of the underwriters
will determine the initial public offering price of our common stock through negotiation. This price will not necessarily reflect the price at which investors in the market will be willing to buy and sell our shares following this offering. In
addition, an active trading market may not develop following the consummation of this offering or, if it is developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them
or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn,
could materially adversely affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of the shares of our common stock could be highly volatile, and purchasers of our
common stock could incur substantial losses. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be volatile. The stock market in general and the market
for stock of biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their
common stock at or above the initial public offering price. The market price for our common stock may be influenced by those factors discussed in this &#147;Risk Factors&#148; section and many others, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enroll subjects in our ongoing and planned clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of our clinical trials and preclinical studies, and the results of trials of our competitors or those of
other companies in our market sector; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory approval of our product candidates, or limitations to specific label indications or patient
populations for its use, or changes or delays in the regulatory review process; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S.
healthcare system; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success or failure of our efforts to acquire, license or develop additional product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">innovations or new products developed by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or
capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing, supply or distribution delays or shortages; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other
strategic partners; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achievement of expected product sales and profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the biopharmaceutical sector and issuance of securities analysts&#146; reports or
recommendations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to obtain additional funding; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our stock by insiders and stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions other events or factors, many of which are beyond our control;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">intellectual property, product liability or other litigation against us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of
volatility in the market prices of these companies&#146; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#146;s attention and resources, which could have a material adverse effect on
our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to meet the continued listing requirements of the Nasdaq could result in a
delisting of our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If, after listing, we fail to satisfy the continued listing requirements of the Nasdaq, such as
the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability
to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again,
stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with
Nasdaq&#146;s listing requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may allocate the net proceeds from this offering in ways that you and other stockholders may not approve.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the
purposes described in the section titled &#147;Use of Proceeds.&#148; Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently
intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment, and the failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest
the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. These investments may not yield a
favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected results, which could cause our stock price to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You will suffer immediate and substantial dilution in the net tangible book value of the common stock
you purchase. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common stock is substantially higher than the pro forma as adjusted net
tangible book value per share of our outstanding common stock immediately after the completion of this offering. Purchasers of common stock in this offering will experience immediate dilution of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set
forth on the cover of this prospectus. In the past, we issued options to acquire common stock at prices significantly below the initial public offering price. To the extent these outstanding options are ultimately exercised, investors purchasing
common stock in this offering will sustain further dilution. For a further description of the dilution that you will experience immediately after this offering, see &#147;Dilution.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>After this offering, our executive officers, directors and principal stockholders, if they choose to act together, will continue to have the ability to
control or significantly influence all matters submitted to stockholders for approval. Furthermore, many of our current directors were appointed by our principal stockholders, and one such principal stockholder, HH Goss Holdings LLC, has the right
to designate one member to our board of directors and have such member appointed to any board committee that it requests effective as of the closing of this offering. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our executive officers, directors and greater than 5% stockholders, in the aggregate, will own
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock (assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options). Furthermore, many of our
current directors were appointed by our principal stockholders, and one such principal stockholder, HH Goss Holdings LLC, subject to certain conditions, has the right to designate one member to our board of directors and have such member appointed
to any board committee that it requests effective as of the closing of this offering. See &#147;Certain Relationships and Related Person Transactions&#151;Board Designation Agreement with Hillhouse.&#148; As a result, such persons or their
appointees to our board of directors, acting together, will have the ability to control or significantly influence all matters submitted to our board of directors or stockholders for approval, including the appointment of our management, the
election and removal of directors and approval of any significant transaction, as well as our management and business affairs. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a
merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other
stockholders. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your
investment will depend on appreciation, if any, in the price of our common stock. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash
dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In
addition, the terms of any future debt agreements may preclude us from paying dividends. Any return to stockholders will therefore be limited to the appreciation of their stock. There is no guarantee that shares of our common stock will appreciate
in value or even maintain the price at which stockholders have purchased their shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a substantial number of shares of our common stock
by our existing stockholders in the public market could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of
our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on shares of common stock outstanding as of September&nbsp;30, 2018, upon the
closing of this offering, we will have outstanding a total of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock after this offering, assuming no exercise of the underwriters&#146; option to purchase
additional shares and no exercise of outstanding options. Of these shares, only the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock sold in this offering by us, plus any shares sold upon exercise of the
underwriters&#146; option to purchase additional shares, will be freely tradable, without restriction, in the public market immediately following this offering, unless they are purchased by one of our affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers and holders of substantially all of our outstanding securities have entered into <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters pursuant to which they may not, with limited exceptions, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any of our
securities, without the prior written consent of Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, Leerink Partners LLC and Barclays Capital Inc. Such exceptions include the ability of certain of our executive officers to sell up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of shares of common stock to satisfy certain tax liabilities related to their previous acquisition of shares. The underwriters may permit our officers, directors and other stockholders and the
holders of our outstanding options who are subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, subject to limitations.
See &#147;Underwriting.&#148; Sales of these shares, or perceptions that they will be sold, could cause the trading price of our common stock to decline. After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements expire, up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be eligible for sale in the public market of which shares are held by directors, executive officers and other affiliates and will be
subject to volume limitations under Rule 144 under the Securities Act. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, as of September&nbsp;30, 2018, up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans will become eligible for sale in the
public market to the extent permitted by the provisions of various vesting schedules, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are
sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">After this
offering, the holders of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our outstanding common stock, or approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our total outstanding common stock as of
September&nbsp;30, 2018, will be entitled to rights with respect to the registration of their shares under the Securities Act, subject to vesting and the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements described above. See &#147;Description of capital stock&#151;Registration rights.&#148; Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities
Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company, and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less
attractive to investors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act, and may remain an emerging growth company
until the last day of the fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period, including if we become a &#147;large accelerated filer,&#148; our
annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such
five-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These
exemptions include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited
interim financial statements, with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements in the assessment of our internal control
over financial reporting; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have taken advantage of reduced reporting burdens
in this prospectus. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging
growth company. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our
common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This
allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to
the same new or revised accounting standards as other public companies that are not emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur significant increased
costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be
subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the U.S. Securities and Exchange Commission, or SEC, annual, quarterly and current reports with respect to our business and
financial condition. In addition, Sarbanes-Oxley, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and
maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and
regulations in these areas, such as mandatory &#147;say on pay&#148; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of
government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently
anticipate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial
compliance costs and to make some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business,
financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For
example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We
cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our
board of directors, our board committees or as executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports or publish unfavorable research
or reports about our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will
depend in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. We do not currently have and may never obtain research coverage by securities and industry analysts. If no
securities or industry analysts commence coverage of our company, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the analysts who covers us downgrades
our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial
statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our internal control over
financial reporting beginning with the annual report for our fiscal year ending December&nbsp;31, 2019. When we lose our status as an &#147;emerging growth company&#148; and reach an accelerated filer threshold, our independent registered public
accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex
and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to upgrade our information technology systems; implement additional financial
and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may
lose confidence in our financial reporting and the trading price of our common stock may decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We cannot assure you that there will
not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our
financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or
significant deficiency in our internal control over financial reporting once that firm begin its Section&nbsp;404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock
could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other
effective control systems required of public companies, could also restrict our future access to the capital markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our charter
documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect immediately prior to the
consummation of this offering will contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of our board of directors.
The provisions in our charter documents will include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to
change the membership of a majority of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect
director candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exclusive right of our board of directors, unless the board of directors grants such right to the
stockholders, to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote
to remove a director for cause, and the prohibition on removal of directors without cause; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the
price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder
approval; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote
to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual
or special meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive
forum for certain actions and proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement that a special meeting of stockholders may be called only by the board of directors, which may
delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of
directors or to propose matters to be acted upon at a stockholders&#146; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise
attempting to obtain control of us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are also subject to the anti-takeover provisions contained in Section&nbsp;203
of the Delaware General Corporation Law. Under Section&nbsp;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among
other exceptions, the board of directors has approved the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated certificate of incorporation and amended and
restated bylaws will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable
judicial forum for disputes with us or our directors, officers or employees. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of
incorporation and amended and restated bylaws will provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty, any
action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by
the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, our amended and restated certificate of incorporation will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any
complaint asserting a cause of action arising under the Securities Act. These choice of forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors,
officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Furthermore, the enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation
has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of
incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use net operating loss carryforwards and other tax attributes may be limited in connection with this offering or other ownership changes.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may
never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire (if at all). At December&nbsp;31, 2017, we had federal
and state net operating loss, or NOL, carryforwards of approximately $1.1&nbsp;million and $1.1&nbsp;million, respectively. Such federal and state NOL carryforwards will begin to expire in 2036, unless previously utilized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under recently enacted U.S. tax legislation, federal NOL carryforwards generated in periods after December&nbsp;31, 2017, may be carried
forward indefinitely but may only be used to offset 80% of our taxable income annually. Our NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service, or the IRS, and state tax authorities. Under
Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code, our federal NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders
over a three-year period in excess of 50 percentage points. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential
changes in connection with this offering. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from this offering or other transactions, or any resulting limitations
on our ability to utilize our NOL carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future tax liability to us and our future cash flows could be adversely affected. We have recorded a full
valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Recently enacted U.S. tax legislation, known as the Tax Cuts and Jobs Act of 2017, or the Tax Act, has significantly changed the U.S. federal
income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate and revising the rules governing NOLs. Many of these changes are effective beginning in 2018, without any transition periods or grandfathering for
existing transactions. The legislation is unclear in many respects and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury Department and the IRS, any of
which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for
computing state and local tax liabilities. As a result of the rate reduction from the Tax Act, we have reduced our deferred tax asset balance as of December&nbsp;31, 2017 by $0.8&nbsp;million. However, due to our full valuation allowance position,
there was no net impact on our income tax provision at December&nbsp;31, 2017, as the reduction in the deferred tax asset balance was fully offset by a corresponding decrease in the valuation allowance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There may be other material adverse effects resulting from the legislation that we have not
yet identified. While some of the changes made by the tax legislation may adversely affect us in one or more reporting periods and prospectively, other changes may be beneficial on a going forward basis. We continue to work with our tax advisors to
determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us, because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a
diversion of management&#146;s attention and resources, which could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus,
including statements regarding our future results of operations and financial position, business strategy, research and development, the anticipated timing, costs, design and conduct of our planned clinical trials for our product candidates and
preclinical studies and clinical trials for our other development programs, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our other product candidates, if approved, the pricing
and reimbursement of our product candidates, if approved, the potential benefits of strategic collaborations and our ability to enter into strategic arrangements, timing and likelihood of success, plans and objectives of management for future
operations, and future results of anticipated products are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be
materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In some
cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148;
&#147;project,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking
statements in this prospectus are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial
condition and results of operations. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described under the sections in this prospectus entitled
&#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our
forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge
from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein,
whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this
prospectus. See &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar
statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements,
such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently
uncertain and you are cautioned not to rely unduly upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_4"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We obtained the industry, market and competitive position data used throughout this prospectus from our own internal estimates and research,
as well as from independent market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. References in this
prospectus to data provided by Datamonitor refer to Datamonitor Healthcare | Informa Pharma Intelligence. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research
and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is
derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated
or the context otherwise requires. In addition, while we believe the industry, market and competitive position data included in this prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are
subject to change based on various factors, including those discussed in &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties or by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds to us from the sale of the common stock that we are offering will be approximately $<B>
</B><B></B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>million (or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to
purchase additional shares in full), assuming an initial public offering price of $<B> </B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B></B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>per share, the midpoint of the price range set
forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of $<B>
</B><B></B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>per share would increase (decrease) the net proceeds to us from this offering by approximately $<B>
</B><B></B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us would increase (decrease) the net
proceeds to us from this offering, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
assuming the assumed initial public offering price stays the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The principal purposes of this offering are to obtain additional
capital to support our operations, to create a public market for our common stock and to facilitate our future access to the public equity markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the offering as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the
research and development of GB001; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the
research and development of GB002; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the
research and development of GB004; </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund research
and development of our other development programs; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder for working capital and general corporate purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We may also use a portion of the remaining net proceeds and our existing cash, cash equivalents and marketable securities to <FONT
STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets. However, we have no current commitments or obligations to do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe, based on our current operating plan, that the net proceeds from this offering and our existing cash, cash equivalents and
marketable securities, will be sufficient to fund our operations for at least the next 12 months, although there can be no assurance in that regard. In particular, we expect that the net proceeds from this offering and our existing cash, cash
equivalents and marketable securities will allow us to complete our ongoing Phase 2b clinical trial for GB001, our planned Phase 1b clinical trial in PAH for GB002 and our planned Phase 1b clinical trial in UC for GB004. However, our expected use of
proceeds from this offering described above represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the proceeds to be
received upon the completion of this offering or the actual amounts that we will spend on the uses set forth above. The net proceeds from this offering, together with our cash, cash equivalents and marketable securities, will not be sufficient for
us to fund all of our product candidates through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of all of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our actual expenditures will depend on numerous factors, including the time and cost necessary to conduct our
planned clinical trials and preclinical studies and the results of such trials and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies, and other factors described under &#147;Risk Factors&#148; in this prospectus, as well as the amount of cash used in our operations and any unforeseen cash needs. Therefore, our actual
expenditures may differ materially from the estimates described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing
obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation
of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition,
results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash, cash equivalents and marketable securities and capitalization as of September&nbsp;30, 2018: </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis to reflect (1)&nbsp;the automatic conversion of all outstanding shares of our convertible
preferred stock into 137,220,799 shares of common stock and the related reclassification of the carrying value of the convertible preferred stock to permanent equity immediately prior to the closing of this offering, and (2)&nbsp;the filing and
effectiveness of our amended and restated certificate of incorporation immediately prior to the closing of this offering; and </P></TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give further effect to our issuance and sale of
<B></B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B></B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B>shares of our common stock in this offering at an assumed initial public offering price of $<B>
</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B></B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B>per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The pro forma as adjusted information below is
illustrative only, and our capitalization following the closing of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in
conjunction with our consolidated financial statements and the related notes included in this prospectus and the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and other
financial information contained in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Pro Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma<BR>As&nbsp;
Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">256,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">256,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.0001 par value per share; 137,220,799 shares authorized, issued
and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value per share; no shares authorized, issued or outstanding, actual;
10,000,000 shares authorized and no shares issued and outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value per share; 221,220,799&nbsp;shares authorized; 69,900,556 shares
issued and 34,802,318 shares outstanding, actual, excluding 35,098,238 shares subject to forfeiture; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, pro forma and pro forma as adjusted;
207,121,355&nbsp;shares issued and 172,023,117&nbsp;shares outstanding, pro forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">246,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">246,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash
equivalents and marketable securities, total stockholders&#146; equity and total capitalization by approximately $ <B></B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B>, assuming that the number of
shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of
1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share would increase (decrease) the pro forma as adjusted
amount of each of cash, cash equivalents and marketable securities, total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The number of shares of
common stock in the table above is based on 207,121,355&nbsp;shares of our common stock outstanding as of September&nbsp;30, 2018, including 35,098,238&nbsp;shares subject to forfeiture, after giving effect to the automatic conversion of all
outstanding shares of our convertible preferred stock into 137,220,799&nbsp;shares of our common stock immediately prior to the closing of this offering, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9,469,500 shares of common stock issuable upon exercise of stock options outstanding as of September&nbsp;30,
2018, at a weighted-average exercise price of $0.65 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for
future issuance under our 2019 Plan, which will become effective in connection with this offering (which number includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares remaining available for issuance under our 2017
Plan as of September&nbsp;30, 2018, which will become available for issuance under the 2019 Plan upon its effectiveness, but does not include any potential evergreen increases pursuant to the terms of the 2019 Plan); and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for
future issuance under our ESPP, which will become effective in connection with this offering (which number does not include any potential evergreen increases pursuant to the terms of the ESPP). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference
between the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2018, we had a historical net tangible book deficit of $91.8 million, or $(1.31) per share of common stock based on
69,900,556 shares of common stock outstanding, including 35,098,238 shares subject to forfeiture, as of such date. Our historical net tangible book value per share represents total tangible assets less total liabilities and convertible preferred
stock, divided by the number of shares of common stock outstanding (including shares subject to forfeiture) at September&nbsp;30, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On a pro forma basis, after giving effect to the automatic conversion of all outstanding shares of our convertible preferred stock into
137,220,799 shares of our common stock and the related reclassification of the carrying value of the convertible preferred stock to permanent equity immediately prior to the closing of this offering stock, our pro forma net tangible book value as of
September&nbsp;30, 2018 would have been approximately $246.6&nbsp;million, or approximately $1.19 per share of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">After
giving further effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock that we are offering at an assumed initial public offering price of $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the estimated underwriting discounts and commissions and estimated
offering expenses payable by us, our pro forma as adjusted net tangible book value as of September&nbsp;30, 2018 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This amount represents an immediate increase in pro forma net tangible book value of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors purchasing shares of common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering
from the initial public offering price per share paid by new investors. The following table illustrates this dilution (without giving effect to any exercise by the underwriters of their option to purchase additional shares): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book deficit per share as of September&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.31</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma increase in historical net tangible book deficit per share as of September&nbsp;30, 2018
attributable to the conversion of convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of September&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to new investors
participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value per
share after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and dilution in pro forma net tangible book value per share to new investors by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts
and commissions and the estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us would increase (decrease) our pro forma as adjusted net tangible book value per
share after this offering by approximately </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and decrease (increase) the dilution to investors participating in this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share remains the same, and
after deducting the estimated underwriting discounts and commissions and the estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the
underwriters exercise their option to purchase additional shares of our common stock in full in this offering, the pro forma as adjusted net tangible book value after the offering would be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the increase in pro forma net tangible book value per share to existing stockholders would be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and the dilution per share to new investors would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, in each case assuming an
initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes on the pro forma as adjusted basis described above, as of September&nbsp;30, 2018, the differences between the
number of shares purchased from us, the total consideration paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the price to be paid by new investors in this offering. The
calculations below are based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of the prospectus, before
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total&nbsp;Consideration</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Average<BR>Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percent</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percent</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional shares of our common stock in full: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the percentage of shares of common stock held by existing stockholders will decrease to approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % of the total number of shares of our common stock outstanding after this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares held by new investors will increase to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % of the total number of shares of our common stock outstanding after this offering.
</P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The foregoing tables and calculations (other than the historical net tangible book value calculation) are based on
207,121,355 shares of our common stock outstanding as of September&nbsp;30, 2018, including 35,098,238 shares subject to forfeiture, after giving effect to the automatic conversion of all outstanding shares of our convertible preferred stock into
137,220,799 shares of our common stock prior to the closing of this offering, and exclude: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9,469,500 shares of common stock issuable upon exercise of stock options outstanding as of September&nbsp;30,
2018, at a weighted-average exercise price of $0.65 per share; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for
future issuance under our 2019 Plan, which will become effective in connection with this offering (which number includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares remaining available for issuance under our 2017
Plan as of September&nbsp;30, 2018, which will become available for issuance under the 2019 Plan upon its effectiveness, but does not include any potential evergreen increases pursuant to the terms of the 2019 Plan); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for
future issuance under our ESPP, which will become effective in connection with this offering (which number does not include any potential evergreen increases pursuant to the terms of the ESPP). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To the extent any outstanding options are exercised, or we issue additional equity or convertible debt securities in the future, there will be
further dilution to new investors.<B> </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_9"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following tables set forth selected historical consolidated financial data as of, and for the periods ended on, the dates indicated. We
have derived the selected consolidated statements of operations data for the years ended December&nbsp;31, 2016 and 2017 and the selected consolidated balance sheet data as of December&nbsp;31, 2016 and 2017 from our audited consolidated financial
statements included elsewhere in this prospectus. We have derived the selected consolidated statements of operations data for the nine months ended September&nbsp;30, 2017 and 2018 and the selected consolidated balance sheet data as of
September&nbsp;30, 2018 from our unaudited consolidated financial statements included elsewhere in this prospectus. The unaudited consolidated financial statements have been prepared on a basis consistent with our audited consolidated financial
statements included in this prospectus and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, necessary to fairly state our financial position as of September&nbsp;30, 2018 and results of
operations for the nine months ended September&nbsp;30, 2017 and 2018. You should read this data together with our consolidated financial statements and related notes included elsewhere in this prospectus and the section titled
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not necessarily indicative of our future results. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In process research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,653</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(109,186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares of common stock outstanding, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,602,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares of common stock outstanding, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,740,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">See Note 2 to our consolidated financial statements included elsewhere in this prospectus for an explanation of
the method used to calculate the historical and pro forma net loss per share, basic and diluted, and the number of shares used in the computation of the per share amounts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">In connection with the issuance of the Series A convertible preferred stock in January 2018, certain of our
founders entered into stock restriction agreements, whereby 20,612,000 of previously unrestricted shares of common stock became subject to forfeiture to us upon the founders&#146; termination of employment or service, which obligation lapses as the
shares vest. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>As&nbsp;of&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:<SUP STYLE="font-size:85%; vertical-align:top">
</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">256,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(821</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements
included elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results
of operations together with our consolidated financial statements and related notes appearing in this prospectus. Some of the information contained in this discussion and analysis is set forth elsewhere in this prospectus, including information with
respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#147;Risk Factors&#148;
section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Our goal is to be an industry leader in each of these therapeutic areas and
enhance and extend the lives of patients suffering from such diseases. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading
biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. Our collective immunology and translational discovery and development expertise serves as the foundation of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are pursuing product candidates with strong scientific rationale to address indications where there is both a high unmet need and an
opportunity to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> programs. We currently have six
programs: three clinical-stage product candidates and three preclinical programs. We commenced a Phase 2b clinical trial for our most advanced product candidate, GB001, in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma in October&nbsp;2018 and expect to conduct an interim analysis in the first half of 2020. If the interim analysis is positive, we
plan on initiating a Phase 3 clinical trial thereafter. We also expect to initiate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase 2 clinical trials of GB001 in CRSwNP and CSU in 2019. We are
developing GB002 for the treatment of PAH, and plan to commence a Phase 1b clinical trial in PAH in the first half of 2019 and a Phase&nbsp;2/3 clinical trial in PAH in the second half of 2019. We are developing GB004 for the treatment of IBD,
including UC and CD, and, following submission of an IND application with the FDA, expect to initiate a Phase 1b clinical trial in UC in the first half of 2019. We also plan to initiate a Phase&nbsp;2 clinical trial in UC in the first half of 2020.
We currently have three programs in preclinical development. GB1275 is an oral small molecule, CD11b agonist in preclinical development for the treatment of oncology indications for which we plan to submit an IND application in 2019. We are also
currently evaluating a portfolio of novel BTK inhibitors for the treatment of autoimmune indications and small molecule cancer metabolism modulators for the treatment of solid tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We were incorporated in October 2015 and commenced operations in 2017. To date, we have focused primarily on organizing and staffing our
company, business planning, raising capital, identifying, acquiring and <FONT STYLE="white-space:nowrap">in-licensing</FONT> our product candidates and conducting preclinical studies and early clinical trials. We have funded our operations primarily
through equity financings. We raised $310.0 million from October 2017 through July 2018 through Series A and B convertible preferred stock financings and a convertible note financing. In addition, we received $12.8 million in cash in connection with
the January 2018 acquisition of AA Biopharma Inc., of which Pulmagen Therapeutics (Asthma) Limited is a wholly-owned subsidiary. As of September&nbsp;30, 2018, we had $256.4&nbsp;million in cash, cash equivalents and marketable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have incurred significant operating losses since our inception, and expect to continue to incur significant operating losses for the
foreseeable future. For the year ended December&nbsp;31, 2017 and for the nine months ended September&nbsp;30, 2018, our net loss was $6.8&nbsp;million and $108.2&nbsp;million, respectively. As of September&nbsp;30, 2018, we had an accumulated
deficit of $115.1&nbsp;million. We expect our expenses and operating </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
losses will increase substantially as we conduct our ongoing and planned clinical trials, continue our research and development activities and conduct preclinical studies, and seek regulatory
approvals for our product candidates, as well as hire additional personnel, protect our intellectual property and incur additional costs associated with being a public company. In addition, as our product candidates progress through development and
toward commercialization, we will need to make milestone payments to the licensors and other third parties from whom we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> or acquired our product candidates, including GB002 and GB004. Our net
losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending in
particular on the timing of our clinical trials and preclinical studies and our expenditures on other research and development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not expect to generate any revenue from product sales unless and until we successfully complete development and obtain regulatory
approval for one or more of our product candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales,
marketing, manufacturing and distribution. Accordingly, until such time as we can generate substantial product revenues to support our cost structure, if ever, we expect to finance our cash needs through equity offerings, debt financings or other
capital sources, including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise
capital or enter into such other arrangements when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise additional capital when needed, we could be
forced to delay, limit, reduce or terminate our product candidate development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product
candidates ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have not generated
any revenue since our inception and do not expect to generate any revenue from the sale of products for the foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Research and development </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development expenses have related primarily to preclinical and clinical development of our product candidates and discovery
efforts. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development expenses include or could include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved
in research and development efforts; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external research and development expenses incurred under agreements with contract research organizations, or
CROs, investigative sites and consultants to conduct our clinical trials and preclinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory supplies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to manufacturing our product candidates for clinical trials and preclinical studies, including fees
paid to third-party manufacturers; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to compliance with regulatory requirements; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent,
maintenance of facilities, insurance, equipment and other supplies. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our direct research and development expenses
consist principally of external costs, such as fees paid to CROs, investigative sites and consultants in connection with our clinical trials, preclinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, and costs related to
manufacturing clinical trial materials. For the nine months ended September&nbsp;30, 2018, the majority of our third-party expenses related to the research and development of GB001 and GB002. We deploy our personnel and facility related resources
across all of our research and development activities. We track external costs and personnel expense on a program-by-program basis and allocate common expenses, such as facility related resources, to each program based on the personnel resources
allocated to such program. Stock-based compensation and personnel and common expenses not attributable to a specific program are considered unallocated research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of our
product candidates and conduct discovery and research activities for our preclinical programs. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical
trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from
expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies
and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#146;s commercial potential. We will need to raise substantial additional capital in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our clinical development costs may vary significantly based on factors such as: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">per patient trial costs; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of trials required for approval; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of sites included in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the countries in which the trials are conducted; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length of time required to enroll eligible patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of patients that participate in the trials; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of doses that patients receive; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential additional safety monitoring requested by regulatory agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost and timing of manufacturing our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the phase of development of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety profile of our product candidates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>In process research and development </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In process research and development, or IPR&amp;D, expenses include <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development acquired as part of an asset acquisition or in-license for which there is no alternative future use, are expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">IPR&amp;D expenses consist of our upfront payments made to Pulmokine, Inc., in connection with the
<FONT STYLE="white-space:nowrap">in-license</FONT> of GB002, the value of our stock issued to former AA Biopharma Inc. shareholders, in connection with the acquisition of GB001, and our upfront payments made to Aerpio Pharmaceuticals, Inc., or
Aerpio, in connection with the <FONT STYLE="white-space:nowrap">in-license</FONT> of GB004, our upfront payments made to Adhaere Pharmaceuticals, Inc., or Adhaere, in connection with the acquisition of GB1275, and upfront payments made in connection
with the acquisition of our other preclinical programs. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>General and administrative </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for
personnel in executive, finance and other administrative functions. Other significant costs include facility-related costs, legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services
and insurance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect our general and administrative expenses will increase for the foreseeable future to support our expanded
infrastructure and increased costs of operating as a public company. These increases will likely include increased expenses related to audit, legal, regulatory, and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with
maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other income (expense), net </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other income (expense), net consists of (1)&nbsp;interest income on our cash, cash equivalents and marketable securities and (2)&nbsp;interest
expense related to the convertible promissory note issued in October 2017. The note converted into shares of our Series A convertible preferred stock in January 2018. See Note 5 to our consolidated financial statements included elsewhere in this
prospectus for a description of the note. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the Nine Months Ended September&nbsp;30, 2017 and 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth our selected statements of operations data for the nine months ended September&nbsp;30, 2017 and 2018: </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(109,186</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,865</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(321</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(108,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(107,854</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Research and development </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $29.4&nbsp;million for the nine months ended September&nbsp;30, 2018, compared to $216,000 for the nine
months ended September&nbsp;30, 2017. The $29.4&nbsp;million for the nine months ended September&nbsp;30, 2018 was primarily attributable to $7.6&nbsp;million of costs associated with preclinical studies and clinical trials for GB001, $7.2 million
of cost associated with preclinical studies and clinical trials for GB002, $6.1&nbsp;million of personnel-related costs and $4.6&nbsp;million of external consultants costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table shows our research and development expenses by program for the nine months ended September&nbsp;30, 2017 and 2018: </P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GB001</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GB002</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GB004</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,713</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unallocated expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>IPR&amp;D </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">IPR&amp;D expenses were $49.7&nbsp;million for the nine months ended September&nbsp;30, 2018, compared to $0 for the nine months ended
September&nbsp;30, 2017. The $49.7&nbsp;million for the nine months ended September&nbsp;30, 2018 was primarily attributable to our $20.0&nbsp;million upfront payment made to Aerpio in connection with the
<FONT STYLE="white-space:nowrap">in-license</FONT> of GB004, $19.3&nbsp;million of costs associated with the issuance of our stock in connection with our acquisition of GB001 and AA Biopharma and our $7.5&nbsp;million upfront payment in connection
with our acquisition of GB1275 and Adhaere. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>General and administrative </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $30.1&nbsp;million for the nine months ended September&nbsp;30, 2018, compared to approximately
$105,000 for the nine months ended September&nbsp;30, 2017. The $30.1&nbsp;million for the nine months ended September&nbsp;30, 2018 was primarily attributable to $20.0 million in stock-based compensation costs, $3.6 million in personnel-related
costs, $2.2 million in professional fees, $1.6 million in facility-related costs and $1.1 million in legal fees. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other income (expense), net
</I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other income (expense), net was $1.0&nbsp;million for the nine months ended September&nbsp;30, 2018, compared to $0 for the
nine months ended September&nbsp;30, 2017. The $1.0&nbsp;million was attributable to $1.0&nbsp;million interest income earned on our cash, cash equivalents and marketable securities during the period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the Years Ended December&nbsp;31, 2016 and 2017 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth our selected statements of operations data for the years ended December&nbsp;31, 2016 and 2017: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Change</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(83<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>)<B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(6,653<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>)<B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>(6,570<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>)<B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(83</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,771</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,688</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Research and development </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Research and development expenses were approximately $0.9&nbsp;million for the year ended December&nbsp;31, 2017, compared to $0 for the year
ended December&nbsp;31, 2016. The $0.9&nbsp;million was primarily attributable to $0.6&nbsp;million in legal fees, $0.2&nbsp;million in external consultant costs and salaries and $0.1&nbsp;million of employee-related costs for research and
development staff. All research and development expenses for the year ended December 31, 2017 were attributable to GB002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>IPR&amp;D </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">IPR&amp;D
expenses were approximately $5.5&nbsp;million for the year ended December&nbsp;31, 2017, compared to $0 for the year ended December&nbsp;31, 2016. The $5.5&nbsp;million was attributable to our upfront payment for the
<FONT STYLE="white-space:nowrap">in-license</FONT> of GB002 from Pulmokine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>General and administrative </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were approximately $0.3&nbsp;million for the year ended December&nbsp;31, 2017, compared to approximately
$0.1&nbsp;million for the year ended December&nbsp;31, 2016. The $0.3&nbsp;million for the year ended December&nbsp;31, 2017 was primarily related to legal fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other income (expense), net </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other income (expense), net was $0.1&nbsp;million for the year ended December&nbsp;31, 2017, compared to $0 for the year ended
December&nbsp;31, 2016. The $0.1&nbsp;million was primarily related to interest expense on the convertible promissory note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital
Resources </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have incurred substantial operating losses since our inception, and expect to continue to incur significant
operating losses for the foreseeable future and may never become profitable. As of December&nbsp;31, 2017 and September&nbsp;30, 2018, we had an accumulated deficit of $6.9&nbsp;million and $115.1&nbsp;million, respectively.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used
to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since our inception, our operations have been financed primarily by gross proceeds of $310.0&nbsp;million from the sale of our convertible
preferred stock and a convertible promissory note. In January and March 2018, we issued and sold an aggregate of 45,714,286 shares of Series A convertible preferred stock at $1.75 per share, for approximately $73.9&nbsp;million in gross proceeds and
the cancellation of a $6.1&nbsp;million convertible promissory note. In January 2018, we acquired GB001 pursuant to a merger agreement with AA Biopharma under which we issued to former AA Biopharma shareholders an aggregate of 20,000,000 shares of
our Series Seed convertible preferred stock and 4,955,752 shares of our common stock. In connection with this acquisition, we received $12.8 million in cash. In July 2018, we raised approximately $230.0&nbsp;million in gross proceeds from the sale
of 71,506,513 shares of Series B convertible preferred stock. As of September&nbsp;30, 2018, we had cash, cash equivalents and marketable securities of $256.4&nbsp;million. Cash in excess of immediate requirements is invested in accordance with our
investment policy, primarily with a view to capital preservation and liquidity. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table shows a summary of our cash
flows for each of the periods shown below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,745</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,021</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(136,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">140,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2018, operating activities used approximately $26.0&nbsp;million of cash, primarily resulting
from a net loss of $108.2&nbsp;million, partially reduced by in process research and development expenses of $49.7&nbsp;million, changes in operating assets and liabilities of $12.2&nbsp;million and stock-based compensation expense of
$20.1&nbsp;million. Net cash provided by changes in operating assets and liabilities consisted primarily of increases in accounts payable and accrued expenses of $14.6&nbsp;million, partially offset by an increase in prepaid expenses due to
prepayments for clinical development activities and security deposits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2017, operating
activities were nominal. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2017, operating activities used approximately $5.7&nbsp;million of
cash, primarily resulting from a net loss of $6.8&nbsp;million, partially reduced by increases in accounts payable of $1.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2016, operating activities were nominal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Investing activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2018, investing activities used approximately $136.0&nbsp;million of cash, primarily resulting
from the upfront payment made to Aerpio of $20.0&nbsp;million in connection with the <FONT STYLE="white-space:nowrap">in-license</FONT> of GB004, the purchase of marketable securities of $115.1&nbsp;million, upfront
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payments of $10.6&nbsp;million in connection with the acquisition of our preclinical programs and the purchase of property and equipment of $3.8&nbsp;million, partially offset by $12.8 million of
cash proceeds received from AA Biopharma in connection with our acquisition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There were no investing activities for the nine months ended
September&nbsp;30, 2017. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There were no investing activities for the years ended December&nbsp;31, 2016 and 2017, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2018, financing activities provided $303.0&nbsp;million of cash, primarily resulting from the
net proceeds from issuance of our Series A and B convertible preferred stock of $303.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There were no financing activities
for the nine months ended September&nbsp;30, 2017. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2017, financing activities provided
$6.0&nbsp;million of cash, primarily resulting from the proceeds from issuance of a convertible promissory note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the year ended
December&nbsp;31, 2016, financing activities were nominal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding requirements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities, together with the
estimated net proceeds from this offering, will be sufficient to fund our operations through at least the next 12 months from the date of this offering. However, our forecast of the period of time through which our financial resources will be
adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital
resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the type, number, scope, progress, expansions, results, costs and timing of, our preclinical studies and clinical
trials of our product candidates which we are pursuing or may choose to pursue in the future; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of manufacturing for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public
company, including enhanced internal controls over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities
increase; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of the milestone or other payments we must make to the licensors and other third parties
from whom we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> our acquired our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is
approved; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors
and adequate market share and revenue for any approved products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with any products or technologies that we may <FONT STYLE="white-space:nowrap">in-license</FONT>
or acquire. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Until such time as we can generate substantial product revenues to support our cost structure, if ever, we
expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into
such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and
the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third
parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. Our
failure to raise capital or enter into such other arrangements when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise additional capital when
needed, we could be forced to delay, limit, reduce or terminate our product candidate development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and
market such product candidates ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations at September&nbsp;30, 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Payments Due By Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Less&nbsp;than&nbsp;1&nbsp;Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">1&nbsp;-&nbsp;3&nbsp;Years</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">3&nbsp;-&nbsp;5&nbsp;Years</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>More&nbsp;than&nbsp;5<BR>Years</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase obligations<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contractual obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;5,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;6,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;3,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Operating leases include our continuing rent obligations through December 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">At September&nbsp;30, 2018, we had $3.6&nbsp;million of open purchase orders. All of our purchase orders may be
cancelled without significant penalty. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under our license agreements with Pulmokine and Aerpio, as well as our other
license and acquisition agreements, we have payment obligations that are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and are required to make royalty payments in connection
with the sale of products developed under those agreements. As of September&nbsp;30, 2018, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales and, therefore, any related payments are not
included in the table above. For additional information regarding these license agreements, including our payment obligations thereunder, see &#147;Business&#151;License Agreements&#148; and Note&nbsp;6 to our consolidated financial statements
included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We enter into contracts in the normal course of business with clinical trial sites and
clinical supply manufacturers and with vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and, therefore, are cancelable
contracts and not included in the table above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We did not have during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">arrangements, as defined under the rules and regulations of the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP.
The preparation of our consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates and assumptions on historical
experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. We base our estimates on historical experience, known trends and events, and various other factors
that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ
from these estimates under different assumptions or conditions. Our most critical accounting policies are summarized below. See Note 2 to our consolidated financial statements included elsewhere in this prospectus for a description of our other
significant accounting policies.<B><I> </I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses as of each balance
sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost
incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically
confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in
connection with research and development activities for which we have not yet been invoiced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We base our expenses related to research and
development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to
negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development
expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our
estimate, we adjust the accrual or prepaid expense accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been
received rather than when the payment is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Although we do not expect our estimates to be materially different from amounts actually
incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there
have been no material differences between our estimates of such expenses and the amounts actually incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We measure and recognize compensation expense for all options based on the estimated fair value of the award on the grant date. We use the
Black-Scholes option-pricing model to estimate the fair value of option awards. The fair value is recognized as expense on a straight-line basis over the requisite service period. We account for forfeitures as they occur. We record expense for
awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a performance-based milestone is probable
based on the expected satisfaction of the performance conditions at each reporting date. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The determination of the grant date fair
value of options using an option pricing model is affected principally by our estimated fair value of shares of our common stock and requires management to make a number of other assumptions, including the expected life of the option, the volatility
of the underlying shares, the risk-free interest rate and expected dividends. The assumptions used in our Black-Scholes option-pricing model represent management&#146;s best estimates at the time of measurement. These estimates are complex, involve
a number of variables, uncertainties and assumptions and the application of management&#146;s judgment, as they are inherently subjective. If any assumptions change, our stock-based compensation expense could be materially different in the future.
See Note 9 to our consolidated financial statements included elsewhere in this prospectus for information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value
of our stock options granted in the nine months ended September&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2018, the unrecognized
stock-based compensation expense related to employee stock options and unvested restricted stock was $3.7&nbsp;million and $28.2&nbsp;million, respectively, and is expected to be recognized as expense over a weighted-average period of approximately
4.0&nbsp;years. The intrinsic value of all outstanding stock options as of September&nbsp;30, 2018 was approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, based upon the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, of which approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million
related to vested options and approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million related to unvested options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Fair value of common stock </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are required to estimate the fair value of the common stock underlying our stock-based awards when performing fair value calculations,
which is the most subjective input into the Black-Scholes option pricing model. The fair value of the common stock underlying our stock-based awards was determined on each grant date by our board of directors, taking into account input from
management and independent third-party valuation analyses. All options to purchase shares of our common stock are intended to be granted with an exercise price per share no less than the fair value per share of our common stock underlying those
options on the date of grant, based on the information known to us on the date of grant. In the absence of a public trading market for our common stock, on each grant date we develop an estimate of the fair value of our common stock in order to
determine an exercise price for the option grants. Our determinations of the fair value of our common stock were made using methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Audit and
Accounting Practice Aid Series: <I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I>, or the Practice Aid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors considered various objective and subjective factors, along with input from management, to determine the fair value of
our common stock, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">valuations of our common stock performed by independent third-party valuation specialists; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy, including the status of research and development efforts of our
product candidates, and the material risks related to our business and industry; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our results of operations and financial position, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently
completed mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of marketability of our common stock as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices of our convertible preferred stock sold to investors in arm&#146;s length transactions and the rights,
preferences, and privileges of our convertible preferred stock relative to those of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public
offering or a sale of our company, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trends and developments in our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our valuations were prepared in accordance with the guidelines in the Practice Aid, which prescribes several valuation approaches for setting
the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its common stock. The cost approach establishes the value of an enterprise based on the cost of
reproducing or replacing the property less depreciation and functional or economic obsolescence, if present. The income approach establishes the value of an enterprise based on the present value of future cash flows that are reasonably reflective of
our company&#146;s future operations, discounting to the present value with an appropriate risk adjusted discount rate or capitalization rate. The market approach is based on the assumption that the value of an asset is equal to the value of a
substitute asset with the same characteristics. Each valuation methodology was considered in our valuations. In determining a fair value for our common stock, we estimated the enterprise value of our business using either the market approach or the
back-solve method. The back-solve method assigns an implied enterprise value based on the most recent round of funding or investment and allows for the incorporation of the implied future benefits and risks of the investment decision assigned by an
outside investor. In accordance with the Practice Aid, we considered the various methods for allocating the enterprise value across our classes and series of capital stock to determine the fair value of our common stock at each valuation date. We
only granted restricted stock awards prior to January 2018. Since that time, we have used a hybrid of the Option Pricing Method, OPM, and Probability-Weighted Expected Return Method, or PWERM. Under the OPM, shares are valued by creating a series of
call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options. The PWERM is a scenario-based analysis that
estimates the value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. Under
this hybrid method, we considered the expected initial public offering liquidity scenario, but also used the OPM to capture all other scenarios in the event a near-term initial public offering does not occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, our board of directors will determine the fair value of our common stock based on its closing price
as reported on the date of grant on the primary stock exchange on which our common stock is traded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent accounting pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">See Note&nbsp;2 to our consolidated financial statements included elsewhere in this prospectus for a description of recent accounting
pronouncements applicable to our consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Qualitative and quantitative disclosures about market risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates,
particularly because our investments, including cash equivalents, are in the form of U.S. Treasury securities and a money market fund that is invested in U.S. Treasury securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are also exposed to market risk related to changes in foreign currency exchange rates. We contract with vendors that are located outside of
the United States and certain invoices are denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these arrangements. We do not currently hedge our foreign currency exchange rate risk. As of
September&nbsp;30, 2018 and December&nbsp;31, 2017, we had minimal or no liabilities denominated in foreign currencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Inflation
generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the year ended December&nbsp;31, 2017 or nine
months ended September&nbsp;30, 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>JOBS Act </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we can take advantage of an extended
transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have
irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We intend to rely on other exemptions
provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of Sarbanes-Oxley. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest of (i)&nbsp;the last day of the fiscal year following the fifth anniversary of
the consummation of this offering, (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.07&nbsp;billion, (iii)&nbsp;the last day of the fiscal year in which we are deemed to be a &#147;large
accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which would occur if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded
$700.0&nbsp;million as of the last business day of the second fiscal quarter of such year, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during
the prior three-year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Our goal is to be an industry leader in each of these therapeutic areas and to
enhance and extend the lives of patients suffering from such diseases. To accomplish this goal, we have assembled a deeply experienced and highly skilled group of industry veterans, scientists, clinicians and key opinion leaders from leading
biotechnology and pharmaceutical companies, as well as leading academic centers from around the world. Our collective immunology and translational discovery and development expertise serves as the foundation of our company. We intend to maintain a
scientifically rigorous and inclusive corporate culture where employees strive to bring improved therapeutic options to patients. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We
are pursuing product candidates with strong scientific rationale to address indications where there is both a high unmet need and an opportunity to develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT>
or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics. We currently have six programs: three clinical-stage product candidates and three preclinical programs. We commenced a Phase 2b clinical
trial for our most advanced product candidate, GB001, in October 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes our current programs: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g05u28.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GB001 (DP2 Antagonist) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB001 is an oral antagonist of prostaglandin D<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB> receptor 2, or DP2, in development for
the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma and other allergic conditions. Eosinophilic asthma is caused by high levels of white blood cells known as
eosinophils and is associated with more severe symptoms, late-onset disease and resistance to steroid treatment. We estimate that approximately 50% of severe asthma patients in the United States have eosinophilic asthma. Despite the availability of
new biologic therapies for these patients, asthma exacerbations remain a significant healthcare problem and unmet medical need. As of July&nbsp;31, 2018, GB001 had been studied in 359 subjects in total and was generally well tolerated. In a Phase 2
clinical trial conducted in Japan, GB001 showed a statistically significant improvement in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-first</FONT></FONT> asthma exacerbation compared to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
placebo. In a separate 248 subject Phase 2 clinical trial, neither treatment group, GB001 nor montelukast, achieved the primary endpoint of improvement in forced expiratory volume in one second,
or FEV<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>, as compared to placebo, which we believe was primarily related to study design and execution issues related to patient selection, including adherence to inhaled corticosteroid, or ICS,
therapy eosinophilic phenotype thresholds and disease severity. We commenced a Phase 2b clinical trial in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma in October 2018. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Furthermore, we believe that there are a number of indications along the allergic spectrum for which GB001 may provide benefit.
Accordingly, we plan to pursue the parallel development of GB001 in chronic rhinosinusitis with nasal polyps, or CRSwNP, and chronic spontaneous urticaria, or CSU. We expect to initiate
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase 2 clinical trials for these indications in 2019. We retain worldwide rights to GB001, excluding Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GB002 (PDGF Receptor Kinase Inhibitor) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB002 is an orally inhaled, small molecule, selective platelet-derived growth factor, or PDGF, receptor kinase inhibitor in development for
the treatment of pulmonary arterial hypertension, or PAH, an orphan disease with high unmet medical need. PAH is characterized by abnormally high pressure in the blood vessels transporting blood from the right side of the heart to the lungs and is a
progressive and often fatal disease. In contrast to the three classes of marketed vasodilatory therapies for PAH, GB002 has the potential to be the first treatment with disease-modifying effects. Modulation of the PDGF pathway has been shown to be
therapeutically relevant in PAH. In 2013, Novartis Pharmaceutical Corporation, or Novartis, announced results from a Phase&nbsp;3 clinical trial in PAH of imatinib (Gleevec), a tyrosine kinase inhibitor with known activity against PDGF and marketed
for oncology indications. These results were notable for not only achievement of statistically significant improvement in the study&#146;s primary efficacy endpoint, but also for systemic toxicities. To our knowledge, no further development of the
drug has occurred in PAH. To date, these toxicities have not been observed with GB002 in our ongoing Phase 1 studies in healthy volunteers. We plan to commence a Phase 1b clinical trial in PAH in the first half of 2019 and a Phase&nbsp;2/3 clinical
trial in PAH in the second half of 2019. We retain worldwide rights to GB002. The U.S. Food and Drug Administration, or FDA, has granted GB002 orphan drug designation for the treatment of patients with PAH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GB004 <FONT STYLE="white-space:nowrap">(HIF-1</FONT></I></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><B><I></I></B><B><I> Stabilizer) </I></B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB004 is a novel, <FONT STYLE="white-space:nowrap">gut-targeted,</FONT> oral small molecule in development for the treatment of
inflammatory bowel disease, or IBD, including ulcerative colitis, or UC, and Crohn&#146;s disease, or CD. GB004 stabilizes hypoxia inducible <FONT STYLE="white-space:nowrap">factor-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, or <FONT
STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, through the inhibition of prolyl hydroxylase domain proteins, or PHDs, key enzymes involved in HIF degradation. Preclinical data from animal models of IBD
demonstrated that <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> stabilization restores intestinal epithelial barrier integrity and function and results in immunomodulatory effects that we believe are
important in reducing inflammation and enhancing mucosal healing in IBD patients. We have completed a Phase&nbsp;1 single-ascending-dose, or SAD, study in healthy volunteers and are dosing healthy volunteers in a Phase&nbsp;1
multiple-ascending-dose, or MAD, study. We plan to pursue clinical development in both UC and CD patients and, following submission of an Investigational New Drug, or IND, application with the FDA, initiate a Phase 1b clinical trial in UC in the
first half of 2019. We also plan to initiate a Phase&nbsp;2 clinical trial in UC in the first half of 2020. We retain worldwide rights to GB004. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Research Capabilities and Preclinical Programs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently have three programs in preclinical development and expect to file an IND application with the FDA for at least one of these
programs within the next 12&nbsp;months. We are continuing to build our research capabilities, specifically focusing on our areas of expertise within immunology, inflammation and oncology, in order to advance new programs into the clinic, as well as
to optimize our existing programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our founders and management team have held senior positions at leading biopharmaceutical companies, including Receptos, Inc., Genentech USA,
Inc. (Roche), or Genentech, Bristol-Myers Squibb Company, GlaxoSmithKline LLC and Celgene Corporation, among others, and possess substantial experience and expertise across the spectrum of drug discovery, development and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Sheila Gujrathi, M.D., our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and President and Chief Executive Officer, was previously Chief
Medical Officer of Receptos until its acquisition by Celgene in 2015, and has also served in senior leadership roles at Bristol-Myers Squibb and Genentech. Faheem Hasnain, our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Executive Chairman
and former Chief Executive Officer, previously served as Chief Executive Officer at Receptos, and has over 30 years of senior leadership experience at both large and small biopharmaceutical companies. Luisa
<FONT STYLE="white-space:nowrap">Salter-Cid,</FONT> Ph.D., our Chief Scientific Officer, was previously the Head of Immunology Discovery at Bristol-Myers Squibb, having overseen immunology and immuno-oncology discovery efforts since 2005. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The development and operational expertise of our executive and senior scientific team will be essential as we execute on our strategy of
building a large, diversified biopharmaceutical company to deliver significant value to both patients and shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the
disease areas of immunology, inflammation and oncology. Our goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases. Critical components of our business
strategy include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Create deep therapeutic centers of excellence by leveraging our immunology and translational discovery and
development expertise. </B>We currently have six programs across the areas of immunology, inflammation and oncology. We will continue to build out our portfolio, focusing on these therapeutic areas, through both internal discovery and strategic
transactions to create a diversified portfolio of early and late-stage product candidates. </P></TD></TR></TABLE>   <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Maximize the impact of our product candidates by expanding development across multiple indications.</B> We aim
to focus our development efforts on product candidates that have the potential to treat multiple diseases and plan to develop them in additional indications where warranted. For example, we believe GB001 has the potential to be effective in a
variety of allergic and inflammatory diseases beyond <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma, and we expect to initiate proof-of-concept Phase 2 clinical trials in CRSwNP
and CSU in 2019. We also plan to develop GB004 in both UC and CD. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expeditiously generate
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data from our preclinical programs to facilitate value creation and efficient capital deployment. </B>We view our preclinical programs as important
drivers of the long-term sustainability of our company. We plan to advance our preclinical programs to generate meaningful data to determine quickly whether each warrants clinical development. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leverage the drug discovery, development and commercialization expertise of our world-class team.</B> Our
executive management team and key scientific leaders have successfully discovered, developed and commercialized small molecule and biologic agents at both large and small biopharmaceutical companies. We plan to utilize this deep, broad set of
expertise and experiences as we execute on our <FONT STYLE="white-space:nowrap">in-house</FONT> discovery and development strategies and evaluate new external acquisition opportunities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GB001 (DP2 Antagonist) </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB001
is an oral DP2 antagonist in development for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma and other allergic conditions. As of July&nbsp;31, 2018, GB001 had
been studied in 359 subjects in total and was generally well tolerated. In a Phase 2 clinical trial conducted in Japan, GB001 showed a statistically significant improvement in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-first</FONT></FONT> asthma exacerbation compared to placebo. We commenced a Phase 2b clinical trial in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma in October 2018 and expect to conduct an interim analysis in the first half of 2020. If the interim analysis is positive, we plan
on initiating a Phase 3 clinical trial thereafter. We have held a Type C meeting with the FDA to inform our Phase 2b and Phase 3 clinical trial design and endpoints. In addition, we plan to pursue the parallel development of GB001 in CRSwNP and CSU
by initiating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase 2 clinical trials for these indications in 2019. We retain worldwide rights to GB001, excluding Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mechanism of Action </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">DP2, also known as
CRTh2, is a receptor for prostaglandin D<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>, or PGD<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>, a lipid mediator produced mainly by mast cells. DP2 is primarily responsible for
mediating the <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> effects of PGD<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>, as depicted below in Figure 1, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the activation of T helper 2, or Th2, cells, mast cells, basophils and eosinophils; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the stimulation of type 2 cytokine production, including <FONT STYLE="white-space:nowrap">IL-4,</FONT> <FONT
STYLE="white-space:nowrap">IL-5</FONT> and <FONT STYLE="white-space:nowrap">IL-13,</FONT> by Th2 cells; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the increased expression of adhesion molecules on eosinophils and basophils. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> effects contribute to airway constriction, swelling in the walls of the airways
and mucous production at sites of allergic airway inflammation, all of which are hallmarks of the airway obstruction seen in asthma. The expression of DP2 is more common in patients with more severe disease, and, importantly, a significant
proportion of severe asthma patients have eosinophilic inflammation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B>Figure 1. Mechanism of DP2 in Allergic Airway Inflammation </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g12d34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Aberrant Th2 cell activation and resulting type 2 cytokine production have been shown to play a prominent
role in various allergic and inflammatory disorders beyond eosinophilic asthma, including CRSwNP, CSU, eosinophilic esophagitis and atopic dermatitis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">DP2 antagonism has been clinically validated by Novartis&#146; oral DP2 antagonist, fevipiprant, in a Phase 2 clinical trial. In this trial,
both the 150 mg once-daily and 75 mg twice-daily doses demonstrated statistically significant improvements in FEV<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> compared to placebo in adult patients with asthma inadequately controlled with
ICS. As of September 30, 2018, fevipiprant, at 150 mg once-daily and 450 mg once-daily doses, is being investigated by Novartis in six Phase 3 clinical trials in asthma patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB001 has been shown in preclinical studies to be a selective antagonist of the DP2 receptor. GB001 binds reversibly to human DP2 with an
affinity, or Ki, of 1 to 2 nanomolar, significantly greater than its affinity for the other PGD2 receptors. No significant activity was demonstrated in a standard selectivity panel of 90 other receptors and enzymes. GB001 has also shown a slow rate
of disassociation from DP2, with a receptor residence time of 19.8 minutes, as measured by half-life. Additionally, in an <I>in vitro</I> assay, GB001 inhibited PGD2 induced internalization of DP2. Combined with our observed human plasma half-life
of 10 to 15 hours, we believe these measurements support the oral, once-daily dosing regimen of GB001. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Asthma </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Asthma is a complex, chronic, highly heterogeneous inflammatory condition of the airways characterized by airflow obstruction, bronchial
hyperactivity and airway inflammation. Symptoms of asthma, which can be fatal, are also called asthma exacerbations or attacks and include episodes of wheezing, breathlessness, chest tightness and coughing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Patients are deemed to have intermittent, mild, moderate or severe disease based on the frequency and severity of their symptoms. Asthma can
also be <FONT STYLE="white-space:nowrap">sub-categorized</FONT> by the composition of the white blood cells that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are causing inflammation in and around the airway wall. We estimate that approximately 50% of severe asthma patients have a phenotype called eosinophilic asthma, which is marked by an increase of
eosinophils in the mucosal sputum that coats the airways. Eosinophils are immune cells that have been shown to play a major role in inflammation and allergic response, and eosinophilic asthma is associated with more severe symptoms, late-onset
disease and resistance to steroid treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of the Asthma Market </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Asthma is a substantial, widespread condition afflicting more than 330&nbsp;million patients worldwide and about 25&nbsp;million patients in
the United States. Approximately 25% and 12% of patients in the United States have moderate and severe disease, respectively, according to Datamonitor. The disease is responsible for more than $50&nbsp;billion in annual direct healthcare costs in
the United States and results in an estimated 420,000 and 3,500 deaths per year worldwide and in the United States, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Total
asthma drug sales in the U.S. market were approximately $7.9&nbsp;billion in 2017 and are projected to reach $13.9&nbsp;billion by 2026, according to Datamonitor. Nearly $5.6&nbsp;billion of the estimated $13.9&nbsp;billion in sales is attributable
to biologic therapies. In the future, we believe asthma market growth may be driven by increasing disease diagnosis and new biologic and small molecule agents entering the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Treatment Paradigm in Asthma </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
treatment guidelines for asthma, depicted below for adolescents and adults in Figure 2, is a <FONT STYLE="white-space:nowrap">step-up</FONT> paradigm. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>Figure 2. Treatment Guidelines for Asthma </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g66h20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LABA = long-acting beta agonist; LTRA = leukotriene receptor antagonist; SABA = short-acting beta agonist </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The goals of the <FONT STYLE="white-space:nowrap">step-up</FONT> treatment paradigm are to achieve long-term control of asthma symptoms,
minimize the use of SABAs and maintain near-normal lung function and activity levels. Reduction in asthma exacerbations is the primary endpoint predominantly used in new product development in asthma, while surrogate endpoints for improvements in
lung function are commonly used as supportive secondary endpoints. Biologics, including the recently approved <FONT STYLE="white-space:nowrap">IL-5</FONT> antibodies, are typically used only in the most refractory, severe patients. We believe this
is because of their route of administration through either subcutaneous (omalizumab, mepolizumab and benralizumab) or intravenous (reslizumab) injection, high cost and concerns about potential adverse events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">While the recent introduction of biologic agents has altered the course of treatment for
refractory, severe patients, the last major change in the treatment paradigm for mild or moderate asthma came with the 1998 FDA approval of Singulair (montelukast), an LTRA, which became the top controller therapy for asthma. Worldwide sales for
Singulair peaked at approximately $5.5&nbsp;billion in 2011, prior to the entry of generic competition. Singulair&#146;s profile as an effective oral drug with a well-understood safety profile made it an attractive option for patients across the
severity spectrum despite inferior efficacy, as measured by asthma exacerbations rate reduction, compared to that of the biologic agents. The success of Singulair highlights the unmet need and opportunity in the asthma market for safe and effective,
orally-administered therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GB001 Product Differentiation </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe there is a significant market opportunity for improved and effective oral therapies in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> asthma with consistent safety and tolerability profiles that can be used prior to biologics. Published Phase&nbsp;2 clinical trial results for fevipiprant appear to be comparable to the
anti-inflammatory effects demonstrated by certain biologics in clinical studies. We believe oral options are generally preferred to biologics due to their route of administration, which leads to improved patient adherence. Furthermore, oral
administration is especially important as children and adolescents are frequent sufferers of asthma. We believe GB001 as an oral agent has the potential to reduce asthma exacerbations and improve lung function, and thereby could be positioned as a <FONT
STYLE="white-space:nowrap">pre-biologic</FONT> treatment alternative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development History of GB001 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We acquired GB001 through our acquisition of Pulmagen Therapeutics (Asthma) Limited, or Pulmagen, a wholly-owned subsidiary of our AA
BioPharma Inc. subsidiary, in January 2018, after its partner, Teijin Pharma Limited, or Teijin, completed a positive Phase&nbsp;2, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial in
Japanese patients. We have rights outside of Japan to all of the data from the two Phase&nbsp;2 clinical trials conducted by Pulmagen and Teijin described below. As of July&nbsp;31, 2018, 359 subjects have received at least one dose of GB001. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Summary of Completed Pulmagen Phase 2 Clinical Trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In December 2014, Pulmagen completed a Phase 2 clinical trial of GB001, the primary objectives of which were (1)&nbsp;to evaluate the safety
and efficacy of 20&nbsp;mg GB001 once daily compared to placebo and an active comparator, montelukast, over a <FONT STYLE="white-space:nowrap">10-week</FONT> treatment period and (2)&nbsp;to evaluate the effect of the
<FONT STYLE="white-space:nowrap">co-administration</FONT> of 10&nbsp;mg montelukast once daily with GB001 treatment in a <FONT STYLE="white-space:nowrap">two-week</FONT> extension. The primary endpoint was improvement in FEV<SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB> over 10&nbsp;weeks. The study enrolled 248 patients with mild to moderate asthma that were uncontrolled on <FONT STYLE="white-space:nowrap">low-</FONT> or medium-dose ICS, randomized 1:1:1 to
placebo, 20&nbsp;mg GB001 once daily and 10&nbsp;mg montelukast once daily. Patients were put on a standard medium-dose of ICS in a four week <FONT STYLE="white-space:nowrap">lead-in</FONT> to the study, during which they were also removed from
their LABA, if applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB001 was generally well tolerated with a treatment emergent adverse event, or TEAE, rate similar to placebo,
but the study did not meet its primary endpoint. Notably, neither the active comparator, montelukast, nor GB001, showed statistically significant differences in FEV<SUB STYLE="font-size:85%; vertical-align:bottom">1 </SUB>improvement<SUB
STYLE="font-size:85%; vertical-align:bottom"> </SUB>as compared to placebo. We believe the lack of statistically significant differences between the active treatment arms and placebo was primarily related to study design and execution issues related
to patient selection, including adherence to ICS therapy, eosinophilic phenotype thresholds and disease severity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Summary of Completed
Japanese Phase 2 Clinical Trial </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In December 2016, Pulmagen and Teijin announced results from a Phase 2 clinical trial of GB001
conducted in Japan. The trial was a double-blind, randomized, placebo-controlled, multi-center study, enrolling 158 patients with mild to moderate eosinophilic asthma who were using LABA and/or medium-dose ICS to control their disease. Patients on
LABA discontinued its use upon entry to the trial, and all patients were brought to a standardized medium dose of ICS for a four week <FONT STYLE="white-space:nowrap">lead-in</FONT> period. Patients were then randomized 1:1:1 to one of two dose arms
of GB001, 5&nbsp;mg or 20&nbsp;mg once daily, or to placebo in combination with a low dose of ICS for four weeks. Following this period of combination with <FONT STYLE="white-space:nowrap">low-dose</FONT> ICS, use of ICS was discontinued, and
patients continued taking GB001 or placebo for 12 weeks. The primary endpoint of the trial was change in morning peak </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expiratory flow, or AM PEF, a measure of lung function, from baseline to the last visit, marked as study completion or termination from the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A total of 91 patients completed the trial, with the dropout rate higher in the placebo arm (62%), as compared to the GB001 arms (40%,
5&nbsp;mg; 25%, 20&nbsp;mg). A statistically significant difference was seen in the AM PEF between placebo and both arms of GB001 (p = 0.015, 5&nbsp;mg; p = 0.027, 20&nbsp;mg). The p-value is the probability that the difference between two data sets
was due to chance. The smaller the p-value, the more likely the differences are not due to chance alone. In general, if the p-value is less than or equal to 0.05, the outcome is statistically significant. The FDA&#146;s evidentiary standard of
efficacy generally relies on a p-value of less than or equal to 0.05. In addition, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-first</FONT></FONT> asthma worsening, a key secondary endpoint, reached statistical
significance for the 20 mg dose arm versus placebo (p &lt; 0.001). Asthma worsening in this trial was defined as a composite measure to help characterize overall asthma exacerbations. Figure 3 below presents the improvement in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-first</FONT></FONT> asthma worsening of patients as measured by the asthma worsening rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B>Figure 3. Improvement in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Time-To-First</FONT></FONT> Asthma Worsening of
Patients with Mild to Moderate Eosinophilic Asthma </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g91g01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The dose response in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-first</FONT></FONT> exacerbation was even more pronounced in the subgroup of patients with high blood eosinophils, defined as those with greater than 300 cells per microliter
(&micro;L), as shown below in Figure 4. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B>Figure 4. Pronounced Improvement in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Time-To-First</FONT></FONT> Asthma Worsening of Patients with High Blood Eosinophils </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g15z05.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subgroup analyses demonstrated patients with high blood eosinophils at baseline treated with
the 20 mg dose of GB001 also had statistically significant improvement in FEV<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> compared with placebo (p = 0.016). GB001 was well tolerated in this trial, with an adverse event profile
consistent with placebo, including nasopharyngitis, gastrointestinal disorders and measures of blood and liver markers. No serious adverse events, or SAEs, were observed in the GB001 treatment arms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These results showed a clear, dose-dependent response to treatment with GB001, both in measures of lung function and asthma exacerbation
reduction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Summary of Pulmagen and Teijin Phase 1 Clinical Trials </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In Phase 1 studies conducted by Pulmagen and Teijin, GB001 demonstrated safety and pharmacodynamic, or PD, parameters consistent with the DP2
drug class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Most TEAEs were mild or moderate and were considered not related to study drug. A single SAE deemed by the investigator
likely to be related to study drug was observed in a Japanese patient who had received a 160 mg dose of GB001, which is eight times higher than the highest dose Teijin tested in its Phase 2 clinical trial. The patient experienced intrahepatic
cholestasis, a liver disorder, which resolved after treatment discontinuation. At the time of the intrahepatic cholestasis, the patient had GB001 levels approximately three to five times higher than other patients receiving the 160&nbsp;mg dose.
Other than this SAE, there were no laboratory testing, physical exam or electrocardiographic findings that were considered to be clinically significant and related to GB001. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Ongoing Phase 2b Eosinophilic Asthma Clinical Trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We commenced a Phase 2b clinical trial of GB001 in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma in October 2018, and we expect to conduct an interim analysis of the results of this trial in the first half of 2020. We have
designed this trial to efficiently assess <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-principle</FONT></FONT> and help enable rapid transition to Phase 3 clinical trials, and we have held a Type C meeting with the FDA
to inform our trial design and endpoints. We plan on enrolling 480 patients in the study in a 1:1:1:1 randomized to three GB001 dose arms of 20 mg, 40 mg and 60 mg per day and one placebo arm with once-daily dosing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We believe that we have designed our trial in a manner to address the potential shortcomings of the Pulmagen Phase 2 clinical trial, in that:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the study population will consist of more severe patients than those enrolled in the Pulmagen Phase&nbsp;2
clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enrollment inclusion criteria will be based on a history of asthma exacerbations within the last year;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enrolled patients will be required to have
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> asthma with eosinophil counts greater than or equal to 250 cells/&micro;L; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enrolled patients will be closely monitored during the run-in period to help ensure that the lack of adherence to
background therapy is not a contributing factor for their poorly controlled asthma. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The primary endpoint is
reduction in asthma worsening from baseline, assessed at week 24, with an additional four weeks of <FONT STYLE="white-space:nowrap">follow-up.</FONT> The parameters included in the asthma worsening composite primary endpoint include changes in FEV<SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB>, AM PEF, rescue medication use and asthma control and severe asthma exacerbations. We will also assess FEV<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> independently as a secondary
efficacy measure. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We plan to conduct an interim analysis after approximately 320 patients complete the <FONT
STYLE="white-space:nowrap">24-week</FONT> treatment period, and we expect the results of this interim analysis to be available in the first half of 2020. If the results obtained in the interim analysis support further development, we plan on
initiating our first Phase 3 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trial thereafter. We expect to report full data from the Phase 2b clinical trial in the second half of 2020. If the full data support further development, we will initiate a second Phase
3 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Plan in Additional Indications </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Because DP2 plays a central role in the activation of Th2 cells, we believe GB001 could be effective in the treatment of other <FONT
STYLE="white-space:nowrap">Th2-associated</FONT> allergic and inflammatory disorders, such as CRSwNP, CSU, eosinophilic esophagitis and atopic dermatitis. Based on unmet medical need and a review of the mechanistic rationale and market
opportunities, we have decided to initially pursue further development in CRSwNP and CSU in parallel with our eosinophilic asthma program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Chronic Rhinosinusitis with Nasal Polyps </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">CRS is a debilitating disorder marked by persistent symptoms including congestion, stuffiness, nasal discharge, pain or facial pressure,
impairment or loss of the sense of smell (anosmia), cough and fatigue. Mast cells and eosinophils are involved in allergic forms of chronic nasal inflammation, including CRS. Nasal polyps are a type 2 cytokine driven inflammatory process, and in
Caucasians, eosinophils are the predominant inflammatory cell. Approximately 80% of patients in Western countries with CRSwNP have eosinophilic upper airway inflammation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">CRS is associated with an increased risk for late-onset asthma, suggesting significant overlap in the underlying pathology of the diseases.
PGD<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB> has been correlated with the recruitment and activation of Th2 cells in nasal polyps, and type 2 cytokines, such as <FONT STYLE="white-space:nowrap">IL-4,</FONT> <FONT
STYLE="white-space:nowrap">IL-5</FONT> and <FONT STYLE="white-space:nowrap">IL-13,</FONT> have been shown to play a pivotal role in nasal polyp formation. Among others, clinical studies of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-IL-5</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-4</FONT></FONT> receptor antibodies and an <FONT STYLE="white-space:nowrap">anti-immunoglobulin</FONT> E, or <FONT
STYLE="white-space:nowrap">anti-IgE,</FONT> antibody are currently being studied in CRSwNP by other biopharmaceutical companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">According to a 2014 study, annual direct costs related to CRS were estimated to be $6.9 to $9.9&nbsp;billion worldwide. The prevalence of
CRSwNP is estimated to be 4% of the U.S. population, or approximately 13&nbsp;million individuals. CRSwNP patients represent 25 to 30% of total CRS patients. CRSwNP patients are initially treated with intranasal corticosteroids. When patients fail
intranasal corticosteroids, oral corticosteroids typically serve as the next line of therapy, although this treatment provides only two to four weeks of benefit while causing systemic side effects such as reduced glucose tolerance, osteoporosis and
weight gain. Failure to control symptoms with corticosteroids presents the need for potential surgical intervention. A long-term study of post-surgical patients showed that nearly 80% of patients had polyps recur at least once, and 36% of patients
required an additional surgery. We believe a significant number of patients in the United States are inadequately controlled with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> steroid treatment.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We plan to commence a Phase 2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in
adult patients with CRSwNP in 2019 and expect data to read out in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Chronic Spontaneous Urticaria </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Chronic urticaria, or CU, is characterized by the recurring eruption of transient, itchy, red welts on the skin. Patients with CU are often
severely impaired in their quality of life, including negative effects on sleep, daily activities, school/work life and social interactions. Urticaria symptoms are caused by degranulation of dermal mast cells, and an allergic-mediated response is
believed to contribute to mast cell activation in many cases. One of the most common forms of CU is CSU, previously known as the idiopathic form, or chronic idiopathic urticaria. In CSU patients, an underlying trigger for the skin lesions cannot be
identified, thus making it impracticable to employ a therapeutic strategy that relies on avoidance of causative environmental exposures. A published estimate of the U.S. prevalence of CSU ranged from 0.5% to 1.0% of the population, and approximately
20% of patients, or approximately 300,000 to 600,000 patients, have symptoms for more than five years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The current treatment guidelines for the management of all forms of urticaria recommend the
use of <FONT STYLE="white-space:nowrap">non-sedating</FONT> oral <FONT STYLE="white-space:nowrap">H1-antihistamines</FONT> as first-line therapy. For patients that do not respond to standard doses of
<FONT STYLE="white-space:nowrap">H1-antihistamines,</FONT> doses are increased by as much as four times. Though this can increase the response rates, side effects may also increase. Patients that do not respond to or are unable to tolerate high dose
antihistamines have few remaining options. For antihistamine refractory patients with CSU, the only currently approved treatment is the biologic agent, omalizumab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We plan to commence a Phase 2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in adult
patients with CSU in 2019 and expect data to read out in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GB002 (PDGF Receptor Kinase Inhibitor) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB002 is an orally inhaled, small molecule, PDGF receptor kinase inhibitor in development for the treatment of PAH. In contrast to the three
classes of marketed vasodilatory therapies for PAH, GB002 has the potential to be the first treatment with disease-modifying effects. Inhaled GB002, which is designed to act on both isoforms of the PDGF receptor,
<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and <FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>, has inhibited and reversed cell overgrowth in lung blood vessels in PAH animal models. In 2013, results from a Phase 3 clinical trial in PAH of
imatinib (Gleevec), an oral tyrosine kinase inhibitor with known activity against PDGF and marketed for oncology indications, showed statistically significant improvement in its primary efficacy endpoint, thus providing mechanistic validation, but
systemic toxicities were also observed. To date, these toxicities have not been observed with GB002 in our ongoing Phase 1 studies in healthy volunteers. We have received FDA feedback through Type&nbsp;C meeting interactions to inform our
Phase&nbsp;2/3 clinical trial design and endpoints. We plan to commence a Phase 1b clinical trial in PAH in the first half of 2019 and a Phase 2/3 clinical trial in PAH in the second half of 2019. We
<FONT STYLE="white-space:nowrap">in-licensed</FONT> GB002 from Pulmokine, Inc. in 2017 and retain worldwide rights. The FDA has granted GB002 orphan drug designation for the treatment of patients with PAH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">PAH is driven by
abnormal cellular proliferation within and around the small blood vessels of the lung that carry blood from the right side of the heart to the lungs. Functional and structural changes in the pulmonary vasculature, known as vascular remodeling, can
lead to smooth muscle cell proliferation and migration from the middle layer of the blood vessel into the inner layer. This can result in the development of plexiform and neointimal lesions that can obstruct blood flow. The obstruction of blood flow
in the pulmonary vessels can also predispose patients to thrombosis, or blood clots, within these small pulmonary vessels that further blocks blood flow. This progressive obstruction of blood flow from the right side of the heart to the lungs can
cause the right ventricle to fail, thus leading to severe breathlessness, reduced exercise tolerance and death. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The PDGF receptor is a
tyrosine kinase receptor which, when activated by its agonist, induces cellular proliferation. PDGF expression is known to be particularly important to stimulating smooth muscle cell proliferation in PAH patients. Further supporting this mechanism,
PDGF receptors and their ligands are both upregulated in PAH. Upregulated PDGF signaling results in endothelial cell and fibroblast dysfunction and the proliferation and migration of smooth muscle cells. This effect results in the overgrowth and
occlusion of blood vessels in the lung. Kinase inhibitors with activity against the PDGF pathway have shown the ability to reverse PAH in animal models. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Inhaled GB002 is designed to act on both isoforms of the PDGF receptor, <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and <FONT
STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>. Data from preclinical animal models and human lung histology from PAH patients suggests that it is important to inhibit both of these isoforms of the PDGF receptor. PDGF receptor <FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> is highly expressed in pulmonary arteriole vascular smooth muscle cells, or PAVSMCs. Inhibiting PDGF receptor <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> may help reduce the abnormal cell proliferation of
PAVSMCs that results in blood vessel thickening. PDGF receptor <FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> is more highly expressed in fibroblasts and myofibroblasts that are involved with the abnormal cell proliferation within the blood vessel
that leads to the obstruction of the pulmonary arterioles. We believe inhibiting PDGF receptor <FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> is therefore important in decreasing the abnormal cell proliferation of these cell
types.&nbsp;&nbsp;&nbsp;&nbsp; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Figure 5 below shows the key role of the PDGF pathway in pulmonary vascular remodeling and
the disease pathogenesis of PAH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B>Figure 5. PDGF Pathway in Pulmonary Vascular Remodeling </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g35s54.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Mechanistic validation of a PDGF receptor kinase inhibitor has been observed in studies of imatinib
(Gleevec), an oral tyrosine kinase inhibitor with known activity against the PDGF receptor kinase, that demonstrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in humans in a Phase 3 clinical
trial in PAH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The IMPRES trial was a Phase 3 clinical trial conducted by Novartis of imatinib (Gleevec) in PAH. Gleevec is currently
approved in certain oncology indications. Imatinib has known activity against multiple tyrosine kinases, including the PDGF and <FONT STYLE="white-space:nowrap">c-KIT</FONT> receptors and <FONT STYLE="white-space:nowrap">c-ABL.</FONT> 202 patients
were enrolled in the IMPRES trial, of which 41% had been treated with prostanoids, oral phosphodiesterase type 5, or PDE5, inhibitors and oral endothelin receptor agonists, or ERAs. As shown in Figure&nbsp;6 below, the study met its primary
endpoint, improvement in <FONT STYLE="white-space:nowrap">six-minute</FONT> walk distance, or 6MWD, versus placebo at week 24 from baseline, with statistical significance (p = 0.002). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B>Figure 6. Improvement in <FONT STYLE="white-space:nowrap">Six-Minute</FONT> Walk Distance of PAH Patients Treated with Imatinib </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g48b31.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As shown in Figure&nbsp;7 below, patients on imatinib also demonstrated statistically
significant improvements in measures of hemodynamics, including pulmonary vascular resistance, or PVR, a standard measurement in the evaluation of patients with PAH. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B>Figure 7. Improvement in Pulmonary Vascular Resistance of PAH Patients Treated with Imatinib </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g37g52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">However, systemic adverse events such as bleeding and poor tolerability led to a high <FONT
STYLE="white-space:nowrap">drop-out</FONT> rate within the active arm of the trial. Subdural hematomas occurred in eight patients who were also being administered oral anticoagulants during the study. Novartis withdrew its supplemental regulatory
applications in PAH in 2013 and, to our knowledge, did not pursue further development of imatinib in the indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Pulmonary Arterial
Hypertension </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">PAH is an orphan disease that is characterized by abnormally high blood pressure in the blood vessels carrying
deoxygenated blood from the right side of the heart to the lungs and is progressive and often fatal. Symptoms include shortness of breath at rest or with minimal exertion. Other symptoms include fatigue, chest pain, dizzy spells and fainting. The
progressive nature of this disease causes the right side of the heart to work much harder and eventually weaken or fail. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Patients are often evaluated by functional class, which categorizes patients by their
ability to carry out physical activity and symptom severity. Worsening symptoms, and thus higher numbered functional classes, are associated with higher mortality. The four functional classes established by the World Health Organization are detailed
below in Table 1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1. PAH Functional Classes </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Functional<BR>Class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;I</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Patients with PAH, but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;II</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Patients with PAH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;III</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Patients with PAH resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;IV</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Patients with PAH with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any
physical activity.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Additionally, recent medical society guidelines have identified intermediate and high-risk categories of PAH
based on several variables including signs of right heart failure, rate of symptom progression, functional class, 6MWD, maximum oxygen consumption, NTproBNP, which is a biomarker for heart failure, and measures of right heart function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Despite the introduction of many new therapies over the last several years, PAH continues to have a high morbidity and mortality. Based on
registry data, newly diagnosed functional class III and IV patients have <FONT STYLE="white-space:nowrap">5-year</FONT> survival rates of 60% and 44%, respectively, while rates for previously diagnosed patients were even lower at 57% and 27%,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><I>Overview of PAH Market</I><B><I> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Diagnosed PAH prevalence in the United States is approximately 53,000 patients, and prevalence is highest among women between the ages of <FONT
STYLE="white-space:nowrap">30-60.</FONT> The number of diagnosed PAH patients continues to increase, and we believe this increase is likely due to enhanced awareness and diagnosis of the disease. Total PAH drug sales worldwide in 2016 were estimated
at approximately $5.6&nbsp;billion and are expected to exceed $6.0&nbsp;billion by 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I></I></B><I>Treatment Paradigm in PAH</I><B><I>
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Current PAH therapies consist of three classes of vasodilators: PDE5 inhibitors and guanylate cyclase stimulators, ERAs, and
prostanoids. PDE5 inhibitors are often used in combination with ERAs as an early treatment strategy. In patients who fail to respond to combination therapy of an ERA and a PDE5, it is common practice to add a prostanoid. Prostanoids are also
commonly used to treat patients with evidence of right heart failure. While existing treatments have led to significant improvements in time to clinical worsening and other composite endpoints in PAH patients, none directly alter the underlying
disease process. The effect of vasodilation, while improving blood flow through the lungs, may eventually be overtaken by worsening cellular </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proliferation and arterial remodeling underlying the condition. We believe an agent with disease-modifying characteristics that safely addresses the underlying cellular overgrowth could provide
utility across functional classes and risk categories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GB002 Product Differentiation </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB002 is an orally inhaled PDGF receptor kinase inhibitor designed to build on the evidence of efficacy seen in trials of imatinib while
overcoming imatinib&#146;s observed systemic safety issues. GB002 was designed with a higher degree of selectivity as compared to imatinib. GB002 has increased potency against the PDGF receptor-<FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT> isoform,
similar potency against the PDGF-<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> isoform, and less activity against <FONT STYLE="white-space:nowrap">c-ABL.</FONT> We believe GB002 has the potential to be a differentiated PDGF-targeted therapeutic
that is designed to potentially provide: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an improved response to PDGF-driven abnormal cell proliferation in pulmonary arteries by addressing the
underlying mechanism that leads to arterial wall thickening, rather than resultant vasodilation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a more tolerable safety profile than imatinib due to the direct delivery to the lungs, as supported by the
absence adverse bleeding observed to date in toxicology programs or Phase 1 studies; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a convenient, simple and portable inhalation methodology and delivery system. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development History of GB002 </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Summary of Preclinical Program </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB002 inhibits both PDGF <FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> and <FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT>, and inhibited and
reversed cell overgrowth in lung blood vessels in PAH in a rat model, as shown below in Figure 8. This rat model replicates many features of human PAH, including the abnormal cell proliferation that can block the small vessels of the lung. GB002
substantially reduced the occlusive lesions in the small lung blood vessels in this model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B>Figure 8. Reversed Vascular Remodeling by
GB002 Through Inhibition of PDGF </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g25h13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Summary of Ongoing Phase 1 Study </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are currently conducting Phase 1a SAD and MAD double-blind, placebo-controlled, randomized studies of orally inhaled GB002 in healthy adult
volunteers. In the SAD portion of the study, we have completed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
five dosing cohorts, each consisting of six volunteers on active drug and two on placebo. We have assessed pharmacokinetics, or PK, parameters and safety. No treatment-related safety issues have
been reported during the study to date. We have completed dosing for the three cohorts in the MAD portion of the study, in which healthy volunteers receive doses of GB002 or placebo for seven days. As of November 1, 2018, no treatment-related safety
issues have arisen during the study. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Summary of Planned Phase 1b Clinical Trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect to commence a Phase 1b ascending dose, single-blind, placebo-controlled, randomized trial of GB002 in functional class II and III
PAH patients in the first half of 2019. We plan to enroll two to three cohorts of approximately eight patients each and follow patients for two weeks of dosing. The primary goal of the trial is to assess safety, and we also intend to assess certain
PK/PD measurements in patients. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Planned Phase 2/3 PAH Clinical Trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We plan to commence a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial in functional class III and IV PAH patients in the
second half of 2019. We have received FDA feedback through Type C meeting interactions to inform our Phase 2/3 clinical trial design and endpoints. Our planned primary endpoint is the change from baseline in pulmonary vascular resistance at week 24.
Key planned secondary endpoints include change from baseline to week 24 in 6MWD and NTproBNP. If we meet the primary endpoint and observe a favorable trend in the key secondary endpoints with a tolerable safety profile, we plan to discuss the
possibility of expedited pathways for review and approval with the FDA. We anticipate reporting topline data from our Phase 2/3 clinical trial in PAH in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GB004 <FONT STYLE="white-space:nowrap">(HIF-1</FONT></I></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><B><I></I></B><B><I> Stabilizer) </I></B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB004 is a novel, <FONT STYLE="white-space:nowrap">gut-targeted,</FONT> oral small molecule being developed for the treatment of IBD
including UC and CD. GB004 stabilizes HIF through the inhibition of HIF PHDs, key enzymes involved in HIF degradation. Preclinical data from animal models of IBD demonstrated that <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> stabilization restores intestinal epithelial barrier integrity and function, and results in immunomodulatory effects that we believe are important in reducing inflammation and enhancing mucosal healing in IBD
patients. We have completed a Phase 1 SAD study in healthy volunteers and are currently dosing healthy volunteers in a Phase 1 MAD study. We plan to pursue clinical development in both UC and CD patients and, following an IND submission with the
FDA, initiate a Phase 1b clinical trial in UC in the first half of 2019. We also plan to initiate a Phase&nbsp;2 clinical trial in UC in the first half of 2020. We <FONT STYLE="white-space:nowrap">in-licensed</FONT> GB004 from Aerpio
Pharmaceuticals, Inc., or Aerpio, in June 2018 and retain worldwide rights. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mechanism of Action </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">HIFs have an important role in protecting cells from low oxygen levels. PHDs are enzymes that hydroxylate HIFs when oxygen levels are normal.
At low oxygen levels, the activity of PHDs are inhibited, and HIFs are stabilized. Stabilized HIFs subsequently activate the expression of genes that protect cells and promote the healing of tissue that has been injured. Pharmacological inhibition
of PHDs can replicate the effects of low oxygen levels on HIF stabilization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">IBD represents a state of chronic tissue injury. In IBD
animal models, stabilizing HIF through the inhibition of PHD promoted the restoration of intestinal epithelial barrier function and reduction of inflammation. GB004 is a PHD inhibitor designed to be
<FONT STYLE="white-space:nowrap">gut-targeted</FONT> with higher intestinal exposure than systemic exposure. GB004 has also demonstrated greater accumulation of
<FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> than <FONT STYLE="white-space:nowrap">HIF-2</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> in IBD animal models&#046; Systemically active PHD
inhibitors, which stabilize <FONT STYLE="white-space:nowrap">HIF-2</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> thereby increasing systemic erythropoietin, or EPO, production by the liver and kidney, are under development for the treatment
of anemia in chronic kidney disease. By contrast, the use of orally administered GB004, which stabilized <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> in an IBD animal model, did not result in higher red
blood cell counts or a clinically significant increase in plasma EPO levels. We believe this is likely a consequence of both the limited systemic exposure of oral GB004 and its predominately selective inhibition of PHDs that stabilize <FONT
STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Gut-targeting </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In animal models of IBD, the reduction in inflammation was similar between oral and intravenously- administered GB004. Oral administration
resulted in lower systemic exposure and greater accumulation of <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> than
<FONT STYLE="white-space:nowrap">HIF-2</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> without an increase in EPO, blood count or HIF-mediated effects outside of the gastrointestinal, or GI, tract, including in the heart, kidney, and liver.
Other data in <FONT STYLE="white-space:nowrap">non-diseased</FONT> animals have also shown that orally delivered GB004 preferentially concentrated in the GI tract at a rate many times higher than in other organs, such as the heart, kidney or liver.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Figure 9 below depicts the proposed mechanism of action of GB004. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><B>Figure 9. Mechanism of PHD Inhibitor to Restore Epithelial Barrier Function </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g34x60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB004&#146;s potential beneficial effects in IBD can be broken into two categories: restoration of
epithelial barrier function and immunomodulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Restoration of Epithelial Barrier Function </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> expression leads to increases in genes known to
promote epithelial integrity and mucosal barrier function. GB004 stabilizes <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, promoting healing of the intestinal epithelial barrier. While current therapies
target the inflammatory response in IBD, GB004 represents a novel mechanism designed to directly enhance the repair of the epithelial barrier. We believe that repairing damage to epithelium and the associated reduction of inflammation would lead to
a significant improvement in the symptoms experienced by IBD patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Immunomodulation </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> is an important modulator of the innate and
adaptive immune response. <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> increases antimicrobial peptides, factors that protect the host from infection. In addition,
<FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> may be critical for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory immune cell function and these cells are important cells for reducing inflammation in IBD. Taken together,
<FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> mediated effects on innate and adaptive immune responses in the gut contribute to resolution of inflammation and complement the epithelial barrier protective
effects of <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> stabilization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of IBD </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">IBD refers to two conditions, UC and CD, that are characterized by chronic inflammation of the GI tract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Ulcerative Colitis </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">UC
is a chronic GI inflammatory disorder that involves the mucosal lining of the colon. Patients with UC suffer from a multitude of GI symptoms, such as diarrhea, rectal bleeding and weight loss. UC is characterized by a chronic course of remissions
and exacerbations. Within 10&nbsp;years of diagnosis, it is estimated that 20% of adults with UC will have undergone colectomy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Crohn&#146;s Disease </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">CD
is a chronic, inflammatory condition that involves the full thickness of the wall of the GI tract, and is characterized by erosions, strictures and perforations of the intestine. Symptoms include diarrhea, abdominal pain, blood in the stool and
weight loss. Maintaining symptomatic control and obtaining remission are critical to minimizing short-term and long-term complications and to improving the outcomes and quality of life for patients with CD. The natural course of CD is a progression
from inflammation of the mucosa to stricture formation of the intestine and of mucosal penetration or fistula formation, with the risk of stricture and fistula increasing with the duration of CD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of the IBD Market </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Approximately three&nbsp;million Americans report being diagnosed with either UC or CD. The U.S. market for IBD biologics reached an estimated
$7&nbsp;billion in 2016 and is projected to grow to over $10&nbsp;billion by 2025, according to Datamonitor. The current biologic market is dominated by the <FONT STYLE="white-space:nowrap">anti-TNF</FONT> inhibitors Humira, marketed by AbbVie Inc.,
and Remicade, marketed by Janssen Pharmaceuticals, Inc., or Janssen, and the growing share of the anti-integrin Entyvio, marketed by Takeda Pharmaceuticals America, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Treatment Paradigm in IBD </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Treatment of
IBD consists mainly of immunosuppressive therapies. Treatment choices depend on the patient&#146;s disease severity and responsiveness to therapy. Medications which treat mild to moderate IBD are generally well tolerated. However, as the severity of
IBD increases, the potential toxicities of the medications required to manage the disease also increase. For example, treatment of mild to moderate patients typically starts with topical agents, such as
<FONT STYLE="white-space:nowrap">5-aminosalucylic</FONT> acid, or <FONT STYLE="white-space:nowrap">5-ASA.</FONT> For those IBD patients who do not respond to <FONT STYLE="white-space:nowrap">5-ASAs,</FONT> or those with more severe disease,
corticosteroids are generally used to induce clinical remission. However, longer-term treatment with corticosteroids is associated with multiple adverse effects. Additionally, approximately 38% of patients who initially respond to corticosteroids
either become steroid-dependent or require surgery within a year of initiating corticosteroids for UC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Patients with moderately to
severely active IBD, who become nonresponsive or intolerant to corticosteroids, are treated with immunomodulators, biologics or a Janus kinase, or JAK, inhibitor. Immunomodulators show a delay in onset of action of one to three months, and can
result in neutropenia, pancreatitis, nephrotoxicity and hepatotoxicity. Therefore, the treatment of IBD patients with moderately to severely active inflammation is dominated by <FONT STYLE="white-space:nowrap">anti-TNF</FONT> biologics given their
better efficacy and side effect profile than immunomodulators. This paradigm is shifting because of the approval of agents in other classes, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such as an anti-integrin, an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-IL-12</FONT></FONT> / <FONT STYLE="white-space:nowrap">IL-23</FONT> and a JAK inhibitor.
Additional immune suppressive therapies for the treatment of IBD are expected in the coming years with the anticipated introduction of oral S1P1 inhibitors and additional oral JAK inhibitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Furthermore, current treatments and those in development focus on immunosuppression, interference in immune cell migration and inflammatory
pathways. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><I>GB004 Product Differentiation</I><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB004 is designed to be <FONT STYLE="white-space:nowrap">gut-targeted</FONT> with higher intestinal exposure than systemic exposure. In IBD
animal models, GB004 has demonstrated greater accumulation of <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> than
<FONT STYLE="white-space:nowrap">HIF-2</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> which may lead to restoration of epithelial barrier function and resolution of inflammation, while avoiding the potential adverse effects of increased EPO.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB004 is distinct, and may have a differentiated profile, from the immunomodulatory or immunosuppressive mechanisms of approved IBD
medicines and those in late-stage development. By reducing inflammation and potentially restoring intestinal epithelial barrier function and restitution through GB004&#146;s <FONT STYLE="white-space:nowrap">gut-targeted</FONT> nature and
preferential stabilization of <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, we believe GB004 could improve outcomes for IBD patients. We believe this mechanism has potential as a standalone therapeutic
as well as a combination therapy with other therapeutic mechanisms in IBD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><I>Clinical Development Plan in IBD and Other Indications</I><B>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Summary of Ongoing Phase 1 SAD and MAD Trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB004 was evaluated by Aerpio in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> Phase 1 SAD
study in healthy male volunteers. The primary objective of the study was to evaluate the safety and tolerability of ascending dose levels of GB004 after single oral administrations. The secondary objective was to characterize the single-dose PK
profiles after escalating GB004 doses. A total of 40 subjects were randomized into five cohorts with 8 subjects each. All subjects completed the study. The five dose levels evaluated in this study were 20 mg, 60 mg, 120 mg, and 240 mg in 50 ml of
solution and 240 mg in 100 ml of solution. All GB004 doses evaluated in this study were determined to be safe and well tolerated. No deaths or SAEs occurred. There were no significant differences in systemic levels of vascular endothelial growth
factor, or VEGF, and EPO between GB004 and placebo patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are currently evaluating GB004 in a randomized, double-blind,
placebo-controlled, MAD study to assess the safety, tolerability, PK and PD effects in healthy male and female volunteers. A total of 40 subjects are planned to be randomized into five cohorts with eight subjects each. Dose levels to be evaluated in
the five cohorts are 60 mg and 120 mg per day in male volunteers, 240 mg per day in four male volunteers and four female volunteers, 120 mg per day in female volunteers and, if required, 60 mg per day in female volunteers. Volunteers unable to
complete seven days of dosing may be replaced. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman"><I>Summary of Planned Phase 1b Clinical Trial in UC </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We plan to submit an IND for GB004 in IBD and, after acceptance, initiate a Phase 1b trial of GB004 in approximately 30 symptomatic adult UC
patients in the first half of 2019. Dose selection for this trial will be informed by the results of the MAD study. The goals of the study are to assess safety, tolerability, PK/PD and target engagement of GB004 in patients with UC. We expect to
report topline data from this trial in the first half of 2020. We expect to initiate a Phase 2 clinical trial in UC in the first half of 2020 and anticipate reporting topline data from the trial by the first half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Research Capabilities and Preclinical Programs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently have three programs in preclinical development and expect to file an IND application with the FDA for at least one of these
programs within the next 12 months. We are continuing to build our research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capabilities, specifically focusing on our areas of expertise within immunology, inflammation and oncology, in order to advance new programs into the clinic, as well as optimize our existing
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><I>GB1275 (CD11b Agonist)</I><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB1275 is an oral small molecule, CD11b agonist in preclinical development for the treatment of oncology indications. CD11b and CD18 are
members of the integrin family of cell adhesion receptors that combine to form the functional adhesion receptor CD11b/CD18 (also known as <FONT STYLE="white-space:nowrap">Mac-1,</FONT> CR3 or alpha- M <FONT STYLE="white-space:nowrap">beta-2)</FONT>
on cell surfaces. CD11b is highly expressed on immune system cells including tumor-associated macrophages, or TAMs, and myeloid derived suppressor cells, which play a significant role in tumor growth, immune evasion and metastases. CD11b is also
upregulated in many tumor types, and the presence of CD11b+ cells is&nbsp;associated with poor prognosis in multiple cancer types. We acquired GB1275 through our acquisition of Adhaere Pharmaceuticals, Inc. in September 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Innate immune cells modulate the tumor microenvironment, or TME, and fuel cancer cell growth and survival. We believe that validation for
targeting the immunosuppressive TME in pancreatic cancer has been supported by evidence of durable clinical benefit in trials with an anti- colony-stimulating factor 1 receptor, or anti-CSF1R, antibody plus nivolumab, an agent approved for oncology
indications, as well as <FONT STYLE="white-space:nowrap">C-C</FONT> chemokine receptor type 2, or CCR2, inhibition in combination with chemotherapy. Our novel approach to integrin modulation, using small molecule CD11b agonists, targets innate
immune cells, which enhances immune-mediated tumor killing. Preclinical data for GB1275 suggest our approach to integrin modulation transiently increases the myeloid cell adhesion to the blood vessel wall and reduces influx of TAMs in tumors,
thereby increasing density of CD8<SUP STYLE="font-size:85%; vertical-align:top">+</SUP> <FONT STYLE="white-space:nowrap">T-cells</FONT> in the TME and decreasing tumor growth. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Preclinical studies have demonstrated tumor burden and improved survival of GB1275 as a single agent and in combination with chemotherapy and
immuno-oncology therapies across multiple tumor models, including pancreatic, breast and colon cancers in mice. Preclinical data also suggest differentiation from other approaches targeting immunosuppressive mechanisms, including anti-CSF1R
antibodies and CCR2 inhibition, and we therefore plan to advance GB1275 in development for the treatment of immuno-oncology resistant tumors, such as pancreatic and triple negative breast cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Preclinical studies and profile characterization of GB1275 support once daily oral dosing with no significant toxicology findings. We plan to
submit an IND for GB1275 and, after acceptance, initiate a Phase 1 clinical trial of GB1275 in 2019. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><I>Autoimmune Program</I><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have a portfolio of novel BTK inhibitors with differentiated selectivity profiles with and without central nervous system penetration. We
are currently evaluating these molecules with the goal of advancing an optimized compound into clinical development for the treatment of autoimmune indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><I>Oncology Program</I><B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are
developing small molecule cancer metabolism modulators that have the potential to treat solid tumors that are refractory to currently available checkpoint inhibitors. We are currently evaluating these molecules with the goal of advancing an
optimized compound into clinical development for the treatment of solid tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by rapid technological advancement, significant competition and an emphasis
on intellectual property. We face potential competition from many different sources, including major and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research
institutions. Any product candidates that we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successfully develop and commercialize will compete with current therapies and new therapies that may become available in the future. Our commercial opportunity could be reduced or eliminated if
our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects or more convenient than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for
their products more rapidly than we do. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, convenience, cost, level of promotional activity devoted to them and
intellectual property protection. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We expect to face competition from existing products and products in development for each of our
product candidates. GB001, currently in development for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> eosinophilic asthma, is an oral DP2 antagonist, a class of medicines with no
currently-approved agents. However, other DP2 antagonists are currently in development by Novartis, Chiesi Farmaceutici S.p.A., Merck&nbsp;&amp; Company, Inc. and Sunshine Lake Pharma Co., Ltd. If approved, we will also face branded competition from
existing biologics, including Xolair <FONT STYLE="white-space:nowrap">(omalizumab/anti-IgE,</FONT> marketed by Genentech and Novartis) and Dupixent
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(dupilumab/anti-IL-4/IL-13,</FONT></FONT></FONT> marketed by Regeneron Pharmaceuticals, Inc. and Sanofi S.A.), for moderate to severe asthma, and
Nucala <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(mepolizumab/anti-IL-5,</FONT></FONT> marketed by GlaxoSmithKline), Cinqair
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(reslizumab/anti-IL-5,</FONT></FONT> marketed by Teva Pharmaceutical Industries Ltd.), and Fasenra
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(benralizumab/anti-IL-5,</FONT></FONT> marketed by AstraZeneca Pharmaceuticals LP) for severe eosinophilic asthma. We will also face competition from generic montelukast, which is
utilized in mild to moderate patients. Several other agents are advancing in clinical trials for asthma, including tezepelumab, REGN3500 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-IL-33;</FONT></FONT> Regeneron),
etokimab <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-IL-33;</FONT></FONT> AnaptysBio, Inc.), GSK3772847 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-IL-33;</FONT></FONT> GlaxoSmithKline) and
RG6149 <FONT STYLE="white-space:nowrap">(anti-ST2;</FONT> Genentech). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Additionally, while there are no agents currently approved
beyond corticosteroids for CRSwNP, several agents approved for or in development for asthma are currently in development for CRSwNP, including Xolair, Fasenra, Dupixent and etokimab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Xolair is currently <FONT STYLE="white-space:nowrap">FDA-approved</FONT> for the treatment of CSU. We may also face competition from agents
currently in development for the indication, including ligelizumab <FONT STYLE="white-space:nowrap">(anti-IgE;</FONT> Novartis) and AK002 <FONT STYLE="white-space:nowrap">(anti-Siglec-8;</FONT> Allakos Inc.). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB002 is a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> PDGF receptor kinase
inhibitor initially targeted for intermediate and high-risk PAH patients. While potentially unique in our class, we expect our primary competition in this patient set will include prostanoids, available in oral form as Orenitram (United Therapeutics
Corporation, or United Therapeutics) and Uptravi (Janssen), by inhalation as Tyvaso (United Therapeutics), and by infusion as Remodulin (United Therapeutics). While we may face some competition from products used in class&nbsp;I and II patients,
such as the oral PDE5 inhibitors, including Revatio (Pfizer Inc.) and Adcirca (United Therapeutics); the sGC stimulator Adempas (Bayer AG); and oral ERAs, including Tracleer (Janssen), Letairis (Gilead Sciences, Inc.) and Opsumit (Janssen), we
believe that, if approved, GB002 would be used along with these background therapies. PAH is also an active indication for investigational drugs, and we may face competition in the future from ralinepag (Arena Pharmaceuticals, Inc.), sotatercept
(Acceleron Pharma, Inc.) and bardoxolone methyl (Reata Pharmaceuticals, Inc.). </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">GB004 is potentially a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">HIF-1</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> stabilizer with the potential to restore epithelial barrier
function in patients with IBD. Patients with mild to moderate UC can initially be maintained in remission using a <FONT STYLE="white-space:nowrap">5-ASA.</FONT> For those patients who do not respond to <FONT STYLE="white-space:nowrap">5-ASA,</FONT>
or those with more severe and/or extensive disease at diagnosis, corticosteroids are generally the next line of treatment. Patients who have become nonresponsive or intolerant to corticosteroids may move to azathioprine and <FONT
STYLE="white-space:nowrap">6-mercaptopurine.</FONT> The treatment of severe patients is dominated by <FONT STYLE="white-space:nowrap">anti-TNF</FONT> biologics, though the paradigm is shifting because of the approval of agents in other classes, such
as anti-integrin, <FONT STYLE="white-space:nowrap">IL-12</FONT> / <FONT STYLE="white-space:nowrap">IL-23,</FONT> and JAK inhibitors. Further disruption is expected in the coming years through the introduction of oral S1P1 inhibitors and additional
oral JAK inhibitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There may be other earlier stage clinical programs that, if approved, would compete with our
product candidates. Many of our competitors have substantially greater financial, technical and human resources than we have. Additional mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated in
our competitors. Competition may increase further as a result of advances made in the commercial applicability of technologies and greater availability of capital for investment in these fields. Our success will be based in part on our ability to
build and actively manage a portfolio of drugs that addresses unmet medical needs and creates value in patient therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Pulmokine</I></B><B> </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
October 2017, we entered into a license agreement, or the Pulmokine Agreement, with Pulmokine, Inc., under which we were granted an exclusive worldwide license and sublicense to certain intellectual property rights owned or controlled by Pulmokine
to develop and commercialize GB002 and certain backup compounds for the treatment, prevention and diagnosis of any and all disease or conditions. We also have the right to sublicense our rights under the Pulmokine Agreement, subject to certain
conditions. We are required to use commercially reasonable efforts to develop and commercialize at least one licensed product in the United States and in at least two countries in the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, we made an upfront payment of $5.5&nbsp;million to Pulmokine and are obligated to make future development
and regulatory milestone payments of up to $63&nbsp;million, commercial milestone payments of up to $45&nbsp;million, and sales milestone payments of up to $190&nbsp;million. We are also obligated to pay tiered royalties on sales for each licensed
product, at percentages ranging from the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits to the high single-digits. In addition, if we choose to sublicense or assign to any third parties our rights under the Pulmokine Agreement with
respect to a licensed product, or our GB002 operating subsidiary undergoes a change of control, we must pay to Pulmokine a specified percentage of all revenue to be received in connection with such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our royalty obligations and the Pulmokine Agreement will expire on a licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis on the later of ten years from
the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product or specified regulatory exclusivity for the licensed product in such country. The agreement may be terminated in its entirety either by
Pulmokine or by us in the event of an uncured material breach by the other party, in the event the other party is subject to specified bankruptcy, insolvency or similar circumstances, or in the event of a force majeure event under certain
circumstances. The agreement may be terminated by Pulmokine if we commence a legal action challenging the validity or enforceability of any licensed patents. We may terminate the agreement, either in its entirety or on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, in the event of potential safety or efficacy concerns affecting a licensed product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon termination of the agreement for any reason, all rights and licenses granted to us under the agreement will terminate and revert to
Pulmokine, and in the event of certain termination events, we would grant Pulmokine worldwide rights to the terminated program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Aerpio
Pharmaceuticals</I></B><B> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2018, we entered into a license agreement, or the Aerpio Agreement, with Aerpio Pharmaceuticals,
Inc., under which we were granted an exclusive worldwide license to certain intellectual property rights owned or controlled by Aerpio to develop and commercialize GB004 and certain other related compounds for all applications. We also have the
right to sublicense our rights under the Aerpio Agreement, subject to certain conditions. We are required to use commercially reasonable efforts to develop and commercialize at least one licensed product in the United States, in at least two
countries in the European Union, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and in Japan, in each case for at least one of the initial indications of UC or CD. The license agreement also includes a sublicense to a patent owned by The Regents of the University of
Colorado, or UC Regents, and non-exclusively licensed to Aerpio. The terms of the license agreement prohibit further sublicensing of the UC Regents patent rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the terms of the Aerpio Agreement, we made an upfront payment of $20&nbsp;million to Aerpio and are obligated to make future development
and regulatory milestone payments of up to $55&nbsp;million, commercial milestone payments of up to $85&nbsp;million and sales milestone payments of up to $260&nbsp;million. We are also obligated to pay tiered royalties on sales for each licensed
product, at percentages ranging from a high-single-digit to <FONT STYLE="white-space:nowrap">mid-teens,</FONT> subject to certain customary reductions. In addition, if we choose to sublicense or assign to any third parties our rights under the
Aerpio Agreement with respect to any licensed product or if our GB004 operating subsidiary undergoes a change of control and the value of such transaction exceeds a specified value, we have an option to pay a specified percentage of all revenue to
be received in connection with such transaction, and if we exercise the option Aerpio will no longer be paid the development, regulatory, commercial or sales milestones or royalties on the sales of licensed products under the agreement. If we do not
exercise our <FONT STYLE="white-space:nowrap">buy-down</FONT> option with respect to a sublicense or assignment of our rights under the Aerpio Agreement or with respect to a change of control of our GB004 operating subsidiary, Aerpio will have an
option to receive a specified percentage of all revenue received in connection with such transaction, and if Aerpio exercises the option Aerpio will no longer be paid the development, regulatory, commercial or sales milestones or royalties on sales
of licensed products under the agreement. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our royalty obligations and the Aerpio Agreement will expire on a licensed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis on the later of fifteen years from the
date of first commercial sale or when there is no longer a valid patent claim covering such licensed product in such country. The agreement may be terminated either by Aerpio or by us in the event of an uncured material breach by the other party or
in the event the other party becomes subject to specified bankruptcy, insolvency or similar circumstances. In the event we commence a legal action challenging the validity or enforceability of any licensed patents, Aerpio will have the right to
terminate the agreement or elect to increase milestone and royalty payments by a specified percentage. We may terminate the agreement in the event of potential safety or efficacy concerns affecting a licensed product. Upon termination of the
agreement for any reason all rights and licenses granted to us under the agreement will terminate, and in the event of certain termination events, we would grant Aerpio worldwide rights to the terminated program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We currently rely on
multiple third-party manufacturers for the manufacture of our product candidates for preclinical and clinical testing. We intend to rely on third-party contract manufacturers for commercial manufacturing if our product candidates receive marketing
approval. We believe there are multiple sources for all of the materials required for the manufacture of our product candidates. Our manufacturing strategy enables us to more efficiently direct financial resources to the research, development and
commercialization of product candidates rather than diverting resources to internally develop manufacturing facilities. As our product candidates advance through development, we expect to enter into longer-term commercial supply agreements with key
suppliers and manufacturers to fulfill and secure our production needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We strive to protect the proprietary technology, inventions and improvements that are commercially important to our business, including
seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our proprietary technology and product
candidates and continuing innovation to develop, strengthen and maintain our proprietary position. We also plan to rely on data exclusivity, market exclusivity and patent term extensions when available. Our commercial success will depend in part on
our ability to obtain and maintain patent and other proprietary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
protection for our technology, inventions and improvements; to preserve the confidentiality of our trade secrets; to defend and enforce our proprietary rights, including any patents that we may
own in the future; and to operate without infringing on the valid and enforceable patents and other proprietary rights of third parties. Intellectual property rights may not address all potential threats to our competitive advantage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>GB001</I></B><B> </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2018, with respect to GB001, we owned one issued U.S. patent directed to compound and pharmaceutical composition claims, which is not due to expire before 2026, excluding any additional term for patent term adjustment or
extension, and a number of patents and pending patent applications in other jurisdictions, including issued patents in Australia, Canada, China, the European Patent Convention, India, Mexico, New Zealand and Russia, and a pending application in
Brazil directed to compound and pharmaceutical composition claims. We owned the rights outside of Japan to one pending PCT application directed to compound claims, which, if issued, is not due to expire before 2037, excluding any additional term for
patent term adjustment or extension. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>GB002</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2018, with respect to GB002, we have exclusively licensed one pending U.S. patent application and one pending PCT
application owned by Pulmokine directed to method of use claims, which, if issued, is not due to expire before 2037, excluding any additional term for patent term adjustment or extension. We also have exclusively licensed two issued U.S. patents <FONT
STYLE="white-space:nowrap">co-owned</FONT> by Pulmokine and Gilead Sciences, Inc., which are not due to expire before 2034, excluding any additional term for patent term adjustment or extension; two pending U.S. patent applications, which, if
issued, are not due to expire before 2034, excluding any additional term for patent term adjustment or extension; and a number of patents and pending patent applications in other jurisdictions, including issued patents in Australia and the European
Patent Convention, and pending applications in Australia, Canada, China, the European Patent Convention and Japan. These patents and patent applications are directed to GB002 compound, formulation and method of use claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B><I>GB004</I></B><B> </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2018, with respect to GB004, we have exclusively licensed from Aerpio nine issued U.S. patents directed to compound, pharmaceutical composition and method of use claims, eight of which are not due to expire before 2030, and one,
directed to synthetic method claims, is not due to expire before 2035, excluding any additional term for patent term adjustment or extension; one pending U.S. patent application directed to compound and method of use claims, which, if issued, is not
due to expire before 2030, excluding any additional term for patent term adjustment or extension; and a number of patents and pending patent applications in other jurisdictions. The patents and pending patent applications directed to compound,
pharmaceutical composition and method of use claims in other jurisdictions, and which are not due to expire before 2030, include issued patents in Australia, Canada, China, the European Patent Convention, India, Japan, Mexico, New&nbsp;Zealand,
South Korea, and Russia, and pending patent applications in Brazil, the European Patent Convention, India, Mexico and South Korea. The patents and pending patent applications directed to synthetic method claims in other jurisdictions, and which are
not due to expire before 2035, include pending patent applications in China, the European Patent Convention, India and Japan. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">With
respect to our product candidates and processes we intend to develop and commercialize in the normal course of business, we intend to pursue patent protection covering, when possible, compositions, methods of use, dosing and formulations. We may
also pursue patent protection with respect to manufacturing and drug development processes and technologies. Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other
requirements imposed by governmental patent agencies. We may not be able to obtain patent protections for our compositions, methods of use, dosing and formulations, manufacturing and drug development processes and technologies throughout the world.
Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States can
provide exclusionary rights for 20 years from the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that covers or claims an FDA approved product can be extended to recapture a portion of the term
effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years
following FDA approval. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded
by a patent varies on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-to-country,</FONT></FONT> and depends
upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Patent term
may be inadequate to protect our competitive position on our products for an adequate amount of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The patent positions of companies
like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of biopharmaceuticals has emerged in the United States. The relevant patent laws
and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or product candidates and
could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in
obtaining and enforcing patent claims that cover our technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may
file in the future, nor can we be sure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, even our issued patents do not
guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and
uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our issued patents may be challenged, invalidated or
circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates. In addition, the scope of the rights granted under any
issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted
under any issued patents. For these reasons, we may face competition with respect to our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that,
before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Government
authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage,
record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new drug must be approved by the FDA through the new drug application, or NDA, process before it may be legally
marketed in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain of our product candidates are subject to regulation as combination products, which means that they
are composed of both a drug product and device product. If marketed individually, each component would be subject to different regulatory pathways and reviewed by different centers within the FDA. A combination product, however, is assigned to a
Center that will have primary jurisdiction over its regulation based on a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determination of the combination product&#146;s primary mode of action, which is the single mode of action that provides the most important therapeutic action. In the case of our inhaled product
candidate regulated as a combination product, the primary mode of action is attributable to the drug component of the product, which means that the FDA&#146;s Center for Drug Evaluation and Research has primary jurisdiction over the premarket
development, review and approval. Accordingly, we plan to investigate this product through the IND framework and seek approval through the NDA pathway. We do not anticipate that the FDA will require a separate medical device authorization for the
device, but this could change during the course of its review of any marketing application that we may submit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug Development Process
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing
regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to
comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#146;s
refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with Good
Laboratory Practice, or GLP, regulations and other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be
initiated; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice, or
GCP, regulations to establish the safety and efficacy of the proposed drug for its intended use; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an NDA; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is
produced to assess compliance with current GMP, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for
use in the United States. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Once a pharmaceutical candidate is identified for development, it enters the preclinical
testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and
analytical data, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The sponsor will also include a protocol detailing, among other things, the objectives of
the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the
IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, places the clinical trial on a clinical hold. In such a case, the IND
sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about
<FONT STYLE="white-space:nowrap">on-going</FONT> or proposed clinical trials or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that
the hold has been lifted. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent in writing for their
participation in any clinical trial. They must be conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be
evaluated. Each protocol must be submitted to the FDA as part of the IND as well as any subsequent protocol amendments, and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An IRB at
each institution participating in the clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to
each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 1</I>: The product candidate is initially introduced into healthy human volunteers and tested for
safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when
the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. Sponsors sometimes designate their Phase 1 clinical trials as Phase 1a or Phase 1b. Phase 1b clinical
trials are typically aimed at confirming dosing, pharmacokinetics and safety in larger number of patients. Some Phase 1b studies evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of
diseases. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 2</I>: This phase involves clinical trials in a limited patient population to identify possible adverse
effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and appropriate dosage. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Phase 3</I>: Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an
expanded patient population, generally at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for
product labeling. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial
marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of
approval of an NDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA or the sponsor may suspend a clinical trial at any time on various grounds,
including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in
accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a
data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to
submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to
provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3
clinical trials that they believe will support approval of the new drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete
additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In
addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed
since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting
a significant risk to humans exposed to the same or similar drugs, findings from animal or <I>in vitro </I>testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction
compared to that listed in the protocol or investigator brochure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">There are also requirements governing the reporting of ongoing clinical
trials and completed trial results to public registries. Sponsors of certain clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products are required to register and disclose specified clinical trial information, which is
publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part of the registration.
Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Combination Products in the United States </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Certain products may be comprised of components, such as drug components and device components, that would normally be regulated under
different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or
mixed and produced as a single entity; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">two or more separate products packaged together in a single package or as a unit and comprised of drug and device
products, device and biological products, or biological and drug products; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a drug, or device, or biological product packaged separately that according to its investigational plan or
proposed labeling is intended for use only with an approved individually specified drug, or device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the
labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any investigational drug, or device, or biological product packaged separately that according to its proposed
labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the FDCA and its implementing regulations, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for
review of a combination product. The designation of a lead center generally eliminates the need to receive approvals from more than one FDA component for combination products, although it does not preclude consultations by the lead center with other
components of FDA. The determination of which center will be the lead center is based on the &#147;primary mode of action&#148; of the combination product. Thus, if the primary mode of action of a drug-device combination product is attributable to
the drug product, the FDA center responsible for premarket review of the drug product would have primary jurisdiction for the combination product. The FDA has also established an Office of Combination Products to address issues surrounding
combination products and provide more certainty to the regulatory review process. That office serves as a focal point for combination product issues for agency reviewers and industry. It is also responsible for developing guidance and regulations to
clarify the regulation of combination products, and for assignment of the FDA center that has primary jurisdiction for review of combination products where the jurisdiction is unclear or in dispute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A combination product with a drug primary mode of action generally would be reviewed and approved pursuant to the drug approval processes
under the FDCA. In reviewing the NDA application for such a product, however, FDA reviewers in the drug center could consult with their counterparts in the device center to ensure that the device component of the combination product met applicable
requirements regarding safety, effectiveness, durability and performance. In addition, under FDA regulations, combination products are subject to cGMP requirements applicable to both drugs and devices, including the Quality System, or QS,
regulations applicable to medical devices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NDA Review and Approval Process </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The results of product development, preclinical and other <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials,
along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The
submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for
its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#146;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA
has a goal of ten months from the date of &#147;filing&#148; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has
approximately two months to make a &#147;filing&#148; decision after it the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether
they are sufficiently complete to permit substantive review The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also
is subject to review before the FDA accepts it for filing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA may refer an application for a novel drug to an advisory committee. An advisory
committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by
the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving
an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA,
it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the
application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an
additional pivotal Phase 3 trial or other significant and time consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA or, addressing all of
the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for
use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase 4 testing, which involves clinical trials designed to further assess a drug&#146;s safety and
effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been commercialized. The FDA may also place other conditions on approval including the requirement for a risk
evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A
REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing
could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or if problems occur following
initial marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs,
for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The
required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe
and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in
adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. The FDA must send a <FONT STYLE="white-space:nowrap">non-compliance</FONT> letter
to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000
individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. After the FDA grants orphan designation, the identity of the therapeutic
agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding
toward clinical trial costs, tax advantages and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. However, competitors, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain
approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of one of our product candidates for seven years if a competitor obtains approval of the same
drug as defined by the FDA or if our product candidate is determined to be contained within the competitor&#146;s product for the same indication or disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, if an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be
entitled to orphan exclusivity. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant
demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare
disease or condition. GB002 has received orphan drug designation for the treatment of patients with PAH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#146;s review and approval of new
drugs and biological products that meet certain criteria. The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs are
eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Unique to a fast track product, the FDA
may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and
determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA
programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy
exists or a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious disease or condition. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug
designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs
under its current PDUFA review goals. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or
conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit,
taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate
and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the
timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDA Safety and Innovation Act established a category of drugs referred to as &#147;breakthrough therapies&#148; that may be eligible to
receive breakthrough therapy designation. A sponsor may seek FDA designation of a product candidate as a &#147;breakthrough therapy&#148; if the product is intended, alone or in combination with one or more other products, to treat a serious or
life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects
observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team
throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary
for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an
efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more
efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. The designation includes all of the fast track program features, which means that the sponsor may file
sections of the NDA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may
initiate a review. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough
therapy, the FDA will work to expedite the development and review of such drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Fast track designation, priority review and breakthrough
therapy designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the
conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result
in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims,
are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are
subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval
of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any drug products manufactured or distributed by us or our partners pursuant to FDA
approvals will be subject to pervasive and continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information,
drug sampling and distribution requirements, complying with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other
types of information on products that are placed on the market and imposes requirements and restrictions on drug manufacturers, such as those related to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#146;s approved labeling
(known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on
the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or
after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds
on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or
communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a
five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not
previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated
new drug application, or ANDA, or an NDA submitted under Section&nbsp;505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as
the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a
certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA by the innovator NDA holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical
investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug.
This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent
for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to
all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an
additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor
to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek regulatory approval.
Sales in the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the Veterans
Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting
the reimbursement rate that the payor will pay for the product. A third-party payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Additionally, in the United States there is
no uniform policy among payors for coverage or reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval
processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. If coverage and adequate reimbursement are not available, or are available only at limited levels, successful commercialization of, and
obtaining a satisfactory financial return on, any product we develop may not be possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging
the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we
may need to conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our
product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price
levels sufficient to realize an appropriate return on our investment in drug development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Healthcare Reform </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the United States, there has been, and continues to be, several legislative and regulatory changes and proposed changes regarding the
healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the profitable sale of product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Among policy makers and payors in the United States, there is significant interest in promoting changes in healthcare systems with the stated
goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In
March 2010, the Patient Protection and Affordable Care Act, or ACA, was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The
ACA, among other things: (1)&nbsp;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations; (2)&nbsp;created a
new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected; (3)&nbsp;established an annual, nondeductible
fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in certain government healthcare programs; (4)&nbsp;expanded the
availability of lower pricing under the 340B drug pricing program by adding new entities to the program; (5)&nbsp;expanded the eligibility criteria for Medicaid programs; (6)&nbsp;created a new Patient-Centered Outcomes Research Institute to
oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; (7)&nbsp;created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (and
70% commencing January&nbsp;1, 2019) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their
coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; (8)&nbsp;established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; and (9)&nbsp;established a Center for Medicare Innovation at the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, to test innovative payment and service delivery models
to lower Medicare and Medicaid spending, potentially including prescription drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some of the provisions of the ACA have yet to be
implemented, and there have been judicial and political challenges to certain aspects of the ACA. For example, since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain
provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not
passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January&nbsp;1, 2019, the <FONT
STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual
mandate.&#148; Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain <FONT STYLE="white-space:nowrap">ACA-mandated</FONT> fees,
including the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Cadillac&#148; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical
device excise tax on <FONT STYLE="white-space:nowrap">non-exempt</FONT> medical devices. Further, the Bipartisan Budget Act of 2018, among other things, amends the ACA, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug
plans, commonly referred to as the &#147;donut hole.&#148; More recently, in July 2018, CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA
risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted. On August&nbsp;2, 2011, the Budget Control Act of 2011 was
signed into law, which, among other things, resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute,
including the BBA, will remain in effect through 2027 unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to
several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed
products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and
manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration&#146;s budget proposal for fiscal year 2019 contains further drug price control measures that
could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug
prices under Medicaid and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. Additionally, the Trump administration released a &#147;Blueprint&#148; to lower drug prices and reduce out of
pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the
out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services has begun the process of soliciting feedback on some of these measures and, at the same time, is implementing others under its existing
authority. Although some of these, and other proposed measures will require authorization through additional legislation to become effective, Congress and the Trump administration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and
implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some
cases, designed to encourage importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Additionally, on May&nbsp;30, 2018, the Trickett
Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or Right to Try Act, was signed into law. The law, among other things, provides a federal framework for patients to access certain investigational new drug
products that have completed a Phase I clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. There is no
obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Healthcare
Fraud and Abuse Laws and Compliance Requirements </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Federal and state healthcare laws and regulations restrict business practices in
the biopharmaceutical industry. These laws include anti-kickback and false claims laws and regulations, data privacy and security, and transparency laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying,
soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service
reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the
government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties
statute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act,
prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement
material to a false or fraudulent claim to the federal government. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The federal Health Insurance Portability and Accountability Act of
1996, or HIPAA, created additional federal civil and criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program. In addition, HIPAA, as amended by the Health Information
Technology for Economic and Clinical Health Act, and their implementing regulations, imposes certain requirements relating to the privacy, security and transmission of protected health information on HIPAA covered entities, which include certain
healthcare providers, health plans and healthcare clearinghouses, and their business associates who conduct certain activities for or on their behalf involving protected health information on their behalf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment
is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians and teaching hospitals, and
applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Similar state and local laws and regulations may also restrict business practices in the biopharmaceutical industry, such as state
anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical
companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other
potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians,
other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health information in some circumstances, many of
which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Efforts to
ensure compliance with applicable healthcare laws and regulations can involve substantial costs. Violations of healthcare laws can result in significant penalties, including the imposition of significant civil, criminal and administrative penalties,
damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, integrity oversight and reporting obligations, contractual damages, reputational harm,
diminished profits and future earnings, and curtailment or restructuring of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Regulation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of
other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a
product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues
discussed above with respect to the United States apply similarly in the context of the European Union, or EU, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative
review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory
approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">To market a medicinal product in the European Economic Area, or EEA (which is comprised of the 28 Member States of the EU plus Norway, Iceland
and Liechtenstein), we must obtain a Marketing Authorization, or MA. There are two types of marketing authorizations: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the
opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency, or EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as
biotechnology medicinal products, orphan medicinal products, advanced therapy products, and medicinal products containing a new active substance indicated for the treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders,
diabetes, <FONT STYLE="white-space:nowrap">auto-immune</FONT> and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant
therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their
respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in
another Member State through </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through
the Decentralized Procedure. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the above described procedures, before granting the MA, the EMA or the competent
authorities of the Member States of the EEA make an assessment of the <FONT STYLE="white-space:nowrap">risk-benefit</FONT> balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Data and marketing exclusivity </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the
EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar
applicants from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which
the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10&nbsp;years have elapsed from the initial authorization of
the reference product in the EU. The <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10&nbsp;years, the marketing authorization holder
obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pediatric investigation plan </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the
EEA, marketing authorization applications for new medicinal products not authorized have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&#146;s
Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The PDCO can grant a deferral of the obligation to
implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when these
data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a
significant therapeutic benefit over existing treatments for pediatric patients. Once the marketing authorization is obtained in all Member States of the EU and study results are included in the product information, even when negative, the product
is eligible for six months&#146; supplementary protection certificate extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Orphan drug designation </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the EEA, a medicinal product can be designated as an orphan drug if its sponsor can establish that the product is intended for the
diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or that the product is intended for the diagnosis, prevention
or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Community and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the
necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method
exists, the drug will be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the EEA, an application for designation as an
orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a <FONT STYLE="white-space:nowrap">ten-year</FONT> period of market exclusivity. During
this market exclusivity period, the EMA or the member state </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
competent authorities, cannot accept another application for a marketing authorization, or grant a marketing authorization, for a similar medicinal product for the same indication. The period of
market exclusivity is extended by two years for medicines that have also complied with an agreed PIP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This period may, however, be
reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify market exclusivity. Market
exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of &#147;clinical superiority&#148; by a similar medicinal
product, or, after a review by the Committee for Orphan Medicinal Products, requested by a member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products
designated as orphan drugs pursuant are eligible for incentives made available by the EU and its Member States to support research into, and the development and availability of, orphan drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical trials </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Clinical trials of
medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on GCPs. Additional GCP guidelines from the European
Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the European Union, it must appoint an entity within the European
Union to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#145;no fault&#146; compensation to any study subject injured in the clinical trial.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the competent authority, and a positive
opinion from an independent ethics committee. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an investigational medicinal product dossier containing information about the
manufacture and quality of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member State in which the trial will be conducted. Under the new
Regulation on Clinical Trials, which is currently expected to take effect in 2019, there will be a centralized application procedure where one national authority takes the lead in reviewing the application and the other national authorities have
only a limited involvement. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used
in clinical trials must be manufactured in accordance with cGMP. Other national and European Union-wide regulatory requirements also apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Privacy
and data protection laws </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are also subject to laws and regulations in non-U.S. countries covering data privacy and the protection
of health-related and other personal information. EU member states and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. Laws and regulations in these jurisdictions apply broadly
to the collection, use, storage, disclosure, processing and security of personal information that identifies or may be used to identify an individual, such as names, contact information, and sensitive personal data such as health data. These laws
and regulations are subject to frequent revisions and differing interpretations, and have generally become more stringent over time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As
of May&nbsp;25, 2018, Regulation 2016/676, known as the General Data Protection Regulation, or GDPR, replaced the Data Protection Directive with respect to the processing of personal data in the European Union. The GDPR imposes many requirements for
controllers and processors of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime,
shortened timelines for data breach notifications, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
limitations on retention and secondary use of information, increased requirements pertaining to health data and pseudonymised (i.e., key-coded) data and additional obligations when we contract
third-party processors in connection with the processing of the personal data. The GDPR allows EU member states to make additional laws and regulations further limiting the processing of genetic, biometric or health data. Failure to comply with the
requirements of GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#128;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and
other administrative penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;1, 2018, we had 72 full-time employees and 1 part-time employee, 23 of whom have a Ph.D. or M.D. None of our employees are
represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and
Development </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have invested $6.4&nbsp;million, $0.2 and $79.1&nbsp;million in research and development, including IPR&amp;D, for
the year ended December&nbsp;31, 2017 and the nine months ended September&nbsp;30, 2017 and 2018, respectively. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are located in San Diego, California, where we currently lease approximately 36,091 square feet of office,
laboratory and vivarium space. We use our corporate headquarters primarily for corporate, research, development, clinical, regulatory, manufacturing and quality functions. Commencing in January 2019, we have agreed to expand our leased space in our
corporate headquarters to a total of approximately 63,667 square feet. Our primary lease for this facility expires in January 2025, and our lease for the expansion space expires in December 2022. We believe that our facilities are adequate to meet
our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are not currently
subject to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact
on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the name, age and position of each of our executive officers and directors as of September&nbsp;30, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheila Gujrathi, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">48</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Faheem Hasnain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">60</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bryan Giraudo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">43</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Waage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President and General Counsel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luisa <FONT STYLE="white-space:nowrap">Salter-Cid,</FONT> Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristina Burow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">44</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Daniel, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">64</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Lim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">47</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">55</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Otello Stampacchia, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qinqing Yi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">46</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Sheila
Gujrathi, M.D.</I> is our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and has served as our President and Chief Executive Officer since July 2018 and as a member of our board of directors since our inception in October 2015. She previously
served as our President and Chief Operating Officer from our inception until July 2018. Prior to joining us, Dr.&nbsp;Gujrathi served as Chief Medical Officer of Receptos, Inc. from June 2011 until the company&#146;s acquisition by Celgene
Corporation in August 2015. Prior to joining Receptos, she was Vice President of the Global Clinical Research Group in Immunology at <FONT STYLE="white-space:nowrap">Bristol-Myers</FONT> Squibb from 2008 to 2011. Dr.&nbsp;Gujrathi also worked at
Genentech, Inc. from 2002 to 2008 where she held roles of increasing responsibility in the Immunology, Tissue Growth and Repair clinical development group, and served as the Avastin Franchise Team Leader. From 1999 to 2002, Dr.&nbsp;Gujrathi was a
management consultant at McKinsey&nbsp;&amp; Company in the healthcare practice where she provided strategic advice on a variety of projects in the healthcare and pharmaceutical industry. Dr.&nbsp;Gujrathi serves as a member of the board of
directors of Five Prime Therapeutics, Inc. and TP Therapeutics, Inc. and previously served as a member of the board of directors of Ambrx Inc. Dr.&nbsp;Gujrathi received her B.S. with highest distinction in Biomedical Engineering and her M.D. from
Northwestern University in their accelerated Honors Program in Medical Education. She completed her Internal Medicine Internship and Residency at Brigham and Women&#146;s Hospital, Harvard Medical School. She received additional training at
University of California, San Francisco and Stanford University in their Allergy and Immunology Fellowship Program. Dr.&nbsp;Gujrathi&#146;s knowledge of our business, as well as her extensive development, clinical and executive management
experience, contributed to our board of directors&#146; conclusion that she should serve as a director of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Faheem Hasnain
</I>is our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and served as our Chairman and Chief Executive Officer from our inception through July 2018, at which time he became our Executive Chairman. Prior to joining us, Mr.&nbsp;Hasnain served
as President, Chief Executive Officer and as a director of Receptos from November 2010 until the company&#146;s acquisition by Celgene in August 2015. Prior to joining Receptos, Mr.&nbsp;Hasnain was the President and Chief Executive Officer and a
director of Facet Biotech Corporation. He held that position from December 2008 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
until the company&#146;s acquisition by Abbott Laboratories in April 2010. Previously, Mr.&nbsp;Hasnain was President, Chief Executive Officer and a director of PDL BioPharma, Inc. from October
2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008, Mr.&nbsp;Hasnain served at Biogen Inc., most recently as Executive Vice President in charge of the oncology/rheumatology strategic
business unit. Prior to Biogen, Mr.&nbsp;Hasnain held roles with Bristol-Myers Squibb, where he was President of Oncology Therapeutics Network, and for 14 years at GlaxoSmithKline and its predecessor organizations. He serves as Chairman of the board
of directors of SENTE, Inc., Tocagen, Inc. and Vital Therapies, Inc., and as a member of the board of directors of Kura Oncology, Inc. He previously served as Chairman of the board of directors of Ambit Biosciences Corporation and served as a member
of the board of directors of Aragon Pharmaceuticals, Seragon Pharmaceuticals, Inc., Pernix Sleep, Inc., Somaxon Pharmaceuticals, Inc. and Tercica, Inc. Mr.&nbsp;Hasnain received a B.H.K. and B.Ed. from the University of Windsor Ontario in Canada.
Mr.&nbsp;Hasnain&#146;s knowledge of our business, as well as his years of experience in drug discovery and development and as a biopharmaceutical executive and board member, contributed to our board of directors&#146; conclusion that he should
serve as Executive Chairman of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Bryan Giraudo </I>has served as our Chief Financial Officer since May 2018. Prior to
joining us, Mr.&nbsp;Giraudo was a Senior Managing Director at Leerink Partners from 2009 to April 2018, where he was responsible for their western North America and Asia Pacific biotechnology and medical technology banking practice. Before joining
Leerink, Mr.&nbsp;Giraudo was a Managing Director in Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated&#146;s Global Healthcare Investment Banking Group. He has been a member of the board of directors of Protagonist Therapeutics, Inc.
since May 2018. Mr.&nbsp;Giraudo received his B.A. from Georgetown University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Christian Waage</I> has served as our Executive Vice
President and General Counsel since August 2017.<B> </B>Previously, Mr.&nbsp;Waage held various positions from November 2013 to August 2016 at Receptos, most recently serving as Managing Director after its acquisition by Celgene, previously serving
as Senior Vice President and General Counsel. From 2012 through its acquisition by Vista Equity Partners LLC in 2013, he served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. From 2008 through its acquisition by
AstraZeneca PLC in 2012, Mr.&nbsp;Waage served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. Prior to 2008, Mr.&nbsp;Waage served as a partner at DLA Piper LLP. He has been a member of the board of directors
of Heron Therapeutics, Inc. since June 2016. Mr.&nbsp;Waage received his J.D. from the University of San Diego, School of Law and a B.A. degree in economics from the University of California, San Diego. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Luisa <FONT STYLE="white-space:nowrap">Salter-Cid,</FONT> Ph.D. </I>has served as our Chief Scientific Officer since August 2018. Prior to
joining us, <FONT STYLE="white-space:nowrap">Dr.&nbsp;Salter-Cid</FONT> worked at Bristol-Myers Squibb in increasing positions of responsibility from 2005 to August 2018, most recently as Vice President and Head of Immunology, small molecule
Immuno-Oncology and Genomics Discovery where she focused on target validation and development of innovative biologic and small-molecule therapeutics to address significant unmet needs in autoimmune diseases and cancer. During her time at
Bristol-Myers Squibb, <FONT STYLE="white-space:nowrap">Dr.&nbsp;Salter-Cid</FONT> led teams that advanced more than 20 compounds into clinical development, and is an author on over 70 publications and patents. Previously, from 2002 to 2005, <FONT
STYLE="white-space:nowrap">Dr.&nbsp;Salter-Cid</FONT> was a Senior Project Leader at La Jolla Pharmaceuticals, Inc. <FONT STYLE="white-space:nowrap">Dr.&nbsp;Salter-Cid</FONT> also held positions at Genset Corporation and Johnson&nbsp;&amp; Johnson.
She was a member of the Scientific Advisory Board of Enterome SA until July 2018. <FONT STYLE="white-space:nowrap">Dr.&nbsp;Salter-Cid</FONT> holds a B.S. in Biology from University of Lisbon and a Ph.D. in Immunology from the University of Miami
School of Medicine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Kristina Burow</I> has served on our board of directors since January 2018. She has served as a Managing Director with ARCH Venture
Partners, or ARCH, since November 2011 and previously held roles of increasing responsibility at ARCH from August 2002 to November 2011. Ms.&nbsp;Burow also currently serves on the boards of directors of Vividion Therapeutics, Inc., Beam
Therapeutics Inc., Sienna Biopharmaceuticals, Inc., Lycera Corp., </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
BlackThorn Therapeutics, Inc., Metacrine, Inc., Scholar Rock, Inc., Unity Biotechnology Inc., AgBiome Inc., Boragen, Inc., AgTech Accelerator and Vir Biotechnology Inc. She previously was a <FONT
STYLE="white-space:nowrap">co-founder</FONT> and director of Receptos prior to its acquisition and of Sapphire Energy, Inc. Prior to ARCH, Ms.&nbsp;Burow was an Associate with the Novartis BioVenture Fund in San Diego and an early employee at the
Genomics Institute of the Novartis Research Foundation. Ms.&nbsp;Burow holds a B.A. in Chemistry from the University of California, Berkeley, an M.A. in Chemistry from Columbia University and an M.B.A. from the University of Chicago.
Ms.&nbsp;Burow&#146;s extensive experience serving on the board of directors of clinical-stage biotechnology companies and her investment experience in the life sciences industry contributed to our board of directors&#146; conclusion that she should
serve as a director of our company. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Thomas Daniel, M.D. </I>has served on our board of directors since January 2018. Dr. Daniel
has served as a venture partner with ARCH Venture Partners since October 2016. Dr.&nbsp;Daniel has been the Executive Chairman of Vividion Therapeutics, Inc. since February 2017. Dr.&nbsp;Daniel was previously Celgene&#146;s Chairman of Research
from January 2016 until June 2016, President of Research and Early Development from December 2006 to January 2016, and Executive Vice President and President of Research and Early Development from February 2012 until January 2016. Prior to joining
Celgene, Dr.&nbsp;Daniel served as the Chief Scientific Officer and director at Ambrx Inc. Prior to Ambrx, Dr.&nbsp;Daniel served as Vice President of Research at Amgen Inc., where he was research site head of Amgen Washington and therapeutic area
head of inflammation. Dr.&nbsp;Daniel also served as the Senior Vice President of Discovery Research at Immunex Corporation until its acquisition by Amgen. Dr.&nbsp;Daniel is a director of publicly held companies, Zafgen, Inc., Magenta Therapeutics,
Inc., and privately-held biotechnology companies, Vir Biotechnology Inc., ImmusanT, Inc., Locana, Inc. and Sana Biotechnology. He was previously a director at Epizyme, Inc. and Juno Therapeutics. Dr. Daniel serves as a member of the Biomedical
Science Advisory Board of Vanderbilt University Medical Center, the Scientific Advisory Board of the Parker Institute for Cancer Immunotherapy and the Board of Overseers for The Scripps Research Institute. A nephrologist and former academic
investigator, Dr.&nbsp;Daniel was previously the K.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. Dr.&nbsp;Daniel received a B.A. from the Southern Methodist
University in Texas in 1974 and an M.D. from the University of Texas, Southwestern, in 1978, and completed medical residency at Massachusetts General Hospital. Dr.&nbsp;Daniel&#146;s significant academic and research experience and his experience
serving on numerous boards contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Richard Lim</I> has served on our board of directors since January 2018. He has been a Managing Director at Omega Funds since November
2008, and has over 25 years of experience in principal investment and strategic consulting, all within the life science and healthcare sectors. From November 2002 until October 2008, he was an Investment Manager and General Partner of MVM Life
Science Partners, and founded its U.S. investment operations. He was previously a Vice President at Saunders, Karp&nbsp;&amp; Megrue, where he specialized in healthcare growth capital and leveraged transactions. Mr.&nbsp;Lim is a member of the board
of directors of GelSight, Inc. He previously was a member of the board of directors of Paratek Pharmaceuticals, Inc., Trident Pharmaceuticals, Inc., Hydrocision, Inc., BioVex Group Inc. and Biocius Life Sciences, Inc. He also serves on the Advisory
Board of the Deshpande Center at the Massachusetts Institute of Technology. Mr.&nbsp;Lim received an A.B. from Harvard College and an M.B.A. from Harvard Business School. Mr.&nbsp;Lim&#146;s extensive experience in the life science industry, and his
experience as a venture capitalist, contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Robert Nelsen </I>has served on our board of directors since January 2018. Mr.&nbsp;Nelsen is a
<FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as a Managing Director of ARCH Venture Partners since 1994. Mr.&nbsp;Nelsen currently serves as a member of the boards of directors of publicly-held biopharmaceutical companies Sienna
Biopharmaceuticals, Denali Therapeutics, Inc. and Unity Biotechnology. Mr.&nbsp;Nelsen also currently serves on the boards of directors of Arivale Inc., Encoded Genomics, Inc., Ensemble Discovery Corp. and as Chairman of the board of directors of
Hua Medicine. Previously, Mr.&nbsp;Nelsen served on the boards of directors of a number of publicly-held biotechnology companies including Bellerophon Therapeutics, Inc., Fate Therapeutics, Inc., Juno Therapeutics, Inc., Agios Pharmaceuticals, Inc.,
Kythera, Syros Pharmaceuticals Inc., NeurogesX, Inc. and Sage Therapeutics </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Inc. He previously served as a trustee of the Fred Hutchinson Cancer Research Institute and the Institute for Systems Biology, and as a member of the board of directors of the National Venture
Capital Association. Mr.&nbsp;Nelsen holds a B.S. from the University of Puget Sound with majors in Economics and Biology and an M.B.A. from the University of Chicago. Mr.&nbsp;Nelsen&#146;s extensive experience serving on the boards of directors of
clinical-stage biotechnology companies and as a venture capitalist contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Otello Stampacchia, Ph.D. </I>has served on our board of directors since January 2018. He has served as founder and Managing Director of
Omega Funds since 2004. Previously, Dr.&nbsp;Stampacchia was in charge of life sciences direct investments at AlpInvest Partners B.V. from 2001 to 2003, and from 2000 to 2001, Dr.&nbsp;Stampacchia was the portfolio manager of the Lombard Odier
Immunology Fund. Previously, Dr.&nbsp;Stampacchia was a member of the healthcare corporate finance and mergers and acquisitions team at Goldman Sachs Group, Inc. from 1997 to 2000. Before joining Goldman Sachs, Dr.&nbsp;Stampacchia helped <FONT
STYLE="white-space:nowrap">co-found</FONT> the healthcare investment activities at Index Securities, now Index Ventures, Inc. Dr.&nbsp;Stampacchia is currently a member of the boards of directors of Replimune Group, Inc., Kronos Bio, Inc., Morphic
Therapeutic and ESSA Pharma, Inc. Previously, Dr.&nbsp;Stampacchia served on the boards of directors of Paratek Pharmaceuticals, Micromet, CropDesign NV and DeveloGen AG. He has a Ph.D. degree in Molecular Biology from the University of Geneva and a
European Ph.D. in Biotechnology (EDBT) from the European Association for Higher Education in Biotechnology. He has an M.S. in Genetics from Universita&#146; degli Studi di Pavia. Dr.&nbsp;Stampacchia&#146;s extensive experience investing in and
serving on the boards of life science companies contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Qinqing Yi</I> has served on our board of directors since July 2018. He is currently a Partner at Hillhouse Capital Group, or, together
with its affiliates, Hillhouse, and has worked with Hillhouse since its inception in 2005. Mr.&nbsp;Yi leads Hillhouse&#146;s healthcare investments and is currently a director of BeiGene, Ltd. Prior to joining Hillhouse, Mr.&nbsp;Yi was an Equity
Research Analyst at China International Capital Corporation Ltd. He received a B.S in Engineering from Shanghai Maritime University, as well as an M.B.A. from University of Southern California. Mr.Yi&#146;s extensive experience investing in the
healthcare sector contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and
Election of Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Independence </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of eight members. Our board of directors has determined that all of our directors, other than Sheila
Gujrathi, M.D. and Faheem Hasnain, are independent directors in accordance with the listing requirements of the Nasdaq Global Select Market. The Nasdaq independence definition includes a series of objective tests, including that the director is not,
and has not been for at least three years, one of our employees and that neither the director nor any of his or her family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of
directors has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the
responsibilities of the director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director&#146;s business and personal activities and relationships as
they may relate to us and our management. There are no family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board of
Directors </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our amended and restated certificate of incorporation that will go into effect
immediately prior to the closing of this offering, our board of directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the directors whose terms then expire
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be eligible for reelection until the third annual meeting following reelection. Effective upon the closing of this offering, our directors will be divided among the three classes as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will
expire at our first annual meeting of stockholders following this offering; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will
expire at our second annual meeting of stockholders following this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their terms will
expire at our third annual meeting of stockholders following this offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of
incorporation that will go into effect immediately prior to the closing of this offering will provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an
increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors
into three classes with staggered three-year terms may delay or prevent a change of our board of directors or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the holders of at least
two-thirds of our outstanding voting stock then entitled to vote in an election of directors. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, our board designation
agreement with HH Goss Holdings LLC, one of our stockholders, provides that it or its affiliates will, effective as of the closing of this offering, have the right to designate one member to our board of directors and have such member appointed to
any board committee that it requests, in each case, subject to our obligation to comply with applicable law and Nasdaq listing standards. See &#147;Certain Relationships and Related Person Transactions&#151;Board Designation Agreement with
Hillhouse&#148; for additional information on the agreement, including termination provisions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors is currently led by our Executive Chairman, Faheem Hasnain. Our board of directors recognizes that it is important to
determine an optimal board leadership structure to ensure the independent oversight of management as the company continues to grow. We separate the roles of chief executive officer and chairman of the board in recognition of the differences between
the two roles. The chief executive officer is responsible for setting the strategic direction for our company and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> leadership and performance of our
company, while the chairman of the board of directors provides guidance to the chief executive officer and presides over meetings of the full board of directors. We believe that this separation of responsibilities provides a balanced approach to
managing the board of directors and overseeing our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors has concluded that our current leadership structure is
appropriate at this time. However, our board of directors will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of Board in Risk Oversight Process </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors has responsibility for the oversight of our risk management processes and, either as a whole or through its committees,
regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees and members of senior
management to enable our board to understand our risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and reputational risk.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The audit committee reviews information regarding liquidity and operations, and oversees our
management of financial risks. Periodically, the audit committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with
our external auditors, and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of our
compensation policies or programs has the potential to encourage excessive risk-taking. The nominating and corporate governance committee manages risks associated with the independence of the board, corporate disclosure practices and potential
conflicts of interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board is regularly informed through committee reports about such risks. Matters of significant strategic
risk are considered by our board as a whole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees and Independence </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors has established three standing committees&#151;audit, compensation and nominating and corporate governance&#151;each of
which operates under a charter that has been approved by our board. In addition, our board designation agreement with Hillhouse provides that Hillhouse&#146;s director designee shall be appointed to any board committee Hillhouse requests, subject to
our obligation to comply with applicable law and Nasdaq listing standards. See &#147;Certain Relationships and Related Person Transactions&#151;Board Designation Agreement with Hillhouse Capital&#148; for additional information on the agreement,
including termination provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The audit committee&#146;s main function is to oversee our accounting and financial reporting processes and the audits of our consolidated
financial statements. This committee&#146;s responsibilities include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the qualifications, independence and performance of our independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving the audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our
independent registered public accounting firm; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our
critical accounting policies; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">discussing with management and the independent registered public accounting firm the results of our annual audit
and the review of our quarterly unaudited financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, overseeing and monitoring the integrity of our consolidated financial statements and our compliance
with legal and regulatory requirements as they relate to financial statements or accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to our board any changes
to such investment policy; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and our auditors any earnings announcements and other public announcements regarding
our results of operations; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparing the report that the SEC requires in our annual proxy statement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving any related party transactions and reviewing and monitoring compliance with our code of
conduct and ethics; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating, at least annually, the performance of the audit committee and its members including
compliance of the audit committee with its charter. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The members of our audit committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serves as the chairperson of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq Global
Select Market. Our board of directors has determined that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is an &#147;audit committee financial expert&#148; as defined by applicable SEC rules and has
the requisite financial sophistication as defined under the applicable Nasdaq listing standards. Our board of directors has determined each
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is independent under the applicable rules of the SEC and the Nasdaq Global Select Market. Upon the listing of our common stock on the Nasdaq Global Select Market, the audit committee will operate under
a written charter that satisfies the applicable standards of the SEC and the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our compensation committee approves policies relating to compensation and benefits of our officers and employees. The compensation committee
approves corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of
these officers based on such evaluations. The compensation committee also approves the issuance of stock options and other awards under our equity plans. The compensation committee will review and evaluate, at least annually, the performance of the
compensation committee and its members, including compliance by the compensation committee with its charter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The members of our
compensation committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serves as the chairperson of the committee. Our board of directors has determined that each
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is independent under the
applicable Nasdaq listing standards, is a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. Upon the listing of our common
stock on the Nasdaq Global Select Market, the compensation committee will operate under a written charter, which the compensation committee will review and evaluate at least annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee is responsible for assisting our board of directors in discharging the board&#146;s
responsibilities regarding the identification of qualified candidates to become board members, the selection of nominees for election as directors at our annual meetings of stockholders (or special meetings of stockholders at which directors are to
be elected), and the selection of candidates to fill any vacancies on our board of directors and any committees thereof. In addition, the nominating and corporate governance committee is responsible for overseeing our corporate governance policies,
reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of directors. The members of our nominating and corporate governance committee
are&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;serves as the chairperson of the committee. Our
board has determined that each of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is independent under the applicable Nasdaq listing standards. Upon the listing of our common stock on the Nasdaq Global
Select Market, the nominating and corporate governance committee will operate under a written charter, which the nominating and corporate governance committee will review and evaluate at least annually. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee has ever been one of our officers or employees. None of our executive officers currently
serves, or has served, as a member of the board of directors or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Diversity </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the closing of
this offering, our nominating and corporate governance committee will be responsible for reviewing with the board of directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole
and its individual members. In evaluating the suitability of individual candidates (both new candidates and current members) for election or appointment, the nominating and corporate governance committee and the board of directors will take into
account many factors, including the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personal and professional integrity, ethics and values; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience in corporate management, such as serving as an officer or former officer of a publicly-held company;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience as a board member or executive officer of another publicly-held company; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">strong finance experience; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversity of expertise and experience in substantive matters pertaining to our business relative to other board
members; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place
of residence and specialized experience; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience relevant to our business industry and with relevant social policy concerns; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relevant academic expertise or other proficiency in an area of our business operations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Currently, our board of directors evaluates, and following the closing of this offering will evaluate, each individual in the context of the
board of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various
areas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We plan to adopt a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, which will be effective upon the completion of this offering. Upon the closing of this offering, our code of
business conduct and ethics will be available under the Corporate Governance section of our website at www.gossamerbio.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of the Nasdaq
Global Select Market concerning any amendments to, or waivers from, any provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and
you should not consider it to be a part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for our executive officers who are named in the
&#147;Summary Compensation Table&#148; below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Sheila Gujrathi, M.D., our President and Chief Executive Officer and former Chief Operating
Officer, Faheem Hasnain, our Executive Chairman and former Chief Executive Officer, and Christian Waage, our Executive Vice President and General Counsel, were our only executive officers during 2017 and, accordingly, are our named executive
officers for 2017. We did not pay any cash compensation to any executive officer or board member in 2017. Cash compensation to our executive officers commenced in January 2018 in connection with the closing of our Series A preferred stock financing.
Mr.&nbsp;Waage, however, received a restricted stock award in November 2017 in consideration of his services to us, which is the only compensation paid to our named executive officers for 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our other current executive officers commenced employment with us during 2018. Bryan Giraudo, our Chief Financial Officer, commenced
employment in May 2018. Luisa <FONT STYLE="white-space:nowrap">Salter-Cid,</FONT> Ph.D., our Chief Scientific Officer, commenced employment in August 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have included information in the following narrative regarding our named executive officers and other current executive officers&#146; 2018
compensation where it may be helpful to an understanding of our compensation program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This discussion may contain forward-looking
statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the closing of this offering may differ materially from the
currently planned programs summarized in this discussion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table presents summary information regarding the total compensation that was awarded to, earned by or paid to our named
executive officers for services rendered during the year ended December&nbsp;31, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and principal position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Salary<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Bonus<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Stock<BR>awards<BR>($)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Option<BR>awards<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>Incentive
Plan<BR>Compensation<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>All
other<BR>compensation<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total<BR>($)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheila Gujrathi, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer and Former Chief Operating Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Faheem Hasnain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Chairman and Former Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Waage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>EVP and General Counsel</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">This column reflects the grant date fair value of the restricted stock award granted to Mr.&nbsp;Waage in
November 2017. In accordance with SEC rules, this column reflects the aggregate fair value of the stock award granted to Mr.&nbsp;Waage during 2017 computed as of its grant date in accordance with Financial Accounting Standards, Standard Board
Accounting Codification Topic 718 for stock-based compensation transactions (ASC 718). Assumptions used in the calculation of this amount is included in Note 9 to our consolidated financial statements appearing elsewhere in this prospectus. This
amount does not reflect the actual economic value that will be realized by Mr.&nbsp;Waage upon the vesting of the stock award or the sale of the common stock underlying such award. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Compensation Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Base Salary </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
compensation of our executive officers is generally determined and approved at the time of their commencement of employment by our board of directors or the compensation committee. As noted above, none of our named executive officers received any
cash compensation for 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the closing of our Series A preferred stock financing in January 2018, our board of
directors established the initial base salaries for each of our named executive officers as follows: Dr.&nbsp;Gujrathi, $475,000, Mr.&nbsp;Hasnain, $475,000, and Mr.&nbsp;Waage, $370,000. In connection with their commencement of employment in May
and August 2018, respectively, the base salaries for Mr.&nbsp;Giraudo and <FONT STYLE="white-space:nowrap">Dr.&nbsp;Salter-Cid</FONT> were set at $400,000 and $350,000, respectively, by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bonus Compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">From time to
time our board of directors or compensation committee may approve bonuses for our named executive officers based on individual performance, company performance or as otherwise determined appropriate. No formal bonus plan was in effect during 2017
and none of our named executive officers received a bonus in 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For 2018, each named executive officer may be eligible for a
performance bonus based upon the achievement of certain corporate performance goals and objectives approved by our board of directors. The employment letters with each of our executive officers set forth their target annual bonus levels, which are
currently as follows: 50% of base salary for Dr.&nbsp;Gujrathi and Mr.&nbsp;Hasnain and 40% of base salary for Messrs. Waage and Giraudo and <FONT STYLE="white-space:nowrap">Dr.&nbsp;Salter-Cid.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For 2018, no formal bonus plan has been adopted by our board of directors and any bonuses payable to our executive officers will be determined
in the board&#146;s discretion based on the company&#146;s performance and individual executive performance during the year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity-Based Incentive
Awards </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our equity-based incentive awards are designed to align our interests and the interests of our stockholders with those of
our employees and consultants, including our named executive officers. Our board of directors or the compensation committee approves equity grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to the completion of our Series A preferred stock financing in January 2018, we issued restricted stock to certain of our executive
officers and consultants. Following the adoption of our 2017 equity incentive plan, or the 2017 Plan, we have generally granted equity awards pursuant to the 2017 Plan (other than awards to Dr.&nbsp;Gujrathi and Mr.&nbsp;Hasnain, which have not been
granted under the 2017 Plan, as described below). Following this offering, we will grant equity incentive awards under the terms of our 2019 equity incentive plan, or the 2019 Plan. The terms of our equity plans are described below under
&#147;&#151;Incentive Award Plans.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since January 2018, we have used stock options as the primary incentive for long-term
compensation to our employees, directors and consultants because they are able to profit from stock options only if our stock price increases relative to the stock option&#146;s exercise price, which exercise price is set at the fair market value of
our common stock at the date of grant. We may grant equity awards at such times as our board of directors determines appropriate. With the exception of our named executive officers, each of whom received awards of restricted stock prior to our
Series A preferred stock financing in connection with the formation of our company or in consideration of services to our company prior to such financing, our executives generally are awarded an initial grant in the form of a stock option in
connection with their commencement of employment. Additional grants may occur periodically in order to specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We granted restricted stock awards to Dr.&nbsp;Gujrathi and Mr.&nbsp;Hasnain in connection
with the formation of our company and pursuant to their employment letters, all of which awards were granted on a stand-alone basis and not under our 2017 Plan. For a description of such restricted stock awards, please see &#147;&#151;Employment
Letters with our Named Executive Officers.&#148; No equity awards were granted to Dr.&nbsp;Gujrathi or Mr.&nbsp;Hasnain during 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Waage was granted 2,349,768 shares of restricted common stock on November&nbsp;18, 2017 under the 2017 Plan, with such stock vesting
over a period of four years from the grant date, with 25% of the restricted shares vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the three years thereafter, subject to continuous
service through each vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On May&nbsp;21, 2018, in connection with his commencement of employment, we granted Mr.&nbsp;Giraudo
an option to purchase 1,825,500 shares of our common stock under the 2017 Plan. The option vests over a period of four years from May&nbsp;7, 2018 (his employment commencement date), with 25% of the option vesting on the first anniversary of such
date, and the remainder vesting in equal monthly installments over the three years thereafter. The option has an exercise price per share of $0.58, which was the fair market value at the time of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Letters with our Named Executive Officers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In 2017, none of our executive officers were parties to employment agreements or other similar arrangements with us. Each of our executive
officers&#146; employment is &#147;at will&#148; and may be terminated at any time, subject to our contractual obligations to them as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Letters with Dr. Gujrathi and Mr. Hasnain </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We entered into employment letters with each of Dr.&nbsp;Gujrathi and Mr.&nbsp;Hasnain on January&nbsp;4, 2018, setting forth the terms of
their employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to her employment letter, Dr.&nbsp;Gujrathi served as our President and Chief Operating Officer through
July&nbsp;23, 2018, at which time she was appointed as our President and Chief Executive Officer. She receives an annual base salary of $475,000 and is eligible to receive an annual bonus with a target amount equal to 50% of her then-current annual
base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to his employment letter, Mr.&nbsp;Hasnain served as our Chief Executive Officer through July&nbsp;23, 2018, at
which time he became our Executive Chairman. He receives an annual base salary of $475,000 and is eligible to receive an annual bonus with a target amount equal to 50% of his then-current annual base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In December 2015, each of Dr.&nbsp;Gujrathi and Mr.&nbsp;Hasnain were each issued 20,612,000 shares in connection with the formation of our
company, which we refer to as the Founders&#146; Equity. Pursuant to their employment letters, each of Dr.&nbsp;Gujrathi and Mr.&nbsp;Hasnain agreed that 50% of the Founders&#146; Equity would be subject to new vesting terms, or the Restricted
Founders&#146; Equity, and would vest over a period of five years from the date of the closing of our Series A preferred stock financing, with 20% of the Restricted Founders&#146; Equity vesting on January&nbsp;4, 2019 and the remainder vesting in
48 equal monthly installments thereafter, subject to continued full-time employment on each vesting date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The employment letters also
provided for certain potential additional issuances of our common stock to each of Dr.&nbsp;Gujrathi and Mr.&nbsp;Hasnain to ensure the total number of shares of common stock held by them and their affiliates (inclusive of any shares subject to
equity awards granted by us and the Founders&#146; Equity) would represent 15% of our fully-diluted capitalization until such time as we raised $300&nbsp;million in equity capital, including the capital raised in the Series A financing. In
furtherance of this obligation: (1)&nbsp;on May&nbsp;21, 2018, we issued 1,131,962 shares of common stock to each of Dr.&nbsp;Gujrathi and Mr.&nbsp;Hasnain; and (2)&nbsp;on September&nbsp;6, 2018, we issued 8,077,604 shares of common stock to each
of Dr.&nbsp;Gujrathi and Mr.&nbsp;Hasnain, or the Anti-Dilution </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Shares. Fifty percent of the Anti-Dilution Shares are fully vested and the remaining 50% of the Anti-Dilution Shares, or the Restricted Anti-Dilution Shares, vest over a period of five years
measured from January&nbsp;4, 2018, with 20% of the Restricted Anti-Dilution Shares vesting on January&nbsp;4, 2019 and the remainder vesting in 48 equal monthly installments thereafter, subject to continued full-time employment on each vesting
date. Neither Dr.&nbsp;Gujrathi nor Mr.&nbsp;Hasnain are entitled to any further grants of additional anti-dilution shares pursuant to their employment letters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to their employment letters, if we terminate Dr.&nbsp;Gujrathi&#146;s or Mr.&nbsp;Hasnain&#146;s employment other than for cause (as
defined below) or Dr.&nbsp;Gujrathi or Mr.&nbsp;Hasnain terminates his or her employment for good reason (as defined below), and other than as a result of death or disability, in either case prior to a change in control (as defined below) or more
than 12 months following a change in control, he or she is entitled to the following payments and benefits, subject to the timely execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a general release of claims in our favor:
(1)&nbsp;continued payment of his or her base salary at the then-current rate for 12 months, paid in accordance to our payroll practices; (2)&nbsp;a payment equal to his or her then current target annual bonus opportunity, <FONT
STYLE="white-space:nowrap">pro-rated</FONT> for the portion of the current calendar year in which the executive was employed, payable in a lump sum payment 60 days following the date of termination; (3)&nbsp;payment of the full premium for continued
health plan coverage for up to 12&nbsp;months following the date of termination or, if earlier, up to the date the executive becomes eligible to receive equivalent or increased health plan coverage by means of subsequent employment or
self-employment; and (4)&nbsp;automatic acceleration of the vesting and exercisability of the executive&#146;s unvested stock awards, including any Founders&#146; Equity and Anti-Dilution Shares, as to the number of stock awards that would vest over
the <FONT STYLE="white-space:nowrap">12-month</FONT> period following the date of termination. The cash severance benefits described in clause (1)&nbsp;above shall be paid or commence on the first payroll period following the date the
executive&#146;s release becomes effective and the first payment shall include all accrued amounts from the date of termination, provided that if the period during which executive may deliver the release spans two calendar years, the initial payment
date shall be no earlier than January&nbsp;1 of the second calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If Dr.&nbsp;Gujrathi&#146;s or Mr.&nbsp;Hasnain&#146;s
employment is terminated by us other than for cause or by Dr.&nbsp;Gujrathi or Mr.&nbsp;Hasnain for good reason, in each case within 12&nbsp;months after a change in control, in lieu of the severance benefits described above, he or she is entitled
to the following payments and benefits, subject to the timely execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a general release of claims in our favor: (1)&nbsp;continued payment of his or her base salary at the then-current
rate for 18 months, paid in accordance to our payroll practices; (2)&nbsp;a payment equal to his or her then current target annual bonus opportunity, <FONT STYLE="white-space:nowrap">pro-rated</FONT> for the portion of the current calendar year in
which the executive was employed, payable in a lump sum payment 60 days following the date of termination; (3)&nbsp;payment of the full premium for continued health plan coverage for up to 18&nbsp;months following the date of termination or, if
earlier, up to the date the executive becomes eligible to receive equivalent or increased health plan coverage by means of subsequent employment or self-employment; and (4)&nbsp;automatic full vesting and exercisability of the executive&#146;s
unvested stock awards, including the Founders&#146; Equity and the Anti-Dilution Shares. The cash severance benefits described in clause (1)&nbsp;above shall be paid or commence on the first payroll period following the date the executive&#146;s
release becomes effective and the first payment shall include all accrued amounts from the date of termination, provided that if the period during which executive may deliver the release spans two calendar years, the initial payment date shall be no
earlier than January&nbsp;1 of the second calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in the event of Dr.&nbsp;Gujrathi&#146;s or Mr.&nbsp;Hasnain&#146;s
termination of employment by reason of his or her death or disability, and subject to the timely execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a general release of claims in our favor by the executive, then the greater of
(1) 50% of the unvested portion of any equity awards then held by him or her immediately prior to such termination, including the Founders&#146; Equity and the Anti-Dilution Shares, and (2)&nbsp;the portion of such equity awards, including the
Founders&#146; Equity and the Anti-Dilution Shares, that would have otherwise vested in the 12 month period following the date of such termination of employment, will vest and will no longer be subject to restrictions or forfeiture on the date of
such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the event we terminate Dr.&nbsp;Gujrathi&#146;s or Mr.&nbsp;Hasnain&#146;s employment for any reason, including for
cause, Dr.&nbsp;Gujrathi or Mr.&nbsp;Hasnain terminates their employment without good reason, or upon their death or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permanent disability, the executive is entitled to receive his or her fully earned but unpaid base salary and accrued and unused PTO through the date of termination at the rate then in effect,
plus all other amounts under any compensation plan or practice to which the executive is entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each of Dr.&nbsp;Gujrathi and
Mr.&nbsp;Hasnain was reimbursed $15,000 for their attorneys&#146; fees in connection with the review and negotiation of their employment letters in January 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The employment letters also contain a Section&nbsp;280G <FONT STYLE="white-space:nowrap">better-off</FONT> cutback provision, which provides
that, in the event that the payments or benefits provided to the executive pursuant to the employment letter or otherwise constitute parachute payments with the meaning of Section&nbsp;280G of the Code, the payments or benefits to the executive will
either be delivered in full or reduced to the extent necessary to avoid an excise tax under Section&nbsp;4999 of the Code, whichever would result in the executive receiving the largest amount of payments or benefits on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Letters with Other Executives </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have entered into employment letters with each of Mr.&nbsp;Giraudo, <FONT STYLE="white-space:nowrap">Dr.&nbsp;Salter-Cid</FONT> and
Mr.&nbsp;Waage setting forth the terms of their employment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to his employment letter, Mr.&nbsp;Giraudo serves as our Chief
Financial Officer. He receives an annual base salary of $400,000 and is eligible to receive an annual bonus with a target amount equal to 40% of his then-current annual base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to his employment letter, Mr.&nbsp;Waage serves as our Executive Vice President and General Counsel. He receives an annual base
salary of $370,000 and is eligible to receive an annual bonus with a target amount equal to 40% of his then-current annual base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to her employment letter, <FONT STYLE="white-space:nowrap">Dr.&nbsp;Salter-Cid</FONT> serves as our Chief Scientific Officer. She
receives an annual base salary of $350,000 and is eligible to receive an annual bonus with a target amount equal to 40% of her then-current annual base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Defined Terms Applicable to Executive Employment Letters </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For purposes of the executive employment letters, &#147;cause&#148; means (1)&nbsp;a willful and material act of dishonesty by the executive
in connection with the performance of the executive&#146;s duties as our employee; (2)&nbsp;the executive&#146;s conviction of, or plea of guilty or nolo contendere to, a felony (other than a traffic offense that does not result in a fatality), or
any crime involving fraud or embezzlement that the board reasonably determines has had or is reasonably likely to have a materially detrimental effect on our reputation or business; (3)&nbsp;the executive&#146;s gross misconduct in the performance
of the executive&#146;s duties as our employee; (4)&nbsp;the executive&#146;s willful and material unauthorized use or disclosure of any of our proprietary information or trade secrets or any other party to whom the executive owes an obligation of
nondisclosure as a result of the executive&#146;s relationship with us; (5)&nbsp;the executive&#146;s willful and material breach of any obligations under any written agreement or written covenant with us; or (6)&nbsp;the executive&#146;s continued
willful and substantial failure to perform the executive&#146;s material employment duties that are lawfully assigned to the executive in good faith by the executive&#146;s reporting superior (other than as a result of the executive&#146;s death or
disability) after written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For purposes of the executive employment letters, &#147;change in control&#148; has the same meaning
given to such term in our 2017 Plan, as described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For purposes of the executive employment letters, &#147;disability&#148; has the
same meaning given to such term in our 2017 Plan, as described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For purposes of the executive employment letters, &#147;good reason&#148; means the
occurrence of any of the following events or conditions without the executive&#146;s written consent: (1)&nbsp;a material reduction in the executive&#146;s base salary or target annual bonus; (2)&nbsp;a material diminution of the executive&#146;s
title, duties, responsibilities or reporting lines; (3)&nbsp;a material change in the principal geographic location at which the executive must perform services, more than fifty (50)&nbsp;miles from the our head office; or (4)&nbsp;a material breach
by us of the terms of the employment letter. The executive must provide written notice to us of the occurrence of any of the foregoing events or conditions within 60 days of the initial occurrence of such event and we will have a period of 30 days
to cure such event or condition after receipt of such notice. An executive&#146;s separation from service by reason of resignation for good reason must occur within 60 days following the expiration of the foregoing 30 day cure period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding equity awards granted to our named executive officers that remained outstanding
as of December&nbsp;31, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number of<BR>Shares or<BR>Units
of<BR>Stock That<BR>Have Not<BR>Vested<BR>(#)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Market<BR>Value&nbsp;of<BR>Shares&nbsp;or<BR>Units&nbsp;of<BR>Stock&nbsp;
That<BR>Have&nbsp;Not<BR>Vested<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheila Gujrathi, M.D.<I> </I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Faheem Hasnain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Waage</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,349,768</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Since we have not yet completed our initial public offering, the market value was computed using
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, which is the midpoint of the price range set forth on the cover of this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">The shares were granted on November&nbsp;18, 2017 and vest over a period of four years from the grant date, with
25% of the shares vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the three years thereafter, subject to continuous service through each vesting date. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">None of our named executive officers vested in any stock awards during 2017 and we did not engage in any repricings or other modifications or
cancellations to any of our named executive officers&#146; outstanding equity awards during the year ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Elements of
Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Perquisites, Health, Welfare and Retirement Benefits </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision, group life,
disability and accidental death and dismemberment insurance plans, in each case on the generally on same basis as all of our other employees. We provide a 401(k) plan to our employees, including our current named executive officers, as discussed in
the section below entitled &#147;&#151;401(k) Plan.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We generally do not provide perquisites or personal benefits to our named
executive officers, except in limited circumstances. We do, however, pay the premiums for term life insurance and disability insurance for all of our employees, including our executive officers. Our board of directors may elect to adopt qualified or
<FONT STYLE="white-space:nowrap">non-qualified</FONT> benefit plans in the future if it determines that doing so is in our best interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution employee retirement plan, or 401(k) plan, for our employees. Our named executive officers are eligible to
participate in the 401(k) plan on the same basis as our other employees. The 401(k) plan is intended to qualify as a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> plan under Section&nbsp;401(k) of the Code. The 401(k) plan provides that each
participant may make <FONT STYLE="white-space:nowrap">pre-tax</FONT> deferrals from his or her compensation up to the statutory limit, which is $18,500 for calendar year 2018, and other testing limits. Participants that are 50 years or older can
also make <FONT STYLE="white-space:nowrap">&#147;catch-up&#148;</FONT> contributions, which in calendar year 2018 may be up to an additional $6,000 above the statutory limit. Although the 401(k) plan provides for discretionary matching and profit
sharing contributions, we currently do not make either type of contribution to the 401(k) plan. Participant contributions are held and invested, pursuant to the participant&#146;s instructions, by the plan&#146;s trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nonqualified Deferred Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We do not maintain nonqualified defined contribution plans or other nonqualified deferred compensation plans. Our board of directors may elect
to provide our officers and other employees with <FONT STYLE="white-space:nowrap">non-qualified</FONT> defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Change in Control Benefits </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our executive officers may become entitled to certain benefits or enhanced benefits in connection with a change in control of our company.
Each of Dr.&nbsp;Gujrathi&#146;s and Mr.&nbsp;Hasnain&#146;s offer letters entitles them to accelerated vesting of all outstanding equity awards, as well as certain other benefits, upon a qualifying termination in connection with a change in control
of our company. For additional discussion, please see &#147;&#151;Offer Letters with our Named Executive Officers&#148; above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incentive Award Plans
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Incentive Award Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we intend to adopt and ask our stockholders to approve the 2019 Plan, which would become effective in connection with
this offering. Under the 2019 Plan, we may grant cash and equity incentive awards to eligible employees, directors and consultants in order to attract, motivate and retain the talent for which we compete. The material terms of the 2019 Plan, as it
is currently contemplated, are summarized below. Our board of directors is still in the process of developing, approving and implementing the 2019 Plan and, accordingly, this summary is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eligibility and Administration </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our employees, consultants and directors, and employees and consultants of our subsidiaries, will be eligible to receive awards under the 2019
Plan. Following our initial public offering, the 2019 Plan will generally be administered by our board of directors with respect to awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and by our compensation committee with
respect to other participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to certain limitations that may be imposed
under the 2019 Plan, Section&nbsp;16 of the Exchange Act and/or stock exchange rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt
rules for the administration of, the 2019 Plan, subject to its express terms and conditions. The plan administrator will also set the terms and conditions of all awards under the 2019 Plan, including any vesting and vesting acceleration conditions.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitation on Awards and Shares Available </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">An aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will initially be
available for issuance under awards granted pursuant to the 2019 Plan. The number of shares initially available for issuance will be increased by (1)&nbsp;the number of shares of common stock available for issuance and not subject to options granted
under our 2017 Plan as of the effective date of the 2019 Plan, (2)&nbsp;the number of shares subject to stock options or similar awards granted under our 2017 Plan that expire or otherwise terminate without having been exercised in full after the
effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the 2017 Plan that are forfeited to or repurchased by us after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019
Plan pursuant to clauses (1)&nbsp;and (2)&nbsp;above equal to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares, and (3)&nbsp;an annual increase on January&nbsp;1 of each calendar year beginning in 2019 and ending in
2028, equal to the lesser of (a) &nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b)&nbsp;such smaller number of shares as determined by our board of directors. No
more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock may be issued upon the exercise of incentive stock options under the 2019 Plan. Shares issued under the 2019 Plan may be authorized but
unissued shares, shares purchased in the open market or treasury shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If an award under the 2019 Plan or the 2017 Plan expires, lapses
or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, any shares subject to such award will, as applicable, become or again be available for new grants under the 2019 Plan.
Further, shares delivered to us to satisfy the applicable exercise or purchase price of an award under the 2019 Plan or the 2017 Plan and/or to satisfy any applicable tax withholding obligations (including shares retained by us from the award under
the 2019 Plan or the 2017 Plan being exercised or purchased and/or creating the tax obligation) will become or again be available for award grants under the 2019 Plan. Awards granted under the 2019 Plan upon the assumption of, or in substitution
for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under the 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Awards </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The 2019 Plan provides
for the grant of stock options, including incentive stock options, or ISOs, and nonqualified stock options, or NSOs, restricted stock, dividend equivalents, restricted stock units, or RSUs, stock appreciation rights, or SARs, and other stock or
cash-based awards. Certain awards under the 2019 Plan may constitute or provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, which may impose additional requirements on the terms and conditions of such awards. All awards
under the 2019 Plan will be set forth in award agreements, which will detail the terms and conditions of the awards, including any applicable vesting and payment terms and post-termination exercise limitations. A brief description of each award type
follows. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Stock Options</I>.&nbsp;&nbsp;&nbsp;&nbsp;Stock options provide for the purchase of shares of our common stock in the future
at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied.
The exercise price of a stock option will not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain
substitute options granted in connection with a corporate transaction. The term of a stock option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). Vesting conditions determined by the
plan administrator may apply to stock options and may include continued service, performance and/or other conditions. ISOs generally may be granted only to our employees and employees of our parent or subsidiary corporations, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>SARs</I>.&nbsp;&nbsp;&nbsp;&nbsp;SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the
shares subject to the award between the grant date and the exercise date. The exercise price of a SAR will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not be less than 100% of the fair market value of the underlying share on the date of grant (except with respect to certain substitute SARs granted in connection with a corporate transaction),
and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan administrator may apply to SARs and may include continued service, performance and/or other conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock and RSUs</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock is an award of nontransferable shares of our common stock that
remain forfeitable unless and until specified conditions are met, and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may also remain forfeitable unless and until
specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. Delivery of the shares underlying RSUs may be deferred
under the terms of the award or at the election of the participant, if the plan administrator permits such a deferral. Conditions applicable to restricted stock and RSUs may be based on continuing service, the attainment of performance goals and/or
such other conditions as the plan administrator may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Other Stock or Cash-Based Awards.</I>&nbsp;&nbsp;&nbsp;&nbsp;Other
stock or cash-based awards are awards of cash, fully vested shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other stock or cash-based awards may be granted to
participants and may also be available as a payment form in the settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees or other cash compensation otherwise payable to any individual who is eligible to
receive awards. The plan administrator will determine the terms and conditions of other stock or cash-based awards, which may include vesting conditions based on continued service, performance and/or other conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Awards </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Performance
awards include any of the foregoing awards that are granted subject to vesting and/or payment based on the attainment of specified performance goals or other criteria the plan administrator may determine, which may or may not be objectively
determinable. Performance criteria upon which performance goals are established by the plan administrator may include: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization and <FONT
STYLE="white-space:nowrap">non-cash</FONT> equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including, but not limited to, gross
profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash
flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity; total stockholder return; return on sales; costs,
reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends);
regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial or strategic milestones or developments; market share; economic value or economic value added
models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters;
strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand;
acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to our
performance or the performance of a subsidiary, division, business segment or business unit, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of
other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions of the 2019 Plan Relating to Director Compensation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The 2019 Plan provides that the plan administrator may establish compensation for <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors from time to time subject to the 2019 Plan&#146;s limitations. Prior to commencing this offering, our stockholders will approve the initial terms of our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program,
which is described below under the heading &#147;&#151;Director Compensation.&#148; Our board of directors or its authorized committee may modify the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program from time to
time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation or other compensation and the grant date
fair value (as determined in accordance with ASC 718, or any successor thereto) of any equity awards granted as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any fiscal year may not exceed
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, increased to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, in the fiscal year of a <FONT STYLE="white-space:nowrap">non-employee</FONT>
director&#146;s initial service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director. The plan administrator may make exceptions to this limit for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in
extraordinary circumstances, as the plan administrator may determine in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT> director receiving such additional compensation may not participate in the decision to
award such compensation or in other contemporaneous compensation decisions involving <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Transactions </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
connection with certain transactions and events affecting our common stock, including a change in control, or change in any applicable laws or accounting principles, the plan administrator has broad discretion to take action under the 2019 Plan to
prevent the dilution or enlargement of intended benefits, facilitate such transaction or event, or give effect to such change in applicable laws or accounting principles. This includes canceling awards in exchange for either an amount in cash or
other property with a value equal to the amount that would have been obtained upon exercise or settlement of the vested portion of such award or realization of the participant&#146;s rights under the vested portion of such award, accelerating the
vesting of awards, providing for the assumption or substitution of awards by a successor entity, adjusting the number and type of shares available, replacing awards with other rights or property or terminating awards under the 2019 Plan. In the
event of a change in control where the acquirer does not assume awards granted under the 2019 Plan, awards issued under the 2019 Plan shall be subject to accelerated vesting such that 100% of the awards will become vested and exercisable or payable,
as applicable, and which may be subject to such terms and conditions as apply generally to holders of common stock under the change in control documents. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT>
transactions with our stockholders, or an &#147;equity restructuring,&#148; the plan administrator will make equitable adjustments to the 2019 Plan and outstanding awards as it deems appropriate to reflect the equity restructuring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For purposes of the 2019 Plan, a &#147;change in control&#148; means and includes each of the following: (1)&nbsp;a transaction or series of
transactions (other than an offering of our common stock to the general public through a registration statement filed with the SEC or a transaction or series of transactions that meets the requirements of clauses (x)&nbsp;and (y) of clause
(3)&nbsp;below) whereby any &#147;person&#148; or related &#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than us, any of our subsidiaries, an employee benefit plan
maintained by us or any of our subsidiaries or a &#147;person&#148; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, us) directly or indirectly acquires beneficial ownership (within
the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of our securities possessing more than 50% of the total combined voting power of our securities outstanding immediately after such acquisition; or
(2)&nbsp;during any period of two consecutive years, individuals who, at the beginning of such period, constitute the board of directors together with any new director(s) (other than a director designated by a person who shall have entered into an
agreement with us to effect a transaction described in clauses (1)&nbsp;or (3)) whose election by the board of directors or nomination for election by our stockholders was approved by a vote of at least
<FONT STYLE="white-space:nowrap">two-thirds</FONT> of the directors then still in office who either were directors at the beginning of the <FONT STYLE="white-space:nowrap">two-year</FONT> period or whose election or nomination for election was
previously so approved, cease for any reason to constitute a majority thereof; or (3)&nbsp;the consummation by us (whether directly involving us or indirectly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
involving us through one or more intermediaries) of (a)&nbsp;a merger, consolidation, reorganization, or business combination or (b)&nbsp;a sale or other disposition of all or substantially all
of our assets in any single transaction or series of related transactions or (c)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: (x)&nbsp;which results in our voting securities outstanding
immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into our voting securities or the voting securities of a successor entity, directly or indirectly, at least a majority of the combined
voting power of our outstanding voting securities or the successor entity&#146;s outstanding voting securities immediately after the transaction, and (y)&nbsp;after which no person or group beneficially owns voting securities representing 50% or
more of the combined voting power of us or the successor entity (provided that no person will be treated as beneficially owning 50% or more of the combined voting power of us or the successor entity for purposes of this clause (y)&nbsp;solely as a
result of the voting power held in us prior to the consummation of the transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Participants, Claw-Back Provisions, Transferability
and Participant Payments </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">With respect to foreign participants, the plan administrator may modify award terms, establish subplans
and/or adjust other terms and conditions of awards, subject to the share limits described above. All awards will be subject to the provisions of any claw-back policy implemented by our company to the extent set forth in such claw-back policy or in
the applicable award agreement. With limited exceptions for estate planning, domestic relations orders, certain beneficiary designations and the laws of descent and distribution, awards under the 2019 Plan are generally <FONT
STYLE="white-space:nowrap">non-transferable</FONT> prior to vesting and are exercisable only by the participant. With regard to tax withholding obligations arising in connection with awards under the 2019 Plan and exercise price obligations arising
in connection with the exercise of stock options under the 2019 Plan, the plan administrator may, in its discretion, accept cash, wire transfer, or check, shares of our common stock that meet specified conditions, a &#147;market sell order&#148; or
such other consideration as it deems suitable or any combination of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Plan Amendment and Termination </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors may amend or terminate the 2019 Plan at any time; however, except in connection with certain changes in our capital
structure, stockholder approval will be required for any amendment that increases the number of shares available under the 2019 Plan. The plan administrator will have the authority, without the approval of our stockholders, to amend any outstanding
stock option or SAR to reduce its exercise price per share. No award may be granted pursuant to the 2019 Plan after the tenth anniversary of the date on which our board of directors adopts the 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Securities Laws </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The 2019 Plan is
intended to conform to all provisions of the Securities Act, and the Exchange Act and any and all regulations and rules promulgated by the SEC thereunder, including, without limitation, Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> The 2019
Plan will be administered, and awards will be granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Federal Income Tax Consequences </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The material federal income tax consequences of the 2019 Plan under current federal income tax law are summarized in the following discussion,
which deals with the general tax principles applicable to the 2019 Plan. The following discussion is based upon laws, regulations, rulings and decisions now in effect, all of which are subject to change. Foreign, state and local tax laws, and
employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual circumstances and from locality to locality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Stock Options and SARs</I>.&nbsp;&nbsp;&nbsp;&nbsp;A 2019 Plan participant generally will not recognize taxable income and we generally
will not be entitled to a tax deduction upon the grant of a stock option or SAR. The tax consequences of exercising a stock option and the subsequent disposition of the shares received upon exercise will depend upon
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
whether the option qualifies as an ISO or an NSO. Upon exercising an NSO when the fair market value of our stock is higher than the exercise price of the option, a 2019 Plan participant generally
will recognize taxable income at ordinary income tax rates equal to the excess of the fair market value of the stock on the date of exercise over the purchase price, and we (or our subsidiaries, if any) generally will be entitled to a corresponding
tax deduction for compensation expense, in the amount equal to the amount by which the fair market value of the shares purchased exceeds the purchase price for the shares. Upon a subsequent sale or other disposition of the option shares, the
participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon exercising an ISO, a 2019 Plan participant generally will not recognize taxable income, and we will not be entitled to a tax deduction
for compensation expense. However, upon exercise, the amount by which the fair market value of the shares purchased exceeds the purchase price will be an item of adjustment for alternative minimum tax purposes. The participant will recognize taxable
income upon a sale or other taxable disposition of the option shares. For federal income tax purposes, dispositions are divided into two categories: qualifying and disqualifying. A qualifying disposition generally occurs if the sale or other
disposition is made more than two years after the date the option was granted and more than one year after the date the shares are transferred upon exercise. If the sale or disposition occurs before these two periods are satisfied, then a
disqualifying disposition generally will result. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon a qualifying disposition of ISO shares, the participant will recognize long-term
capital gain in an amount equal to the excess of the amount realized upon the sale or other disposition of the shares over their purchase price. If there is a disqualifying disposition of the shares, then the excess of the fair market value of the
shares on the exercise date (or, if less, the price at which the shares are sold) over their purchase price will be taxable as ordinary income to the participant. If there is a disqualifying disposition in the same year of exercise, it eliminates
the item of adjustment for alternative minimum tax purposes. Any additional gain or loss recognized upon the disposition will be recognized as a capital gain or loss by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We will not be entitled to any tax deduction if the participant makes a qualifying disposition of ISO shares. If the participant makes a
disqualifying disposition of the shares, we should be entitled to a tax deduction for compensation expense in the amount of the ordinary income recognized by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon exercising or settling an SAR, a 2019 Plan participant will recognize taxable income at ordinary income tax rates, and we should be
entitled to a corresponding tax deduction for compensation expense, in the amount paid or value of the shares issued upon exercise or settlement. Payments in shares will be valued at the fair market value of the shares at the time of the payment,
and upon the subsequent disposition of the shares the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock and RSUs</I>.&nbsp;&nbsp;&nbsp;&nbsp;A 2019 Plan participant generally will not recognize taxable income at ordinary
income tax rates and we generally will not be entitled to a tax deduction upon the grant of restricted stock or RSUs. Upon the termination of restrictions on restricted stock or the payment of RSUs, the participant will recognize taxable income at
ordinary income tax rates, and we should be entitled to a corresponding tax deduction for compensation expense, in the amount paid to the participant or the amount by which the then fair market value of the shares received by the participant exceeds
the amount, if any, paid for them. Upon the subsequent disposition of any shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the
participant&#146;s tax basis in the shares. However, a 2019 Plan participant granted restricted stock that is subject to forfeiture or repurchase through a vesting schedule such that it is subject to a &#147;risk of forfeiture&#148; (as defined in
Section&nbsp;83 of the Code) may make an election under Section&nbsp;83(b) of the Code to recognize taxable income at ordinary income tax rates, at the time of the grant, in an amount equal to the fair market value of the shares of common stock on
the date of grant, less the amount paid, if any, for such shares. We will be entitled to a corresponding tax deduction for compensation, in the amount recognized as taxable income by the participant. If a timely Section&nbsp;83(b) election is made,
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
participant will not recognize any additional ordinary income on the termination of restrictions on restricted stock, and we will not be entitled to any additional tax deduction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Other Stock or Cash-Based Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;A 2019 Plan participant will not recognize taxable income and we will not be
entitled to a tax deduction upon the grant of other stock or cash-based awards until cash or shares are paid or distributed to the participant. At that time, any cash payments or the fair market value of shares that the participant receives will be
taxable to the participant at ordinary income tax rates and we should be entitled to a corresponding tax deduction for compensation expense. Payments in shares will be valued at the fair market value of the shares at the time of the payment, and
upon the subsequent disposition of the shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2017, our board of directors and our stockholders approved the adoption of the 2017 Plan. Our board of directors and stockholders
subsequently approved four amendments to the 2017 Plan to increase the share reserve thereunder in each of December 2017, May 2018, June 2018 and July 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A total of 17,121,225 shares of our common stock are reserved for issuance under the 2017 Plan. As of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock were subject to
outstanding awards under the 2017 Plan and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock remained available for future issuance under the 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">After the effective date of the 2019 Plan, no additional awards will be granted under the 2017 Plan. However, the 2017 Plan will continue to
govern the terms and conditions of the outstanding awards granted under it. Shares of our common stock subject to awards granted under the 2017 Plan that expire, lapse or are terminated, exchanged for cash, surrendered, repurchased or forfeited
following the effective date of the 2019 Plan will be available for issuance under the 2019 Plan in accordance with its terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors administers the 2017 Plan, unless it delegates authority for
administration of the plan. Subject to the terms and conditions of the 2017 Plan, the administrator has the authority to select the persons to whom awards are to be made, to determine the type or types of awards to be granted to each person,
determine the number of awards to grant, determine the number of shares to be subject to such awards, and the terms and conditions of such awards, and make all other determinations and decisions and to take all other actions necessary or advisable
for the administration of the 2017 Plan. The plan administrator is also authorized to establish, adopt, amend or revise rules relating to administration of the 2017 Plan, subject to certain restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>.&nbsp;&nbsp;&nbsp;&nbsp;Awards under the 2017 Plan may be granted to individuals who are then our employees, consultants
and members of our board of directors and our subsidiaries. Only employees may be granted ISOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The
2017 Plan provides that our administrator may grant or issue stock options (including NSOs and ISOs), restricted stock, RSUs, other stock-based awards, or any combination thereof. The administrator considers each award grant subjectively,
considering factors such as the individual performance of the recipient and the anticipated contribution of the recipient to the attainment of our long-term goals. Each award is set forth in a separate agreement with the person receiving the award
and indicates the type, terms and conditions of the award. As of the date of this prospectus, awards of stock options and restricted stock are outstanding under the 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator has broad discretion to equitably adjust the provisions of the
2017 Plan and the terms and conditions of existing and future awards, including with respect to aggregate number and type of shares subject to the 2017 Plan and awards granted pursuant to the 2017 Plan, to prevent the dilution or enlargement of
intended benefits and/or facilitate necessary or desirable changes in the event of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain transactions and events affecting our common stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate transactions. The plan administrator
may also provide for the acceleration, <FONT STYLE="white-space:nowrap">cash-out,</FONT> termination, assumption, substitution or conversion of awards in the event of a change in control or certain other unusual or nonrecurring events or
transactions. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our stockholders, or an &#147;equity restructuring,&#148; the plan administrator will make equitable adjustments to the 2017
Plan and outstanding awards as it deems appropriate to reflect the equity restructuring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In the event of a change of control where the
acquirer does not assume awards granted under the 2017 Plan, awards issued under the 2017 Plan held by persons who have not experienced a termination of service will be subject to accelerated vesting such that 100% of the awards will become vested
and exercisable or payable, as applicable, immediately prior to the change in control. Under the 2017 Plan, a change of control is generally defined as: (1)&nbsp;a merger or consolidation of our company with or into any other corporation or other
entity or person; (2)&nbsp;a sale, lease, exchange or other transfer in one transaction or a series of related transactions of all or substantially all of our company&#146;s assets; or (3)&nbsp;any other transaction, including the sale by us of new
shares of our capital stock or a transfer of existing shares of our capital stock, the result of which is that a third party that is not an affiliate of us or our stockholders (or a group of third parties not affiliated with us or our stockholders)
immediately prior to such transaction acquires or holds capital stock representing a majority of our outstanding voting power immediately following such transaction; provided that the following events shall not constitute a &#147;change in
control&#148; under the 2017 Plan: (A)&nbsp;a transaction (other than a sale of all or substantially all of our assets) in which the holders of our voting securities immediately prior to the merger or consolidation hold, directly or indirectly, at
least a majority of the voting securities in the successor corporation or its parent immediately after the merger or consolidation; (B)&nbsp;a sale, lease, exchange or other transaction in one transaction or a series of related transactions of all
or substantially all of our assets to an affiliate of ours; (C)&nbsp;an initial public offering of any of our securities or any other transaction principally for bona fide equity financing purposes; (D)&nbsp;a reincorporation solely to change our
jurisdiction; or (E)&nbsp;a transaction undertaken for the primary purpose of creating a holding company that will be owned in substantially the same proportion by the persons who held our securities immediately before such transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination of the 2017 Plan</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may terminate, amend or modify the 2017 Plan.
However, stockholder approval of any amendment to the 2017 Plan must be obtained to the extent necessary and desirable to comply with any applicable law, regulation or stock exchange rule, or for any amendment to the 2017 Plan that increases the
number of shares available under the 2017 Plan. If not terminated earlier by the compensation committee or the board of directors, the 2017 Plan will terminate on November&nbsp;17, 2027. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Securities Laws and Federal Income Tax Consequences</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2017 Plan is designed to comply with applicable
securities laws in the same manner as described above in the description of the 2019 Plan under the heading &#147;&#151;2019 Incentive Award Plan&#151;Securities Laws.&#148; The general federal tax consequences of awards under the 2017 Plan are the
same as those described above in the description of the 2019 Plan under the heading &#147;&#151;2019 Incentive Award Plan&#151;Federal Income Tax Consequences.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to adopt and ask our stockholders to approve a 2019 Employee Stock Purchase Plan, or the ESPP. The
material terms of the ESPP, as it is currently contemplated, are summarized below. Our board of directors is still in the process of considering the ESPP and, accordingly, this summary is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Shares Available; Administration.&nbsp;&nbsp;&nbsp;&nbsp;</I>A total of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock are initially reserved for issuance under our ESPP. In addition, the number of shares available for issuance under the ESPP will be annually
increased on January&nbsp;1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the lesser of: (a)&nbsp;1% of the shares outstanding on the final day of the immediately preceding calendar year and (b)&nbsp;such smaller number of shares as is determined by our board of
directors. In no event will more than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock be available for issuance under the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors or its committee will have authority to interpret the terms of the ESPP and determine eligibility of participants. We
expect that the compensation committee will be the initial administrator of the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Eligibility.&nbsp;&nbsp;&nbsp;&nbsp;</I>Our
employees are eligible to participate in the ESPP if they meet the eligibility requirements under the ESPP established from time to time by the plan administrator. However, an employee may not be granted rights to purchase stock under our ESPP if
such employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of our common or other class of stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Grant of Rights.&nbsp;&nbsp;&nbsp;&nbsp;</I>The ESPP is intended to qualify under Section&nbsp;423 of the Code and stock will be offered
under the ESPP during offering periods. The length of the offering periods under the ESPP will be determined by the plan administrator and may be up to 27 months long. Employee payroll deductions will be used to purchase shares on each purchase date
during an offering period. The number of purchase periods within, and purchase dates during each offering period will be established by the plan administrator prior to the commencement of each offering period. Offering periods under the ESPP will
commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offering periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The ESPP permits participants to purchase common stock through payroll deductions of up to __% of their eligible compensation, which includes
a participant&#146;s gross base compensation for services to us, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. The plan administrator
will establish a maximum number of shares that may be purchased by a participant during any offering period or purchase period, which, in the absence of a contrary designation, will be shares. In addition, no employee will be permitted to accrue the
right to purchase stock under the ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our common stock as of the first day of the
offering period). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On the first trading day of each offering period, each participant will automatically be granted an option to purchase
shares of our common stock. The option will be exercised on the applicable purchase date(s) during the offering period, to the extent of the payroll deductions accumulated during the applicable purchase period. The purchase price of the shares, in
the absence of a contrary determination by the plan administrator, will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final
trading day of the applicable purchase period. Participants may voluntarily end their participation in the ESPP at any time at least one week prior to the end of the applicable offering period (or such shorter or longer period specified by the plan
administrator), and will be paid their accrued payroll deductions that have not yet been used to purchase shares of common stock. Participation ends automatically upon a participant&#146;s termination of employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A participant may not transfer rights granted under the ESPP other than by will, the laws of descent and distribution or as otherwise provided
under the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Certain Transactions.&nbsp;&nbsp;&nbsp;&nbsp;</I>In the event of certain transactions or events affecting our common
stock, such as any stock dividend or other distribution, change in control, reorganization, merger, consolidation or other corporate transaction, the plan administrator will make equitable adjustments to the ESPP and outstanding rights. In addition,
in the event of the foregoing transactions or events or certain significant transactions, including a change in control, the plan administrator may provide for (1)&nbsp;either the replacement of outstanding rights with other rights or property or
termination of outstanding rights in exchange for cash, (2)&nbsp;the assumption or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (3)&nbsp;the adjustment in the number and type of shares of stock subject to
outstanding rights, (4)&nbsp;the use of participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (5)&nbsp;the
termination of all outstanding rights. Under the ESPP, a change in control has the same definition as given to such term in the 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Plan Amendment; Termination.&nbsp;&nbsp;&nbsp;&nbsp;</I>The plan administrator may amend, suspend or terminate the ESPP at any time.
However, stockholder approval of any amendment to the ESPP will be obtained for any amendment which increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the ESPP, changes the corporations or classes
of corporations whose employees are eligible to participate in the ESPP or changes the ESPP in any manner that would cause the ESPP to no longer be an employee stock purchase plan within the meaning of Section&nbsp;423(b) of the Code. The ESPP will
terminate on the tenth anniversary of the date it is initially approved by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Securities
Laws.&nbsp;&nbsp;&nbsp;&nbsp;</I>The ESPP has been designed to comply with various securities laws in the same manner as described above in the description of the 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Federal Income Taxes.&nbsp;&nbsp;&nbsp;&nbsp;</I>The material federal income tax consequences of the ESPP under current federal income tax
law are summarized in the following discussion, which deals with the general tax principles applicable to the ESPP. The following discussion is based upon laws, regulations, rulings and decisions now in effect, all of which are subject to change.
Foreign, state and local tax laws, and employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual circumstances and from locality to locality. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The ESPP, and the right of participants to make purchases thereunder, is intended to qualify under the provisions of Section&nbsp;423 of the
Code. Under the applicable Code provisions, no income will be taxable to a participant until the sale or other disposition of the shares purchased under the ESPP. This means that an eligible employee will not recognize taxable income on the date the
employee is granted an option under the ESPP (i.e., the first day of the offering period). In addition, the employee will not recognize taxable income upon the purchase of shares. Upon such sale or disposition, the participant will generally be
subject to tax in an amount that depends upon the length of time such shares are held by the participant prior to disposing of them. If the shares are sold or disposed of more than two years from the first day of the offering period during which the
shares were purchased and more than one year from the date of purchase, or if the participant dies while holding the shares, the participant (or his or her estate) will recognize ordinary income measured as the lesser of: (1)&nbsp;the excess of the
fair market value of the shares at the time of such sale or disposition over the purchase price; or (2)&nbsp;an amount equal to 15% of the fair market value of the shares as of the first day of the offering period. Any additional gain will be
treated as long-term capital gain. If the shares are held for the holding periods described above but are sold for a price that is less than the purchase price, there is no ordinary income and the participating employee has a long-term capital loss
for the difference between the sale price and the purchase price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the shares are sold or otherwise disposed of before the expiration
of the holding periods described above, the participant will recognize ordinary income generally measured as the excess of the fair market value of the shares on the date the shares are purchased over the purchase price and we will be entitled to a
tax deduction for compensation expense in the amount of ordinary income recognized by the employee. Any additional gain or loss on such sale or disposition will be long-term or short-term capital gain or loss, depending on how long the shares were
held following the date they were purchased by the participant prior to disposing of them. If the shares are sold or otherwise disposed of before the expiration of the holding periods described above but are sold for a price that is less than the
purchase price, the participant will recognize ordinary income equal to the excess of the fair market value of the shares on the date of purchase over the purchase price (and we will be entitled to a corresponding deduction), but the participant
generally will be able to report a capital loss equal to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the difference between the sales price of the shares and the fair market value of the shares on the date of purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Historically, we
have not paid cash or stock-based compensation to directors for their service on our board of directors. In 2017, we did not grant any equity awards to the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors. As of
December&nbsp;31, 2017, none of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors held any outstanding equity awards. On May&nbsp;18, 2018, however, we granted to Mr.&nbsp;Daniel an option to purchase 590,000 shares of our common
stock pursuant to our 2017 Plan in connection with his commencement of service on our board of directors, which option vests in 36 equal monthly installments commencing on January&nbsp;14, 2018. The option has an exercise price per share of $0.58,
which was the fair market value at the time of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have reimbursed and will continue to reimburse all of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors for their travel, lodging and other reasonable expenses incurred in attending meetings of our board of directors and committees of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to adopt and ask our stockholders to approve the initial terms of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation program. The material terms of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program, as it is currently contemplated, are summarized below. Our
board of directors is still in the process of considering the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program and, accordingly, this summary is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will provide for annual retainer fees and/or long-term
equity awards for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. We expect each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an annual retainer of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors serving as the chairs of the audit, compensation and nominating and corporate governance committees will
receive additional annual retainers of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively. <FONT STYLE="white-space:nowrap">Non-employee</FONT> directors serving as members of the audit, compensation and nominating and corporate governance committees
will receive additional annual retainers of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively. The <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will also receive initial grants of options to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, vesting over &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; years, upon election to the board of directors, and thereafter
annual grants of options to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, vesting on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Compensation under our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will be subject to the annual limits
on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2019 Plan, as described above. Our board of directors or its authorized committee may modify the <FONT STYLE="white-space:nowrap">non-employee</FONT>
director compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, subject to the annual limit on <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2019 Plan. As provided in the 2019 Plan, our board of directors or its authorized committee may make exceptions to this limit for individual <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors in extraordinary circumstances, as the board of directors or its authorized committee may determine in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT>
director receiving such additional compensation may not participate in the decision to award such compensation or in other compensation decisions involving <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify our directors and
officers to the fullest extent permitted by the Delaware General Corporation Law, which prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payment of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that if Delaware law is amended to
authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. This limitation of
liability does not apply to liabilities arising under the federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that we shall have the power to
indemnify our employees and agents to the fullest extent permitted by law. Our amended and restated bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her
actions in this capacity, regardless of whether our amended and restated bylaws would permit indemnification. We have obtained directors&#146; and officers&#146; liability insurance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have entered into separate indemnification agreements with our directors and executive officers, in addition to indemnification provided
for in our amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement
amounts incurred by this person in any action or proceeding arising out of this person&#146;s services as a director or executive officer or at our request. We believe that these provisions in our amended and restated certificate of incorporation
and amended and restated bylaws and indemnification agreements are necessary to attract and retain qualified persons as directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of our amended and restated certificate of incorporation, our amended and restated
bylaws and our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated
bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful,
might benefit us and our stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as
indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or
threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_14"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following includes a summary of transactions since our inception on October&nbsp;26, 2015 to which we have been a party in which the
amount involved exceeded or will exceed $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of any of the foregoing
persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#147;Executive and Director Compensation.&#148; We also
describe below certain other transactions with our directors, executive officers and stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Convertible Promissory Note </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;2, 2017, we issued and sold in a private placement a $6.0&nbsp;million convertible promissory note, or the ARCH note, to ARCH
Venture Fund IX, L.P., or ARCH IX. The ARCH note accrued interest at a rate of 8% per annum. The ARCH note, including $0.1&nbsp;million in accrued interest thereon, was automatically converted into shares of our Series A convertible preferred stock
in the January 2018 Series A convertible preferred stock financing described below. ARCH IX is a beneficial owner of more than 5% of our capital stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger Agreement </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;29, 2017, we entered into a merger agreement, or the Merger Agreement, with AA BioPharma Inc. and AAB Merger Sub, Inc., or Merger Sub, a Delaware corporation and our wholly-owned subsidiary. Pursuant to the Merger Agreement, in January
2018, Merger Sub was merged into and with AA BioPharma, with AA BioPharma surviving as our wholly-owned subsidiary. Pulmagen Therapeutics (Asthma) Limited is a wholly-owned subsidiary of AA BioPharma. In connection with the Merger Agreement, all of
the issued and outstanding shares of AA BioPharma were converted into shares of our stock, including 4,955,752 shares of our common stock issued to one investor and 20,000,000 shares of our Series Seed convertible preferred stock issued to Omega
Fund V, L.P., or Omega V, a beneficial owner of more than 5% of our capital stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock Financings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Series A Convertible Preferred Stock Financings</I>. In January 2018, we entered into a Series A preferred stock purchase agreement,
pursuant to which we sold to investors in an initial closing and subsequent closings from January 2018 to March 2018 in private placements an aggregate of 45,714,286 shares of our Series A convertible preferred stock at a purchase price of $1.75 per
share, for an aggregate purchase price of approximately $80.0&nbsp;million, including the conversion of the ARCH note described above for approximately $6.1&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Series B Convertible Preferred Stock Financing</I>. In July 2018, we entered into a Series B preferred stock purchase agreement, pursuant
to which we sold to investors in July 2018 in private placements an aggregate of 71,506,513 shares of our Series B convertible preferred stock at a purchase price of $3.2167 per share, for an aggregate purchase price of approximately
$230.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All purchasers of our convertible preferred stock are entitled to specified registration rights. See the section
titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for more information regarding these registration rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth the aggregate number of shares acquired by the listed
directors, executive officers or holders of more than 5% of our capital stock, or their affiliates. Each share of preferred stock, including the shares identified in the following table, will convert into shares of common stock at a ratio of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> immediately prior to the closing of this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participants</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series Seed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Convertible<BR>Preferred<BR>Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Convertible<BR>Preferred<BR>Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Series B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Convertible<BR>Preferred</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheila Gujrathi, M.D.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Faheem Hasnain<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bryan Giraudo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Waage<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Daniel. M.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or Greater Stockholders</B><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with ARCH Venture
Partners<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,142,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,108,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omega Fund V, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,124,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,165,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HH Goss Holdings LLC<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,383,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents securities acquired by family trusts. Dr. Gujrathi, our President, Chief Executive Officer and a
member of our board of directors, is a trustee of one of these family trusts, and is a beneficial holder of more than 5% of our capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents securities acquired by family trusts. Mr.&nbsp;Hasnain, our Executive Chairman of the board of
directors, is a trustee of one of these family trusts, and is a beneficial holder of more than 5% of our capital stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents securities acquired by the Waage Trust Dated June&nbsp;11, 2008. Christian Waage, our Executive Vice
President and General Counsel, is a trustee of the Waage Trust Dated June&nbsp;11, 2008. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents securities acquired by the Thomas Oran Daniel Living Trust. Thomas Daniel, M.D., a member of our
board of directors, is a trustee of the Thomas Oran Daniel Living Trust. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Additional details regarding these stockholders and their equity holdings are provided under the section in this
prospectus entitled &#147;Principal Stockholders.&#148; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents securities acquired by ARCH IX and ARCH Venture Fund IX Overage, L.P., or ARCH Overage. Robert Nelsen
and Kristina Burow are currently, and were at the time of the Series B convertible preferred stock financing, members of our board of directors and are Managing Directors of ARCH Venture Partners, which is an affiliate of ARCH IX and ARCH Overage
and their affiliated funds. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Richard Lim and Otello Stampacchia, Ph.D. are currently, and were at the time of the Series B convertible
preferred stock financing, members of our board of directors and are Managing Directors of Omega Fund Management, which is an affiliate of Omega V. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Qinqing Yi is currently a member of our board of directors and is a Partner at Hillhouse Capital Group, or,
together with its affiliates, Hillhouse, which is an affiliate of HH Goss Holdings LLC. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Designation Agreement with Hillhouse
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On July&nbsp;20, 2018, we entered into a board designation agreement with HH Goss Holdings LLC, a beneficial owner of more than 5% of
our capital stock and an affiliate of Hillhouse. The agreement provides that HH Goss Holdings LLC or its affiliates will, effective as of the closing of this offering, have the right to designate one member to our board of directors and have such
member appointed to any board committee that it requests, in each case, subject to our obligation to comply with applicable law and Nasdaq listing standards. The Hillhouse board designation agreement terminates at such time as HH Goss Holdings LLC
and its affiliates cease to beneficially own at least 5% of our outstanding voting stock, or upon the later of (a)&nbsp;18&nbsp;months following the closing of this offering or (b)&nbsp;six months following the first public read out of interim
results from our planned GB001 Phase&nbsp;2 clinical trial. Upon termination of the agreement, the director seat will be filled by our stockholders in accordance with our amended and restated certificate of incorporation and our amended and restated
by-laws, as described in &#147;Management&#151;Board Composition and Election of Directors.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Rights Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We entered into an investor rights agreement in January 2018, which was amended in July 2018, with the holders of our convertible preferred
stock, including entities with which certain of our directors are affiliated. This agreement provides for certain rights relating to the registration of their shares of common stock issuable upon conversion of their convertible preferred stock and
certain additional covenants made by us. Except for the registration rights (including the related provisions pursuant to which we have agreed to indemnify the parties to the investor rights agreement), all rights under this agreement will terminate
upon closing of this offering. The registration rights will continue following this offering and will terminate five years following the closing of this offering. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional
information.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We entered into a voting agreement in January 2018, which was amended in July 2018, with certain of our stockholders, pursuant to which the
following directors were each elected to serve as members on our board of directors and, as of the date of this prospectus, continue to so serve: Sheila Gujrathi, M.D., Faheem Hasnain, Robert Nelsen, Kristina Burow, Richard Lim, Otello Stampacchia,
Ph.D., Qinqing Yi and Thomas Daniel, M.D. Pursuant to the voting agreement, Dr.&nbsp;Gujrathi, as our Chief Executive Officer, and Mr.&nbsp;Hasnain serve on our board of directors as a representative of holders of our common stock, as designated by
a majority of our common stockholders. Mr.&nbsp;Nelsen and Ms.&nbsp;Burow were initially selected to serve on our board of directors as representatives of holders of our Series A convertible preferred stock, as designated by ARCH Venture Fund IX,
L.P. Messrs. Lim and Stampacchia were also initially selected to serve on our board of directors as representatives of holders of our Series A convertible preferred stock, as designated by Omega Fund V, L.P. Mr.&nbsp;Yi was initially selected to
serve on our board of directors as a representative of holders of our Series B convertible preferred stock, as designated by HH Goss Holdings LLC. Dr.&nbsp;Daniel was initially selected to serve on our board of directors as a representative of
holders of our common stock and preferred stock, as designated by a majority of our common and preferred stockholders, voting together as a single class. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The voting agreement will terminate upon the closing of this offering, and members previously elected to our board of directors pursuant to
this agreement will continue to serve as directors until they resign, are removed or their successors are duly elected by holders of our common stock. Mr.&nbsp;Yi shall also continue to serve pursuant to the board designation agreement with HH Goss
Holdings LLC. The composition of our board of directors after this offering is described in more detail under &#147;Management&#151;Board Composition and Election of Directors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Founders&#146; Equity Grants </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;3, 2015, we issued and sold to each of Sheila Gujrathi, M.D. and Faheem Hasnain 20,612,000 shares of our common stock for a per share purchase price of $0.001 per share. For more information regarding these and additional stock
issuances to Dr.&nbsp;Gujrathi and Mr.&nbsp;Hasnain pursuant to their employment letters, see the section in this prospectus entitled &#147;Executive and Director Compensation&#151;Employment Letters with our Named Executive Officers.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have entered
into employment agreements with our executive officers. For more information regarding these employment agreements, see the section in this prospectus entitled &#147;Executive and Director Compensation&#151;Employment Letters with our Named
Executive Officers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director and Officer Indemnification </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things,
require us or will require us to indemnify each director (and in certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#146; fees, judgments,
fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#146;s services as a director or executive officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify each of our directors
and officers to the fullest extent permitted by the Delaware General Corporation Law. Further, we have purchased a policy of directors&#146; and officers&#146; liability insurance that insures our directors and officers against the cost of defense,
settlement or payment of a judgment under certain circumstances. For further information, see &#147;Executive and Director Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Option Grants to Executive Officers and Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have granted restricted stock and stock options to our executive officers and certain of our directors as more fully described in the
section entitled &#147;Executive and Director Compensation.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Transactions and Arrangements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Aaron Hasnain is the son of our Executive Chairman, Faheem Hasnain, and currently serves as our Director, Business Development at a salary of
$140,000 per year, a position he has held since January 2018. In November 2017, we granted 226,732&nbsp;shares of restricted stock to Aaron Hasnain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies and Procedures for Related Person Transactions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors will adopt a written related person transaction policy, to be effective upon the closing of this offering, setting
forth the policies and procedures for the review and approval or ratification of related-person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the
Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 and a related person had or
will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness
and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable
to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_15"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our common stock as of September&nbsp;30, 2018, and as
adjusted to reflect the sale of shares of common stock in this offering, by: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person<B> </B>or group of affiliated persons known by us to beneficially own more than 5% of our common
stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under
these rules, beneficial ownership includes any shares as to which a person has sole or shared voting power or investment power. Applicable percentage ownership is based on 207,121,355 shares of common stock outstanding on September&nbsp;30, 2018,
which gives effect to the automatic conversion of all outstanding shares of our preferred stock into 137,220,799 shares of our common stock and includes 35,098,238 shares subject to forfeiture. In computing the number of shares beneficially owned by
a person and the percentage ownership of that person, shares of common stock subject to options or other rights held by such person that are currently exercisable or will become exercisable within 60 days of September&nbsp;30, 2018 are considered
outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address of each beneficial owner listed below is c/o
Gossamer Bio, Inc., 3013 Science Park Road, Suite 200, San Diego, California 92121. We believe, based on information provided to us, that each of the stockholders listed below has sole voting and investment power with respect to the shares
beneficially owned by the stockholder unless noted otherwise, subject to community property laws where applicable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>Before and After the<BR>Offering</B></P></TD>

<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially Owned</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Before<BR>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>After<BR>Offering</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% or Greater Stockholders</I></B></P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B><I>&nbsp;</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Funds affiliated with ARCH Venture
Partners<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,251,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Omega Fund V, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,290,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HH Goss Holdings LLC<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,383,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trusts for the benefit of Mr.&nbsp;Hasnain&#146;s family<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,174,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trusts for the benefit of Dr.&nbsp;Gujrathi&#146;s family<SUP
STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,114,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Named Executive Officers and Directors</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sheila Gujrathi, M.D<SUP STYLE="font-size:85%; vertical-align:top">(6). .</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,172,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Faheem Hasnain<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,174,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Waage<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,365,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristina Burow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Daniel, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Lim<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,290,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Nelsen<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,251,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Otello Stampacchia, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,290,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Qinqing Yi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (11&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104,452,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Less than 1%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 18,125,817 shares of common stock held by ARCH Venture Fund IX, L.P., or ARCH IX, and (ii)
18,125,816 shares of common stock held by ARCH Overage. ARCH Venture Partners IX, L.P., or the GPLP, as the sole general partner of ARCH IX, may be deemed to beneficially own certain of the shares held by ARCH IX. The GPLP disclaims beneficial
ownership of all shares held by ARCH IX in which the GPLP does not have an actual pecuniary interest. ARCH Venture Partners IX Overage, L.P., or the Overage GPLP, as the sole general partner of ARCH Overage, may be deemed to beneficially own certain
of the shares held by ARCH Overage. The Overage GPLP disclaims beneficial ownership of all shares held by ARCH Overage. ARCH Venture Partners IX, LLC, or GPLLC, as the sole general partner of the Overage GPLP and GPLP, may be deemed to beneficially
own the shares held by ARCH IX and ARCH Overage. As managing directors of GPLLC, each of Keith Crandell, Clinton Bybee and Robert Nelsen, or the ARCH Managing Directors, may be deemed to share the power to direct the disposition and vote of, and
therefore to beneficially own, the shares held by ARCH IX and ARCH Overage. The ARCH Managing Directors disclaim beneficial ownership of all shares held by ARCH IX and ARCH Overage except to the extent of any actual pecuniary interest. Director
Kristina Burow owns an interest in GPLP and Overage GPLP but does not have voting or investment control over the shares held by ARCH IX and ARCH Overage and disclaims beneficial ownership of such shares, except to the extent of any pecuniary
interest therein. The address of ARCH IX, ARCH Overage, GPLP, Overage GPLP, GPLLC and the ARCH Managing Directors is 8755 West Higgins Road, Suite 1025, Chicago, Illinois 60631. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 31,290,380 shares of common stock. Omega Fund V GP, L.P., or Omega V GP LP, is the general partner
of Omega V. Omega Fund V GP Manager, Ltd., or Omega V GP Ltd, is the general partner of Omega V GP LP. Mr.&nbsp;Lim, Dr.&nbsp;Stampacchia, Claudio Nessi and Anne-Mari Paster are Managing Directors and all the shareholders and directors of Omega V GP
Ltd and have shared voting and investment power over the shares held by Omega V. The address of Omega V, Omega V GP LP and Omega V GP Ltd is 185 Dartmouth Street, Suite 502, Boston, MA 02116. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 22,383,188 shares of common stock held by HH Goss Holdings LLC, a limited liability company
incorporated in the Cayman Islands. HH Goss Holdings LLC is beneficially owned and controlled by Hillhouse Fund IV, L.P. which is a Cayman Islands limited partnership. Hillhouse Capital Management, Ltd. acts as the sole management company of
Hillhouse Fund IV, L.P., which is in turn ultimately controlled by Mr. Lei Zhang. The registered address of HH Goss Holdings LLC is Citco Trustees (Cayman) Limited, 89 Nexus Way, Camana Bay, PO Box 31106, Grand Cayman KY1-1205, Cayman Islands.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Eric I. Weitzen is the trustee of the trusts for the benefit of Mr. Hasnain&#146;s family, and in such capacity
has the sole power to vote and dispose of such shares. Mr.&nbsp;Weitzen disclaims beneficial ownership of the shares held by the these trusts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Ms. Adee Cohen and Dr. Sunil Gujrathi are trustees of the trusts for the benefit of Dr. Gujrathi&#146;s family,
and in such capacity have joint power to vote and dispose of such shares. Ms. Adee Cohen and Dr. Sunil Gujrathi disclaim beneficial ownership of the shares held by these trusts. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 18,172,081 shares of common stock, including 14,910,783 shares subject to forfeiture, held by a
separate family trust. Dr.&nbsp;Gujrathi is a trustee of such family trust and in such capacity has the power to vote and dispose of such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 15,174,487 shares of common stock, including 14,910,783 shares subject to forfeiture, held by a
family trust. Mr.&nbsp;Hasnain is the trustee of such family trust and in such capacity has the sole power to vote and dispose of such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,365,311 shares of common stock held by the Waage Trust Dated June&nbsp;11, 2008, or the Waage
Trust, including 2,349,768 shares subject to forfeiture. Mr.&nbsp;Waage is the trustee of the Waage Trust and in such capacity has the sole power to vote and dispose of such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of 171,429 shares of common stock held by the Thomas Oran Daniel Living Trust, or the Daniel Trust, and
163,888 shares of common stock underlying options held by Dr.&nbsp;Daniel that are exercisable as of September&nbsp;30, 2018 or that will become exercisable within 60 days after such date. Dr.&nbsp;Daniel is the trustee of the Daniel Trust and in
such capacity has the sole power to vote and dispose of such shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of the shares described in note 2 above. Mr.&nbsp;Lim is a Managing Director of Omega V GP Ltd, which
is the sole general partner of Omega V GP LP, which is the sole general partner of Omega V, and as such may be deemed to beneficially own such shares. Mr.&nbsp;Lim disclaims beneficial ownership of such shares except to the extent of any pecuniary
interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of the shares described in note 1 above. Mr.&nbsp;Nelsen is a Managing Director of GPLLC, which is the
sole general partner of GPLP, which is the sole general partner of ARCH VIX and ARCH Overage, and as such may be deemed to beneficially own such shares. Mr.&nbsp;Nelsen disclaims beneficial ownership of such shares except to the extent of any
pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of the shares described in note 2 above. Dr.&nbsp;Stampacchia is a Managing Director of Omega V GP Ltd,
which is the sole general partner of Omega V GP LP, which is the sole general partner of Omega V, and as such may be deemed to beneficially own such shares. Dr.&nbsp;Stampacchia disclaims beneficial ownership of such shares except to the extent of
any pecuniary interest therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Consists of (i)&nbsp;the shares described in notes 6 through 12 above, (ii) 80,458 shares of common stock held
by Bryan Giraudo, our Chief Financial Officer, and (iii) 783,256 shares of common stock held by Luisa <FONT STYLE="white-space:nowrap">Salter-Cid,</FONT> Ph.D., our Chief Scientific Officer, all of which are subject to forfeiture.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following description
summarizes some of the terms of our amended and restated certificate of incorporation and amended and restated bylaws, the amended and restated investor rights agreement and of the Delaware General Corporation Law. Because it is only a summary, it
does not contain all the information that may be important to you. For a complete description you should refer to our amended and restated certificate of incorporation, amended and restated bylaws, and amended and restated investor rights agreement,
copies of which have been filed or incorporated by reference as exhibits to the registration statement of which the prospectus is a part, as well as the relevant provisions of the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Following the closing of this offering, our authorized capital stock will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred stock, $0.0001 par value per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2018, there were 207,121,355 shares of our common stock outstanding and held of record by 107 stockholders, assuming the automatic conversion of all outstanding shares of our convertible preferred stock into<B> </B>shares of
common stock, which will automatically occur immediately prior to the closing of this offering. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of
directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so
choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a
majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that our directors may be removed
only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of
the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of
the provisions of our amended and restated certificate of incorporation. See below under &#147;&#151;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws&#151;Amendment of Charter Provisions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably
those dividends, if any, as may be declared by the board of directors out of legally available funds. In the event of our liquidation, dissolution or winding up, the holders of common stock will be entitled to share ratably in the assets legally
available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. Holders of common stock have no preemptive or conversion
rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. All outstanding shares of common stock are, and the common stock to be outstanding upon the closing of this offering will be,
duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock
that we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, all of our previously outstanding shares of convertible preferred stock will have been converted into common
stock, there will be no authorized shares of our previously convertible </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
preferred stock and we will have no shares of preferred stock outstanding. Under the terms of our amended and restated certificate of incorporation, which will become effective immediately prior
to the closing of this offering, our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to
be included in each such series, to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the
number of shares of any such series, but not below the number of shares of such series then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors may
authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection
with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and other
rights of the holders of common stock. We have no current plans to issue any shares of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2018, options to purchase 9,469,500 shares of our common stock were outstanding, of which 155,833 were vested and
155,833 were exercisable as of that date. For additional information regarding the terms of this plan, see &#147;Executive Compensation&#151;Incentive Award Plans&#151;2017 Equity Incentive Plan.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2018, upon the closing of this offering holders of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, which includes all of the shares of common stock
issuable upon the automatic conversion of our convertible preferred stock immediately prior to the closing of this offering, will be entitled to the following rights with respect to the registration of such shares for public resale under the
Securities Act, pursuant to the amended and restated investor rights agreement by and among us and certain of our stockholders. The registration of shares of common stock as a result of the following rights being exercised would enable holders to
trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Demand
Registration Rights </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Form <FONT STYLE="white-space:nowrap">S-1.</FONT> </I>If at any time beginning six months following the
effective date of the registration statement of which this prospectus forms a part, investors holding at least 3,000,000 shares of our common stock, which we refer to as major investors, who also hold at least 30% of the registrable securities
request in writing that we effect a registration with respect to at least 50% of the registrable securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of selling expenses, would exceed $10 million) in an
offering, we may be required to register their shares. We are obligated to effect at most two registrations for the holders of registrable securities in response to these demand registration rights, subject to certain exceptions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><I>Form S-</I>3. If at any time we become entitled under the Securities Act to register our shares on Form
<FONT STYLE="white-space:nowrap">S-3,</FONT> major investors holding at least 20% of the registrable securities request in writing that we register their shares for public resale on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and the price to
the public of the offering is $5.0&nbsp;million or more, we will be required to provide notice to all holders of registrable securities and to use all reasonable efforts to effect such registration; provided, however, that we will not be required to
effect such a registration if, within the preceding 12 months, we have already effected two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the holders of registrable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If the holders requesting registration intend to distribute their shares by means of an underwriting, the underwriter of such offering will
have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If at any time following the closing of this offering we propose to register any shares of our common stock under the Securities Act, subject
to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the
managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our investor
rights agreement contains customary cross indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us,
and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any
registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for
the selling securityholders, blue sky fees and expenses and the expenses of any special audits incident to the registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination of
Registration Rights </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The registration rights terminate upon the earlier of: (1)&nbsp;five years after the closing of this
offering, (2)&nbsp;upon the closing of an acquisition of our company or (3)&nbsp;with respect to a particular holder, such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all shares by such holder
without limitation during a three-month period without registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and
Bylaws </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws
contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It
is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment
of a premium over the market price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are intended to discourage coercive takeover
practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our
potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement
of their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The ability of our board of directors, without action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock
with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in
control or management of our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Meetings </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board, chief
executive officer or president, or by a resolution adopted by a majority of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for Advance Notification of
Stockholder Nominations and Proposals </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws establish advance notice procedures with respect to
stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elimination of Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written
consent without a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Staggered Board </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term (other than the directors
initially assigned to Class&nbsp;I whose term shall expire at our first annual meeting of stockholders), one class being elected each year by our stockholders. For more information on the classified board, see &#147;Management&#151;Board Composition
and Election of Directors.&#148; This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for
stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our
stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholders Not Entitled to Cumulative Voting </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors.
Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our
preferred stock may be entitled to elect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#147;interested
stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction
in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or
within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction
resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the
Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any
of our directors, officers, employees or agents to us or our stockholders, creditors or other constituents; (3)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or
our amended and restated certificate of incorporation or amended and restated bylaws; (4)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (5)&nbsp;any action asserting a claim
governed by the internal affairs doctrine. The provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended. Furthermore, our amended and restated certificate of incorporation
will also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under
the Securities Act. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be
inapplicable or unenforceable. Our restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to
this choice of forum provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Charter Provisions </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock,
would require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The provisions
of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary
fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board and management. It is possible
that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent and registrar&#146;s address
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Nasdaq Global Select Market Listing </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have applied to have our common stock listed on the Nasdaq Global Select Market under the symbol &#147;GOSS.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification Matters </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For a discussion of liability and indemnification, see &#147;Executive and Director Compensation&#151;Limitations of Liability and
Indemnification Matters.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in
the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock. Although we intend to apply to have our common stock listed on the Nasdaq Global Select Market, we cannot assure you that
there will be an active public market for our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Based on the number of shares of our common stock outstanding as of
September&nbsp;30, 2018, and assuming (1)&nbsp;the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares in this offering, (2)&nbsp;the automatic conversion of all outstanding shares of our convertible preferred
stock into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, which will occur automatically immediately prior to the closing of the offering, (3)&nbsp;no exercise of the underwriters&#146; option to
purchase additional shares of common stock and (4)&nbsp;no exercise of outstanding options, we will have outstanding an aggregate of approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Of these shares, all shares sold in this offering will be freely tradable without restriction or further registration under the
Securities Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. Shares purchased by our affiliates would be subject to the Rule 144 resale restrictions described below,
other than the holding period requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
of common stock will be &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify
for an exemption from registration under Rule 144 or 701 under the Securities Act, each of which is summarized below. We expect that substantially all of these shares will be subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT
STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, of the 9,469,500 shares of our common stock that were subject to stock options outstanding as of September&nbsp;30, 2018, options
to purchase 155,833 of such shares of common stock were vested as of such date and, upon exercise, these shares will be eligible for sale subject to the lock&#150;up agreements described below and Rules 144 and 701 under the Securities Act. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, along with our directors, executive officers and substantially all of our other stockholders and optionholders, have agreed with the
underwriters that for a period of 180 days, after the date of this prospectus, subject to specified exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to sale of, or otherwise dispose of or transfer any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a
registration statement related to our common stock or enter into any swap or other agreement that transfers to another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Such exceptions include
the ability of certain of our executive officers to sell up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of shares of common stock to satisfy certain tax liabilities related to their previous acquisition of shares. Upon expiration of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, certain of our stockholders will have the right to require us to register their shares under the Securities Act. See &#147;&#151;Registration Rights&#148; below and &#147;Description of Capital
Stock&#151;Registration Rights.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, Leerink Partners LLC and Barclays
Capital Inc. may, in their sole discretion and at any time or from time to time before the termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, in certain cases without public notice, release all or any portion of the
securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between the underwriters and any of our stockholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement
providing consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period,
substantially all of the shares subject to such <FONT STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Following the completion of this offering, certain of our officers, directors and significant stockholders may adopt written plans, known as
Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify their assets and investments. Under these <FONT
STYLE="white-space:nowrap">10b5-1</FONT> trading plans, a broker may execute trades pursuant to parameters established by the officer, director or stockholder when entering into the plan, without further direction from such officer, director or
stockholder. Such sales would not commence until the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by such officer, director or stockholder in connection with this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Affiliate Resales of Restricted
Securities </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a
part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90 days before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s
transactions&#148; or certain &#147;riskless principal transactions&#148; or to market makers, a number of shares within any three-month period that does not exceed the greater of: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our common stock then outstanding, which will equal
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after this offering; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume in our common stock on the Nasdaq Global Select Market during the four calendar
weeks preceding the filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Affiliate resales under Rule 144 are also
subject to the availability of current public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of
$50,000, the seller must file a notice on Form 144 with the SEC and the Nasdaq Global Select Market concurrently with either the placing of a sale order with the broker or the execution of a sale directly with a market maker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Resales of Restricted Securities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not
an affiliate of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell
such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule 144(b)(1) without regard to any Rule 144 restrictions, including the <FONT
STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701,
any of an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan or other written </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement before the effective date of a registration statement under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on Rule 144. An affiliate of
the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period requirement, and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule 144 without having to
comply with the current public information and holding period requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register
all shares of common stock subject to outstanding stock options and common stock issued or issuable under our equity incentive plans and employee stock purchase plan. We expect to file the registration statement covering shares offered pursuant to
these stock plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by affiliates
in the public market subject to compliance with the resale provisions of Rule 144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2018, upon the closing of this offering holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, which includes all of the shares of common stock issuable upon the automatic conversion of our convertible preferred stock
immediately prior to the closing of this offering, or their transferees will be entitled to various rights with respect to the registration of these shares under the Securities Act upon the closing of this offering. Registration of these shares
under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See &#147;Description of
Capital Stock&#151;Registration Rights&#148; for additional information. Shares covered by a registration statement will be eligible for sale in the public market upon the expiration or release from the terms of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_18"></A>MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all
potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S.
Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in effect
as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary
position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This
discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This
discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the alternative minimum tax or the Medicare
contribution tax on net investment income. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a
conversion transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies, and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and
investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise
as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to our
common stock being taken into account in an &#147;applicable financial statement&#148; (as defined in the Code); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of
the interests of which are held by qualified foreign pension funds. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If an entity treated as a partnership for U.S. federal income tax purposes holds our common
stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the
partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>THIS
DISCUSSION IS FOR INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE
PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE
INCOME TAX TREATY. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common
stock that is neither a &#147;U.S. person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof, or the District of
Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more
&#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As described in the
section entitled &#147;Dividend Policy,&#148; we do not anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such
distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S.
federal income tax purposes will constitute a return of capital and first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be
treated as capital gain and will be treated as described below under &#147;&#151;Sale or Other Taxable Disposition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to the
discussion below on effectively connected income, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends
(or such lower rate specified by an applicable income tax treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable documentation) certifying qualification for the lower treaty rate). If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds the stock through a financial institution
or other agent acting on the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide appropriate documentation to the agent, who then will be
required to provide certification to the applicable withholding agent, either directly or through other intermediaries. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that
qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors
regarding their entitlement to benefits under any applicable income tax treaty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are
effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S.
federal withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying
that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as
adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable Disposition </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct
of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real
property holding corporation, or USRPHC, for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point
above generally will be subject to U.S. federal income tax on a net income basis at the regular graduated rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of
30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by
an applicable income tax treaty), which may be offset by U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not considered a resident
of the United States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the
determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there
can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market, and such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually or constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should
consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable withholding agent does not have
actual knowledge or reason to know the holder is a United States person and the holder either certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information
returns are required to be filed with the IRS in connection with any dividends on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the
sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent
receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted
through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information reporting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement
to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit
against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections are commonly referred to as the Foreign Account Tax
Compliance Act, or FATCA) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax
may be imposed on dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each
as defined in the Code), unless (1)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have
any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3)&nbsp;the foreign financial institution or
<FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in clause
(1)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United States persons&#148; or &#147;United States owned
foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain
other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends on
our common stock and will apply to payments of gross proceeds from the sale or other disposition of such stock on or after January&nbsp;1, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in
our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, Leerink Partners LLC, Barclays Capital Inc. and Evercore Group L.L.C. are acting
as representatives of each of the underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has
agreed, severally and not jointly, to purchase from us, the number of shares of common stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>of&nbsp;Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Merrill Lynch, Pierce, Fenner&nbsp;&amp;
Smith<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting
underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against
certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officers&#146; certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set
forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. After the initial offering, the
public offering price, concession or any other term of the offering may be changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price,
underwriting discount and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="74%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Without&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>With&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, payable by us are estimated to be
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have also agreed to reimburse the underwriters for certain of their expenses incurred in connection with, among others, the review
and clearance by the Financial Industry Regulatory Authority, Inc. in an amount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated,
subject to conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directed Share Program </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At our request,
the underwriters have reserved for sale, at the initial public offering price, up to 5% of the shares offered hereby for our directors, officers, employees, business associates and related persons who have expressed an interest in purchasing common
stock in the offering. The number of shares available for sale to the general public in the offering will be reduced to the extent these persons purchase the reserved shares. Any reserved shares not so purchased will be offered by the underwriters
to the general public on the same terms as the other shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors and our other existing security holders have agreed not to sell or transfer any common stock or
securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith
Incorporated, Leerink Partners LLC and Barclays Capital Inc. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any option or contract to purchase any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase any option or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any option, right or warrant for the sale of any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lend or otherwise dispose of or transfer any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">request or demand that we file or make a confidential submission of a registration statement related to the
common stock, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership
of any common stock whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The lock-up exceptions, among others, include the ability of certain of our executive officers to sell up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of shares of common stock to satisfy certain tax liabilities related to their previous acquisition of shares. This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock
and to securities convertible into or exchangeable or exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement
later acquires the power of disposition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have applied to list the shares of our common stock on the Nasdaq Global Select Market under the symbol &#147;GOSS.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Determination of Offering Price </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Before
this offering, there has been no public market for our common stock. The initial public offering price will be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be
considered in determining the initial public offering price are </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial information, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the history of, and the prospects for, our company and the industry in which we compete, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an assessment of our management, its past and present operations, and the prospects for, and timing of, our
future revenues, </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the present state of our development, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of approval for our product candidates, and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in
activities similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">An active trading market for the shares may not develop. It is also possible that after the
offering the shares will not trade in the public market at or above the initial public offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters do not expect to
sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions
and Penalty Bids </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from
bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the
open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing
shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect
investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. The
underwriters may conduct these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to the
direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these
transactions or that these transactions, once commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Affiliates of Leerink Partners LLC purchased 699,475 shares of our Series&nbsp;B convertible preferred stock in our July 2018 Series&nbsp;B
convertible preferred stock financing.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area, no offer of shares which are the subject of the offering has been, or will be
made to the public in that Member State, other than under the following exemptions under the Prospectus Directive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I> that no such offer of shares referred to in (a)&nbsp;to (c) above shall result in a requirement for the Company or the representatives to
publish a prospectus pursuant to Article 3 of the Prospectus Directive, or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each person located in a Member State to whom any offer of shares is made or who receives any communication in respect of an offer of shares,
or who initially acquires any shares will be deemed to have represented, warranted, acknowledged and agreed to and with the representatives and the Company that (1)&nbsp;it is a &#147;qualified investor&#148; within the meaning of the law in that
Member State implementing Article 2(1)(e) of the Prospectus Directive; and (2)&nbsp;in the case of any shares acquired by it as a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, the shares acquired by it in
the offer have not been acquired on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any Member State other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than qualified investors, as that term is defined in the Prospectus Directive, or in circumstances in which the prior consent of the representatives has been given to the offer or resale; or
where shares have been acquired by it on behalf of persons in any Member State other than qualified investors, the offer of those shares to it is not treated under the Prospectus Directive as having been made to such persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company, the representatives and their respective affiliates will rely upon the truth and accuracy of the foregoing representations,
acknowledgments and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the basis that any offer of shares in any Member State will be made
pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Member State of shares which are the subject of the
offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for the Company or the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer.
Neither the Company nor the representatives have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the Company or the representatives to publish a prospectus for such offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer of shares to the public&#148; in relation to any shares in any Member State
means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in that Member
State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended) and includes any relevant implementing measure in each Member State. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling restrictions set out below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19 (5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order
(all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment
activity to which this document relates is only available to, and will be engaged in with, relevant persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Switzerland </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any
other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure
standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating
to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Neither this document nor
any other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares
will not be supervised by, the Swiss Financial Market Supervisory Authority, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to
acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or DFSA.
This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying
any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this prospectus relates may be
illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized
financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities
and Investments Commission, or ASIC, in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or the Corporations Act, and does not
purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section
708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of
allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is
pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and
Futures Ordinance and any rules made under that Ordinance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or
to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph,
&#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or
purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person
pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any
other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant
person which is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business
of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of
that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under
Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person
arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures)
Regulations 2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of its obligations pursuant to Section&nbsp;309B of the SFA, we
have determined, and hereby notify all relevant persons (as defined in the CMP Regulations 2018), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as
defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the<B> </B>shares<B> </B>must be made in accordance with an exemption from, or in a transaction not subject
to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may
provide a purchaser with remedies for rescission or damages if this prospectus<B> </B>(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time
limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of
these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the
government of a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (NI <FONT STYLE="white-space:nowrap">33-105),</FONT>
the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_21"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The validity of the shares of common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, San Diego, California.
The underwriters are being represented by Cooley LLP, San Diego, California. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_22"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements at
December&nbsp;31, 2016 and 2017, and for the years then ended, as set forth in their report. We have included our consolidated financial statements in the prospectus and elsewhere in the registration statement in reliance on Ernst&nbsp;&amp; Young
LLP&#146;s report, given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc626950_23"></A>WHERE YOU CAN FIND MORE
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the
Securities Act with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and
schedules filed therewith. For further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the contents
of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed
as an exhibit to the registration statement. Upon the closing of this offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Exchange Act. You may read and copy this information at
the Public Reference Room of the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may obtain information on the operation of the public reference rooms by calling the SEC at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330.</FONT></FONT></FONT> The SEC also maintains an Internet website that contains reports, proxy statements and other information about registrants, like us, that file
electronically with the SEC. The address of that site is <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we will become subject
to the information and periodic reporting requirements of the Exchange Act and, in accordance therewith, will file periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information
will be available for inspection and copying at the public reference room and website of the SEC referred to above. We maintain a website at www.gossamerbio.com. Upon the completion of this offering, you may access our annual reports on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports filed or furnished pursuant to
Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our website address does not
constitute incorporation by reference of the information contained on our website, and you should not consider the contents of our website in making an investment decision with respect to our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Gossamer Bio, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="toc626950_24"></A>Index to Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B></B><B>Page</B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin626950_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin626950_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin626950_3">Consolidated Statements of&nbsp;Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin626950_4">Consolidated Statements of Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin626950_5">Consolidated Statements&nbsp;of&nbsp;
Convertible Preferred Stock and Stockholders&#146; Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin626950_6">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin626950_7">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin626950_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders&#146; and the Board of Directors of Gossamer Bio, Inc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of Gossamer Bio, Inc. (the Company) as of December&nbsp;31, 2016 and 2017, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders&#146; deficit and
cash flows for the years then ended, and the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial
position of the Company at December&nbsp;31, 2016 and 2017, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of
America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our
audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst &amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San
Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October 11, 2018 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin626950_2"></A>GOSSAMER BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and par value amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;September&nbsp;30,&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Pro Forma<BR>September&nbsp;30,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>445</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>262,181</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued interest&#151;short-term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Note payable to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Convertible note payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued expenses&#151;long-term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,307</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,592</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Commitments and contingencies&#151;Note 10</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series Seed convertible preferred stock, $0.0001 par value; 0&nbsp;shares authorized as of
December&nbsp;31, 2016 and 2017 and 20,000,000 shares authorized as of September&nbsp;30, 2018 (unaudited); 0&nbsp;shares issued and outstanding as of December&nbsp;31, 2016 and 2017 and 20,000,000&nbsp;shares issued and outstanding as of
September&nbsp;30, 2018 (unaudited); liquidation preference of $20,000 as of September&nbsp;30, 2018 (unaudited); no shares issued and outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series&nbsp;A convertible preferred stock, $0.0001 par value; 0&nbsp;shares authorized as of
December&nbsp;31, 2016 and 2017 and 45,714,286 shares authorized as of September&nbsp;30, 2018 (unaudited); 0&nbsp;shares issued and outstanding as of December&nbsp;31, 2016 and 2017 and 45,714,286&nbsp;shares issued and outstanding as of
September&nbsp;30, 2018 (unaudited); liquidation preference of $80,000 as of September&nbsp;30, 2018 (unaudited); no shares issued and outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Series B convertible preferred stock, $0.0001 par value; 0 shares authorized as of December 31,
2016 and 2017 and 71,506,513 shares authorized as of September 30, 2018 (unaudited); 0 shares issued and outstanding as of December 31, 2016 and 2017 and 71,506,513 shares issued and outstanding as of September 30, 2018 (unaudited); liquidation
preference of $230,000, as of September&nbsp;30, 2018; no shares issued and outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common stock, $0.0001 par value; 41,224,000, 125,000,000, and 221,220,799 shares authorized as of
December&nbsp;31, 2016, December&nbsp;31, 2017 and September&nbsp;30, 2018 (unaudited); 41,224,000 shares issued and outstanding as of December&nbsp;31, 2016 and 2017 and 69,900,556&nbsp;shares issued and 34,802,318&nbsp;shares outstanding as of
September&nbsp;30, 2018 (unaudited); 207,121,355&nbsp;shares issued and 172,023,117 outstanding, pro forma (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">361,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,069</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Total liabilities, convertible preferred stock and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt"><B>60</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt"><B>445</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:8pt"><B>262,181</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:8pt"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin626950_3"></A>GOSSAMER BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">In process research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(83</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,653</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(321</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(109,186</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(83</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,771</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(321</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(108,175</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,602,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares outstanding, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,740,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin626950_4"></A>GOSSAMER BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on marketable securities, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(83</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,771</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(321</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(107,940</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin626950_5"></A>GOSSAMER BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Series Seed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Convertible</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Preferred&nbsp;Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Series A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Convertible</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Preferred&nbsp;Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Series B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Convertible</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Preferred&nbsp;Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Common Stock</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Capital</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Accumulated<BR>Other<BR>Comprehensive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Income</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman" ALIGN="center"><B>Total<BR>Stockholders&#146;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Deficit</B></P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; " ALIGN="center"><B>Amount</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>41,224,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(40</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(40</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;</B>&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>41,224,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B> &#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(123</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(123</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>41,224,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,894</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,862</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of Series&nbsp;A convertible preferred stock for cash, net of $400 in offering costs
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,215,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of stock for asset acquisitions (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,955,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of Series A convertible preferred stock to convert debt and accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,499,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Issuance of Series B convertible preferred stock for cash, net of $500 in offering costs
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,506,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Vesting of restricted stock (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">9,234,566</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:7.5pt">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:7.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Incremental vesting conditions placed on previously issued common shares (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,612,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Stock-based compensation (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net loss (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(108,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Unrealized gain on marketable securities, net of tax (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman"><B>Balance as of September&nbsp;30,<BR>2018<BR>(unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,200</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>45,714,286</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79,615</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>71,506,513</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>229,552</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34,802,318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;23,054</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(115,069)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;235</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(91,778</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin626950_6"></A>GOSSAMER BIO, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months</B><br><B>Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(321</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">20,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">In process research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">49,659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(130</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(1,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">3,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">103</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">824</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">3,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">126</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">7,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accrued interest&#151;short-term</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Other Assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(267</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Security deposits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(556</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(5,745</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(26,021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Research and development asset acquisitions, net of cash acquired</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(17,721</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchase of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(115,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(3,168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(136,030</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of convertible note</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from long term note payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of Series A convertible preferred stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Proceeds from issuance of Series B convertible common stock, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of common stock, net of fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Repayment of notes payable to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">6,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">303,003</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">255</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">140,952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, at the beginning of the period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Cash, cash equivalents and restricted cash, at the end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>60</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>315</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>141,267</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash investing and financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Acquisition of in-process research and development through the issuance of stock, net of cash
acquired</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Issuance of Series A convertible preferred stock to convert debt and accrued interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Change in unrealized gain on marketable securities, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin626950_7"></A>Gossamer Bio, Inc. Notes to Consolidated Financial Statements
</B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Information and amounts as of September 30, 2018 and thereafter and for the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>nine months ended September 30, 2017 and 2018 is unaudited) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1&#151;Organization and Basis of Presentation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Gossamer Bio, Inc. (the &#147;Company&#148;) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and
commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company was incorporated in the state of Delaware on October&nbsp;25, 2015 (originally as FSG Bio, Inc.) and is based in San Diego, California. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements include the accounts of Gossamer Bio, Inc. and its wholly owned subsidiaries. All intercompany balances
and transactions among the consolidated entity have been eliminated in consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Split </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In December 2017, the board of directors of the Company approved a stock split of the Company&#146;s common stock at a ratio of 20,612 shares
for every one share previously held. The stock split became effective on January&nbsp;4, 2018. All share and per share data included in these financial statements reflect the stock split. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity and Capital Resources </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has incurred significant operating losses since its inception. As of December&nbsp;31, 2017, and September&nbsp;30, 2018, the
Company had an accumulated deficit of $6.9&nbsp;million and $115.1&nbsp;million, respectively. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Since inception, the Company has
funded its operations primarily through equity financings. The Company raised $310.0&nbsp;million from October 2017 through July 2018 through Series A and Series B Convertible Preferred Stock and convertible note financings. In addition, the Company
received $12.8 million in cash in connection with the January 2018 acquisition of AA Biopharma Inc. The Company expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As a result, the
Company will need to raise capital through equity offerings, debt financings other capital sources, including potential collaborations, licenses and other similar arrangements. Management believes that it has sufficient working capital on hand to
fund operations through at least the next twelve months from the date these consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in acquiring additional funding, that the
Company&#146;s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2&#151;Summary of Significant Accounting Policies</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) and include all adjustments necessary for the fair presentation of the
Company&#146;s financial position for the periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expenses during the reporting period. The most significant estimates in the Company&#146;s consolidated financial statements relate to accrued expenses, the valuation of preferred and common
stock, the valuation of stock options and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be
reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could
differ from those estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Interim Financial Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accompanying interim consolidated balance sheet as of September&nbsp;30, 2018, the consolidated statements of operations and cash flows
for the nine months ended September&nbsp;30, 2017 and 2018 and the consolidated statement of stockholders&#146; deficit for the nine months ended September&nbsp;30, 2018 and the related consolidated footnote disclosures are unaudited. In
management&#146;s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair
presentation of the Company&#146;s financial position as of September&nbsp;30, 2018 and its results of operations and cash flows for the nine months ended September&nbsp;30, 2017 and 2018 in accordance with GAAP. The results for the nine months
ended September&nbsp;30, 2018 are not necessarily indicative of the results expected for the full fiscal year or any other interim period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Balance Sheet Information </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma balance sheet information as of September&nbsp;30, 2018 assumes the conversion of all outstanding shares of
convertible preferred stock into 137,220,799 shares of the Company&#146;s common stock immediately prior to completion of the Company&#146;s planned initial public offering (&#147;IPO&#148;). Shares of common stock issued in the IPO and any related
net proceeds are excluded from the pro forma information. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for
evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents are valued at cost, which
approximate their fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Marketable Securities </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company considers securities with original maturities of greater than 90&nbsp;days to be marketable securities. These marketable
securities consist of U.S. Treasury securities. Marketable securities are recorded at fair value and unrealized gains and losses are recorded within accumulated other comprehensive loss. The estimated fair value of the marketable securities is
determined based on quoted market prices or rates for similar instruments. The Company evaluates securities with unrealized losses to determine whether such losses, if any, are other than temporary. Realized gains and losses are calculated using the
specific identification method and recorded as interest income or expense. We do not generally intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost
bases, which may be at maturity. The Company has determined that there were no other than temporary declines in fair values of its investments as of September&nbsp;30, 2018. As of September&nbsp;30, 2018, the Company held U.S. Treasury securities
with an amortized cost of $115.2&nbsp;million, an unrealized gain of $326,000, an unrealized loss of $91,000, a fair market value of $115.4&nbsp;million and are scheduled to mature in less than twelve months. As of December&nbsp;31, 2017, the
Company did not hold any marketable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Restricted cash serves as collateral for the Company&#146;s corporate credit card program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk and <FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Risk </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and marketable securities are financial instruments that are potentially subject to concentrations of credit risk. The
Company&#146;s cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company believes it is not exposed to significant credit risk due to the financial strength of
the depository institutions in which the cash and cash equivalents are held. The Company maintains its cash equivalents in U.S. Treasury securities with maturities less than three months and in money market funds that invest in U.S. Treasury
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s available for sale securities are also invested in U.S. Treasury securities. The Company has not
recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents and available for sale securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Property and equipment, net, which consists mainly of office equipment and leasehold improvements, are carried at cost less accumulated
depreciation. Depreciation is computed over the estimated useful lives of the respective assets, generally three to seven years, using the straight-line method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company records rent
expense on a straight-line over the term of the lease. The difference between rent payments and straight-line rent expense is recorded as deferred rent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All
research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research
organizations and other professional services), in process research and development expenses and license agreement expenses. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the
goods or services are received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company records accruals for estimated research and development costs, comprising payments for work
performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractor&#146;s bill monthly based on actual services performed, while others bill periodically based upon achieving certain
contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial site costs related to patient enrollment are accrued as patients enter and progress through the trial. Upfront costs,
such as costs associated with setting up clinical trial sites for participation in the trials, are expensed immediately once incurred as research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent Costs </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Costs related to
filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain. These costs are included in general and administrative expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Income taxes are
recorded in accordance with Financial Accounting Standards Board (&#147;FASB&#148;) Standards Codification (&#147;ASC&#148;) No.&nbsp;740, <I>Income Taxes</I> (&#147;ASC 740&#148;), which provides for deferred taxes using an
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or
tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to
reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company
recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is
based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
provisional impact of the Tax Cuts and Jobs Act (&#147;Tax Act&#148;) is the Company&#146;s current best estimate based on a preliminary review of the new law and is subject to revision based on its existing accounting for income tax policy as
further information is gathered, and interpretation and analysis of the tax legislation evolves. The Securities and Exchange Commission has issued rules allowing for a measurement period of up to one year after the enactment date of the Tax Act to
finalize the recording of the related tax impacts. Any future changes to the Company&#146;s provisional estimated impact of the Tax Act will be included as an adjustment to the provision for income taxes. Deferred tax assets and liabilities reflect
the future tax consequences of the differences between the financial reporting and tax bases of assets and liabilities using current enacted tax rates. Valuation allowances are recorded when the realizability of such deferred tax assets does not
meet a <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> threshold. For tax benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company is subject to taxation
in the United States and state jurisdictions. As of December 31, 2017, the Company&#146;s tax years since inception are subject to examination by taxing authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The
Company expenses stock-based compensation to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> over the requisite service period based on the estimated grant-date fair value of the awards. The Company records the expense for
stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable. Management evaluates when the achievement of a
performance-based milestone is probable based on the expected satisfaction of the performance conditions at each reporting date. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the
assumptions used in calculating the fair value of stock-based awards represent management&#146;s best estimates and involve inherent uncertainties and the application of management&#146;s judgment. All share-based compensation costs are recorded in
the statements of operations based upon the underlying employees or <FONT STYLE="white-space:nowrap">non-employee&#146;s</FONT> roles within the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements&#151;To Be Adopted </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT>
<I>Leases (Topic 842)</I>, which requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU
<FONT STYLE="white-space:nowrap">2016-02</FONT> is effective for fiscal periods beginning after December&nbsp;15, 2018, with early adoption permitted. The Company is required to adopt this new guidance beginning in 2019 using the modified
retrospective method and early adoption is permitted. Although the Company is in the early stages of evaluating the impact of adoption of ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> on its financial statements, the&nbsp;Company currently
believes the most significant changes will be related to the recognition of lease liabilities on the Company&#146;s consolidated balance sheets for real estate operating leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation&#151;Stock Compensation
(Topic&nbsp;718)&nbsp;&#150; Improvements to Nonemployee Share-Based Payment Accounting</I>. The amendments in ASU <FONT STYLE="white-space:nowrap">2018-07,</FONT> expand the scope of Topic&nbsp;718 to include share-based payment transactions for
acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards for specific guidance on inputs to an option pricing model and the period of time over which share-based payment awards vest
and the pattern of cost recognition over that period. The amendments also clarify that Topic&nbsp;718 does not apply to share-based payments used to effectively provide (i)&nbsp;financing to the issuer or (ii)&nbsp;awards granted in conjunction with
selling goods or services to customers as part of a contracted accounted for under Topic 606, <I>Revenue from Contracts with Customers</I>. ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> is effective for the Company in January 2020, with early
adoptions permitted, but no earlier than the Company&#146;s adoption date of Topic&nbsp;606. The Company has elected to early adopt ASU <FONT STYLE="white-space:nowrap">2018-07,</FONT> full retrospective as of January&nbsp;1, 2017. The Company has
no revenues and therefore the adoption of Topic 606 did not have an impact on the Company&#146;s financial statements. The adoption of ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> did not have a material impact on its consolidated financial
statements and related disclosures, financial position, results of operations or cash flows.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In February 2018, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-02,</FONT> <I>Income Statement&#151;Reporting Comprehensive Income, (Topic&nbsp;220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income,</I> which allows a reclassification
from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the newly enacted federal corporate income tax rate under the Tax Act. The amount of the reclassification would be the difference between the
historical corporate income tax rate and the newly enacted 21% corporate income tax rate. The new standard is effective for fiscal years, including interim periods within those fiscal years, beginning after December&nbsp;15, 2018 with early adoption
in any interim period permitted. The Company has elected to early adopt ASU <FONT STYLE="white-space:nowrap">2018-02,</FONT> as of January&nbsp;1, 2018. The adoption of ASU <FONT STYLE="white-space:nowrap">2018-02</FONT> did not have a material
impact on its consolidated financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January 2017, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2017-01,</FONT> <I>Business Combinations (Topic&nbsp;805): Clarifying the Definition of a Business</I>. The amendments in this update clarify the definition of a business with the objective of adding guidance to
assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The definition of a business affects many areas of accounting including acquisitions, disposals, goodwill, and
consolidation. The guidance is effective for fiscal periods beginning after December&nbsp;15, 2017, including interim periods within those periods. The Company adopted ASU <FONT STYLE="white-space:nowrap">2017-01</FONT> starting with the GB002
acquisition, which occurred prior to the effective date of ASU 2017-01 and the financial statement issuance date. The adoption of this guidance did not have a material impact on its consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-18,</FONT><I>&nbsp;Statement of Cash Flows
(Topic&nbsp;230): Restricted Cash,</I> which clarifies the presentation of restricted cash in the statements of cash flows. Under <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-18,</FONT> restricted cash is included with cash and cash equivalents
when reconciling the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-period</FONT></FONT> total amounts shown on the
statements of cash flows. The Company adopted <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-18</FONT> as of January&nbsp;1, 2018. Cash, cash equivalents and restricted cash total as presented in the statements of cash flows consist of cash and cash
equivalents of $32.1&nbsp;million and restricted cash of $0.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-09,</FONT> <I>Stock Compensation Improvements to Employee Share-Based Payment Accounting</I>, which simplifies several aspects of the accounting for share-based payment transactions, including the income tax
consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU <FONT STYLE="white-space:nowrap">2016-09</FONT> became effective for the Company on January&nbsp;1, 2017. The adoption of
this guidance did not have a material impact on its consolidated financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In May&nbsp;2014, the FASB
issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT> <I>Revenue from Contracts with Customers</I>, which created a single, principle-based revenue recognition model that will supersede and replace nearly all existing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. GAAP revenue recognition guidance. Entities will recognize revenue in a manner that depicts the transfer of goods or services to customers at an amount that reflects the consideration to
which the entity expects to be entitled to receive in exchange for those goods or services. The model provides that entities follow five steps: (i)&nbsp;identify the contract with a customer, (ii)&nbsp;identify the performance obligations in the
contract, (iii)&nbsp;determine the transaction price, (iv)&nbsp;allocate the transaction price to the performance obligations, and (v)&nbsp;recognize revenue. For nonpublic business entities, the guidance becomes effective for annual reporting
periods beginning after December&nbsp;15, 2018. The Company has elected to early adopt ASU <FONT STYLE="white-space:nowrap">2014-09,</FONT> as of January&nbsp;1, 2017, the adoption of this guidance did not have any impact on its consolidated
financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number
of shares of common stock outstanding for the period. Diluted net loss per share excludes the potential impact of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, and Series B Convertible Preferred Stock, common stock
options and unvested shares of restricted stock because their effect would be anti-dilutive due to the Company&#146;s net loss. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per common share are the
same. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share
because to do so would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issuable upon conversion of Series Seed Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issuable upon conversion of Series A Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,714,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issuable upon conversion of Series B Convertible Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,506,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issuable upon exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,469,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-vested</FONT> shares under restricted stock grants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;5,874,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,098,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Net Loss Per Share </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes the Company&#146;s unaudited pro forma net loss per share (in thousands except share and per share data): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Numerator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and pro forma net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(108,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Denominator</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,602,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustments to reflect assumed weighted-average effect of conversion of convertible
preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,138,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute pro forma net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,224,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,740,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro forma net loss per share, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3&#151;Accrued Expenses </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Accrued expenses consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>September&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued accounting fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued consulting fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4&#151;Fair Value Measurements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major
asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such
assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Level&nbsp;1: Observable inputs such as quoted prices in active markets; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Level&nbsp;2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Level&nbsp;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own
assumptions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, and 2017, the carrying amounts of the Company&#146;s financial instruments, which include
cash, accounts payable and accrued expenses, approximate fair values because of their short maturities. Included in marketable securities as of September&nbsp;30, 2018 are U.S. Treasury Securities with a carrying value and fair value of
$115.4&nbsp;million based upon a Level&nbsp;1 fair value assessment. The carrying amounts for the Company&#146;s other financial instruments approximate fair values as of September&nbsp;30, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As of December 31, 2016, December 31, 2017, and September 30, 2018, the Company did not have any Level&nbsp;2 or Level&nbsp;3 securities. </P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5&#151;Convertible Note Financing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;2, 2017, the Company issued a convertible promissory note (the &#147;Note&#148;) in an amount of $6.0&nbsp;million to an
investor. The Note accrued interest at 8% per year and had a maturity date of October&nbsp;2, 2018. The Note was subject to an automatic conversion upon a qualified equity financing defined as a raise of $40.0&nbsp;million, excluding the conversion
of the Note and other indebtedness. The conversion was equal to the outstanding principal amount of the Note plus all accrued and previously unpaid interest thereon, divided by the lowest price per share paid by investor for qualified equity
financing. The carrying value of the Note for the year ended December&nbsp;31, 2017 was approximately $6.1&nbsp;million which approximated the fair value of the Note which was determined using Level&nbsp;3 inputs. On January&nbsp;4, 2018, the Note
converted into 3,499,209 shares of Series A Convertible Preferred Stock. For the year ended December&nbsp;31, 2017 and for the nine months ended September&nbsp;30, 2018, the Company recorded aggregate interest expense of $0.1&nbsp;million. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6&#151;Asset Acquisitions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following purchased assets were accounted for as asset acquisitions pursuant to ASU <FONT STYLE="white-space:nowrap">2017-01,</FONT>
<I>Business Combinations (Topic 805): Clarifying the Definition of a Business</I>, as substantially all of the fair value of the assets acquired were concentrated in a group of similar assets, and the acquired assets did not have outputs or
employees. Because the assets had not yet received regulatory approval, the fair value attributable to these assets was recorded as in process research and development (&#147;IPR&amp;D&#148;) expenses in the Company&#146;s consolidated statement of
operations for the year ended December&nbsp;31, 2017 and for the nine months ended September&nbsp;30, 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition of License from
Pulmokine, Inc. (GB002) </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On October&nbsp;2, 2017, the Company, entered into a license agreement with Pulmokine, Inc. under
which it was granted an exclusive worldwide license and sublicense to certain intellectual property rights owned or controlled by Pulmokine to develop and commercialize GB002 and certain backup compounds for the treatment, prevention and diagnosis
of any and all disease or conditions. The Company also has the right to sublicense its rights under the license agreement, subject to certain conditions. The assets acquired are in the early stages of the FDA approval process, and the Company
intends to further develop the assets acquired through potential FDA approval as evidenced by the milestone arrangement in the contract. The development activities cannot be performed without significant cost and effort by the Company. The agreement
will remain in effect from the effective date, unless terminated earlier, until, on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, the later of ten years from the date of first commercial sale or when there is no longer a valid patent claim covering such licensed product or specified regulatory exclusivity for
the licensed product in such country. The Company is obligated to make future development and regulatory milestone payments of up to $63.0&nbsp;million, commercial milestone payments of up to $45.0&nbsp;million, and sales milestone payments of up to
$190.0&nbsp;million. The Company is also obligated to pay tiered royalties on sales for each licensed product, at percentages ranging from the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits to the high single-digits. The Company made an
upfront payment in the year ended December&nbsp;31, 2017, recorded as IPR&amp;D of $5.5&nbsp;million. As of September&nbsp;30, 2018, no milestones had been accrued as there were no potential milestones yet considered probable.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AA Biopharma Inc. Acquisition (GB001) </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On January&nbsp;4, 2018, the Company acquired AA Biopharma Inc. pursuant to a merger agreement, and with the acquisition acquired the rights
to GB001 and certain backup compounds. In connection with the merger agreement, the Company issued an aggregate of 20,000,000 shares of Series Seed Convertible Preferred Stock and 4,955,752 shares of Common Stock to the AA Biopharma shareholders.
The Company recorded IPR&amp;D of $19.3&nbsp;million in connection with the acquisition of AA Biopharma. </P>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition of License from
Aerpio Pharmaceuticals, Inc. (GB004) </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On June&nbsp;24, 2018, the Company entered into a license agreement with Aerpio
Pharmaceuticals, Inc. (&#147;Aerpio&#148;) under which the Company was granted an exclusive worldwide license and sublicense to certain intellectual property rights owned or controlled by Aerpio to develop and commercialize GB004, and certain other
related compounds for all applications. The Company also has the right to sublicense its rights under the license agreement, subject to certain conditions. The Company is obligated to make future development and regulatory milestone payments of up
to $55.0&nbsp;million, commercial milestone payments of up to $85.0&nbsp;million and sales milestone payments of up to $260.0&nbsp;million. The Company is also obligated to pay tiered royalties on sales for each licensed product, at percentages
ranging from a high single-digit to <FONT STYLE="white-space:nowrap">mid-teens,</FONT> subject to certain customary reductions. The Company made an upfront payment of $20.0&nbsp;million, which represented the purchase consideration for an asset
acquisition. As of September&nbsp;30, 2018, no milestones had been accrued as there were no potential milestones yet considered probable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adhaere Pharmaceuticals, Inc. Acquisition (GB1275)</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On September&nbsp;21, 2018,&nbsp;the Company acquired Adhaere Pharmaceuticals, Inc. pursuant to a merger agreement for an upfront payment of
$7.5&nbsp;million in cash, and with the acquisition acquired the rights to GB1275 and certain backup compounds. The Company is obligated to make future regulatory, development and sales milestones of up to $62.0&nbsp;million and pay tiered royalties
on worldwide net sales, at percentages ranging from low to mid-single digits, subject to customary reductions. As of September 30, 2018, no milestones had been accrued as there were no potential milestones yet considered probable. The Company
recorded IPR&amp;D of $7.5&nbsp;million in connection with the acquisition of Adhaere. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company recorded the following IPR&amp;D
expense on the consolidated statements of operations (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year&nbsp;Ended<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;December&nbsp;
31,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Nine&nbsp;Months<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ended&nbsp;
September&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GB002</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GB001</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GB004</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GB1275</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other preclinical programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;5,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7&#151;Income Taxes </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No provision for federal or state income taxes has been recorded for the years ended December&nbsp;31, 2016 and 2017. The difference between
the Company&#146;s effective tax rate of 0% and the U.S. federal statutory tax rate of 34% is largely due to the Company&#146;s net operating losses and the effect of the federal corporate rate change beginning January&nbsp;1, 2018, which are offset
by the corresponding valuation allowance. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
Significant components of the Company&#146;s deferred tax assets and liabilities as of December&nbsp;31, 2016 and 2017 are shown below. The Company has established a valuation allowance against net deferred tax assets due to the uncertainty that
such assets will be realized. The Company periodically evaluates the recoverability of the deferred assets. At such time as it is determined that it is more likely than not that the deferred tax asset will be realized, the valuation allowance will
be reduced. The change in the valuation allowance for the year ended December&nbsp;31, 2017 was an increase of $1.8&nbsp;million. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred state income tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,895</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2017, the Company has federal and California net operating losses (&#147;NOL&#148;)
carryforwards of approximately $1.1&nbsp;million and $1.1&nbsp;million, respectively. The federal and state NOL carryforwards begin to expire in 2036. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The NOL carryforward may be subject to an annual limitation under Section&nbsp;382 and 383
of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax
respectively. In general, an ownership change as defined by Section&nbsp;382 and 383, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than 50 percentage points over
a three-year period. The Company has not completed a Section&nbsp;382 and 383 analysis to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#146;s formation due to the complexity
and cost associated with such study and the fact there may be additional such ownership changes in the future. If a change in ownership were to have occurred or occurs in the future, the NOL and tax credits carryforwards could be eliminated or
restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership
changes, if any, will not impact the Company&#146;s effective tax rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the United States and
California. Due to the Company&#146;s losses incurred, the Company is subject to the income tax examination by authorities since inception. The Company&#146;s policy is to recognize interest expense and penalties related to income tax matters as tax
expense. As of December&nbsp;31, 2017, there were no significant accruals for interest related to unrecognized tax benefits or tax penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, the President of the United States signed into law the Tax Act. The Tax Act amends the Internal Revenue Code to
reduce tax rates and modify policies, credits, and deductions for individuals and businesses. For businesses, the Tax Act reduces the corporate tax rate from a maximum 35% to a flat 21% rate. The rate reduction is effective on January&nbsp;1, 2018.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">As a result of the rate reduction, the Company has reduced the deferred tax asset balance as of December&nbsp;31, 2017 by
$0.8&nbsp;million. Due to the Company&#146;s full valuation allowance position, there was no net impact on the Company&#146;s income tax provision at December&nbsp;31, 2017, as the reduction in the deferred tax asset balance was fully offset by a
corresponding decrease in the valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In conjunction with the Tax Act, the SEC staff issued Staff Accounting Bulletin
No.&nbsp;118 (&#147;SAB 118&#148;) to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting
for certain income tax effects of the Tax Act. There was no net impact on the Company&#146;s consolidated financial statements for the year ended December&nbsp;31, 2017 as the corresponding adjustment was made to the valuation allowance. The
ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and
actions the Company may take as a result of the Tax Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8&#151;Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Preferred Stock</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series Seed
Convertible Preferred Stock</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On January&nbsp;4, 2018, the Company issued an aggregate of 20,000,000 shares of Series Seed
Convertible Preferred Stock in connection with the merger agreement with AA Biopharma Inc. (See Note 6). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series A Convertible Preferred
Stock</I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In January and March 2018, the Company issued an aggregate of 45,714,286 shares of Series A Convertible Preferred Stock
at $1.75 per share for approximately $73.9&nbsp;million in cash and the conversion of approximately $6.1&nbsp;million in principal and accrued interest under the Note (See Note 5). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series B Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On July 20 2018, the Company issued an aggregate of 71,506,513 shares of Series B Convertible Preferred Stock at $3.2167 per share for
approximately $230.0&nbsp;million in gross proceeds. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Holders of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock and Series&nbsp;B Convertible Preferred Stock
(collectively, &#147;Series Convertible Preferred Stock&#148;), in preference to the holders of common stock, shall be entitled to receive, but only out of funds that are legally available therefor, cash dividends at the annual per share rate of
6.0% per annum (based on the original issue price). Such dividends shall be payable only when, as and if declared by the Company&#146;s board of directors and shall <FONT STYLE="white-space:nowrap">be&nbsp;non-cumulative.&nbsp;No</FONT> dividends
have been declared as of September&nbsp;30, 2018. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Holders of Series B Convertible Preferred Stock are entitled to receive a liquidation preference (the &#147;Series B Liquidation Amount&#148;)
prior to any distribution to the holders of Series Seed Convertible Preferred Stock, Series&nbsp;A Convertible Preferred Stock and common stock in the amount per share equal to the greater of (i) $3.2167, plus all declared and unpaid dividends, or
(ii) the amount the holders would receive if the Series B Convertible Preferred Stock were converted into common stock prior to such liquidation event. After payment of the full Series B Liquidation Amount, holders of shares of Series Seed
Convertible Preferred Stock and Series&nbsp;A Convertible Preferred Stock are entitled to receive a liquidation preference prior to any distribution to the holders of common stock in the amount per share equal to the greater of (i) $1.00 per share
with respect to the Series Seed Convertible Preferred Stock and $1.75 per share with respect to the Series A Convertible Preferred Stock, plus all declared and unpaid dividends, or (ii)&nbsp;the amount the holders would receive if the Series
Convertible Preferred Stock were converted into common stock prior to such liquidation event. Thereafter, the remaining assets of the Company legally available for distribution, if any, shall be distributed ratably to the holders of the common
stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The shares of Series Convertible Preferred Stock are convertible into an equal number of shares of common stock, at the option of the holder,
subject to certain anti-dilution adjustments. Each share of Series Convertible Preferred Stock is automatically converted into common stock (i)&nbsp;upon the closing of a firm-commitment underwritten public offering pursuant to an effective
registration statement under the Securities Act of 1933, as amended, resulting in at least $100&nbsp;million of gross proceeds to the Company, or if such offering is otherwise approved by vote or written consent of at least 65% of the outstanding
shares of the Series Convertible Preferred Stock, or (ii)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of each of the holders of (a) at least 65% of the outstanding shares of the Series Convertible
Preferred Stock and (b) at least 65% of the outstanding shares of Series B Convertible Preferred Stock </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The holder of each share of Series Convertible Preferred Stock is entitled to one vote for each share of common stock into which it would
convert and to vote as one class with the common stockholders on all matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Presentation of Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Series Convertible Preferred is classified outside of stockholders&#146; equity (deficit) because the shares contain certain redemption
features that are not solely within the control of the Company. The Company is not adjusting the carrying value of the Series Convertible Preferred as it is uncertain whether or when a redemption event will occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock</I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">On December&nbsp;3, 2015, the Company issued 41,224,000 shares of common stock as founder shares for services rendered to the Company, valued
at $0.0001 par value per share, for a total of approximately $4,100. On January&nbsp;4, 2018, incremental vesting conditions were placed on the previously issued founder shares. Fifty percent of the previously issued founder shares vested on
January&nbsp;4, 2018, and the remaining founder shares are subject to vesting restrictions over a period of five years. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to
the employment agreements with the Company&#146;s founders executed January 4, 2018, the Company provided for certain potential additional issuances of common stock (the &#147;anti-dilution shares&#148;) to each of the founders to ensure the total
number of shares of common stock held by them and their affiliates (inclusive of any shares subject to equity awards granted by the Company and the Founders&#146; Equity) would represent 15% of the Company&#146;s fully-diluted capitalization until
such time as the Company raised $300 million in equity capital, including the capital raised in the Series&nbsp;A financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In
furtherance of this obligation, on May 21, 2018, the Company issued 1,131,962 shares of common stock to the founders for services rendered to the Company, valued at $0.58 per share with an additional 1,131,962 shares of restricted stock subject to
the same vesting restrictions and vesting period as the founder shares. In addition, on September 6, 2018, the Company issued 8,077,604 shares of common stock to the founders for services rendered to the Company, valued at $2.14 per share, with an
additional 8,077,604 shares of restricted stock subject to the same vesting restrictions and vesting period as the founder shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Each share of common stock is entitled to one voting right. Common stock owners are entitled to dividends when funds are legally available and
declared by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares of Common Stock Subject to Repurchase </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In November 2017, in connection with the issuance of the Series A Convertible Preferred Stock, certain employees entered into stock
restriction agreements, whereby 5,874,420 shares are subject to forfeiture by the Company upon the stockholder&#146;s termination of employment or service to the Company. In January 2018, the Company&#146;s founders entered into stock restriction
agreements, whereby 20,612,000 of previously unrestricted shares of common stock were subject to service vesting conditions. These shares are also subject to forfeiture by the Company upon the stockholders&#146; termination of employment or service
to the Company. Any shares subject to repurchase by the Company are not deemed, for accounting purposes, to be outstanding until those shares vest. As such, the Company recognizes the measurement date fair value of the restricted stock over the
vesting period as compensation expense. For the years ended December&nbsp;31, 2016, December&nbsp;31, 2017 and September&nbsp;30, 2018, 0 shares, 5,874,420 shares and 35,098,238 shares of common stock, respectively, were subject to repurchase by the
Company. The unvested stock liability related to these awards is immaterial to all periods presented. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 9&#151;Stock-Based Compensation
</B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2017 Equity Incentive Plan (the &#147;Plan&#148;) permits the granting of incentive stock options, <FONT
STYLE="white-space:nowrap">non-statutory</FONT> stock options, restricted stock, restricted stock units and other stock-based awards. As of December&nbsp;31, 2016, December&nbsp;31, 2017, and September&nbsp;30, 2018, 0 shares, 5,889,357 shares, and
17,121,225 shares of common stock were authorized for issuance under the Plan, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2017 and
September&nbsp;30, 2018, 5,874,420 and 14,746,172 shares outstanding have been awarded and 14,937 and 2,375,053 shares, respectively, remain available for issuance under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The fair value of
each employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The Company is a private company and lacks company-specific
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
historical and implied volatility information. Therefore, it estimates its expected volatility based on the historical volatility of a publicly traded set of peer companies. Due to the lack of
historical exercise history, the expected term of the Company&#146;s stock options for employees has been determined utilizing the &#147;simplified&#148; method for awards. The expected term of stock options granted to
<FONT STYLE="white-space:nowrap">non-employees</FONT> is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to the U.S.&nbsp;Treasury yield curve in effect at the time of grant of the award for
time periods approximately equal to the expected term of the award. Expected dividend yield is zero based on the fact that the Company has never paid cash dividends and does not expect to pay any cash dividends in the foreseeable future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The grant date fair value of stock option awards is determined using the Black-Scholes option-pricing model. No stock options were granted for
the years ended December&nbsp;31, 2016 and 2017. The following assumptions were used to estimate the fair value of stock option awards: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months<BR>Ended<BR>September&nbsp;30,&nbsp;2018</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$0.58&nbsp;-&nbsp;$1.02</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.3&nbsp;-&nbsp;6.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">69.13%&nbsp;-&nbsp;77.62%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.65%&nbsp;-&nbsp;2.96%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;&nbsp;&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity during the nine months ended September&nbsp;30,
2018: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-</B><br><B>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Life (in<BR>years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total<BR>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,587,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,469,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options vested and exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value in the above table is calculated as the difference between fair value
of the Company&#146;s common stock price and the exercise price of the stock options. The weighted-average grant date fair value per share for the stock option grants during the nine months ended September 30, 2018 was $0.43. At September&nbsp;30,
2018, the total unrecognized compensation related to unvested stock option awards granted was $3.7&nbsp;million, which the Company expects to recognize over a weighted-average period of approximately 3.6 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The summary of the Company&#146;s restricted stock activity is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Weighted-Average&nbsp;Grant<BR>Date&nbsp;Fair&nbsp;Value&nbsp;Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nonvested at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,874,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nonvested at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,874,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,056,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeitures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(597,748</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,234,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nonvested at September&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,098,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">At September 30, 2018, the total unrecognized compensation related to unvested restricted stock
awards granted was $28.2&nbsp;million, which the Company expects to recognize over a weighted-average period of approximately 4.0 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense has been reported in the Company&#146;s consolidated statements of operations as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year&nbsp;Ended<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;December&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;Months<BR>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ended&nbsp;September&nbsp;30,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">For the nine months ended September 30, 2018, $17.3 million of the stock-based compensation expense
related to the issuance of the anti-dilution shares. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 10&#151;Property and Equipment, Net </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company&#146;s property and equipment, net consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Estimated&nbsp;Useful<BR>Life (in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in process</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No depreciation expense was recorded for the years ended December&nbsp;31, 2016 and
2017. Depreciation expense for the nine months ended September&nbsp;30, 2018 was approximately $163,000 and was recorded in general and administrative expense in the Consolidated Statements of Operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 11&#151;Commitments and Contingencies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Office
Lease </I></B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company subleases certain office and laboratory space under a
<FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease expiring in January 2025 for the initial leased space and December 2022 for expansion space leased pursuant to an amendment to the lease agreement entered into in August 2018.
with an option to extend for the entire premises through the expiration of the initial terms of the master lease. The <FONT STYLE="white-space:nowrap">sub-lease</FONT> is subject to charges for common area maintenance and other costs, and base rent
is subject to an annual increase in 3% of each subsequent year. The sublease did not commence until January&nbsp;15, 2018, therefore there was no rent expense for the years ending December&nbsp;31, 2016 and 2017. For the nine months ended
September&nbsp;30, 2018, the Company recorded approximately $1.1&nbsp;million in rent expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Future minimum payments under the <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> operating lease as of September&nbsp;30, 2018 were as follows (in thousands): </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Remainder of 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Years ended December&nbsp;31,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the
Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 12&#151;Subsequent
Events </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The Company has completed an evaluation of all subsequent events through October, 11 2018 for the consolidated financial
statements as of and for the year ended December 31, 2017 and through November 29, 2018 for the interim consolidated financial statements as of and for the nine months ended September 30, 2018, to ensure that these consolidated financial statements
include appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred but were not recognized in the consolidated financial statements. The Company has concluded that no subsequent event has
occurred that requires disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (the 25th day after the date of this prospectus) all dealers that effect transactions in these securities, whether or not
participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </P>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g626950g80k69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>BofA Merrill Lynch </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Leerink Partners </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Barclays </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Evercore ISI
</B></P> <P STYLE="margin-top:72pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018
</B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P><center>
<P STYLE="line-height:3.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P></center>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Part II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Item&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Expenses of Issuance and Distribution. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than
underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq Global Select Market listing
fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="72%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Amount&nbsp;paid&nbsp;or<BR>to be paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accountants&#146; fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer Agent&#146;s fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">To be provided by amendment. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Item&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Directors and Officers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of
directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional
misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides that no director
of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General
Corporation Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director,
officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#146;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or
completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding,
had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall
have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such
person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation, which will become effective
immediately prior to the closing of this offering, provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in
the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar
capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#147;Indemnitee&#148;), or by reason of any action alleged to have been taken or omitted in such capacity, against
all expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and
in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our amended and restated
certificate of incorporation provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to
become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other
enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in
connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be
made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to
indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually
and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We have entered
into indemnification agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#146; fees, judgments, fines
and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides
services at our request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of
our corporation arising out of claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In any underwriting
agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the
Securities Act, against certain liabilities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Item&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recent Sales of Unregistered Securities. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding unregistered securities issued by us since October&nbsp;26, 2015. Also included is the consideration
received by us for such securities and information relating to the section of the Securities Act, or rule of the SEC, under which exemption from registration was claimed. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Issuances of Capital Stock and Convertible Promissory Notes </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In December 2015, we issued and sold 41,224,000 shares of common stock to our founders at purchase price of
$0.001 per share for aggregate consideration of approximately $41,224. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In October 2017, we issued and sold to an investor a convertible promissory note, or the Note, in the aggregate
principal amount of $6,000,000. The Note, including interest thereon, converted into 3,499,209 shares of our Series A convertible preferred stock in January 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In December 2017, we issued 4,955,752 shares of our common stock and 20,000,000 shares of our Series Seed
convertible preferred stock to investors pursuant to a merger agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In January and March 2018, we issued an aggregate of 45,714,286 shares of our Series A convertible preferred
stock to investors at a purchase price of $1.75 per share, for aggregate consideration of approximately $80.0&nbsp;million, including the conversion of the Note. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In May 2018, we issued 2,263,924 shares of common stock to our founders at a purchase price of $0.58 per share,
in consideration for services rendered for aggregate consideration of $1.3&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In July 2018, we issued an aggregate of 71,506,513 shares of our Series B convertible preferred stock to
investors at a purchase price of $3.2167 per share, for aggregate consideration of approximately $230.0&nbsp;million. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In September 2018, we issued 16,155,208 shares of common stock to our founders at a purchase price of $1.02 per
share, in consideration for services rendered for aggregate consideration of $16.5&nbsp;million. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">No underwriters were
involved in the foregoing issuances of securities. The securities described in this section (a)&nbsp;of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in
Section&nbsp;4(a)(2) under the Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All holders of securities
described above represented to us in connection with their purchase or issuance that they were accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in
connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time. The holders received written disclosures that the securities had not been registered under
the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Grants of Stock Options and Restricted Stock </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From October 2015 through September&nbsp;30, 2018, we granted stock options to purchase an aggregate of
9,469,500 shares of our common stock at a weighted-average exercise price of $0.65 per share, to certain of our employees, consultants and directors in connection with services provided to us by such persons. None of these options have been
exercised or cancelled through September&nbsp;30, 2018. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From October 2015 through September&nbsp;30, 2018, we granted an aggregate of 5,874,420 shares of our
restricted common stock to certain of our employees, consultants and directors pursuant to restricted stock agreements in connection with services provided to us by such persons, at a purchase price of $0.0049 per share. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The restricted stock, stock options and the common stock issuable upon the exercise of such options as described in this section (b)&nbsp;of
Item 15 were issued pursuant to written compensatory plans or arrangements with our employees and directors, in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 701 promulgated under the Securities
Act or the exemption set forth in Section&nbsp;4(a)(2) under the Securities Act and Regulation D promulgated thereunder relative to transactions by an issuer not involving any public offering. All recipients either received adequate information
about us or had access, through employment or other relationships, to such information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All of the foregoing securities are deemed restricted securities for purposes of the
Securities Act. All certificates representing the issued shares of capital stock described in this Item 15 included appropriate legends setting forth that the securities had not been registered and the applicable restrictions on transfer. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Item&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits and Financial Statement Schedules. </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits.</B> See Exhibit Index attached to this registration statement, which is incorporated by reference
herein. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statement Schedules. </B>Schedules not listed above have been omitted because the information
required to be set forth therein is not applicable or is shown in the consolidated financial statements or notes thereto. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Item&nbsp;17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes to provide to the underwriter, at the closing specified in the underwriting agreement,
certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit
or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The undersigned hereby undertakes that: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For purposes of determining any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of
this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description of
Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws (currently in effect)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation (to be effective immediately prior to the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws (to be effective immediately prior to the closing of this offering)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen stock certificate evidencing the shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Investors&#146; Rights Agreement, dated July&nbsp;20, 2018, by and among the Registrant and certain of its stockholders</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Latham&nbsp;&amp; Watkins LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gossamer Bio, Inc. 2017 Equity Incentive Plan, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of stock option agreement under Gossamer Bio, Inc. 2017 Equity Incentive Plan, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of restricted stock agreement under Gossamer Bio, Inc. 2017 Equity Incentive Plan, as amended</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Founder restricted stock agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gossamer Bio, Inc. 2019 Incentive Award Plan and form of option agreement thereunder</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Gossamer Bio, Inc. 2019 Employee Stock Purchase Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, dated January&nbsp;4, 2018, by and between Sheila Gujrathi, M.D. and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement, dated January&nbsp;4, 2018, by and between Faheem Hasnain and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement for Directors and Officers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sublease Agreement, dated December&nbsp;29, 2017, by and between The Medicines Company and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Sublease Agreement, dated August&nbsp;24, 2018, by and between The Medicines Company and the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exclusive License Agreement, dated October&nbsp;2, 2017, by and between GB002, Inc., the Registrant and Pulmokine, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14&#134;**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement, dated June&nbsp;24, 2018, by and between Aerpio Pharmaceuticals, Inc. and GB004, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Board Designation Letter Agreement, dated July&nbsp;20, 2018, between the Registrant and HH Goss Holdings LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">List of subsidiaries</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Ernst&nbsp;&amp; Young, LLP, independent registered public accounting firm</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description of
Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Latham&nbsp;&amp; Watkins LLP (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included on signature page)</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Previously submitted. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential
treatment pursuant to Rule 406 under the Securities Act of 1933. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the San Diego, State of California, on this &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; day of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GOSSAMER BIO, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sheila Gujrathi, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">We, the undersigned officers and directors of Gossamer Bio, Inc., hereby severally constitute and appoint Sheila Gujrathi, M.D. and Bryan
Giraudo, and each of them singly (with full power to each of them to act alone), our true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, with full power of substitution and
resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any other registration statement for the
same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be
done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT>
and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Pursuant to
the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sheila Gujrathi, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President,&nbsp;Chief&nbsp;Executive<BR>Officer&nbsp;and&nbsp;Director<BR>(principal executive
officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Bryan Giraudo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer<BR>(principal financial and accounting officer)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Faheem Hasnain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Chairman of the Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kristina Burow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Thomas Daniel, M.D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Richard Lim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert Nelsen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Otello Stampacchia, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Qinqing Yi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g626950g05u28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g05u28.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 3("4 ,!$0 "$0$#$0'_Q  ?  $  00" P$             !@,$!0<(
M"0$""@O_Q !M$  !! (! 0(%# H*#@0*"04$ @,%!@$'  @1$@D3%!DA%187
M&#%76':6U-76(D%15%:3E)>UTQHC,C4W<968L;<D,S0X4EEA9'*!D;;!V IT
MLL(Y0D-$4V*"A)+1)39S=X.SM,/$)D5EH:3_Q  = 0$  @,! 0$!
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MXA]E5YGXS]M4.W/W<_[<\9#XA]@K7S/QG[36-(SGQR_3G_Q?MY_P4\N0#2.
M[?:'QFJ'^$?J\PJS?SGN8].?W6/M_P"3/+4 SZ!T?$/C%5/T?7^8UB7OW?\
MJQRZM27M_P"C^FL,]G/<]W/NX^WGF:=/U?G%:3]'U_F-84K.?&8].?W&/M_Y
M5<VDZ/K_ #"M1_A'ZO-6'(SGQ6?3GW4_;S]WFX@&H<!V^U]%<QR=)XGM=L_&
M*PK^<]J?3GW,_;S]WEV0^(?95!X]/'P\:Y11G[VQ_P#U$3_].WSQDW\;+_2/
M_P 1KZE:D\FM^)_B(>W^36KI><X[.S/9[O\ PY75V9/2<ZI+SGNY].?M?;_R
M\D?F/F-8M\$_^=NJ'(JFL:]G/C5^G/N_=_R8Y>.@> >:M*3X;>&K-_.>Q/IS
M[N?M\MC[?U?GJB3M?7^:L0]G/>7Z<_;^W_DY:.D>$>>M5_A'ZO,*Q16<X0GL
MSV?9?\,\V4 S/ ='Q5K3]"^'\U85_.>\OTY]S[N?\''+UZ1X1YZY\G2W@_-6
M#*SGQ>/3G]WC[>?\%7-I.GZOSBM&;X'UBL 3G/C/=S^YQ]O/^7FTH&0.0S_[
MUJ'B<SQ/QGIKD_S\Q5]XIQ2G%*<4IQ2G%*<4IQ2LC$_OD)_]K_W5<W,/_NVW
M_I!YC5]M_'Q^$_\ ":V/SVE=FG%*<4IQ2G%*<4IQ2G%*<4IQ2HW8?_-/_>/_
M -GG4PW_ !W_ +?_ /I7 QWHMO#-YHZBCGNJ_B_X<ZE>=/0? ?-5MQ5%6;O]
ML5_J_P"SCER?!'U^<U2_PC]7F%6K_P"XQ_I8_HSRU.GZOSBJGZ/K_,:Q3W[O
M_5CEM:<G2W@_-6,?_<8_TL?T9YL5IOT?7^8UBGOW?^K'+4Z/K_,*U7Z?J_.:
MPKW[C_7CER=/U?G%:\WP/K%8I_\ =X_T<?TYYM)T?7^85SWZ?J_.:PA/]K<_
MCQ_V\<VAT#P#S5I/\$_5YQ6V=5_O?*_]<9__ "<\X&,?QL/]&?\ B->PV5_N
M>[_ID_X*V6Y[BOX_^/./7J3T'P'S50XJBK%?[M7^DK^G/+QT#P#S50>D^$^>
MK5__ ,3_ -K_ (<N3H^O\PJJ3M?7^:L2[^Z7_K_HY8.D>$>>M*3H;P_GK&O_
M /B?^U_PY?6I)VOK_-6(?]US^)7]'+QT#P#S5J'I/A/GK#O^XG^//]'+8^W]
M7YZUI_Y'_P"7YJQ+_P"Z7_%_W<<VD^"/K\YK0DZ6\'YJP17[A/\ I?\ #/-J
MM-^CZ_S&N0% _P#JI&?Z1WZ0*YY7$O[MF_\ ;_Y4=?0MG_[TVWAG_P"HEJ7K
M]S_7_P ,\T:[-4N*5;\5KU:O_N\?Z./Z<\VH/@'_ $CYA53]/U?G-6CW[C_7
MCEIZ1X?S&M>;X'UBL4_^[Q_HX_ISRV/M_5^>M2L,_P#N5_Q_]['+$_D__C^:
MM23X#>"L*7[J/XL_TXYL5I5@2?W+O\>?^US9CZ5\'YJYT_1)X6\]1\O]Q_J5
M_P!WFW'V_J_/7.?X)^KSBN0U1_\ JQ#_ /4L?]I?/*WO]US_ -(:^D8/_>RS
M_H1YS6:7[G^O_AGE"=/U?G%;[]'U_F-4<^YG^+/]'+:JJAQ6O6-(_MR__9_[
M*>7)\$?7YS5+_"/U>859O_N,?Z6/Z,\M3I^K\XJI^CZ_S&L4]^[_ -6.6UJ2
M]O\ T?TUA7OW'^O',TZ?J_.*TGZ/K_,:PI7]LQ_H8_[2N;2='U_F%:C_  C]
M7F%8<C^U9_C3_3S=3X0^OS&N6_P3]7G%85_W4_Q9_IY=5-<HXS][8_\ ZB)_
M^G;YXN;^-E_I'_XC7U&U_N:W_H(O^6M73GVO]?\ PY75]45_N<_ZOZ<<D=/U
M'S&L7^"?J\XJCR*IK&/_ -M7_'_PQR\= \ \U:4GPV\-6;_N)_CS_1RV/M_5
M^>J).U]?YJQ#O[I?^O\ HY:.D>$>>M5_A'ZO,*Q97[A/^E_PSS:3I^K\XK6G
MZ%\)\U81_P#=+_B_[N.7#I'A'GKGR=+>#\U8,K^UX_T\?]E7-I.GZOSBM&;X
M'UBL 3_;/_9Q_P >;:?!'U^<UJ5V*>QU7_\ "D/REOYOSX-U)M?CE^^/1K])
M\@M_\O[W_:GL=5__  I#\I;^;\=2;7XY?OCT:<@M_P#+^]_VI['5?_PI#\I;
M^;\=2;7XY?OCT:<@M_\ +^]_VI['5?\ \*0_*6_F_'4FU^.7[X]&G(+?_+^]
M_P!J>QU7_P#"D/REOYOQU)M?CE^^/1IR"W_R_O?]J>QU7_\ "D/REOYOQU)M
M?CE^^/1IR"W_ ,O[W_:GL=5__"D/REOYOQU)M?CE^^/1IR"W_P O[W_:GL=5
M_P#PI#\I;^;\=2;7XY?OCT:<@M_\O[W_ &JL/08(9YM]M1W?;5WD]XAO*>WL
MSCTX\1CM]W[N.618=;PR)*F\U(=0S8$9_2-(\]9)90HP==>8Z.RS^CXJS'K=
MC_ND?C$_J^=+6?H_K_36QH'T_P!7Z*>MV/\ ND?C$_J^-9^C^O\ 330/I_J_
M13UNQ_W2/QB?U?&L_1_7^FF@?3_5^BGK=C_ND?C$_J^-9^C^O]-- ^G^K]%/
M6['_ '2/QB?U?&L_1_7^FF@?3_5^BGK=C_ND?C$_J^-9^C^O]-- ^G^K]%/6
M['_=(_&)_5\:S]']?Z::!]/]7Z*>MV/^Z1^,3^KXUGZ/Z_TTT#Z?ZOT4];L?
M]TC\8G]7QK/T?U_IIH'T_P!7Z*>MV/\ ND?C$_J^-9^C^O\ 330/I_J_14-+
MA@S+DS!/>.\A167I?&4KPE_RO,JR'Z7.[G'BO$X]".YV]_/>[W9Z.7PW<L <
MII[(KGF">C5EV_IK4NK""[W8EUY)K*Z6"_"TYY]B?B%9G.OX#/;VX-]/^<X_
M5<NZIW/Y/[A]*M4X'8GA[]^(/0KT]CRO?Y]^4X_5<=4[G\G]P^E6'4"P^.?\
M0>A5-6MZXK.59]4.W/W"D_:QV?\ H>9#%;H#+*+[A]*H.SV'GB=_^*/0JFK6
M=:5CLSZH=G;V_P!U)_4<R&+W8Z-U]P^E6)V<PX\#O_Q1Z%4%:KJRL]N?5+M_
MZXG]1R>K%Y^2^Y^U59V8PPYY\HX_EAZ%45ZCJ:\=F<RGN]OH,1\WS]WF?5R]
M_(_AGTJK.R>$GIY3^,/0J@K3=/5GMSF6[?\ KR/FW,ACU\. $'X9].L#L?@Y
M.9%U^./0JW5I&E*QV9]5^S_KZ/FW,AM!?CHW'X9].L#L9@S#(\K(_IU_-'5!
M6BJ,K/;GU9[>SL_?!'S;F8VDQ$<!R?\ "/IU2VPV!L<_X8.UPN%_/$:M5]/U
M!7C.%9G.Q7ISC$BU]WM^\^WW>9]<^)_YO^"?3JL[ X"1E_#?&5]55M6-;UR%
MMMEK@7E_J<-7*?-M>.*2X1Y;,2=V ,[SN&4XRSXB  \4WW,90OQZLJ5XS&$:
MMQC=[<E6EW.:YJ-,9'#@?E'MFM^QV3PK#UDCM^4Z9"KMKF#', CAE&,AE6P,
MZ^KZNWMP;Z?\YQ^JYK]4[G\G]P^E6^<#L3P]^_$'H5Z^QY7O\^_*<?JN.J=S
M^3^X?2K#J!8?'/\ B#T*I9UM7,YSG_Z0].<Y_NI/V_\ \'F8Q6Z'#*+[A]*L
M>M[#_P O^*/0KT5K*M+[.WU0]';V?V4G[?\ ^!_DY(Q>['1NON'TJ@[.8<W3
MRCA^5'H5;JU555=N<^J7I]W^S$_J.2,9O!Q]Z^Y^U59V7PLYYBXX_EAZ%45Z
MBJ2^SMS*>CM]PU'V^S_-\_<YGU<O?R/X9]*JSLGA)Z1<_C#T*MU::IR^WMS+
M?9>[_9R/M^C[VYD,?OP,O>/PSZ=5G8[!SG_=7'\N/5U05I&DK[,9]5_1_GZ/
MFW,AM!B Z-Q^&?3K!MB\&;+5RLY='OX'3X(ZH*T115=N<^K/;G[D@C[G9]Z\
MS&TF) 9?P?\ "/IU4=A<#8G,WO'_ #A?55:+Z?* YC&%9G,XQGM_?)K'_P##
MYGUT8I\=O^"?3JL[ 8">!Y;XROJJJT:BP;8]ABT^6>2P-GD(D'M(3ESR7 D>
M?CQR_%=CCOCSW_L\)3CN=Q/=^Q[<Z4^,7<\AE?=:W U9(0.Q&@<-1[2CZZZE
MGLUAMI MO#RC=QL^G5*&;LG+G,Z!GQ8]KHJ;9H,!GW?+?RG'ZKE75.Y_)_</
MI5M=0[+\M^(/1KQ[']?^X;^4X_5<=4[G\G]P^E3J'9?EOQ!Z->GL>5[_ #[\
MIQ^JXZIW/Y/[A]*L.H%A\<_X@]"J:];UQ>>W/E_N=GH*3^IS]WF:XM=J,ANL
ML\_@?M5!V>P\].__ !!Z%4U:SK2L=F<R'9_UI'ZCF75B\_)?</I5BVSF&L,C
MO\OZ4>A5!>JZLO/;G,EV]G9Z"T?J,\D8U>KT;GC^3/I57UKX7\5Q^,/0J@K4
M517C.,^JGI]WL-3]WM_]!S(8Y>C++<\.CWL]K_\ *JSLGA+ @\IR/Y8>A5LY
MI>FN=F5>JWH]SL.1C_\ C<SZOW_Y _\ MG\SU7UG8/\ YT/_ 'Q^>,U:+T91
MU]["LS/8KM[>R0;Q[N>W[UYD-HL1&66XX?DCZ=4ML/@C9Y\L[+//^$+V_P#V
MJM7- 4%S'8KU;[/3[DBWCW>S_-,_<Y8-IL3'1R?\(^G5)V P$\,[[QA?4U6H
M5*A2*ZM#GE?8!8KK",=U_&,^15^YS\&!W_VO/>>\ACQ_'N8[,./=]S"485A.
M-*7%KN61I&W6I\F.2$#,@9Y#577MMG<.MH(X(]_HB&A=4H+9 GI.@9GZJF&=
M?5_/NX._*<?JN8#%+D= C^X?2JXX%8GIWWX@]&O7.NZ]GT?V=^4I_5<RZK77
MQ1?</I5'4&P^*;\3]FO3V.*[_G_Y4G]3QU6NOBB^X?2K#K=P[\O^*/0JBO6-
M96K*L^J';GL[>PM/VL8Q_P"@_P G)&,7@X#=?</I5B=F\-)S_A'XH]"J:M6U
M=>.S/JE[O;Z"T?J.9#&KT',;K\/]JL3LSAAZ>4?BCT*H*U)4U9[<YE.W_KB/
MF_,NKE[^1_#/I5@VRN%-T\I^+^.'H5;*TW3E8[,^JO9_UY'S;DC';X<1N?PS
MZ=5'8_"#P)NOQE]75NO2-)<SWE>J_;V=GH/1CT>G_-O\O+!M#B X 6_X;>LK
M [%X,>)Y7^.OJZMUZ'HJT]U69KL_R2#?VO\ W7F8VEQ,'/\ @Y\,1_,XJ@["
M8$1E_#/&!ZJK973[0%]F<^KGH_\ \DW\TYEUT8G_ )N/_9/YWK#K!P'X[X?_
M ,A?SPUD*'4HF8HU,EB_*?*Y2J5V1*\4]A#7E!L0&2]XM&6U90WXQU7<3E2L
MI3V8[<]G;SGOBERSLQW>99B>P/223\JNW'@-BD<:+OLD15&<@SR50!GV'Q"I
M5F@0&?=\M_*<?JN8]4[G\G]P^E6?4.R_+?B#T:]<Z^K^<=G8;^4X_5<=4[G\
MG]P^E4' K$C+W[\0>C7K['E>_P ^_*<?JN.J=S^3^X?2K'J!8?'/^(/0J@K6
ME;6K*LYD.W/I]!2.S_\ (YF,5NAPRB^X?2K [.8:221/F?RO[-4U:OK*^SMS
M)>C_ #M'ZCDC%[L=&Z^X?2K$[,X8W2+CA^5_9J@K4U45G.<^J?I]W^S$?-^9
M#&;P=J'[A].JSLKA1[5QG_3?L507I^HN8QA697LQGM]!J,?_ ,;F8QV^'$;G
M\,^G6#;)82^0/*>'Y8>A5LK2E+5G.<YE^W/N_P!GH^YV?>W,NK]_\4'X9].J
M3L7@S9Y\KX_EQX/YNK5>B:,YCL5F9SC&>W]\&\>GTX^]?\O,QM'B(XC<?A'T
MZJ;8; V&1Y9E_K"^JJU7T_4!S/>5F<[>SL]$DWZ/_P#DY8-I\3' <G_"/IU7
MU@X#\=\/_P"0OYX:WASSM>VIQ2G%*<4IQ2G%*<4IQ2M-]0=XG-;::OMXK2A$
MSM=B6#(Y1P_E8F'G)($57CQ^^WXU/BB'.Q/?3V*[%=OHYU<$LX;_ !6RL[C5
MN9Y2DFAM+9"-VX-D<N*CM5YO;#%+K!-FL6Q6R,8NK.W62$RIO(]1FBC.I,UU
M#2YX9CCE73WYQ#J*^^:7\E\?/^?4NL; ODW?C'[%?G#GDVS^7AGB']M3SB'4
M5]\TOY+X^?\ '6-@7R;OQC]BG/)MG\O#/$/[:GG$.HK[YI?R7Q\_XZQL"^3=
M^,?L4YY-L_EX9XA_;4\XAU%??-+^2^/G_'6-@7R;OQC]BG/)MG\O#/$/[:GG
M$.HK[YI?R7Q\_P".L; ODW?C'[%.>3;/Y>&>(?VU/.(=17WS2_DOCY_QUC8%
M\F[\8_8ISR;9_+PSQ#^VIYQ#J*^^:7\E\?/^.L; ODW?C'[%.>3;/Y>&>(?V
MU/.(=17WS2_DOCY_QUC8%\F[\8_8ISR;9_+PSQ#^VIYQ#J*^^:7\E\?/^.L;
M ODW?C'[%.>3;/Y>&>(?VU/.(=17WS2_DOCY_P =8V!?)N_&/V*<\FV?R\,\
M0_MJQGM^M_\ JQB=\HI_E^(Q43C/K:QXKR1123,X\7Y=_;/')Q]GWOW/:GL^
MWR>L; LLM-W\?]T?L4YX]L^G7AGB ];63\XAU%??-+^2^/G_ ".L; ODW?C'
M[%.>3;/Y>&>(?VU/.(=17WS2_DOCY_QUC8%\F[\8_8ISR;9_+PSQ#^VIYQ#J
M*^^:7\E\?/\ CK&P+Y-WXQ^Q3GDVS^7AGB']M3SB'45]\TOY+X^?\=8V!?)N
M_&/V*<\FV?R\,\0_MJ><0ZBOOFE_)?'S_CK&P+Y-WXQ^Q3GDVS^7AGB']M3S
MB'45]\TOY+X^?\=8V!?)N_&/V*<\FV?R\,\0_MJ><0ZBOOFE_)?'S_CK&P+Y
M-WXQ^Q3GDVS^7AGB']M3SB'45]\TOY+X^?\ '6-@7R;OQC]BG/)MG\O#/$/[
M:GG$.HK[YI?R7Q\_XZQL"^3=^,?L4YY-L_EX9XA_;4\XAU%??-+^2^/G_'6-
M@7R;OQC]BG/)MG\O#/$/[:L8UU];_9F#YU!%/\ND8R)B2<YK6,L^20I4T8%A
M#?EWV#F'IX_QJ^]GQB<LI[$^+[5.L; NC3=^,>#_ "/HISQ[9?+PSQ#^VK)^
M<0ZBOOFE_)?'S_CK&P+Y-WXQ^Q3GDVS^7AGB']M3SB'45]\TOY+X^?\ '6-@
M7R;OQC]BG/)MG\O#/$/[:GG$.HK[YI?R7Q\_XZQL"^3=^,?L4YY-L_EX9XA_
M;4\XAU%??-+^2^/G_'6-@7R;OQC]BG/)MG\O#/$/[:GG$.HK[YI?R7Q\_P".
ML; ODW?C'[%.>3;/Y>&>(?VU/.(=17WS2_DOCY_QUC8%\F[\8_8ISR;9_+PS
MQ#^VIYQ#J*^^:7\E\?/^.L; ODW?C'[%.>3;/Y>&>(?VU/.(=17WS2_DOCY_
MQUC8%\F[\8_8ISR;9_+PSQ#^VIYQ#J*^^:7\E\?/^.L; ODW?C'[%.>3;/Y>
M&>(?VU/.(=17WS2_DOCY_P =8V!?)N_&/V*<\FV?R\,\0_MJQD=U];_BUR;@
MI%/PJ6DWI8OQE:PO&2WQQAEY;QY=CN-^*$9[$>GL5WL]OV7H=8V!?)N_&/V*
M@>['MD,^SPSB<_[@'K:R?G$.HK[YI?R7Q\_XZQL"^3=^,?L5//)MG\O#/$/[
M:GG$.HK[YI?R7Q\_XZQL"^3=^,?L4YY-L_EX9XA_;4\XAU%??-+^2^/G_'6-
M@7R;OQC]BG/)MG\O#/$/[:GG$.HK[YI?R7Q\_P".L; ODW?C'[%.>3;/Y>&>
M(?VU/.(=17WS2_DOCY_QUC8%\F[\8_8ISR;9_+PSQ#^VIYQ#J*^^:7\E\?/^
M.L; ODW?C'[%.>3;/Y>&>(?VU/.(=17WS2_DOCY_QUC8%\F[\8_8ISR;9_+P
MSQ#^VIYQ#J*^^:7\E\?/^.L; ODW?C'[%.>3;/Y>&>(?VU/.(=17WS2_DOCY
M_P =8V!?)N_&/V*<\FV?R\,\0_MJ><0ZBOOFE_)?'S_CK&P+Y-WXQ^Q3GDVS
M^7AGB']M6,B>OK?\**Z&$13\,O2<U++\;6L.*\KGI@^=/SA7ER>QO)TB3EE'
M9^UL]QOM5W.]EUC8%\F[[7_S'Q</D4YX]LOEX9XA_;5D_.(=17WS2_DOCY_Q
MUC8%\F[\8_8ISR;9_+PSQ#^VIYQ#J*^^:7\E\?/^.L; ODW?C'[%.>3;/Y>&
M>(?VU;XT?X1HYV7]1=YQP#<6<^G EOK,>^QF'RO"4]R9A4NE+, [W:O)D;_9
MHWI3D Y*\+'XV,;!H(M[@\CF1%[*UN'#;W+,YQ2Y+ID[6B3L&^6F63>LV6]V
MB5KCDNU4$0@E<"/$;&)DY-GD,KFVU.9(<^.]@]]CXC<S YIVMPDY#66)!G:_
M* 34-)CH*CY2,*9-!,'7^Y=')86MIQ/;C*5=U7:A:5(7A*TJ3CYK-#+;RO#/
M&\4L;%7CD4HZL.TRD C\XXCA7Z M;JVO;>*ZLYXKFVG0/#/!(LL4B'^4CH2I
M&>8.1X$$'(@BLKRNKZ<4IQ2G%*<4IQ2H+J_^#/7?Q%J/Z C^2>D^$^>H'0/
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M*O7-6;!;49C%6DGD@-Q;K[PGDYHRD3;YXL1Y(6(^^-(*DC8J2CPVP'27'Y$
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MH=TQAAB4R(^H1UQEA]YK"?%+*WW@>7-HF571%9FS:2*(Z> 5]VTT>]"L6CU
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MG^)7Z3#)E_BWZ3GNVD4%J_5.RFW&";6P V4O)[]$#7.&7#*+F+++4\1X+<P
M]$T70"N^2%V"5R(YPJ]C3BE.*4XI3BE075_\&>N_B+4?T!'\D])\)\]0.@>
M>:IUR*FG%*<4IQ2G%*<4IQ2G%*<4IQ2H_;*W'W*K66H2RB415KK\S6Y-8;B&
M3$1\Y'$Q9JA'G&GVVB4C%.98<<9>0AW"5*:<3C*,JAE#*RGH8%3E\1&1K@3!
M^"_Z:&R*,7LC%MW^103J,J+;WJC7MVAI&M:NU9M'4VL:'.5,77L'33:C0(?<
M5[LM>:9KPD\J]R35IF)Z5,'2A2M,6$'8:]4V@IEO=#@B..2.-"N@*502NR]B
M#K.HDD5O.B]*M:U[N#;&YX38FRB9S;-=%JQ,#*^QL57Z)"1(T:)6(K6Q;6MQ
MKG6:]4&0"7*Y2W;?)T0:3G;%8#*N=8Y@J7RJU+=4DDE#R9R*%(.@J@&04)V&
MI57+L5U%,RS%2Q)K05(\%CTOZX5 IIA.V8H*%!K#3\:=L>1M <[.574N]=+"
M6^5S;Q)\P6PGTKJ$N[<JBNEP-?)D@*J6S C-0SHQRJEL($TZ-X-.GAK+9E(Y
M8@QU!N.B9\\L@2%X<*LR?!9Z#)E*H8N\[H]2*=<*?>HJH.SU"-K"K)26]"XA
MY%QB1UN;+"FK?Z=:(\9*1$O&33@TA<H$>3&J]F*@FU1R"$E3JER5U<+J73J7
M<Y'X&?3 AS!!XNN>EM-:5U-X(V+@X6RQFT]X721>>J4#IVE$ZQ9AZX[6NGR#
MUG.:D,U(Z]=(:]>55^RT><3"NF+8=V#6Q82&-C-G'6K$E:Y!5<>'  B25CV(
MB71DNF$1F,Q=D'[%E.6?PUR!$A;-CR93X-SIV:=@U#O7X<>NV"]V&, ;GXEP
M-!&PMW['W[-!/((KC[I$<-<]H6(",9=>4^S6F(F.*)-,&(DS%; LX1EEJ&3.
MPXCI>5Y3VN@,Y _R<AQRSJ0].70=JKIBGZ_8Z#<=H29E>K]^JS -GDJ2NOO5
M_8!VNY(R(%K=9H57@:I&01NLH JOQ= CZC%H,-L4C-!3<E.FF*4AM(X&5D:0
ME5=<F*:=+E#EI5%50N[72$"#I+!B2:V1U@_WM6VOB^+^FXKG?V7_ +_X9_3M
M_P J2O)^Z-_@3M#_ *FG_505\^50M2:P]-,EQC4U!V:$<KMBB7"707#(S,G%
MS@Z@Y!E#K@!X$U"1,F&3X@EGQP262Q"PGB17OM]U;<H$160PS6\PG@E"APLF
M[DA8,A(#H\4TL;+J4Y/FK*X5A^/\-Q#D#72R0+=6M]:FSO;<NT1E@W\%TACF
M4,8IH;FUMYXI-$BAX@LD<D;.C;>,Z@7Y$?U-/K\J_&-5R*K8SV+U/>N50\19
MK!9QRY"S/LDDFDNE6$H<AID4$%(S K00@;+2&4\M<#$;;Q)XA(9Y9V!LH>3Z
MI;>"W94MU*JJA8%926=RQ8NSDYUZ*7;!IH]Q-9W#P+9062-U6N^6E+>]N[U)
M)KUE=Y7:2\D1U6.*+0L:QQQJH%69W4!+'ENSRZ^"Q;1!K#%UJ>'/-RB#AK.*
MD&4%)!+P6Y.2'DCLI@>8.D$DK*G)4V3;DR%B*$S3!(D00;]VM6:"2XA9$SFE
MMW,D;*Z:1#'K$6<2)I"PQI&8UU!JY=L+B61KLV<*XC&EY!8W:RR$6MK?1B*X
MC>*3>&ZFW;3Z+F642&2ZN)9Q.[1F/$%;ASBR5*=AZN'$CUB\2VQ7(K,D6<S(
M6BP%0;\QE)+C;3P</EJN10<7'=TDB/8;?6_(R!!+CW+%PK."ZAFN7E:XLXK#
M>[M$*6T"S"+L02&ESGD>1^Q5V( 1%4"M=]I<KW#KNVP^*W2PQ6YQDV^_DE6:
M_O'M6N,I&57CMM-E!'!#[X\2!BTTKN6K6,?+#QA=?D!8Y.#84YH\EU93RT2;
MHQZ#!DK:SCNB):;;2,KQ.5>,QVNJ[%Y[.=%XFD6=&D["9"B@* 8PR%&R/\K,
MDMQZ.CHK@PW"026<L<($MM*LKL9&(G9)1(@*Y91A5 0Z<]7PCQJ9R&V+3,3-
MHF)D^1F%6.-LL4R+*2\B>S""V8A#Y#<9Y4\[EIMC#;;2&48;;<0A&%I^Q3C&
MJF&VT<5O%$D<6XDMY2T<4:&9K=2%,FD#,G,DGB0>BNG/M!?W5U?7-U+-<F]A
MO8%CN+F:9;6.]<.ZP;QFTJF055&2D 9CA4U:WTM,9( N5 #!$E!GU\PH22=!
M2<";4XRL-.RB6@E&R!<?ZELE 8<D6XX=D@L=$<DUQF58TS@P,B/RI]*3).BM
M&'T.ES)<$1YOH19-X5?*/>,55MYHU1MU%VN(@FB.'1!Y[6:TDDCG,0EBDP^"
MP5I],6]FDAW"R1 SB%%>11 )66X3)N]1A#I!F5U1"A9-M#DJ2N;R_:#S6)%$
MB#@BUDQ#YQ\7']I80@TTQ+S. Y$W+UB>.\D.$K& J%3^$]E&2(U$.FW1&C,;
MZ;990B22=B[-"8HM<:90!-2->VVCL\F>'+NYP&G<W6N^EE6831:\0DMWEF@A
M]\BC2Z2XN=U-+JO&EW<L<$K&TDPDQ<K!(0+A\[;C7#<3<=.F1$U!9,+/-EVH
M>7('F9 94LX8RV5(((1,Y&$R+F36/(2;1>[<8<9HK2!)@D-JH7=20K+%-H5$
MB,L2M$C;L*2J$&+4VK=ZDC*\FQQ\6MSB=Y-:--=XC*9>50W<EM=6N]DFEN%M
M[EDN9D-PTB"28.MSHCW>_*33K)ZS6SQY&ND0P%9:C#3JS"TL^65+EGX(K$#-
MAV($9 #S#3;$FY)QD7DR22\IMT2/;88 &=(.)*18<8YUE>X,B)<37:1;I4TW
M$\+0.Q<$EHQ'))HCT@AI"6=@J*L76.I-9O;0V*P2S6-MADUP;F2;78VEU'>1
M((F10DYG@@WDX;)HX0JQ(SRO)<Q^V&0L0DP]4PR[W6($>NP-K5*&-#,"QX+D
M7!R9\ AM3)\]78Y0XD,8V>%'I3&QCDE$R3P[[A6+X87,T0N76RN)S//:[M"S
M,[B2:-)\PR0SR!FE0H[^^2".2,$!<X=H5C%K<MA\<F+6%HEG:8ARB18UCAB:
M"UGFLPI66[LH2D=M*LT4($$#3V\[*QDSE<VZR3+38=C&&CX"W("8G'FTG%K:
M&B]>V"D##-Y&SY4,DS,NR6N28'D'8M\=LC$-.#-/1!M,^%E8H6@9GGMM1A!T
M*"TE]#=LQU=B=.[*B,L@D5BN]B8B1=RRVC5Y[J*]CCAM,1$2W3@2R%4@P:[P
MJ-%T>^1[SE"R&=4F:W=%<6UTBM;RY*V[IA79+Q5<KJ2 Z[!-UZDRI9QK"XYH
MO5U6UK/$& +2M4PRMNNKE*^HE<8^.05XV6%*&RF&$KM<)F$>=Q/I:XF,]Y&J
M*VLKB-Q?PJC@@1$&<1SA1(K!<HF4^^M=B.T]JTX6RLP\5E:+9X7/)+*NY$N
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M-<"U5A:S<;DS&W$ &C/>FX5H F6HSJ8@-X"M59.A6B$B967G(Q^&1$2E;BB
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ME5(4GAV@3D?IK6O6#_>U;:^+XOZ;BN=_9?\ O_AG].W_ "I*\9[HW^!.T/\
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M^0WI@2Z%G=&VDFY/'<<GFW#SYD;E)M&[:;,$;M6+Y@C3PJH94K5'G9C)"LV
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M<JV=T=_);QVR<FN#)=&YCGDB:V41$3(5MW.:$DYJ4##45MI&IST1'OR$G'D
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MWID/4HF?AI:(++:FY7ID@2) :98F8UIJT2Q(4</:(J M,>IU.7-3O6R5UD
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ME!M>MO?QW:6D[1PPV,,4;7(#*++'DQH,&$156<*T/8J-+NTHSS*'UI>^6*S
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M*KVZZA!>M..75;(?!T6>H5E@LN6*-:EY"0I-CV#8_))<CU"=&:C#W]AFL(:
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M(^,'/S5DN*FN%/A%_P"\HZ@OBB#_ +SP//4;%_X48/\ ZP__ $\U?.O=:_\
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M1X!B;R*#@K)TL%#.2L5ZKRD..?%QC<I&O'&,,GB+>S3%</D>"-+J-FN(TDA
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MZMGE68D1/&MQ#$TD;$$;U T:G(,PU#/KW>RN.V:RO+:0R1P<I$\EIB&&XA'
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M1P:W((C#$J%BS<2S$LVICV\V)/Q #H &0X5JOPB_]Y1U!?%$'_>>!YZC8O\
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MR-EDCD@@*Q#9@C+A7A^+DA7A1B8XX<@YD<@)A\0AEXP<S^Y'Q6G&TK(9*_\
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MZ[E%E@$Y<=RA*$9<7G'>7E"$)RK.>ZE..S&/4;%_X48/_K#_ /3S5XWW6O\
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M:Y)(X'DACARREFWMJB1L<Q:VKX-+T)L?=C%YUDXW8FG=F7#8@K3D#/PT>;"
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MVW*H8UN]$%O>*MOB#BSBG]Y2:2-IQ*5C6M;I6+)88#6=<C)"0I@>DRK#K<T
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M0;C%]MPD\W8RP[/Q.&@C/ J<3GC;*=P>)M(&, R FFG5GA'?!&QL=#QX43$
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MSUYXWAOKJ:_W/OS'#?)6T'LM/9O\!#]R@_FJW_\ 4[C3[I?\]>>-X;ZZFO\
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MC-MK?+$A<GE""H442RT,G+N-&_O]O\,A%Q>W5_%#JTF19+695/:WA@,N[!Z
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M)/3]0\PJ!T?6?.:G7(J:<4IQ2G%*<4IQ2G%*<4IQ2G%*@NK_ .#/7?Q%J/Z
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MCCQ+J?:16]OV2R&VMY!;?PF:/>3,J%TM.$:T>W:!1[5M^2L73MK/<90-Y'A
MXE&P;EU%JMMQD2Z',Q\-*WRKZP@-,-V2>>(D(>#L[[?K^$E+&_8P3Z5DODY4
M+!KB&R6/$[JR#6YD+\F@PP0PH+A&=+>6[DOC%& KR19\G*1B)EVVAP>9L.ZL
MQV5SBTEQ@&&XNR7JPI%R^\V@Y7=R-8S1PRWUMAL.#BXG+20P7)'+EEN&N(WA
M0FH-,(:KK#-:IDU'YID!-4ZTF;FQ&2&W]BF:2F[;9->V>O-V%EN(BH7:K ]3
M:(KZM?2T=F,$I!DI.V:_0EDAKFO;[5*3+.C;^1)X5L=2V5J+^.&*YBE,1UO)
M9DS92<H1@[7 2.*VDBDU$PC"--N%M[.:/D=O-9W38ONWQ?$'P::[N;"Y@%PH
MBBAQ,+:AK<V$L>Z2R:2XN;^&XAE<KKK2OK0"@H.(HECN4"5L>VP^IR=A(;BS
M=ASM"Z($V2@%VZ-M458Y>OTAZ;W6?5H]%T8D292E24)ZX9^0CIS$U2EU?;]I
M)'N(K>1;6)[P6Q+K;1W./&*X$+0M$DEP([%96,!54G23=QJT>[V9</P?DL<$
M,5E<7D#7]U%A;7X$3XA/8[&"XL'NH[J*XEM[,S8P]J@O%D:2RDA-Q/)'.)J^
M=(].\8W:96$J45LNB5.O;(NMIL8VV7&K! V*G7100>JX5J(GPH^T5=ZHMB$"
M7 &NF&6<J5+L$/9!XBMR4;ER_$WW*/,]K<32VL$41LP8Y(IH0S7CEXV:*43$
M@PM(HB"+&\6N56J3@V QBZE@M(L1LK6WQ&\N;E<483P7%I>%$PR%89T2YMC:
M*K+=I SW+2//%<+%;2QG66Q=6:\UO#[[UI%&C6-5(U/4;\Y<DD>4#RUYF]\5
M,;7#T*ZG.&QDD=/6RE9E(-OQ;^)HJQD2;"WZVPT!M6UW<W4F'7;J8]_>36VY
MRTE+>/#YC=!QTMEB5KV$AS&@1!2!*2W.Q##,/PZ'',.B=;@V6%VE\UWJU++>
MS8Y:KAQA/ #5@&(G>PC(B9[AI%+6RA.!//15X:G%*<4IQ2G%*<4IQ2G%*<4I
MQ2NV#P5M^ZYHC:[=8Z6HY^WT4B0$*V75[H^:SIV.!(4EMZ8FYCN.^M*>6,TI
M4>=7$/625\C0PF&L@0CL6KQ^UUO@#VF^Q9A#<!6%K+ %-Z[#H2-.&^CS(U++
ME$FK/>1$AZ^H>YE?;:Q8H+;9F-KNR:16Q&VO"ZX1&C<#+/-D>23E03&]N#<2
MZ HAN44Q'[/&<O*9:40AMHC+;>7VV75/LMO93C+J&GULCK>;0OO);=6.PIQ.
M,+4RUG.4)^('+,Y9D9\"1D2.UF,SD?HS.7QFOU^,\AJ !R&8!S /; )"D@'H
M)49].0Z*J<BIIQ2G%*@M*_NJ]?'J1_0\%R3T#P?G-8K_ "O](U.N165.*4XI
M3BE.*4XI3BE.*4XI3BE077?[P2'QZVA_69;N2>GZAYA4#H^L^<U.N14TXI3B
ME.*4XI3BE.*4XI3BE.*5!=7_ ,&>N_B+4?T!'\D])\)\]0.@> >:IUR*FG%*
M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*INM-/M.,/M-O,O(4VZRZA+C3K:\9
M2MMQM>,H6A:<Y2I*L92K&<XSC.,\4KW2E*4X2G&$I3C"4I3C&$I3C'9C&,8]
M&,8QZ,8QZ,8]&.*5YXI3BE<"_"??WA74I\2X[_>VN<]#LI_A#A?].W_)EKP_
MND_X#[1?ZG'_ -5;U\*?/O\ 7XGIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2K]V4DG
MXX*(?.*=BXTH\V/CW'EK$"+E$ MR1 S"LY0RZ<B,CTDJ;PG+ODC'?[<HQGF(
M10S.%4.P568 :F":BH)Z2%U-EGT:CETUF9)&C2(NQCC9W1"251I @D91T N(
MT#$=.A<^BK#F584XI3BE; C-J[(A:QZRXJ[6,"I^58,]0!Y,A$9XW$B#,*;\
MF[V4^1NR\9&RQ$?_ ' 3* !2) SA@K#R-9[.UDEW[P1--IT[PH"V6EDZ?E!'
M9 WP@C,H(5B#OQXIB,-MR.*]N$M=0?<+*PCS$B39:<_@F:..5D^ TL:2,I=%
M88.7N%JGWK 1-V&8E7[7-,62RNGGDE.3L\+B3P-+RJG7%9-/'Q-2V&"'\K<:
M3(EX;RG#Z\9L2&&,1B.-$$,9BB"J!NXSHS1,AV*G0F8' Z5SZ*HEN[F=IVFN
M)I6NIA<7!DD9C/.N\TRRDDZY%WTN3-F1O'RZ34;Y;6O3BE.*4XI3BE.*4XI3
MBE><8RK.$IQE2E9QA*<8SG.<YSV8QC&/3G.<^C&,>G.>*5W>="_@;]C;N]1]
ME=1J9G5&J7O$2$=4O%>1;*O(BNZXUG(I;2_65 EISV^J$J,Y.FCX_P#HZ'&&
M+$G&_!X_MM;6&NUPS1>78S5IL]5K;MT=(_CY!\E"(U/PG)!C/V?8GW(\0QG<
MXCM#OL+PMM,D=IEHQ&]3I&:N#R.!Q_C)%,[K_%Q*KI./J?U9J;7&DZ7%:\U5
M3X6D4Z%;[H4-"#>);6\I*$OGGDN*<-E98SQ:%GR\H29)GNX\:86^Y]ESY)=W
MEU?SO<WD\EQ._P )Y#F<AT*H&2HBY]BB!44<% K],X9A>'X-9Q6&&6D-G:0C
M)(85R!/#-W8YO+*^6;RR,\CGB[$UL3FM70IQ2G%*<4J"TK^ZKU\>I']#P7)/
M0/!^<UBO\K_2-3KD5E3BE.*4XI3BE.*4XI3BE.*4XI4%UW^\$A\>MH?UF6[D
MGI^H>85 Z/K/G-3KD5-.*4XI3BE.*4XI3BE.*4XI3BE075_\&>N_B+4?T!'\
MD])\)\]0.@> >:IUR*FG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4K2'4C3-4["T?L.F;PL@=0U1/PXXETLA]EC*<)%1J)6/)9??LLQE,9$I7
M(,!L8(+SAM:G4L8_;'4<WL-N;JTOK>YLDWEU$Y:%-VTNIBK+ENU[)NQ)X#PU
MR,>L,.Q/"+ZPQ:;<8=<Q*EU+OTMM$8E1P=_)FD>;JHS;X\AQ(KI3]H3X%[X5
ME(_G::E_7<]IUT[8_,&\EW%?)N;?W+>[2_[0V/Z*>T)\"]\*RD?SM-2_KN.N
MG;'Y@WDNXIS;^Y;W:7_:&Q_13VA/@7OA64C^=IJ7]=QUT[8_,&\EW%.;?W+>
M[2_[0V/Z*>T)\"]\*RD?SM-2_KN.NG;'Y@WDNXIS;^Y;W:7_ &AL?T4]H3X%
M[X5E(_G::E_7<==.V/S!O)=Q3FW]RWNTO^T-C^BGM"? O?"LI'\[34OZ[CKI
MVQ^8-Y+N*<V_N6]VE_VAL?T4]H3X%[X5E(_G::E_7<==.V/S!O)=Q3FW]RWN
MTO\ M#8_HI[0GP+WPK*1_.TU+^NXZZ=L?F#>2[BG-O[EO=I?]H;']%/:$^!>
M^%92/YVFI?UW'73MC\P;R7<4YM_<M[M+_M#8_HI[0GP+WPK*1_.TU+^NXZZ=
ML?F#>2[BG-O[EO=I?]H;']%1[/0MX''UUIC?;2TKU&S7E'9)]M9JGNXD\22&
M$L>5>.\5WLBY4YY/_;,XQXS]SC/'73MAE_<#=K_Z7<?33FX]R[/^_*]O_P"X
M;'Z/HJ0^T)\"]\*RD?SM-2_KN.NG;'Y@WDNXIS;^Y;W:7_:&Q_13VA/@7OA6
M4C^=IJ7]=QUT[8_,&\EW%.;?W+>[2_[0V/Z*>T)\"]\*RD?SM-2_KN.NG;'Y
M@WDNXIS;^Y;W:7_:&Q_13VA/@7OA64C^=IJ7]=QUT[8_,&\EW%.;?W+>[2_[
M0V/Z*>T)\"]\*RD?SM-2_KN.NG;'Y@WDNXIS;^Y;W:7_ &AL?T4]H3X%[X5E
M(_G::E_7<==.V/S!O)=Q3FW]RWNTO^T-C^BGM"? O?"LI'\[34OZ[CKIVQ^8
M-Y+N*<V_N6]VE_VAL?T4]H3X%[X5E(_G::E_7<==.V/S!O)=Q3FW]RWNTO\
MM#8_HI[0GP+WPK*1_.TU+^NXZZ=L?F#>2[BG-O[EO=I?]H;']%/:$^!>^%92
M/YVFI?UW'73MC\P;R7<4YM_<M[M+_M#8_HJ/#="W@<7+5-1SO5+2DPPE?K)H
M!7MK-4I2])R$E;6)=C!>7O%/*&%C(1Q0Z/VP7!27'?L2VN.NG;#+^X&SX_\
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M]JI^QIZ)\+2V_FDA_KWQUZR]SX_&&]53F?MN[L_B$?M5/V-/1/A:6W\TD/\
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MHQ\;;$D7"&U_>*MTFR,=9KK"BP\M&ASXDYU65H8L1<Y$51X>)E(J/M1EA9A
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MEGF<^ ' #Z,RQ[9S8\>C*O,Y =H9_:>DGZ@!X .WF3!.344XI3BE.*5W8>#
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MO^9+CJL/FY_&'J:<A_*_[G[=/V'R[_C#&_YJ"O\ F2XZK#YN?QAZFG(?RO\
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9U3KD5-.*4XI3BE.*4XI3BE.*4XI3BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g626950g12d34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g12d34.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2B<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $P< 5H  QLE1QP"   "   < E  "')R,CDS-S0Y' (% "M-:6-R;W-O
M9G0@4&]W97)0;VEN=" M(#8R-CDU,"!'<F%P:&EC<RYP<'1X.$))300E
M   0D'# SK0\]09X"7NS4.*4TCA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  (#P
M  $  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8             !#L   1K          $
M                 0             $:P  !#L
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P  !#L     4F=H=&QO;F<   1K
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   0[     %)G:'1L;VYG   $:P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      >(@
M  $   "@    F0   >   1[@   >!@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M[*RV2WQVL_EJKD/Z5=U2O+M^SV,]$,?OQB^XEMC,K%VY/YM-5K/693Z?\_\
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M_OM_P6]-;]8\"]GH5LOWY V5EU3FM]PV[R]^UOI_RO\ ,24__];T_$_HM/\
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M !;OR%<,G9]-O]8?E24__]DX0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (
M  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!*  #
M 0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"':0 $
M     0   +P   #H "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,3@Z,3 Z,#D@,3(Z,3<Z,C  <G(R.3,W-#D
M  .@ 0 #     ?__  "@ @ $     0  !&N@ P $     0  !#L
M!@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !
M  (   (!  0    !   !1@("  0    !              !(     0   $@
M   !.$))30/]       (          #_X0%(34T *@    @ " $2  ,    !
M      $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   >    ?@$R  (    4    G $[  (    )    L(=I  0    !    O
M .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q.#HQ,#HP.2 Q,CHQ-SHR, !R<C(Y,S<T.0       Z !  ,    !
M__\  * "  0    !   $:Z #  0    !   $.P         & 0,  P    $
M!@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !
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M 0$! 0$! 0$!_\  $0@!6P%J P$1  (1 0,1 ?_$ !\  0 " 04! 0$
M       '"0@#! 4&"@$""__$ &$0  $$ @(  @4##0L%"PL#!04" P0& 0<
M"!$2"1,4%2$6&5<7&#$V-W9WEZ:UMM76(B,R05%45I&6F-<*.%-ATB0E0G%X
MDJ&BM[CA,S0U8G)U@9.CL>*4LL)#4G/1\/_$ !T! 0 !!0$! 0
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MES L2F2:238-LI&U::GW>D(8[S7Q:%9!L&D>$0&%K?/>U4*.\0$<>)P_<>%
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MNKG8V#V8I%EMT&MMU_Y)WPE09<L/; >PZ':98X!6;$JQZTV/6O($OE0RS:&
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MB=[$<EAXHJMG?=/U=')N%K]56;VMUJ)86Q)5A+68[$:,(HGC,$[H#(.U_P
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MVFVDX_@I^/)3%%%!%'!#''###&D,,,2+'%%%&H2.*.- $CCC10B(H"HH"J
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M,9M7M^Z>85AMR]B<2,Y<1B&AH@[.R\U-L8I<3V!J$N;[=@W4;%7,0/4>VJM
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M,:S3K7%C2U"DRQ2I/$''[7/'W>'*A'!61.XE&'FI/(X/!R,M:5;J=U\NEJG
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MP!MJO)\O.M*!S\O/Q#P/M/!X]>#Z9CCVP:_]]I+G'SXMP$\<>? \)>2//CS
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M="*S!US6=7WOUL;OSVU4'CS K2D<_, ^(O(Y]#P#]PS'_7?U_P M+=(^1-J
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M :6_!?1_T='\8R*^]_\ FK[)_P#>&M?^U>C\W/3O]_\ 2_Y5H?ZU%FAZI_\
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MK&/'.,?9SS$HD+KZ+,0 *50DD\ ?@(_4GR&9VT!;;;)5!9CLKP  ))/O4OD
M/,_DS0W&\S(UXM]AUM]AVU:Q<:>96EUIUM6S*?E*VW$94A:%8SXI4G.<9Q\<
M9XND&JQ!Y!DJ$$>8(-NOP0<JU8(N@$<$5[X(/D010L\@C).ED( ]+2I\V)"2
M^YAEE4N2S&2\\KXI::R\M&''%8QG.&T>*L^'PQS++*O'<0O)[1R0.6/H!SZD
M_8//->JLW(568@%CV@G@#U)X] /F?09$VR_M]Z[?A8LG_8%NKF':_=.K_GL_
M_I.SS84?W)NO\FP?^M:C)9<GP&93$%Z;$:FR4J7&AN2642I"4^;S*8CJ7AUU
M*?*KS9;0K&/*KQS\,\S"P#!20&8<JI([B/M ]2/Q9KPK%2X5BJ\!F /:"?0$
M^@Y^7.15'^[Z6_ _7OTTL_,(?WR?^8Q?ZQ-FP;^\\7^4I_\ 5:^2JW/@/2GX
M+,V([.BI2N3#;DLKE1TJ\/*I^.E>7FDJ\R?+EQ"<9\V/#/QQS,#*6*AE++P6
M4$%@#QP2/4<\CCG[1FO*L%#%6"L2%8@A6(]0#Z$CCSX],B+5GV[]E?PX _\
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M:1W=@'(Y$2HH/D2UOV:Z>IK^G:>PCC4WMFLD\]C@>((Q,\<,"/QW+"L<2NR
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MVUH0Q\*&(<_ $7CDKP7?ND;EV8GIVATM31:JOKJL: +"GO,@4=UN=D'C3S,
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MCUYFC8K(P<QMV,,FM]=MC6^! FH#J+9J'1XID;8+!$(QIANU6XB"E,D0(K,
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MC6ZZ4O7@?7AV@UXR]!S>"!SV@R6,CX$EJ<Y6 $,./<@L S,R/%:-'3,M,V8
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M_H_\,O\ )^P_H_MQ\BFO]%C^K/'C_P"-_1_X8Y/V']']N/D4U_HL?U9X\?\
MQOZ/_#')^P_H_MQ\BFO]%C^K/'C_ .-_1_X8Y/V']']N/D4U_HL?U9X\?_&_
MH_\ #')^P_H_MSNE+$>Y94MM./*W+91G./#X9<85G*,_'^/R..?U?ZN69G#A
M?7D$^HX\B//_ $#].4/\O(C\W_MSDB\Q\MXXQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,9Y^;U]N]Q^^JP_G>9QC+GNN/W -+?@OH_Z.C^,
M9-'&,<8QQC'&,<8QQC'&,<8QQC'&,XHX""6<01K]E#"K" ,178!8&<'Q"P@I
M!?3Y7X9$;/9D0IL5Y/[EV/)9=9<3\%HSCE+*KJR.JLCJ5=6 965@0RLIY#*P
M)!!!!!(/E@'@@CR((((]01Y@C[P?,9]" PM9$#J_7 XNO@1$5J )"!!\04(%
MP6$^1B&.&P&6(<**RC&$M1XS+3+:?W*$8Q\.%5454155$4*BJ JJJ@!551P%
M50       /+!))))Y))))\R23R23\R3YD_,YRG*L8XQCC&4@;;])3LC05T[@
MA)XFAVV-I^X;RN]5SLJXHUL.E:_TYI'J,=3IV@S1%5+/6G8]DM^\C=@@)*Y=
MDQX#*QZ\R6)X]P*QDW](-XW_ &KO;L0)ONU3UA^2FW>T]1K=%E[(ZXS 0NM:
MY[.7'7U3]VZHIE.%[[K;]>IX$*+<L&P+*4$F/:I!-Q$E\V&D,,9:AQC--UO#
MJ,HSGPQGP\?AX_8SC/\ ]\8XQFU]@;_E_P"K_P"/&>\G[3^<X]@;_E_ZO_CQ
MCD_:?SG'L#?\O_5_\>,<G[3^<Y^/98WK/4^M1Z[",.Y:\4^L]7E64X<\GF\W
MDRK&4X7X>7S8SCQ\<<8Y/VG\YS]^P-_R_P#5_P#'C')^T_G.?MN(AM:5IS\4
M^/\ %_+C.,_Q_P F>,<G[3^?-WQGF.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&>?F]?;O<?OJL/YWF<8RY[KC]P#2WX+Z/^CH_C&31QC'
M&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8S#[N!U;#]D=>N!WY!IYP')?L
M>=>PC$4!3-N2&LC%SJ3L5]L<\52(N 07)H\TP()"R, '82C;[I :Y(%R6,R
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M.N>P=P=&)5JV'J3?6H[3H3:<BT2A%MU_?@VRJP6KZ9MQKM!+10=#GGF1GRH
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M"B>-1YO\( E5?B 7Q #\?$'ZGT4D[-L::=[]H]ZA0?&P4<"9 /K,% $BCXB
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M]QRG]->5_3FVK;*A</;6MPS/_ 5^)/M_:V[9./O[?]&3/#ZUSNJE#GENJVM
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M!BS#@GR!\SY9L=1M%U^UUM\A"*=^I:(<<H1!/'(0R@DLO"GE1YD>7SSG@K(
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M>.?"NY7CW: +(',!6TN,PS[HW(\4-F%#>O7C2&Q&9HD4".1"!*J#R"D,0DH
MX"$O&55>"7\N/F#KSV&U-]L+.WZ=O5]/?MRO-=U]R*3Z,FLN>Z2Q#)622Q0D
ME?NDGB6K;BEED9HUJ@%'QN!]*]_%;+#JA0& JQ><MK$8=(L4"Z6:<AUSU:E
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M&2'D L[#D/*0.02B +W%_GCJ_K:;J']A4UDJZI'#%6/$UQU/*O/P>%B4\-'
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M'FR*Q\O3S()\OEEU)YXAVQS2QK_!21T'GZ^2D#)"UBYUCUY:#.A]-.:)I%U
MC&;+8=.:T70*Y:0XA[,-ABP&]?U?,,O 'NYG0&FRL\2U'<S-AH3(SF2QA=8
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M2&JV[;2;&6-<8QQC'&,<8QQC'&,<8QQC'&,<8QQC*&%>C\[F SG;I%.LM-'
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<5[-#1'B1_:)<AY[U$6.Q&:\_JV&6FDI0EC/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g626950g15z05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g15z05.jpg
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M 1$  A$! Q$!_\0 '@ !  ,  @,! 0            <("04& 0,$ @K_Q !
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MDGK 8# 8# 8# 8&:?1S^4]Y8/[ZU??Y'^I^&L6F#]L_WQ-+,,F P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MQDURPP8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# S1\PW\V]V;_ +%@'^+D R3I/2?1
M8UCK'JTNRH8# 8# 8$2EZ$I*0&IC)#M2UV8/V$&WCTY,DX@">DI8%50!-EAQ
MYXX9*+$F[AM%8HW<ZN=U-G*,4BR2^RFD;":L0[W%HI&8/'A42AL?#Q:, FNK
M(-'P YJ)$#&NN^ZGL&0]DDBV;Z;*J*+*>S3XY575564YW54WWV#/+HY_*>\L
M']]:OO\ (_U/PUBTP?MG^^)I9ADP& P& P& P& P& P& P& P& P& P& P&
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M?6K[_(_U/PUBTP?MG^^)I9ADP& P& P& P& P& P& P& P& P& P& P& P&
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M5K#&\TW/D55UB!S:4(A=#FQA^LZ<JO"?+[EZZ5<+J+K[[+*<[!ZX_P!=^O\
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MU?:1<"9-:5 O!XE'/A1-!=QI8Z[2GVDW'6I)P5O,IE(QC(@/K44&'ZQ F63
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MR_U=P*3%R\$)/>?^D+$8VZ*CO^W/6N%Q9S.5:9?)>+"& P& P& P& P& P&
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M*\MXVT)LA0)=PBKJ4D E/C17<3AK_+#/2_/1XKSN9,YZPL-Z_P"AO>.M]X'
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MD.N&K*0DY2%<OD8CM#O>G:3(8]5;[RG[R.]VNJ_W?<>R+$93-:5GM_UH5A#
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M+N1W$QJ.,$!88=N7*O3A/9FQ;:Z((<ORY)^2<^IKQ[5X\<+;>G=3;GD.WX#
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M?EW^OI+4#"& P,T^CG\I[RP?WUJ^_P C_4_#6+3!^V?[XFEF&3 8# 8# 8#
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MG'K.5AX06UWW_:DS1U_@X)FYF=TWX0P& P& P& P& P& P& P& P& P& P&
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MJQ,"WK7;G?V7K[!0GHY_*>\L']]:OO\ (_U/PUBTP?MG^^)I9ADP& P& P&
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M1]%I\(8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8%>NTM?G[.I@K$XZ$;2IQS-:=DQF%O'(YLVG\)@=R0&=V)7*O)M
M9M'W>MB0&-R6$\"Y,[914SL>X$RA\QC[TD[1+&OWME/R1[75,V^$ZJ*U7$IU
MIUWL9[(9^;A)H7&(E9:-+0^577); AE:LHL6W6@Y9O :O+B:D39,%EXT&1&>
MO%7"XX:(6W%Y[_7QY3GJJIXPHS/H=;GD]C5H6:M<D[%]T(;I(+*7A\?@*TG5
M<=->KSQDMO$8M_V$/]GC'#(/PF/_ (#K4?P_7_ZITOA<6F#E\/\ ]8FN6&3
MB2[(I;<T@3P%25NBZ0GJQ :NSGQ>M!ULLF8]LXX4)#]H:4D<6:.E";?TMTWN
MQ=/=AMS[?1%?;^!@4N^'#R7?,SK_ .@B#_[Y87+:?./8^'#R7?,SK_Z"(/\
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MP7&T=_<^&/R/?-#&_0Y3GZWP7&T=_<^&/R/?-#&_0Y3GZWP7&T=_=T"V*/\
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M8@S+YMMQHX9B2+IOOSKKOQJLW9K+);<Z;<<Z[<:[Z:\\Z[<<Z[<<>CGCGCG
MQ'KGR#3",P"M9(VNB$]H>+(I.FI-)C,B,UA%A537G- 9>1&*T?3*KHI$Z^&I
M2&.Q^6%@,4LEW&C<85A3[@W/B*TJBH!P:F,YRJO2ZO.?OY9RKOY.Y$2AFLD
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M,"*[NGIRKZIFT]C<67F9R-">'@Z.H<$]_>UE7C5GLZ=) Q9PZN-$).5#)5J
M"&3[H8/=MP8DD659LEPSQ@/D=DLSL: POBL&>P1_-!T!F\S:-;#;1_4A(+^N
M[K_'I&P)EH>T&P 07-5".*QD39KP:0L0O.=*^@#XV<C*Q,Z:X?'QY;1/*[N]
M>53;6+#)@,!@,"LIV[)Z.MZW:R%UL&*HP.CHG;,+(+SC88O.B<@.38(_CY-/
MF./48<Q%N8CHFB5YVD"[[WQ9Q]GMM&Z23DN66?7+3OGV1+7?:ZQ9],^N(AG7
ML3<A;FJVN[$EC ')#)J:0$/.JKD<[7GAMFR!K HM7H^6AQ58QS::E@AJQ#I<
MR[BVN^\-<BSA.7W]_<;KZ8# 8# ]+G==-NNHV1U<N=$5=V[?97A#5POKIMLD
MCLOSHIPCJJIQKIRKRGOPGQMZ_.FW''HY#.QKW(M9^'J DVJB&_;DYL>P85(:
M\'30W)YLJWK[L8[I*6/H.P!Q39=X"K^+,GMDSJQ96/CD'8<H@XFLX%.I@T*A
MBUKTC/K%_P"N_)!L9\LD70BD/DMM,*OJ5U9<0B]I06,6'*[<A4A6K:= V)J+
MD]FW-$2AJ=0YW5(B]Y(->LF!$@+?HIAQJK-='"S@GEG67+WEL7ADP& P/QNF
MFKKQJIIHIKQMIOQKOKKOKQNGOJHGOQQMQSQZR:FNN^FW\>F^NNVO/&W''.!U
M,/ XF",RZ0CA/&IJ=N1;F4$'KTB56(:!!J8H..1X*NWJ8H$+:ZK[CXZ(T8 6
MA B:+(#="ITR]?AV_ CLY4E8R:<1NRI!!(P8GT01T0C<L?B6K@V)21Y([--6
M[S?3G?;D;N8,JA]EO:[AEC1E85LS5+$=W(2)@,!@,!@>-M==]=M=N.-M=N.=
M=M>>/3QSKSQZ.>.>/_/'/'/HYXP.HCZ_@XD?!!(R)Q]@,J]%LWKE@T%M$&D(
M091E]"VB,7032U3#)MHD2(1M'1CJCPF%>N1^O'#9;=/D.WX# 8# 8$7RNE:F
MG,N SZ75_&)!-8P@U:Q^4$1J2QH4U8D_MIHU:/\ ^"OHV;EN>2*3?G;9'5WS
MRMQIZ_///(M[JWIVK*?9D1]70&+P-D659J/VL9$MAB*R8UORS$L==$-->&X@
M(RVV9 0K;V(@$RWW9AV3)MOLER$E8# 8# 8$5SRCJ@M!QL\L*MXC+WN_,=YV
M?' S1X^],1XE_$8YX>;Z>\Z_8'%@3C45ZJO'N6LMD.J'J:EGG"HM((4,*C@<
M5'P;%N+"@QS(0(&M-/9M1XP<V3:,63;3T\^H@U;(I(I:^GGU4]->/3SZ,#D\
M!@,!@=<EL0B\]CI.)3,"+DT:,)HID@QAHD\8N?=72#YDMRDKQS[-V/(-6I$<
M]1Y3=CB+1H08KMWC9!=,(W"]<*%CAV)28%4D#%2&"M5V<4,LH^Q1(B-'+R2D
MEG*;K5/VKDEL2FLV)<%WNSDKH2FTS()O-7DLD*Q()KP& P& P.%?1P 2, Y"
M0##7IV,\$^(\6=-$5R 3[:;)LRW(MTIILJRV(LTDVKS9OMILNWU]BISRGMMK
MR'5H!4M957P>XKB"1B%<2<CP5/?=P2U&?:3S3A7AO[?W?37U6C+A=SP.')>S
M'#>'3KA@U;<.G'M!:0\!@,!@,", -+5+%Y7)IQ'J\B8>6S),LE)3S .T0?E$
MY _0*R33??73U&^LH+M6IF4\--&_WF,M&A<]]H$FR#I,.^!0PF.!Q,> #60<
M$!&, P40-;I-!XH2+:I,1PU@T1UT1:LF+-!%LU;I::I(H):)IZZZZ\<<!R>
MP& P.!E$7CLUCQB)RX*-D<:D#%<8:!EVB3T:28N-?55;.FRVNR:FG/[-M>?1
MQNDIKHJEMHKIIOJ$8,.MM"#"\2/CZD@K4W!D44(N42 L^'P[W8T:DS1PJXYT
MY4)OV4HDLEE3 D6Y?$&,IDDBDC-RB<.EG[P7*;<!@,!@,#@MXO'%#;V2*!!>
M\@) FT7(&=F2'))['&;L@_:!'+SG3VZPML]+$W2++??E!-P_=JZZ<;KJ<[!'
M ;KS1T<E8B<Q^K(6$EP$2%!!SXD(U'D!P:. -8J &-E&NJ6NC(-&]- 8QOSI
MRFR&::,T.-$=-=> F3 8# 8# A=[USHD@>!RAW5$(4D,:=D7P$SH":($!;LQ
M+2$]*KM7+?1+?3<C-2I.4O?3SMPY.D'A);C=RX54V%SN^8)UEZ[QUNY:AZ0J
MQLV=/-WJB*D'CSQ-)79!NUT09ZOF#G@>.:M&C9H/$L/=A8UHW1:CV;9NGJGP
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g626950g25h13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g25h13.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2 :4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %0< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(R.3,W-#D< @4
M*TUI8W)O<V]F="!0;W=E<E!O:6YT("T@-C(V.34P($=R87!H:6-S+G!P='@X
M0DE-!"4      ! PF^0B)/LZ6Z!(M8<0BH!F.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0&RO7"         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P
M  $  0/      0 !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             G$   6G          $                          0
M           %IP   G$                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   G$     4F=H=&QO;F<   6G    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   )Q
M     %)G:'1L;VYG   %IP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    "3A"24T$#      5@0    $   "@    10   >
M (%@   590 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 10"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MM'VXX'HN;Z;6_P"C]F]ZIL8RYGL#\AECM]FT>D][;#[_ +.=EE3*][_2N?\
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3
M #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %
M     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!
M,@ "    %    )P!.P "    "0   +"':0 $     0   +P   #H ",$$
M)Q  (P00   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z
M,3 Z,#D@,34Z-30Z-#  <G(R.3,W-#D       .@ 0 #     ?__  "@ @ $
M     0  !:>@ P $     0   G$         !@$#  ,    !  8   $:  4
M   !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("
M  0    !              !(     0   $@    !.$))30/]       (
M      #_X0%(34T *@    @ " $2  ,    !      $:  4    !    ;@$;
M  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
MG $[  (    )    L(=I  0    !    O    .@   /      0   \     !
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HQ,#HP.2 Q-3HU
M-#HT, !R<C(Y,S<T.0       Z !  ,    !__\  * "  0    !   %IZ #
M  0    !   "<0         & 0,  P    $ !@   1H !0    $   $V 1L
M!0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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MP[:P-3.''$GJQ&.XT!Y85SM!*ON%"CXXX(ZEBX&1+WCDX>CYV-J6;&/^^+!
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MEO\ VQIN+C"/&PVP\M(55E:./B-WI?)%D$>U#BAU7;?#J?3=*Q\V'-R,^/\
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MW04U=7TPD%).\0JI3)/[CS.$/R)"!2 J 9Z<M"T# U]%UG5F634)X7 B* )
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M]WB]#7;/7=%V>UM8NY%!JR\UOY?<:K6.H)[I24=4\C4\%--51RR1B&;*R1/
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M,&],$,018^:AM%7UTEGK9[#<I[C-7ZE-2N\Q[KO<0QE.<E3[V%8#)+,&.W&
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MY^*XYX\\'CP??Z=%I*^XE3_RC6KM!;BKGP1C )&\89C@^>%7! XZ$,\B\@[
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M5%D^+KIB[_[?[J[^U+2SI^JQ:=HN+@XT,?XUQ!'^,DW,R(02TDK5;#A@ J^
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MO= G@ ?IRWCL_P"AF'N961Z86EOE+2U-R^IC$B.\]7*085>M]N(10I K,(Q
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M=F"I(VW36[$?9@*33!(8?<''^O\ QZDW;8_B99W;:2+]3S)X_0_XUU).W?\
MB90H'Y8O/V,G\NH(N\M#!-HVZ-4SFGCCIWDD=<JP4*, 8P3SC)X(;QD'IW]0
M+DPCTM[>I\H+'EA1^M7?UK^?5M=I2,V?'' %$DC;;/BB#9OD@B^.+^OVA\[;
M6V&K[KS7NELE"8[;<)*);W4S>U5QR2NH$B*-S2+_ 'AO7X'($@(SU?6ER9>-
MH!BDG6--03U'QMBEE.T<;@*V\41=DWQ]9=WGH.E2C'FDAR<K4\6%V_$0L2A<
MH3M;G;0!)H#R+/(ZGRTS2N;-;'F56D:@I"70[E=A3IN*DYX/!5LKD8.3G/5"
M:T"V9EM Q:3\1(A4"E^20[?'!X-BQQ7@]4A8)(;>NT@C<::A8"-7%BJ<GP1X
MZZM8649W%RQ&$!"@8!!X Q\<Y'))+8&?NW.+=4902%7>" :/!^G /]??KP!F
M<TS*O_*&L$>UD^#Y_P!CK80H4;'MC!PJL<$.P&"25'CC ^(SSGST7.$85^51
M]/ \51^I)'TZ+>*5B!NM?[WTH^+_ $^A_G[='$#+LSP'/Z 6((.3@8\D9X&
MH&.<=-IBWD@*)$!_*3YKW^Q^_P!?/GH_\NU3P*O["AYK]+^_1Z-6/D9PH5E8
MDJOZN1C&0,9"C/G.1G'2>8L&1!O7GP%% $76XG[$_P"/72NEEKLJ/!\&N!7/
M[?YUT=0!B1M10"&P?B,@J2O\D.".3]CDY('2,EXH_FD__+/N9>2RE2:%U9]N
M3Y_H<"DC*W!/D _;VH#Z<5[\^>BMTO-MM=--55=3#2I "7DDD6) BKEB=^U%
MPH(\_?G@]1_-SPB1([*6).V(L3,19 .P60/OXX_8N6#@YFJ2)#AXTN0V]%J.
M-B.2 "/EKDGC[C]^H#/6=ZI=2Z]U5=M*Z7%JFT):4EI(IZBW037&KN"?#WJ6
M:>*8K#[AVK[:AA[98[,CJT>PNR,B3"DU;47R&R<A]^+AP@H!C;AL,C+?J<$E
MK'@K?D]:K[/[7TGMW$PS/%#_ &N\/JYV2^25=*"M%"817S$GEB>.!SSTSJ-!
M3=D=?]T:JXU$NM-(W*R4UDL=53T]=;ZZEN,D4,D=1#+'N4@M/,(RA4K'\5"[
M@)IF;FU?2^W-.PS')J$;>OG1O3XD2#E@I&TMNH5]#YXY=.Z-4UG1X,C6F6.3
M1X]-R<B3%2UD>;&3=CH)D&[YG_,;5F^M\=%NR?J9UO!VHU!:[G8=/TNKZO5M
MJN=CO5LLM';&%EIRDE=;JA*&&*2K>9_\TWP<>Y^O**"^=Q]@Y8ET##_M3+R<
M&,97XZ.6<>H79*@*J%KDFFL@* %KGJI_AMJC]YG6.Z=:TD8[PB6#35#3F$HR
MH[RMZK,VZ-0RJ57:Q'@66Z^^I3U*]PSK'2]HN-GO<<-+!35%)0O[E&E3#4;"
M:D)&ON2Y&$C=C(XE&=P/'33VC\,95U',RH0N3(\RA9O6$JQA:_@HH5@MDD-8
M!-_S=.Y_B9VEV%ID&&^/^)FU-I3,8* 1$.QI&D8@%EX:A0JN#?4X/I5]2-'W
M;[@6*P5.GZS1M]TWH-;?>;5=0D-55RRQVRJH7B@'MRH5C]R0I+&'(DWJQ!/5
M4]U]IZAHV/W'E9<L>3%+JP&-+C%'2,*:;E#7!M>+ (J^H+W3I&G1]NZ9J^D9
M39V+J['+8B(JT"D!Z<-\U"Z-7?F^I-,Y9=H&., @#.%\D^"#QD' YSG/5.[)
MRK .OI!B-KJ=S+S\ZT#7-"[-<_IU7CQAMAC^9%:]P][\'CV]QX^XOCK%.S1P
MM*&(1$;+ @$ !?VP?/&W)).?VX23-MK@DT!7%W[V?<\^2/O[]&J&9C&3O3Y3
M0'.Y_ L?K7Z\>_4?W>3OQ98SKD1:[:QU.B:F.WTUFM]6M/55M?[5/5U-362!
M@\M.(W*Q0[A@"3>"S=2G2]',T>*RZ?D9F1G,1%+(&$$"JP1PBC@[@>+H>.;%
M]6MV]V?JT@Q3%BQQX<L33YV3E1AG>/:?X<8<@*FW^_[D@]0Z^H/MK5=^==VG
MN7<:&.RW*2@CHZF_3)*8[A%"46URU$$!^<Z!UCDF4_I.'0LN#I#LC4)>W-.F
MT3+:+*@5V,<<2;\C&:3ET9;NJY\\$^1XZ><OM;MU,G$U'#>5<_3AN$+3M!"%
MCIBVX_+5C<%\>?8];7L_Z?=7:2HKT]-9Q#=!0-)^=7>&XT=FOL=1*^(:"L"Q
M2>XDD8Q$[1*=P8R9P .YLB'+6"-WQ8<-@J!$BCER 4%R/D(&L-(#\MGW ^_1
MR]T]NP>CC)G2:CG23F3*6',LX[,22F]F$>VZ  \*>*\]=[HGLE7:EUM:JS5$
MFIM12Z=^MK+F]'#+)::2L]U:E:2&>ID?W)(D2*./:V6B7VL?+);Y]6P].TO(
M73,:'#25/1BDD<KD2;TV%HXEX"WR=U>P%CQYJVNEOX;ZI@XD3_,N,2C/L%!3
M(3_?KS]?-V:*<5W<K6VF/4!7ZEH+AJF..FK7M=OHZNUUYIDB6E6FFIJ6TLU/
M3K)@11S3H#(V^0AW!)+%F=K:?'VC'%-A^MJ.?_'DRD(]=V+;CZDJDA%(H <G
MSU:?:.-I?<VB28$>H:8\,<,4F3NE"1*5+,TU@%E=1Y4WX KSU)IVY]7&B=,4
MMEC[HTLM'?+G5+&OTD+5$\<\TC;?K+=(%JX0-RA9%,L3#]).T9K#-[3UZ7'E
M@T?';*6"$22>(J2C85KIG6J(')J_<=5/W#V%CZAGYDFF9T*8<>XQ/(Z&"01[
MAP6;<-P4\$>.>23U(A;>X>C[C;J*XTE^M<E'<1'],WU<4>YF"D1E)'$BRHK@
M-$<, .5!R.JPRL'.QV/JXLZY"V'C!?R+LG@DD$>?IR//582=MYL4\F/'C/-L
M+;YH]TD>U>-X* A1?M^_CQUU-74U9&LM+)#-$P+*\4F\$GCRK/X7'(PV<CI
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M%/BQXW'JSNXM#[JR.WYX]2_#Q*T1]>6 E7V!AN9?F90Q!^@YOWKIR^'/Q,[
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M+_LOM[=I>/BS-,(XV(CC')+!MQMQ\UD\DW9\]3A=KK%VCU%31V"'MS9K6;A
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MW(^O4+>M],0ZDT_6VV4!H:BG<$#()4CD,1C ;'V\8_5^SZ)5BR4E"[BK!@S
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M*4-[5;#&D$S;A\O>,:K[A<8&74O@%2>,=.^'WCK>)ARX<>7OB"JP_$.93P.
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MD7^(GL4?6EL?0[VX_;KJNE/1/0Z'0ZJJ_P#"A]0673>@O1]7W2YQ4%2NK>\
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MBER\NL=@P&- 0D1#?F%*%9@W ^:^. =O2_04L<*JD$:+&B+MB4*B(%"J"-H
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MN@ *4^/<?O8X[]3YK L'AO/]XU[_ -: ^W)Z+,I);D@8P%;!P% (P <@9''
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M>K^FN0)W7TR\[[V"'FE\TO\ X1Q[\UTS-\4>X,?&EP] 2#MV#(9GR3I0,39
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M(Q52NQ1?=V[3/+N8JID+-AL+YZ=]0[+P(YAD0XJ21$%Q_P ,;=QYM20HYXW
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M17^'681Y SP2> 7&/BIP,<>0> >1D']STWP( Q:1"RE7OTFO@77YK)X\'^?
MZXDF1F](*20!Y)(Y''/V^O06%@P:7/*D,5*XW#('( PQ\\G/&!D]>L%90N-
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MZCP0//F_\0/!Z(R0$E@S$'@H&VD9Y!8 ?(\$$C&."#UX"[@5*I6Z(+>/H?\
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MNXAO>_O5GW(^O(_PX//7LH.!M/G'[8^^2.,_RX_;[>?"%9/.RO\ E%$U[V?
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M T20!^G)/3)IW:+Z7--BRRM#AYH(;'RD--=6H!X+4!XHCVKGKOKC;-':@O\
M:*6;05'5Z?I8D]VE6*!UB:%7*E5:)$ @4M($;=_< 7[!D@U/7,;#R,@Y[1YK
MLQ#AI =A/CS9NN3[\\WT_KV[I\6'+!*_J+-M$,;8J,@ -JI5E((4FQ=G@$5T
MJ>HNW=KJ:-J:R0UTM@N=MK$NXF,9ABI$I(TASEX_:A59O8C&5\ 8PH'3!A:_
M.F;'DSC'&;BS_B(MK-N,@._<2;)<L+9#S]?/47R<4G%S-+S?2<YF[&A01  Q
MRJ8R*K@45HK].*ZB\[O>GJ\V&EL>DNPEBMEXLFHKM)5ZFN$]SA%905=NDA%#
M'4/5U*;8%]^K:-D]\@*41$=R7OO0N\\+60^H]S:C!ILV+&$C@D0!9HI%^<Q
M*;=BJCFJ% V#Q17<?9?<G8F-CZ1V5VI)FP:EE+DY^<K2NN,RRI+$2JU:@EO<
M_* JCGAWESUGW>[,=JTN5)%9KAK2X_E]@OMST]#3"MAA%'$\51.U,R3A52,1
M33LVYYL.ZJH $"CTGM_N?7GC&9D?V9CF7*Q\;(9A$_SD&--_R@&PP4*;!L'P
M#:&&\(.!+J^D319+P*)PD;B%YZ^:5@Q(LNS-M/)'')YZTG>[L[VV[B^FKLQJ
M;7VI[W:>X6I*^]U2O2@5CM4U\D@)N=OE#FHDF-!%*6,D4B(Q595Y7I5VQW9F
MZ!W=W#I6#I463H^)%"C&@JQ1Q@*K0RUR0&/'S 5=6M]1#O3L+,[\RI<"+,.!
MBX,:3XSJ2L,DI4D*X8$,Q#@51NN.3RV?4&E/3IV&H]'Z3[CU'=2Y_P#("7FY
MWVR6BWQ6.X5E?452O!3"6I5C/2111Q>V92\43*S[B_#S)K/>&NSYVI]O:9I\
MV.)'Q8$GRV.2GI6H]14%#>3N5F7D>!0Z5:3JN-\.^WXNWM9U>'!APT]96R--
MRI,:;>?XK//'"(R[<_*W]T >1TJ':KOAZ5M::CO7;_M#VXU(+Y]!65.G]1Z[
M2U5%KJKO3VZ5J>LAH(99ZBC6ED)D5)9&,FTN0A&WJ*Y^'\1<-H-1[DRX,;3]
M\<.5#A-*K'&:0"17=B%9R&JPIL>./!6B]VZ5WKD:CB:%KL6?E:1MS!CQXOX?
M'>(N+,$IHRJ20KA@"O)YJ^D7[?:SU+VSUEK*V]R];72ZUMU4T<EFC:NJ[$RB
MJ6I:HA6H,5-#M$?L4RP4R)#&2!A<#J5]V:'IFIX.DY/;^DF-X]LHSHECCDVA
M?F!86.>"_()JSR2>I5\.EU>?*U*/NGN#$R)LF</@Z9)'SB1H25$-QC82.:!H
M+S\S&PYOT,]G:/O1ZO=!UG;K3EQIK#8+NFM=>U];11TL%(MNK)I49:FE$B;:
MRH^EAI89'$DLAF=@VUSU&?B-J^9I_86;!J^1$LCXPPL)?4!:=7V?FLC<P0$D
M_-Y!Z6]V'MCL?0.Y<S$3&AU#5I)4:1(1#+D9+H4)W24S@<LVSV:[ ;JYE1TO
MT\$5..%BC502/L%VYVG)P0IP? !Y'!ZQ%&H4M$GY3].2=],QO]6KQ_4=8.R9
MER)7D7@N[2L>*MCR?W\U]/KT&3))/_S/WR.3_3_6?W\.D1"H$*!Z %L-U#R1
MQ7U/\_T/24M9OZ>_U^_^7G@CHK(F1S_,9!QC'!SG_7C_ '==T39CB*B[)%*
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M>_[#_#VZ(J"KOF/<3@[5&=F<_'&1M ^P_;H&!T)5MP^@)(^_^_I]^NC(B_\
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M2^D[=,DDM(UV9)4,5OC$<.]F'MQ2/$-SX4X<M[@B7]1!\J<(96H3/Z2NT,;
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M)628J&]8@FN=QKY; H<\]8C_ .T:^7!JT& 6C&/CF0J$W O9!61[9OG*D#V
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M9Q;K?.JE#3A&KI8CRU*0"7?N7OOM+L# _!:88NX=?].I'C<G P)F&P^K(O\
M\0RMP8U^7@[F(M1A[7_BU\0N^.Y<V;3\G^R-'Q\B5$E=%,F0L;[5BBL'?\HW
M;["&J%@WU8 [:=C^V/:B@2VZ%T78]/I&(U>>AM]-#53%!RTM0![\DI!^3,YW
M L#SXR_K_>'<O<T[+JFH3)CJ?4]&.2L=5\J$1:7;QX(K^5=(F>?*=\G/R9\W
M*7EY)W+U?_*GY4%CD*/\#TJBQ% <1J"Q)60;5V[O+'_L_<@-SD9/48EQ )A,
M9 \)0G=&@2*V/A]MDFZLD79Y/7 #@@LJR;O V"HQ=@GZGVYYKR/?K,D1Y#[9
M"5W,^<84-PJ+R.00<C'^WI'/$L1*E%DW>-K'8 2"NWF_'!_?VZ5[-V\#AAZ9
M++\I%C\H\4"*! OF[X\$JN@IJQ&@JHHJB&5#$R3QB5'5N6#!UVD$8SE2/ .?
MLC'XG$;UHY),=@MQ/&Q5U]P ;N_/M?\ D0_HEU&Q7)%,6!)(_7S0JAS_ )=0
M8_B>?APP:ZHIO4!V)H*>S:^TQ0!M4:;ME/#0T6J;52#+UD0B"*MXHJ53$N5/
MUM/&M.Q#Q0'K1OPE^*D63)%VAWADF:":AI6I91+#$D ;9CROM9@DK<I+QL;A
MOE8D,3)JO;>IPZSH$TD#>J!D1QR-\ZMYM68JT;?E96%!2#QU GVTT]07C4UH
MN-&SV2F>MI[?J*&/,*T-6U2(4K' !6#=-\BSA0CCE@0,WQJ^0,+"RH\Y$E.+
M$[8[MRLOR_(!R23Y(]SQ?6GNQ\"#5,W%[E[<F_ 192E-8T]/X0BR50D,5H+_
M !) &85R ?'GJ;KTJ^IS478O6B:&[ABX7?3]<:&+^T"S_4J;?-A*>X3QJS^W
M54 WQ5DD8(J*='ESE QSIW?VE@]WZ:NJZ48DG#,9,=B1,LJEO44<IY8\+M\'
M@^W4O[E[57N? RI OX348M[?E0)*8P0-A(\$\D<638)/R]3ZV"^6O4-MH;I:
MJF.MMM;3QS4]53.IBFBE17216\[?D"HR""1D!L9SQ+BSX328TR/ \,K(!*-A
M<J38-DV+\?R''69L_3\K3\CT<F%HS':/NL[F4D;@0 =I%<?KUT*J!\0Q(8Y.
M,84#@><??_$$<#]T^R<(@H*]!=QHV+Y\?WS?/L31KCA$QJ10UTUFA=5QX%5S
M?CSQ^PRLRQA=Z[CSEU4#.!\CAF&3R,GSC./VZ3(DJ$/OMB6W)S2\T :YLB_]
MUUV9%*;0I8^1XXKD_K?MP/Y]>E]O:20P(_\ KB%W8^2C&  1]MPVXXST:#=H
MHY;EMU_E^Q\^X^O[]>,=SJQH*0-NTBZ^_)NR?\J')Z"(00S99?/((_Q_GD<\
M\>#CHJ4>E'Z"E3+(0:H@!"+LU]P/?]KZ-B=^=R@H/R[@0/U\^:X]OIYN\V%=
M64?''."1PY\K@D9\@^#@'/\ /I'Z#H:L<EB#?L?%W=_;Z_MR;9)W,!Q\M"P*
M)X]R?;SX^OUZ+&(A20,<CR#_ #))S@MGD^3G/G@8#-L%>H&)]['RU9Y!\V*'
MM_3KAU(4,.3Y%_T''[??Z^.L1A4#&T!^/]+QE6'G]62<C'D>2-H'7#Q2,H9I
MD*&BH'RF@>0P(YY!'RBB//L>O%/\()0LL6;[>?O[??\ 2J/1&95##!W #&>0
M Q&&XS_="C*^22.1T46#NBQL J<T.!9LD@ ^;^]>QN^O$949MR L .>>37'@
MCP+Y^O\ /HI+%QP,+Y;@_I QCDA<G'&"OW;S@%1)"K0L%O?(X9GOYKJ[X%#Z
M'CZ]=,0=HVT2VXKS5>W'D6/_ %^A*:,$;0"!\<#])'@ CC/&!G(YP,9&!T9%
MZ<47(;U!7@W=_8W7GV H>WMUZL@6PI-N"% K\O-\_7S7@5[>W7/W(U4,:"DC
M5W>1%D+<A4(^1501\L$X!(\<<''2_%6$.\JML^5AZ9(V[D(Y\W9OFS7Z>>B9
M9678"OYN"3S0/O5CZWT:IMH4[UVN0I;:&Y)!\_JQCQ^_G.?LI"A[(B+'W(D(
M^X'GGCP>ED)98P(RH'-^UG[V>3_AXZBV[K?B,]X].7BMJ;34Z?%JCK9XDBS4
M/.\RU3+[$Q7*Q#8"6?)7!VD#]0WKIG96+)&WXF7*DD_,/E 58MHY'G<03]?%
MD'K2?;?PP[9U)<3&DB@QI)XZ?+R& 56* HM?+?J,=HJO%WQTZ'LMZVK]W%T'
M27TW>P#4\M6*1=,/554%74/NPTD+^RR)$F'^<C*.&'V!+-JW;,6'DB)8Y3$5
MWF=H_P J;;!/S<FZ^4?7CWZANN_#R'1-;S\+)PU?"Q3M&; T;PN2 4557DE@
M>*Y%50/36_4E^(7W6TUJ:[Z1HJ>DM<-L2DBKJD5\E:TT54BM4O1J((U=J=&V
MJ&PA=2NXX'3'V]VWI.LSS0:C+*\4F1+C0Q)%)'911Z9>0,0J/9H\^U^_5^=N
M?!'0H^Q1WA"('S,>)\J*+)7TTB$+G_B4-Q\*?EY(-_7J+>G[0Z:]1'?&IU$_
M<&N0WT&OFJ[U35=75S5I26=Z&FF9ECIU<HZTR2%8HN-K'&3>&@S:=\-.W\H8
MVAJ)U]0[H70NR#G>Q(W.3QN /)-\7U2_Q/\ AMW!WYEZ'JF'J$1TK'Q8(IX5
M;9CXT8D"UC1!P"Q%!F(/BQRW2A&C[2:ZK-0=MFNE#J>>V+^25.F0M535\\MO
ME6.EE@G,2JU9%41*RR4DTDD#L%PP8H6_3\[4,W'QNX\7#*PODF:/*EC5T@E8
M[F!1BQ4 -[A;YI@1?4CUQ>TH-.'P_P!6UC&=(],QX\W&CF_CC%]-"WJA5M7&
MT.M$,!1M6%F9/\.7L)K/M0+?W1U5::GMUVXT/9;_ $]/!>I%2IKZ:LI6]VJD
M+M[\BKL61JEXU,IX4'CJOOB;W#!+C:B<W*BS<_4XXD5(A062]B*J"]O+ 5Y!
MV_4CJH=>S>S,_#T3X=?#C!RI%QM21YLW(W2R2SL$]2F;\RA=Y ' !XYYZ:7W
MFN%C[RZD[B=SK;JSZ45NJY8=.4\LX0U]'"6BCA2D3>]0,?Q1'N0;&W-M9<=%
M]LXTF@:1I6FR8)9FA]7)WBWB]:WLN?!JE\<&Q7MUJ_MB'/TJ?3M#$<AQ=)TF
M.*>52KH,A:FD+L6J,$MM'!\4+!HM\O.J:;1VH=*17ZOAHIHJVD,%4RI"):J"
M2-X92X)*;9T48## V,3G?U)]+QVSCE'"4S%%</$I+,J$?-QP3:'R0?!'CJ8]
MYKA9/9FHQY?IX\61\IEE=60N\9/HJGYO4;;N6N:!XX%7 ^P>O$[C]J='ZH:1
M'K*JTTL5>%8.!5T\2QS?)201(0'!_2VX$'G'5%=P8?X/4<F,;0AWRH.:*W\P
M-^#=C]1R!?7ROU[3UTS6<W% 84]I8H,&Y5EL#Y:H"O%<=+,,+MP> "<D <>/
MY C/'/\ L'4>=PMN:8$#: .?]*\F^F< ,Q4^PL\'[\<>_P!/I9ZR$J2/WP>,
M+SXY^.[G(^YXYX &0ED<'D[?F(L<V /K9\D_Y5?75;"-J,PYOC]_)Y]@./)_
M;KP1QP.3S\>2#QGP3^Q_8C[C]N&2F#(%*<'Y;W?-SR+_ -^/ ZY(1J8#^I%5
M]/?]0?\ U^ !,Y)\^/N#_P#\/&/Y_?HN2($6//-$$C[_ +^.?/U Z,5C&";L
M&C1 KCVO@WS_ %!OHA(\YJTA2(F!T+O/D?PRHX3'W+>1]@>///1 C=MWS50]
MSXYKBS[_ /H>.CPL)3>HVM]/%W=^U\?R\^.O=0BE&R2,\G_5Y\?_ .^1S]^D
MKAB=IXXHEAN# #\O[\#[<]$QDJ"?%GR*)Y-?Y^_];ZI_?C8]N;Y%ZEH;_=(:
MFYZ<U/HJW+2((IFBMC4577TLJF11MC,SM[JX* G<#]@-0_ 2?%B[>SHHTCBS
M4U%YI@62Y2Z1E:!KYD (\FJX//.PNPSIG<_P[Q= S8C/AK/D8^3"GR,LD\2D
M3%E(:QL(L#@#DT:ZA8T?V=2*O2XTB3M3Q2AY)%B+*B%N#*X(7"X!; S_ /7$
M]:#GUZ.&%XEC5))(ZHE [';S8&ZSXX'[\7TB[5_[/&GZ+K6'K<VIROCX^49H
M855][A6+(F\'@BQ7')]_<R'=CNSFKZQI;QIFV4MRO,-.XM]-6)+[DS2^XKS"
M&-7VQK$%:+W4"D-[@8?:J.X]?TN&L;.R3!!))\[*!2D$&M_ LLW)!\\=:7R\
MO+PH/5*^GCPHR22F90)(=HVI;5_%6R&VD\WY-=.8TCJ/M)V!MM)J[O!6T=ZU
MN?J#3Z<HS&ST]2)6C*5M3+$Z4J[F+,JB5MI"$ $GJ =Q:UJ6I-_9_:ZR&%RJ
MME$'8(JL% &7>21[U9%>.3$X>Q]5[Q_[UJDF+H7;T;[FU++RTA62VM!&^]/R
MA5O<PL7QTE_>3UP:F[CT$]LM%;!I[1=/OEM]@TW 8(Y07V(:NKA514F1&"RM
M,$B4#.P X*/M[X;Y$[IFZPTN7GRAQOR9!LBV\!D2RR'<!P7^6R/KU?G;/:/P
M\^'VFG5XVBUW(/H_][QW7,25#0_A2JSQIR020:4!BQKGI+K%WL_.[15I<8J*
MBJJ6.-;?+61Q&6OGE*Q"&GJ(DS*Y)7*L%(4,0RX(ZD&=V1GXDJ-#.,E3PX5?
M^" H;=\Q*[19 \'V]QTY8^O=N9^9COCC(PHY920F1L3<+W JRMRI/"W1)'@U
MUJ=5^H?6';JOL4"**FBO%D6LHJAYWV39FF@J8(UC8K&]%*@ADB/(!5BH5EZ5
M:;\/UUG'R<AG*M#-Z4H0TR%1:N0PHAOE-\6+/)X$)[O^)/9VA:]_8FJ8<LV1
M.=\,L17@QL%(VLC&1MM&P0O/'W[NS:D[77Z*U1ZQU)4Q:LOI/T6G;?#//,M3
M7MF*&MJTQ! 9-Z.L;,SMN"N%(*],^9HNN:5/GC3<-IL'&"7DR[$1PE-(8MQW
ML$HV:(-<>>I"_>L[286/ISX^#&ZAH1E3Q)D2H%L^G%YM0"?'-4IX!Z2WN-3W
MSLTCWZZUTUNL$MR$-IM8JF>Y54LL4\\4U."'C"!8G^H+X50H4?/;EUP=)TKO
M!/3C3U-0B@$KF'_AQ[6HB3;L&XDD!01= ^QZ\[@^,VG=IX_XC5)()<81^E-/
M(D;RMD'@)$O%LQNKX(4FP+Z4+L[ZFK+<[W9*344=0%JB*5HS##,'@G.UQ+_"
M+EF1B050?(C+< ],?<'9>HZ-#+D8P9TAB,EEB"H0 [!7EB.>"0?< >44'<O;
MWQ"TXIHF8N/J4V-)/'@3J\<^Y0"'#<QTP#$<@T>GP:[KZ_3=%0U^B+M:[CIB
M\?EQHZMJ*FG-!FJB62&:)L24E?'"\NV61E4H!*@.PXC_ &_D8^IJR9S9,&3&
M)/4C#O"Y=5)!W 45M:8"S]/KU7)TV61\C'UC"E_'XV]#&2T:21?_ #K\R#@&
M[OZ\'I'?5%<.X-O[)UEPH+Q-IT4D[72IKK=4+!6S1M41QQ+4%D,D8J7;9[D#
MJ[D8]P(VWJ7]E86F9'<T.+D0_C8Y4>%4="R"U)9G,F[>RT>230YXX/4%[@;$
MQ=+U#*TS-3"SL"!F65PC"-H_G,8#AE.Y?E\$B_K73)^V&D>X?JSI+/+KN[EK
M5H&.MIXM8U$4%-<(*<0&LIK77.R1"\4M7-&D4,V6JJ.5][L\3 &SM=S-%^',
M>6F&C%]3:,C"CW%=\K>F7C^;^$4!!8<*P' L ]57I,V?W<ND:YDXN^7"SS,W
MH*8$RGBD4#UXMP5ED'+;5 8#@#:2-A=N^M+I'55I[;:63ZG4LD=#;$NT4--4
M00U*U+TLL$9A8M(U2J% [E=BN"<Y)$0QNWLK6(\G/SGF_ LTDR1L[VJD%XRS
ME]R<J77:O (LBS5W9_=_:6FZQI?;N3&,/4M2QVRFQ8(T;&L[T/XG915V96(4
MJ=H(+'B^B5QT!:+M>+A?]"T=@CN%T(_M);X+C;+76&[JS-6UGTE940RM#52#
MW&=5]II][(6W<P3OOMKN+N=\7&EU&6*/"B08_K02O%)&!\H>6(J"0M !OF-<
MGJXO@[W=\.OAK%JL,>B0X65J\[9,^9IL WY*R&_XY^9]UV6) !-<6.N5[@=L
M=345!I]]54'TU!1S-46J*;$JP35;F5I8BBF.7ZCV%9I%DER$4#XA1T2F5G]H
MZ!(N/+%GS4?Q@500$4;+B$@)3:/9C0/S7M\S>>#L'XL]SXDD20-D:7)%DXT\
MBLLQF7D#9\AE*,+96M17%CGH:)TM'K766GM'U'UK0W*LBAJZRC(BGAIP?XDB
M-[<B%QP &1D+;5^X'4<[2AE?'U'7<["BRXE:2=1D2@['4_PP/%\TU#@U0!ZF
M_P 2]472M&DP8),A<G#Q R9<0]%3Z=@(=H ?<2;%\$"N/%SKT7=FK;V>[-Z9
ML%O5A"+?![?O!6E]A5S&9"  7=I)))&(W,[$MD^*=[NU0ZQK61D$QP_Q'9(H
MA\B 4%0"O J@/WOSU\=?BOW)F:_W!E/E2F1UE:.[OA: N_%?E%5X_?IXI!*!
M?VP!CRS<8VYY&<Y_P/'3!&7,J-\IM;-< ??^8%_MSYZJDL%0+5$&O\;/^)]O
M\NB\BY&'7]\+DC.2>3X'D><8&?VZ,,93\1(22U@*OLW@-[6:O^G\^-RG@'VJ
M_>R3X-7]//O^G11@HSN)(;^ORP3M !X )(YY/[=+(CN6@"2 +((L?8$G]1R/
MUZ\"V"I-77/%>/W]_P#"_?E\&C^-*::'[6*U?^"AZG6(*Q<8<_\  B\U?_#7
MZ<=1^<5-*+NI'%_6F(O]_?KH^E'170Z'0ZK\?CRZ;O6K+#Z9;)9:ZDH9JJZ]
MV_>DJU 4QK;^W^"*@8DIU!)21HC[C+)\58KQ:/PU;'C;6ILK>88DP&<+9OY\
MKY2H_,31H4>1QU:GPOU:+2)]8GE@,YDBPHT0 %E8MD_Q%!X.R[L^.*YY%>C2
M7HCK]=ZMLE\OFL+O8HZ<PT5MM-GK9%IXA1R;ZZ>-DQ)41U;+N-5*<L) I#;5
M'5PP=XZ?I2SB/ 7-FR5]1GD6T6*B(D"D[$8"K&TG@41XZ[[]UW-U3U$T_-EQ
M4Q(WCGD4[%RIY3N+RU7J$)42CG:!0 /4X&F[/!IRR6BR122SI;Z.FI8YW;=*
MZ0QB,/(S$X9RF2<DECSR#U3NH9S9^?F9)C2/UW+*NX$1KP. O@<#_3GJK<./
M($ W,68'^,SJI9W;YB>/'/M]_KUU40#;550% QG.0P!W>#Y&<8&<\Y X!Z9)
M75G./1!H$ #AP"+9>*KZ \UTO4 \^_ULCFA[?S(KVZS/$/L-WGXKO QNRBG/
M[@X\X/\ +&01DQLS*9%8( %*>Y VTPKFA7MQ5=! RI*RI;6+H62"3P17G[^?
MZ]9((F9E)P=V,*H&44# "C)W'. 5(X(R/OTG52N52K5-ZA!6Z0*6-$\WYN^/
M\^OFCA$D:TQ-.A()LGV^OV_2Q5UUL$1AO]O&=C8)().6(QR2,CD,1C."#QM'
M7&2$ $@4 RHBJ2I/(+W8/%>:]OKYZ-BI5+I&ZM1)%_*6JKJZ]OMX_3K77.BF
MJ+=5(\NV26+V]V >2-H4XW'/'D'D';C[],&I!1&B ;=I#$QKM)NC5+YL59_E
M7/3SI$FR>*?=4OJPDQ-1L<$IS8&X?3DWXOJNIZ^=24]3>*S345J4WVA>X+2W
M"M%+#)51)B:!86D8RI0_4*REF:)I'7@!<LL[^'VGYTZS.V3LTJ=0[XP=@JRE
MO34S+XL#E>*!N^ >MH]HY<&)I']JX>(AU"")OP^ZMHE,9!1&- *6J^;6R 10
MJ(^A[;]S]>O1:CMK5E#;)KK'0R4T%3-'%];"H#-'3PR/D*J@B9E0,> V#@Z8
MP-+T'38\9,IHMSQAXXI 6_AJ-K% ;46:-6"?(H56=NX\[XB=Z:UD:E%GG1(D
ME)RHQ,V*+CD52RA2?54!/E&X;K)-WNZL:>@OTJ7[\IM?<+N_;89+G:ZVGKM-
M&9(9*VK6"!8J:LJI%C;?''(!*D<C*?J$WR!R&9JG[][LT[1FFP^WV7U<Z"5)
M=B@0Q2FP9" 5 <UX!/GV]H_WAWCE:T6[?@R)'P\6+'BS<KE4RWC'\:*,J:N1
MJ,AY!XJ^1U,5'$H8!=VW;CXC&W80-H7PH^QQY\_L!FUV,DS3LC2REF=G+&KL
M[VH_WK/'C[^_4-A"$-$/E3Y %7@;0/E'BO?_ *7SUJ+W00UM!54TI 2HC>,Q
M[E(",A4YX)R2#@[1R2/MRV',]%F,D18\MR:*J;HF_->WL>G+&'H_/OV$N$"/
MRQ"&^"ORF[\<\=0,>NOMGVM:GM\W<#5%QLEIL,M=)5T5IH8ZF[7*FD1IHZ&E
MEG!B25F]M0\RR1;!NDVJ 1:'9'<N5#DL<+ ?4YI8$&-%&XBCCDK_ (TKGD1Q
M\%A>XT0#R>K][8;5M8T/+QTCQX\7+2),V?*DJ-<=%W/N1?F84#PIL_?WA%NB
M:'UOW(T]H7M7HN2T6*S4S5=WN-P$%5?*IFS5U3UU51(L#P4]+[,40B1%WL<?
MJ &A-$G[A3#S]8[DR(]D*[(<.%1Z(X4(JU;.S.0GS,=UUQ1ZB,FF=L3=X:!V
M5V]IN*^6^3#F:MJ<$7I"*)"&:",$AOF0J&.XDLRBQU-%^&WZ;Z;7/<.[=V-2
MT$-1IC11-LTY3U<"RP5%_7V2*_VY%"NMNI@!'\,?4RA@<Q\U;\0NY#VWVW+'
MCOZ&MZ]-O,D8*G'Q9696-K^3>WRT#5 78ZE?QY[J8R:=V7IV1)CXN-AQ_CA&
M2A"1* J$^3ZC ;P;/'\[!,-.M-#'%&BQ! JHBC VA1@ $YQMQC&#D9.1GK,<
MC.[1_B!4C?.2&-LYY9F<DEK8W1NS?5#!6CAB6,!/3 JJ7BJIJXKZW][)/1H*
MQ)PHY &X'&[=@;1C&" #SR2 ?WQTGFI7<NZLSMMKW()&U:\<'SXKHV,E]AH;
MO[]"@;'Y:O@#V_<^.O83/N8&(T QD$@$G).>"%.T8P#YYR,=$,RK$\?"HRG<
M'O<3Y\C^@'U%\V29(2K-Z0-B@P%$'CQ9NN/)_P!GXT*LQ^.P+E1M+@,!X!."
M1GG'G)\C'2!9F!4,/4CY4,!^0 $>?(HT/T]NO*:R2XCW!/D(/! LW^I/\OTZ
M^>U%@,1CY 89>&R=W!X.YN!D@[?.T @]%Y&^U5I$8?G"@\;>?J>2+_SKKE"E
M[;#E/H*)\_6_K5<?S\%*REBJH9:>1%EAE22&2-@'5UEW!XV0C++@M]_N21]N
MD<PDQ_3?'E*3 K(C60 0?E"E0/<"P;%UQ5]<.^\E70A *^:R:/!("_8<#_8J
M(>M?L;J;TE^L6XWBUIN[5=YVGN-#"M-LMZ0U1IA?K')&JB'W:2L9*JF*JCI%
M41.AW(S=;:[,U/"^(GP[@FEF U;2$_#Y);<)8LC')]"1R;+B10I!YY#WP1U)
M?A7W-J/;O?\ C:6[ME:?JSIC3PR*?302J3!DA3^5XRMV" 1N#"KO4-K*HT3K
MG0U]*&OT3J.>Y:(KXE<2BGN-"^+761"7<(IA15UN>18V3W(5JXWR6(#?AZ3_
M &CV]J6*CK%J&GRF=,C\G/YK.VF96IUMN?Z]:DU[49=,[AT[1Y]YPM5*JP4$
M2+/*&>!T9:(4E6C*[J]Z)\3">E[N5W#[/:RI-"]QYHSHG61I9]%RJ6ECMM7-
M'&\E!!4;GS25*L\D(R$BD1E&%VXIGO#0=(U_&&7I(DDU3"-ZB$<A6$"_.VU@
M !N_, =QX]Q756]TXV/K\>>N'"8<O3F?U_50HSQHU$@'EBM<&C8)/'M,31R>
M^%<-RZKMP"5PPR/F3ACA<G&,$_?GJBUE_#O(L^YU+$JP%E"I("<_0>2/U_2E
ML@&&8CR%^6^"?O=4/]\^>CX**[(S(2OA>"2OC."2<#QN(QSC'.3R\A&Q8[0%
M;=V^]W^XKD"S_EUZ9="RV#YX\ <7?V-#[\_7QGBCY/(*C<5!'Z0<E<E\84'D
M8&/N.BU_.ZLQ*>FRF46#9X%#SR>>0;_7KQBH%,*;BB+XKS7[C_T]_*J68+PI
M4DC/@;@%W$\9!/."01]^#T"H.R65PK-$$C/VC!H_K]_V//'7;[F552BPKY?'
MGW)/TX'M^W7MP0263:<@ KSC(!RH.2,8SGR"3C!Z;MY=BNX/16B+!.VQ?CD?
M4 #[=>HY(*O0('/WK]2;!/Z^/TZ][0\>=HVIM QD './D<98@;AD'D'=YQUT
M[?Q%CG55W KO4'=1XLC_ "(/[CK@ JP.XE;NOO[BO;^=_>O!8@!&9U4J-V?
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M9%0_/;>GX8+QN8BOR]=KWWTV>Y.B[>FG:RGONK],1K55BVIIVF"P9-7!-$^
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MOXQA3 "Q207M5WM6-[CX%GS\OGP?\>BU(NJ4'R/Y"OT_W7TZQ&,E1D\8 Q@
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M?!R"1G<?*8'\O)(Z(E$A@540O0"[[L@![)4'P2!5@\>?/'7@6(KPS62!R &
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M?6*_C/\ "=OAMFR*F1)ZVJS_ (U\<S%XT,DTC/Z8(!^5K#+9HD42!?5M+>J
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MBXVSVDC:0T2VU45OE4<@L5LUQ]9@?AU@:-E0:?W'W#@Z;JD[HB:7"TF3G(S
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MB1UR=A 7:R?N#X8:;'B32Z3)DX^9@,$EQ,B4L96;_E4(H %$'SS7VZL?O/\
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MG!8IC@\8SX89R,$_<],4L"CU9%;;*QH;C\NT7?(]V%<>W[7TK0>E(&D7<=M
M@4P/GS[\7X"^U\><S)R' !/MDM&"23^HJ<#&068'&<_%@?&.N#OC6F4FZ($8
M!*I[[OF%'R:('ZUUWL#M*Z,:7YG5C0)\D #SQX/Z?7KR5''@<,H#9R00'(4>
M?ECC<  >//2"?TQ+<8E8@<<+7 ][:C].#Q7ZCHR8 1KZ9^3;5$$7?//VOQ]1
MSX\?6&Y?BN-H" *"2 ? PN>/MD#.<A3D])H%:;U8]H0D%Y)7&PJ%Y&UK8'P
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MCN1<=0U^HRVS,!]J^OTZL"TTL4T4<T62LB@AL@A@W@A@-H&!]CR/\.LVP*4
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M2LF,'9HS8X)!#*M<50XY]S?'72D[2RCY6_O>0!9KDCGV'L>>B<L)_66^04D
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MIC#<_JO=[@.6+*!:L/'CD=07NG(;/Q]0AUV&7+BSXCC:=!$'94,;*QD0<A0
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M6:4T4C:Z9K;\HL$G^]SU5'Q ^)^4[YW9FB8[9)U**33BN A14.0-CR Q$NH
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M!","P(^8'?N+"P&X HW?5W:#J>/C=N?$#7-9P)<K3)T>+)Q NU)3DB.%D]4
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MDS32M64"86,R-(TDLM/&(Z65VP0T6W<X3<97@1XK1LNFP)!C _)LI8Y+YWJ
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M1D8Z3N/FW-8K@5>W<!^2Q]// _0]>QB$<V-H/]_D?TO_ '7B^O4*RP%%5@T
M782Y8EL' "DG )/ZN1S^V>":,NYV4 70 ))->2=P_4V/;[]&DH IC"^G(P!
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M@<@6QH#V\];Q-ID!0?\ TLL0S$+@J-J[1NVJ,8Q@G['SD-N65],(9HK7DLW
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M?)Y!Y! YQQZZ-E$"-8HG .Y@P*GZ-Q8)'@BP?%UUXSJH5A3$D*5  8$UR?
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M^B1-_##OE.0J_P )8Z(8V1N)!6@?%&^H'V9BRZQW1*,^3^#@O84V"')//-4
MINS5 G@GCJM5I*\6WO\ WK66D+.;105\[55QL%DN52E+_:JI<R?6VU)IQ[4=
MUKHWFDIDW1HLN(%<!\]:1S-.FT32M.U"8S9, 00SRQH&$$7RA)&''\)30/DU
M\WM1LO0?B'VWF=R:UH+0)/A9)&+FS668W'Z9/I&F:$\QN"/R'=5\=(&.TMC[
M57Z:]:CLMXM M]QCIFMUT@,FVN1Y&:GI4VHLZ(4*C=,8U3+^Y)A5$GP=7R=0
MPTPM/DAE:>$ S1L"QAH!=[4S)P>3R;^4@<L8!JOPF^&W:6H9G=B9F0V-ZAFQ
M,)F8P8F1/(2JQ$%G?:2?D8%0!Y'4FO>RR=Q_5Q-V4TC:*>CLFBZW2=E:1J=T
M*VFQ6R."AM%L6C:3W#65H$E0K?-5:H5Y'*PE6J[MI=+[,U+N+6LZ23(U.+*E
MJ,;O^\3FR2&VD!(P%4^-VW@6>'#N:%,GL:+MWM:!DT_7IQ-JVHRG<%BC*3RL
MHMK#RJH%41LV\;STP/ULO3]K^Y=9VGT1(T5!V]I*+2$]1N)]RXV^"-[@T9.X
M(KU$K1J$_O1%CN=F8R3L23)[K7)US,("YN1-*%Y!V%R(T)%'A=OCCFA6T$M/
MQ![RU/X<]@]K=M]LSMCSYV&D\\\("[4)&S\P!]1T!9B#=L+)KKC^T=!J"Y4M
M)=;A0-64%/5TK2F3*^_ )E^HCC?R&"$J6')9B%))QU*M>_"XCB"%EAEEB:U6
MR1)M^1FOP;-D>.>:OJ;_  ?US7-8[8R3W-(V44&[!R)N9A9+$* P(Y4$EN"1
M1XKJ83T9^JBC[;>L<=IM0:*L-@TG7Z-N4EAOTK2T\M56-8Q>K-62RR,L,<->
MD%10LI5S'/A6<EF44CW=V7EZK\/=4UN//FR<['R#_"1;J,N8V157Y]Z?EN_F
M4$U1 ZAG?O=ZZMW1@=C0:7E(Q&%D+GF?>DP::FC2$*%^7YA9D8_*0?S=,7]7
M_=&_ZE_M946)ZBAMMWU)=:>X-3A)J<TXN,]3'%'. [0I.8XW#1>W[L*-&S%"
MR%Y^&/:^'B/@+G!#.,2)W4[E9R\>P[E+"Z/UNB6]SUHWXRY.L=M_"'#71)95
MU3TL6&3+ALOC0"!_7-1@["X*HQ!!'(OF^F9VO35OU5HFINEPCD>Z6BHA2BN)
MIB\D:2$97<1DJ)% V[B5##@ Y%B]PSSZ5KF+!A&.+$R(':2,M;M3I2J""0#9
ML C@'B@0:L[ [4TKXG_"K,U3N16R>X=!R0FF:S)CL^="R*KA0 %.1&S&OG+%
M+)&T#I//[1:XH;HE%0)7TE2)(Z:FNM'4RTQ6,E69HY8F1U:1![;X/@%<MGEV
MQ<#3YHR9TQV1E$DBL1R;W<?,/S4 #Q1 XZI/6^[_ (G0:H.W\;$U/U))H=.Q
M=02XH##OC)>BM$G:H8,#X(#?5:>[O;R\RZMLNI#?--5%7?[#IUJJ\37"&AJF
MN/Y52PWJJNU"\:5 JGK4J#5524S_ %!+2J3(74E:%J6FI%E0A<F)8,F?TXE0
M[5B223TEB<(5=2FT*-R[1\O@"SN[>PN[SJ>!JN/C8::@,?'PGS7FBB,LQ5O7
M<HSK&6E7GY;H';P.C^KKKI33$.C]*4<5+<;O0TR4=]NEJBJ:>.[UE9.TK[6J
ME20^Q%*L,3""(R_YQT4,$7G CSM5RM2RV,D>,SWBPS%6].)%_,5!H602PWL0
M* OSU9&1W5I7P\TC0]'U7^/K.8L4.7'AE46"1HPDI:5%/+%MQ16-U9(OJ0G3
M/>'MMZ6-0:DM%!V!E2WZ.T_9JW46L-07>NIJNXWZ\VJGJJ..W"=9C<&JJJK-
M-1TD)A@AC6KF=HTA?JEM7T/NSO*(A>XH88I\J?%Q\'!C0%(892&9W1@ZML0;
MCP&9ECY8T$F3J/:PT_*3\7GXQB0ZCDY)2)<$*S-4:D[GGF:]E[5^;Y00WF/S
M6/JG[C>J7N=5:/NNH_[&Z6O5;)5?V?MV*2P04='!)5337BIACCJ*V&C@A:HF
MFKI'@C96=4A0*.K,T;M+0NSL!'D@?4LW BW?B9]SSR.YMMA+,J'<VT!0HJP0
MUGJFM*[YF[HU\]M:7++I&FL)2CI'&^3G+&I>19\F@T"N@HJK!2I(9OJSB]TU
M1>GJ*&>HH(+?2W>?V+F*O=3UZ(Y6,PEL$&58PT3'RC#<!SU+85BD(GM0)#ZB
MC:0[!JH$@$<  *%->Y'CJ$:Z-2U@3Z7D/C8F'@ZE*L>H/G*T.0$)4+&&86[+
M\RFP/8GBRJ6D[?JJ^W:RZ7JK0*VPUTU&]MFAHHF3:VVF]\5U.AD:2-2??$DH
M=-IWA01U[FR##QLG4%S-OI1%V0NOIA%'";6YM5ODBSX'5B=@8NI]Q=T:+VCK
M?;D.9V[-/A"+-3!02)C@(AREU"!>6V'<X>4,2"#R>I;O3[V0M]IU/:*.(@PV
MVGCKJ^:3+1-L56FC/Z62&,NBE@3(P\#PPS+KG<LV?-FY,Q]5/5,>,?RB-KX
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M:*GIJ;Y33SU#DT\$40+KEG7XCJ@=.#X7Q,TZ(*TLCXTT2XL1 >1B"2S\T%
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M/YJ#<#D\$_<3/LCM3NG4>UL3# 3/;3_Q E6-=V+"N2SM&AL5NB!556@P"FK
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MG.">.NFQZ$8+R!5*U?O8YW5?T]K^_CKOUB64%0XX]0>[_P#+=7Q=\'^?CHY
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M2.O9)T?&]-G*_B:(H>!$P'/''^8/)XKKK8X)$<OY3NHB@P\7QX->1SQ71F,
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ME=6BT/8X/I4DFDJ*Z[3PT$QCCCW.745=5(0H)W#'@];T@CB@;"]8JB.P9"X
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MX:KJF/D?P(<J2'#(  ,$;ND-QCFRJ6S&^#U(,R60QQ^H5!BC2%8UXC585"J
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MW(SSG!)^_DW*>!U6+W-^G0K=]*/'W^@_7QUP$;>P46":;^7GW_\ 3[=8I Q
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MFJDGAD9*CZ>*176>>EXDA*1\2+M9<ABK,,$7GBYF[!19D]"7T]ML:4E@  K
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MJRHCK(CJ_*R+A@@^99D88(4Y .",#QR.J!:.4",J)"R22*RA2=ED&B"0*O\
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MR3GP<9))QD\D\YSTZPJ9%+>FHYY%NXO[$_Y<?3H2DQA-U_,I(X;QQ_R^*OW
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MOTRNT5\J@CZ?E]P?)H\]2\"G C^W@_R.[&,8P!^R\ 8\#^=)&+:P+'<+-"_
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M6B]>%BK.Z>G;%V=ME^>@'<*"[4,U'&(9H[@L5,E3')/CYF"$H68I(@;));(
MZB'8J'$U7)U/+4'^Q-D\CCY44\@W>T'FZ /T\WU*.ROPNGX^;J>7AQY$7IQP
MK3,"ZY@]%Q'R:8K)P/%CP *%;[LQV$I^VG<GN1HS4]S@>2Q:=OU313GW$HK-
M<[64EHJV>J=E41LY2E6(LSNTPQE5).FM9[IBUGM+&RL,WZF5BHBE=KR122>G
M)Z:63N:^"/%$VM]6=V1V9-V%J[:II67+EX.M>C)'@2I\T4(<M4S618L\@V46
MSUWME[S]NNZ>CINW^I7@H=041J:.TU]:0\<VV1VCH7J%&0'F:1:268>WLD6&
M4@!3U7^I]HZQHN:FNZ4#E81V2RXY!$T9'+O2G:XVAN1\W@<7U<VC]X]OZUJ^
M3CIF8\,Y>3'S]+D8(L^WY'6)3\K>J#? LGQSQTSVJTMJ[MQK.+46BKO5V6NH
M:Q)H&I9I*=Z62-PZSTSQ\O$P'Z3N5N0V1U:_;_=F/EX'X75,=,F)U,+Q3Q@I
MM_*ZRQ-?MY!!Y!(-]5!\0/@;GX6LMKW9V4N-B9;&:?"D)>,EAO8!"&5XVMN&
MXKZ>>K!'H^_%!M\>G;)HKO?5I'>**".WC4+XBCN/LY FG+#VDGVA1*A*EF8M
M'@$**)^(OPG3*U.?5>U8ECBRHG8X4-A8Y&()]-18 HV!=@>>HCE_#*?*ABR<
M'(6+,96&5BR6@]8?F$09N4+ D5^4'SQU,QH;O%H#7=MBN6F]26RXTDR>X'BK
M87= ?EM:/>Q7:2%*D 8&0< 9SWG:'J6E/(F?I\Y,7G8KLY8\ T19KR?J![]5
MWJG;^KZ3*8,C%EW4?$15:^HL#CW^IOCKN9;Y:(HLSUU(JN6V,U1$"00W)(QD
M'D><<\'."&CT/X_X@>OZJ@ 0E-I)VCC: !QXNO;SSTSK@ZAZ@$>-(3QNM6/D
M7?T]_P!:]CYZ237OJ,[.]MJ*6JU;KS35D2*)BJ55WHX'(0;L>W),KR<@K^D^
M1CGIP@[9[EUF5$TS3LK(]0[C4$CTI--\ZJ5\_4G]*'4@PM U/*%B-H=WR_Q*
M1:/ECO( KW/D5U"UZN?QB+32T-?H7T^VHZDO]8%@36!<-9;5$QQ+40B/<U=5
M*H_AH/;@1R'D=@HB-W=H? AF:+4^Z,C\+##M<X(8#(G:K4405502 P"AS5<"
MSU(</2H-(RL/&2&;N#4)26_#XH+8>.JT=^9EQ@A-MDA 6)]R >H!=7]Y;E6W
M:Y7>MKFN5_N#SUMPN=5NJ)Y;K.0SRY& <R$;!G:  H "X%_:=VNV3%$JJD&!
MCJ4BB1=G\-#2\<*1S=DWR=U^]M:Y\9],[/A_LO2H(_[0&(JD[1,D$\B4PC N
MJ:P+ \"^:Z?IZ7;'W!T?V)UWJ5XJL:]]0=30Z2T3;JI3!<:G1\&Z2[7X(P$T
M=OK:N>..*7;[<L-%+(28U+"'=_C2\_6M$TR"13AZ"?QFH2!@T)R"%CB@;:>9
M=NXT>%##P>HS\-\K5M:R<K6.YI7E@&2^I-ZPVK%_<QUMJ7<"2VU3:JPL"^)+
MOPX?PZ*GMIKJ;U"=RKI2WN\2TCIHBWI%4J+)]0BQ7&Y51D_77OAZ.F**(DI6
MEE)#S[8Z\^*OQ>BSNVSVEH$4L<K4-4ED95#0H!_!B5"Y90U.20-P"J!5]57W
M/A1GNG5M1.2V4\[TK,34:[B2B@$V_ W$<55?WNI\H(D6-=K<A1@[B5R5\#))
M&>>/_L3^XRN+1C.RO<HK:VX@L.1*J\[?S$T /TKGIJL?E56)W,0'V^]#@<U[
MW=>/Y1F_BRT6LZST?ZTH]$"MEK*NOM5/<$H8'J9S;9JE$F*) 'D5>0LCA257
M+< 9%O\ P$_L['^(41U/:0N+D2022L%"9.P&-@78"R":H\&N+KI5AID2O+!B
M3'%S9<::/$D)" 2E"!;#\H(^6P1RWU'51%-/]X=!:=M5<\NJ--UTU\B>F^AK
M+I:JR6E>', 62G>GJ"DDJI*I7*9Y)+=;B?(T+4=0DBFBPLR-(-S!Q%*&!_-Q
M9 H^.:N_<]2R/0N^M-[)TX+G9+Y<NM!4QL7(,SQ8[K2"787.R20 FP>#\U7U
M=!_#][BZN[@^F[M[7ZXGKZO4U!9::U7JYUX9FKJJC4PF422?Q9)S"D1J7D&7
MJ"QSECU@+XHZ9@:=W?J*8$D:8,T\LOH*JIZ8:MP  M57D)5)M!HDUU[W=ILN
MGYR^K&D>3-!!-DB-CM7(>('("H0 !ZH9^*Y;D'BGS?K!!^6SE6RC%1D8)_NY
MP>1Y  QSU7"+!#*Z?G>M\3#Y@B$FKJ_TH@_6O<0L?F)"LQV_,WBOK]#]_K?Z
MGK!M ' *Y 8X\Y!VCGY>2,X4G[9Z]5A))3(C 5\QH".S\S\T#QR!1 /@#KRE
M4D@L+!X%_F/ //Z_X=%I\Q$;MK*>=V[/ )RN-I8G&,#   YXR>B<H1%2'9VV
MRN8Y +%O=>.*)KS[#S?1PB50KJX#@KZG-@@T;5?RFK /!YL7[]$_D.-_#,Y'
M!^*G:>"1\<# R. O[=$I#(D8"NL9;Y@JDDN0?S-NNAY-"A]NN@[-,#:A!Y-@
M6?'/]/(!^YZ)NR9);<<;CC/W.0<GY D?XDC&./!T>]R5FD -;5OW-\B_;^=>
MWM71SDQ3;RZ/$UVM7P>3\O'GBA]!]?)*0D H&4Y"?I8Y3&2P^Y_=CG!YQC['
MTJ4F-@[38)(_YA0/L?/@CCSS].%9)2S1KPA/E2O/T_/^_P"W6NF)WD8R?U!E
M!P,$[O P2?U8^_ZOOPX8P5X[;Y2@4&O[U.2; /N#7/M5W[]^HP)5"JV""#=^
M*OD?R/[_ ')<.Q8\L#M3(.>,@^/TG_6.E"LR%@GJJI-@)R/ZV!7VX^WU+,2Y
M%%YA\M@!C5?7S7T'U']>FIU'XT'IIAO+V"QW&NJ8:>MJZ3W_ **XLJF&H>,A
MG>C&[+ _,$CG(&/&_7^&/<.1&TS1(2L:R!4FBM@4!!I9"?%>W'Z^(WIW:^E3
M)BEM1@DDFE"M15MC%O#<FJ/%^U?J.N1U%^);<^X-[J=.Z M,ZT44#3U%^KWE
MMMNI:?8CK/MJ*835'# A(5+%V"_'(Z9,7LV>+'DEU1A#ME*)!:S3L18H%#M
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M=)%-0W.F@K:NE%8DL>Y6$&Z<,GS1P0S*>UN\L" 3P:H\>/AY*?PVD#212^J
MDL;$ CE6((<@'<:/!ZKOX_=@96%KVE:OI0+Y4<,"R0MQ Z6Q1DDO8-UE94:K
M5O-\=2S]@^^W=C7G<+1-[[I:7EIJW2]E_LI))63/#51W*H22GK9'H9(&,=0Q
M#@1!F945FW[>16G=>@]O8>#W(NBY DAU29)N%4[40 F-&!^8!B02"+_Q<?\
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M#,B)\T9)B-<$$;00;KGF_?WZK/O[X;299_$:7J3:',78N#<L$H)^0( VY6'
MO:1[D_5&K1J/U$:&N[::T]J/5>GKA3U/M20T$U5&V]?B D(.221DX&T_$\C#
M&RTR>V-9PSE2P8TD+Q[[GAB=64 U\[K?OSR#]:KJDL_1/B;#F0Z0^1#J,8E4
M)F/'#D#90H!I58_*/*DC:1S7CI?+7W#]4U?-##?>[6M:J&EP/H:VLF40L0 R
M$9W)AA_>R3C XXZA6?-V3&V_&T33)) K.TP@AX0%E-4MC<P-$5R?H>;6[5^'
MFM8LRY6NZYIYQW*?]T73<1PTA%_-*%  7D6#9\>X/25:H[2ZIUKJ)[WK34^H
M[^)9':KFK*R>>*%'S(5EFED9HXE!(VHL:%<9(ST?B=[8V#B)BX&'BXP2-BJH
M4!(/*_( 3N-BU )/UN^C=6^!&BZMJS:IK7<NI9& 9!(NGQ*,?'0'DQQK%(%V
M^QV@$CGSUU>G^T>D[Q<:30]!J>BMGUM-6?3U5$M,](D\$1$4%QN#3EJ=I9BJ
MD[9@!N#E,;@RCN;4)F_&9.G9+I$\:[07 ?U'K<JF/R+'M1_;J6:IVWH6B=KY
M.%H446+#&@*B!X3DL@VH3-.P>44Q4T6H_P!X#I.[#9NS^DKNUEIF3N;K"S7V
M%ZVIIX7ET4!2RF22BBK%4F[()8H(96BQ22GW2DC(H#3Z7,UC+@+<:7@F+Y#N
M/XFB#9],@"/Z_P#,*W$^W6?NU=![-R]3DP%1M7U%I&:?)DQFE$,P);F?YHHQ
M&2.;8@BS54)=>R245%<W[T=_[W3VK4-;IIK'H"PB#Z&S:<M-12?34#TL,.Z&
MEE"S'Z>,[1!"))'?+-U1O<>>H5>WNW(OQ4TN8<C/S13RY#@EGC?AKW'@D'R.
M .+GFL:)GKB+I7;^.!AH1/F(KJ"\EDLI8BR+YL'Z"N.I7^P7J"LNM*JBL.CK
MK;]1Z8TK3P6":NL0DJ'NEV2.)9'FF/QCC@0[I0JE3*Q*R[2!U3O<_;$NGM-D
MYT$VGZCE$SA&"[%A>OS,PIKH&A]>.>JCUWMN+&Q9<R7;%DNS$H6#A=ORM\P-
M"CP 3[=/V,8JZ7VY7(253D .K+&P&<NF&1LG83D$G)SC&*U+%6$WJ[UC#!$K
M;OJ@77=5W]O%>![57(*DD_O.C'=MY!^E$?0[K\^*/CC6FPVUJ%[1-3I644JL
MLE+6_P"5Q;/ULA^H+EU<DDY\9(&!QUYDY^4)!D8L312, 0\=K)Z8X)6OJ!7F
MJ_K[3R4WY":MCPPY%5]_L >?-^>F2=[?1K9NY>K;%>*.CM=):()&%UI/HHB1
M$C^[%44Q<%%:/&P!40[2!G'4[[<[^RM/QG,^5DB<QNN."S"K'Y6/FF(\$^1[
M=6)VOWGD:)C20 ,Y%[)'=OE:O8,&XL<>/KTZ/M7VIT_VET^=-:7CDAM+5,M:
MM+([.L$U4J-5>PTCOMCEEW2B-"$0DA5"X ANOZEE:]DOFSPH<E8MD[;[+)1V
M4!0+^S5R#^A/48UC7<S6IXLG,G+LBLI2N0"Y(Y'DA0*Y\&_MTJ[-&AVKMS@8
M']W 'G()4\C<%!SGC)Z0IL1BZI&FV)$(\V;/M_UXOV\=-# FWC8 D\*>./J/
M?CQ[^?-7T6E(*H%P1GG)"GC)SYY_O<9)(/'1<<L6R?:@,E[0K<@LU[A?!)V_
M,H^OCGKPK),54\>_VXOWX_3^711RD?QV[R3G@_I\9(7#'@''!&,CR>B+@E$J
MQ%T E4[2+!-&Z^H! X^OZ\GM$T=TH(V^ ?E4U_=\_K?'G[=%)%P5'W&1XSDX
MR!NP<8 &//(Q_+KI9=DA%;C5!C^90:LU_,>W[=(UC9RS$TGLOL?T\7SS[#W^
M_12<C<"$_3GQDC+'!+;0O(.2"%)Y&!^_)4F<(PW@G?M\#;=\D6*H<_H1[WTO
MB*,H&SP*L\D?<#]O'T^M=:N8H, $8W<$\ Y.,$%=Q)\<G/&1TY3*$=G(]8L$
M^4\(B#_D^I%6?;_/A%M6 -$L0?K?'F[H7_NKZ)2.2Q 50H+*#P1\SM_5]F&1
MM'[\<;>A RHCOMX;A1X_8"[-$U?\_KT%IGY%*E M[$@\?S!Z\H>3E5\+C(;C
M()QE5(XX\8'\O)*W'9V4E$!%@&Q[U^A^O^Q77<L<;D,ZGQ\NT<5_+S_7[GVI
MC/V(U3VJ[HW:#7%LFH*:ENM7<%]\NT4Z-5R3(*>12T<F]0-R$YC 8/SU]9M*
M[CQLO0W>&19<J4"'8E@H50*P)8 [30(-<GD'D$/F#\'M076,!-/RDETJ8PSG
M*O< "P,JLA(*,#7D"JX)'3D[;W,N&O=0J+=74]IHK5#'2T-OBQ%%(D&Q4+JF
MTROE%PS E=Q_42<1G^QQB8[331F<Y+^JSFWHFQM7S0\^*\&Z/'5_:KJND:;C
MXN@8$ADEP\9X<G+&Q;.WY_F-FAX*J0"![5U,!8(+A4=I]$5%RDI*34E\I:ZG
M2F;:E9=:*G#!TB@^+NK)M4A 0 ZAL[L&J=52%=2R(85WP*HDD!)(3=P&:N ;
ML"_-'_E/4*[6U%&FS7R-TN/B9D:PSA=L:N6 &USPYI0-NZ^38L<(%V'IE[#=
M^O\ C0O$D$*TEX2Y34,&4$=JJ*AXZU95WD)*L!8A'(!(Y!)XD$V<N=HF/H\(
M+7&8"Y((+E3L X\6?/''GP>A\1>UINZL?4M2B#1PPX@EQF=#N8XRB1R.*)^6
MQM'N/I?3YOQ#Z_M[4Z!J[]J<+4:=UQ9Z*-+A#'(\CT%<(9*=(I('$A$KR0LX
MB8$G&#\>JHTC(32-7BTUYTAEAS#,WK?+%ZB$FVX*\ ?*6( ^I'2WX%Z=D]QQ
MK@X432RXD$PCB+!?4^1HY4;?\HW@,#=>?-BNH1.\OX=/<2M[)2=V^Q%52]P-
M%52Q276/3U5-4UMKAD^FGE6IMSQO.13*3'42K(988_XC*4!87G#\0\>3.P]+
MUAOP?JRQ"++F*KCOL;=L,B@UOVC8?E!W>1[M'=&G8ZMW)VAAXTW;7<_ISXZZ
M?DLR1YC.V[8V^T$CK&3&R"K=0!9'36['V$L':CMS4]P>Z5965E5626^ETO9=
M,S).U1<:IY_=%;72Q20TL=)%33&5WA*LP$<0=R&-C9'=9SM0Q=$T/TT+%QE9
M&4"!L4+S&M[FO>-O(('GZ=59VQ\-I.W]-SM>[H@=X<:-6./$DDKB=V*11[!M
MY+>6) 4<D>QL4?@H^I'2,UWOO8N*HN,4U^M,>I[)15;PM24U5;4ABN%%'M8,
M:KV9$FE/M+N2$GRO-,?%?MC/.(=8G2.48LQC:1%.Y@;*/R.%-4/F(\<"^HSW
M_F:3+/ITV%%Z#'&6-H'%21%R+W4;!"@>>15]6.MON*R2(&!X^0)!'_:_;SC]
M^!SUG6:/=\Q )OP>%H<BO>_]>.H,D[14RLPYVJP*[5(_O78(]N;HFZYXZ8WZ
MI]#6Z\T ;Z&A9URTCBF1I(V8J%<80GQD'# \G.1TY:)(8\D$2.IC)**K4#N
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M[RP(SJ.;J6("T.1G9.T@$Q^F9'8$&ZH6 #?^75)?$G0%?,RM5A8,KY)1_3Y
MC0&RI7Y0I/ JP/%?1]QJ8CM3W$R2-JEAS@\^"#Y!\C^6W/B). T6X[MY\[3]
M/^HK_'JF55S9$>X"P2H)L@\#Z>UGW]ZKGKXWR))_NY\$@#C[9_\ M/\ AT;C
M%0I#*2>*)4\^Y]ON1[57CWZ*/-U8H^+(_4$US[^/'[=>'&0,9"@YY.>1D'G
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M.$^0^J!]#L'DV3P#[GCHX$-6TLJ@U1\63^W^_P!>C$:+*BNI+I&2'+G<S#(
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MNM*6GFTA>K+57*EJ!4U<5%21T][IZ>K426>Y7%&2&02)[3U"U(B;!YLGNO\
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M^""*X]QUU.HN[^D=-VBDJZ;2E'<J^_"2CI:ZJM=/25U/)*&6&*.KJ%-5M!4
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MNB-K>/G/%#[G]2>C%MOXE[*'@FC7^ %<\#W/Z]%V*[R<K@ D,&))) SDX/V
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M"2:4-\2S;&Q\NK ^(/>$>3VG)I;Q?]]<0H_(-*H9C9LV^X $^+!YOGKY4?\
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M%)51F:5J6L9YWD'N&17C"1S;Q.S.6!B<;R,V)D:CH\F@YF4^1#)A8\<D;,C
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M0#1"_F"_3I_P>[L;2]/SL[N5!BQ@@1.B;Q+*1:B./FF8!N 5-+Y\GIJ%9?\
MM_2=NJ3U,6FZ7ZXZLM=6E5!IZZ6NBHJ%*[ZOVQ5Q8CD2ICH)9>3#)AO;#^VA
MC*A^?2]3R=?7M:4)C8S0O&9X97=Y8F4L4:V!4T*8-=<&R#S8D?Q%AP.Q=0U
MX46?VYD8 SO4C'_?L="$#HBR?.C,  Q4A:+$?+1ZZGTP_B*5.G^\51KK76I;
MM8K28U:6VTCU5R2OK#CW9&B145 Y+%0B1JH(4@XQT]=T?"N.704TO PX,C(
M($K%(V05>Z[MCXW&[)%\'QF/%[Q[>[I@S\6*:/"A>5A#!F[69E<DU&PY/!V[
MF)-CQ]+#783U:R^HQ[;K/2DUP_)4N$=+##4>]1QU#>X$82(PXR,MG#$G (XQ
MUF'N/LT=G))@Y_I297SS!5*G:MWM% W5V>3^O/7.1VMI>#@,@CB6&6&20R@
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M'V3])E=:M,TU-27?4,EQO%RJ_;6(5M37S%4FP$3?"M$D<5,K<*@!7SSF#O\
MU"34=2PL9M_H8RQ1L%7>$C+#>&0WN+51\U?/ L9W[/RCW1\46U?5,F3(49:D
MR/*S^FL(^54-D"G)!]K'TZ@"[C=A;9>M2W>OHXY'JYIJN2NH*3V((5B4;VK9
M?:BDG$LD\@4HI7>5)W#EA87:HCPHUF5?3C<1E Z!18/"A/E7A1Q[#CBSS]']
M6^+.3H6A0Z)AB'(7(Q0B2SDR31IL91L8D,H6S5V%_P"6Z'4V_P"%QIE=,65[
M5)-%4UT-FGFG9%]H4D35T2Q1@8)8G9MWECN"#S@](^]YUR(Y90OHQ&:(!CR2
MP6^?!^8\T/M^WS,^,N5+EYV^:5S-)E/(49R_J67+-9LD+8L _;J9 2;5"8Y/
MW)QG&0"#C/G_ %_MU4\R\AE&WYN/OX^;Z^>/M7N*ZI8D!A7!+1^/T3V_J3?\
MCTT'O]JD4-?%;F5W6>EE"1(!EYGPJ!OOC@D8 /GY<=+=(QO7CGE-G9(G'U"\
M@\'^?\CUH7X9:6KQ).S&/^,#ZG"_E+$#<!9NN/O7'CIFO:^[:UL'JMT);HKC
M!3Z/N>D+E2U]F"%I)[A/+'+%4@CQ["J/D1@GDDY!$SAAP\GMC7?Q$;OE03(\
M,@) B1%8L*)H[B :'/G]W7XJY!DP<%XBGIK/*DI9?XDVU5 5&KCD'[^>? *0
M^K>[S4O=>]06AH(Z]5JJ>*>=8Q]1+6F:*2DCCD.V1C$&(QDLPR,8'3;VE%_[
MK#E'5#/O<$V^U6#;K'(4MX^@->+NXOAGA0S:%@G/_P"2%XU5BIA8!/29MIYX
M+7_S'S]>H"?5#J[4=R:U]N*22V:=O%<"E-;XJ*"@6J7ZR6&-:NX0@-%57.JI
MV=VE^#!D]QHT?'6@^T,)")M8"R9<>-M+-O9U4 6RHAL 1J>2 2".%:NG_ON?
M'T[29M#TK4X\'4]9W_A,G)9CZC( 719%%Q[[$:M1JB-O((;15WKN'IC2M#2:
M@:Z:5OECKJJQ)#6K-%)543 2+])(XQ,$)D#S1%H3'[15_F 9TD&C9^H"3&CB
MRH<V%<B1%96,4R;E(D"D436X#[-QQQ5^DZMW;I7:.2NMR?V5E8.HK!B3N"T>
M;'+8WP2@U(9*L,;! 8W76EJZ/72..X4]XO<=1-;(+3]+%42-27BT4HC4Q30P
M3<4J1QH\D9C>"1E:52LI9NCD;28IY=-]&-HWDWL2JW!,?#*66PY:ZH\<UYY1
MY/;FNY<D??N-JD\6=I^"8Y,*"1GCRXA\IE]-05+[&9GHW8O@GJ9[M)J;T;=Q
M.Q'_ !MTV@TTOZ@+%8GMFI8K+.C+=:VVV_V*6Z4M/4''_*#I3/52%(9 ^[W9
M),J327=F-WUINO0Z'#J#9/;65DQ3Q/*M>A&\H9HS(&MU"W0' LUQQT7V0,K,
MU5]8GDQYX)-RR;PC9*%=I=6(&\4II?('BO/4&]YN5?3ZGJJN45"R&JF>=IF8
MR"H:1FD][*K(0\A8.'_4I(\$=:#PHHFP1"I0D1QA @%;=H%CSR!X-^W'2/N+
M-S(>X5E=)OP37\[,VU+8E" **+6TCGQ^4U72QZ7[A]P+C1BW0V^NNFGC%+35
MMIM].SPH9 YAJ:945O9F. 0L87(1L\G(CF=I&DI*9FEB@R^'CFD?:QJ@ZO9&
M]1?)/N17 YG6AZUKDF/$QQ)IL>1W1P6WD1H+C>+<PX;CBK7B_;J0CLOJ"\CM
MT\.I;+?(JJJD?Z2LK;@UON,=+$[Q4T82>.2H6--V2Q(9UY]P*"W53]QX^,NJ
MDXF1CLJ(/46)/4B9R S'Y"$LGC@'GR.>K1T*#.S<=&GA:'YR8XI-N\@FR=W]
MTKR2"3P.!TN%/%>H=/UNH'MD%3:Z2"22MNTTE)65OTD4$LS/$DQD1S'[?,DB
MJ-XPIW$#J&SK$V5#!',4EFF1(\= R*LC.JJS55+?FK^G4JFU3 QD_"2.XR8E
MW5NVK_#%D$CP*!/Z<\GJ%[N[7:C[T=PZBK[7&Z7>Q30P02T\TBBIM=4CRK+)
M)%#(T8AE"B='";0S&-QN4EM%Z##%V[IL*ZN,:*7:")E( :K:P"+:@57;\Q-?
M0BLE=_Y'=??>LC'['U1<C24:2#.CBR_3.+D>J;+<AF-  $!KKCSU)KV7BTSV
M>[=Z;M_=K5;4]7<Z&"W3VZY72BIYZ6.:2*=&I1*_\:GIGD=0A/NQQY'Z2%ZJ
M3N)\CN'6,S(T+#61(9"_JP1,R,0""&46%:2AR!7V\=79I>/J.@=LZ=INH9J?
MBDBC4Y67(09)E4!U$A(+6*5;]@*YNT2[]>G[7.@[O0=S=$=];=40:CO,M7I>
M&6Z1V*GDM4D@:..V2M<98JC\M,J15--].08G5@O)!D?:O=FG:ACSZ/J';&5$
M^)#MR&DQS,3( 5+$H@(#LNX&]U\'ZBO=;TGN?5-8&3@=P"!DD1I,/*9?PC*
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MOXOZ#VZ,B8,S"?F10+/D$<?OYK[7YZ/)\U+-\N<X.<$ *%XSM('C!&,D9 .
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MJ\&C?G_(1LP6AR&/.XVU7[?T/[^>O 8DGR2, \$ $?MM(!'WSY_?I8S*:W,
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M)(T<>.H'CZ1FY.KF3#QR,J"9,S%+J5WB,[Q0(^8$J#Y- WT@U]M,S(L]F<8
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MFH:.E@$-/24D,<,$42J J111;(XU48 5548&2,@=5/E94^3,SY$^0TC6+?\
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M9Z:LEIJ[W462$I&S-[K9_@Q[8O.<.S!?[IZ?M/\ 5TS&R,B( R1;9:/Y66O
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MOG,(N$2A)Z&=TD]FFJD(V>VZ*RI.2 S84KN(ZD?:VL1YF<FEY&U)VWM'OO\
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MG)+-NPP.!P-S#)SY\$+SC/(/!0+Y2D(R1,BC<P!&_P!Z'MYX]O?I679'WTQ
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MCD+B[G=8PZ<>'*G;8L[ .!8X]QR?IT#  $F9V_-?GCQ]_P#?T^V)W"LY!;G
M)SM!\@8QC=QG!YR2#GKF1(XXP"#RZ@1K^<LA_,:N_P!O/GI4T@WJ5E.W;7\^
M/8U_GSQTA??'4QT]V\U17P['-%;IYG$K97VL8?'@CACNP&.>/&.IKV9A-E:[
M$&]1VED_@(%Y212Q!NK%G:!Q[<BP1UT(3++ $/IA'42,*&Y6(JO/)YH\<^?-
M]5&M;=LM.6CNWJ+7-J1*:S:OEJ;E]53,\E$E9+42SUU+'*3- C"J9&DB1@$S
M@(,D=:MUJ?4M:P-*&1CNN1BH,:57CD5]R;8_60,/!4#DT"5^QZU#\'^U.V]
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M[ <6.!XOG_?CQQT&5" "%8<-\@,!AG:%4# (R?.3P"" .N NY"6%MX^X'^'
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M)Z(R$2.4SLAEA# TEL2Q HM[6&/U\<?3KW&2,(0^XM\Q(/Y;))X!(^U\'WZ
M;< !\5"X"C"_$YVD C*_;CG(_;&>D4P6=QD-O5DX0+6VB. ;()VBN:L'C[=*
M$9R"K(54< "C[_?@>?O]1]>O)D!W(G[X(XP)&4;<88G/&6 &!D_X](D:@%K:
M(C<ZDC<23\VT<_*/;QT&;D1KR?-GZGGR.;'Z#SY/7W<JJ5R>0-WZ6+-G!&3S
MC/)_IR>>DS>AO95)4!CLOA@#QM)Y^GL2.?KT>OY:8<GP:X\#R:XYOCZ?4]>9
M'!5?[F/*AE7)./(&"?WW!AP3YR,\3M'&JG8&8U3UQ5D\M=W?Z^?VZ]5+8 BQ
MM\"ZKGVX^G\CS76 EV.26.WD#<3X( )_TL^-P\8Y^XZ)(EE13M)7\P(/ ^HY
M.[P1[>..NPIC-J"%(H^??VX^WU_GUB)P0&XP1N&!P&X XYSD<EA@#&0?NC1Y
MIV9$5&]+;98L%56-$\CGD#GCP??HT.B*%4WN=2P/N*Y ^A/\OOUB8Y!; (X&
M5Y(&<@GGP?'QYY\ 9Z.95?U)<B-/D+1 Q _,2*5@#Q7!Y\\^.C8OE#&@69CM
MJB0.*4^X//(_:_/6%W8+M#E?'/C'ZLL2 0,G'\]H_J.NT50L<3J6V,* )"U1
M\U6XGB^+X]^O6$WBQ3,A('!I3S?CBON1?[67]Q<,RN3N4L<D$%2 25(!QR1C
M'WQDX/2'?+,XC6'8I,J7Q9V\7Q?\_L35W?5;"P7S*]U9.T57 ]@?H/)^AZ*2
ML5"H''Q _40!N3G)&-Q^6,G(P.0&/GPH%,"M'ZBB1@0;L$+P>3S7- FKY\]*
M8T(!4D[MMV23Q8X^OG]OM71267<,!F;)PVXMM!+?$ X'!4Y&#C^?7MJ&>$R-
M$9(UV!1;6*):Q=#S?U]^NX8W!D8504W9]N U7];NO?S^NM,SYV_$C)/)Y7/G
M:3MR0<DY+']B.CF8E$CDF69!9*@'Z #=0/T]K //0219%$0C%<ECX 'VKW'G
MS_GT6G91P6SP!@MDE1M*G[9^X&>.0<9/1(4*W >.-N"5 ]Q0 Y#<D\FK _H6
M)64,JW(JUL+>UFB.?(H_3^G1%I5+@#XYPN1X Q@;2!@-Y!P!_+/2I(XHP=@V
M%QQ9W!]O#59)!L7X\CS[]*1\]"N#^93X_P"G/U^P\=$Y6VY)SA3RP(7(^QQS
MX).3\1G&.F^2A)3(_K(=T!%D%+LEC[M].3?GGV]=%X%[02./:N/[W/%<@?Y^
M6#^M!=02=EN[=/I]*NIKJS1EZCHX:99'G,\5%(ZK$$^6Y@IPR'>6\9XQ<GPP
MS\:#NK0<K*5$C.7$CE]JK>[W!(%?-\UGS?'U/EC1\+-(D8-%&Q1UOB0*2@'%
M^:H_^+P#U3ETQI3N%-15%Z>]R4MM22:KEM,M=4),H20"21J63:BNP4Y )D9E
M.]1]]9ZQKZ9.;D:?AX+S2+,8CD>F?25JL[&\,H!MB0H]A[=6'\/^PN[<318>
MZLO7#C:8\0R#@?BV,K1LP.Z5">-U&AR?8^>D2U%4&Y7VXU2"8$R+&^_Y;FBW
MIO'!QO !*X&#QTXYI*IB0_BPCQ0+ZE-5L]'P" *K^O(^M):_!_;.M:GGPQ9,
M4<N9,JAE+%PC;=]GGYJOR?/GJUEH[TKZ7]3=^CM^O-*W.35VE[U7K;ZVAJ9X
MC/2S7"1Y*>K:"7V!3*0'D$I.".-N2I]Q]0?0]1DUG2IA%^)PT@D23F,[44!U
M1A?J!?E%<$5[B^K3^)$>F8&E8N#JLV/J&.3'E)Z;;)8<@J$M6!W!7 I_[K"B
M1U.5V%](7;CM9'8+I<[5;Z^^62G]JV5$\:NEKC;XA*7<I&X @/*Q)QG##CJ'
MZIW)EY3Y BE(;(8G(8-R] \D#[@T+XH#J@M8U?+U6&'#QE:/2H%"PQ1V0"O@
M[AS9YYHFC['I\M/74KYCBFB)C4 !'1L87[ 'C QSX_K]H9+&X9I 7^=0&M"V
M^O<_2_O^WGICD1UACC(](\@+Z?R@<'\VWW(^G)Z3[N9W3L7;C3UROEXN,%'#
M0TDE034/&F[VXV8*$8Y9G8;510SLQ( Z(3%ED%0Q&6;< J!?.\C@DBN/OX\\
M<7*.V.V,K7<R*.*-I#ZD88;2@;<5W&Z -7?/ZGCJO7JWO)WJ]7W<S4<6F+C7
M6[3EK6II]/6V*6II:#VXV*/=KB(3#-4-*^!#3;U7VU .U7;%HXFC:?V]I\,L
M\:R9605;)/#N@Y(ABL$+5UO(/)H<CK5F#IW;G9,6/B94>V:./>\U*TDF0ZG;
M''PP*QGDV";^XKIH?J"]'G>RYV^BJKU>+=5BBG>65ZZ1**-(7 4JC.\A9%.Z
M1MY;+')8^>I3V]W9HN%EMMQIH;'RA/XF\[6'(XN@0 1X(H<^'74<C&[PTA=+
MQ,ED<212$M$7,@4$^G0*[1N/DJ/ XXX9SJC3%9VVM%JTG8KS272MKYJR2]-0
MUD;P2SS)%%[7LAMXBIXU$2NZK[C[V!VC:)?#JBZWG/D9&+(F/&L:P&5#\D2E
MB9-U'YF8^!X!')Z<-,[7G[4T)FTX1MGR9*RRHY$<K-M8D*-W\3:-H"@'FNI!
M?2SV9O&I>W5[H[+<D@[C6VVUU_M=$^98[G3PQ*)K;&'=&2IC4F2/:<@\  #B
MO.]=;B@S$R5@>73HY$AR5BH2!2U&870VKY87R+%_4K!S9-'S8!KRLV-J,BLN
M1(HK%D>MJE?!5BQY-FN#QQT@FM-&ZLU]JW1NFJ\U%-=*RYB*\2U+L)8Y)*I8
M(*8H#OEG=0WMHPQ&JLTAX7+UH65BX\>7E0JCXRP*\&T\&T+,Q^@%B_J>!['J
M9]XZ]AZ+VOZ<4EYF1/L102+B5+#*1X4CPM_]+>OH_P"S5M[/]J=/VV*/-?-;
M*(5E0\>)&81 [<ACE5&0 #@9^YSUGGN_5'SLN=?K,9.#\I%G]";KD5[#].L+
M=[Z]-K&HM;%HH0$1;)"%>&YNMVXGGS5?;IWJ-@-\AL).  <JHR.>#_4$??C'
MW$(DVD[PO/% #Y:]^.1=W?!_E74,21C8\BO'GQ=5=_7_ *]$K@ADHJE =P>)
MU))P/TX_;S^V.<_?'35J$;38TT<@L21NJ@#P6%#CVHT?V_;I?@NPG@=:&R1&
MNZ( 96]A]0.?Y^+ZH1>MK3%T[:^MONUIJK@J)+1J_5%=<Z&.$N8ZBEU!,TL;
MJIX,D-<[;P.,Q^.1G7?P>S<;6OAMCPJ43*TB+TMSD$AL=5!4@\TR?F'@7X]^
MMB:9W7JFE]U=EY,HGR-'[IT7&TS+B7<T4;*GX9W :U$B1>FYJK5AXXIG?=_M
MUJ;05QM-MOCM+1UCQ5M']-.\D4;R#/MS!/C#.@(]Q3Y3!!(ZL/MWN7#UAUA_
MX>5AN84)!4RNBLI(X%BB0O-%3[&^H_\ &/X?:OVW^%R\?)RM1[:U3,$T;!)0
M,20R!E21;(C8![0@_,MD5R.E#M5TU#I)[7]15HL$-!3N*&5%>*:BJX5DIO=1
MUXR'60-)ELJ,94CI;*F)J,V0HBN1I2"R$JRR(U$@_J"*''Z]6!B86HZ-V]IL
MPU**+'@QMZH Q=XWW"G8_,ML:()(-57-]7A_P\*2R3>G#1>J+;!4Q2WV@@FJ
M'J8##DQ4U.C"- %_A,X=HV"@,O//'6.OB2)\?7'P6D7;&TC;5-E2&8#<]V?E
M-!3XKV-]9.[PU;(U759#*WR(3LYX8,3;;;H%@17Z<=/Q6K0LW\L^-V?\3YP
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MD>,;L#.<$E#-&D8)0!ZE+*I!^>PM\GSS9\7[^>CQ(\2J 6=BP7YB> 31YY(
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M*917 ]Q0%?K76$3!LK(V V<>,KELA2>#R3SSR,<''241MO))&VB%4,U&_>J
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M1Y')OQYZ>EZL.X,>L8M,Z<J+U2T\NH)FFHK7/4- ]:L*)/)'E"C.H)C\\;B
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MNAU7B_$@],5#?-8_\85)IJGK-3T<;U=HO,[S!:1D*L/<CC:-)@A#-&)O<V.
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MQ4CJ>]C210Y1,CE'DD18D!)-;2#O446W&N:OZ^*ZU%\$];B,(TZ><AIDHJS
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MF!US)'8%LA!'@CG]>#Y]_P!?K9Z->X$(P790,_$AL CE.."<C.<'!Q_+I--
M'$9$4GR\[KI; LW7WL>W7C;E;:MM%2A!7S$L+;]C9(/-<=&XR_Q<C/C:I+
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MIYNRUH. &J[-?0==*[/:^JD86R >30'@$BQ^_P!Z/7GW%\CYXVJ-N0I(\@J
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MU7Z< 7T2#/(XE<OE<ABK9VJ?&%'Q/'DC)R//74LS-$@]-58*4X %"^.?\O\
M7@Y;2Z)_3BO]WUY>3 *X(<,%RWZ=O!R,<KEL@_T\'HIF9 5(/RH"/[Q()Y%C
MC_8^E]=+'O# $#BS]SX\>Y_RZUSN^\(P4,<\Y^V>2<Y&3QGP<?+]^@L>,\:2
M26CBQ8N[KWYXOGR#X\'KRI%( 0-5BVK@7[#[\&O[O/OUXD/M@E@&SC&%QS\A
MEC@!L8 4'QG^?210RN^W<5/'UK[C]O\ ?T-D8LE'@E@10^GL/V(_GT1D;Y'9
M@8!."N"#@?OG.3C/W_;CKT0@$T69C94'_F(XJ_\ #_KT"-A#;K(K[']O!X\_
M8^3?163"MO8[6;:#\<DDYP1@?? XR!G_ %="1;:.1OS* KI].>37CFO\>:Z
MJ[<T6-7='F@/H/->W1-V;G#X);"MR/// S@+R,D<_P \;NC7KYE1;)H CVNO
M?R/]/%#CHSTE()!(=/E"GA:\A_>_J?\ #Z%C(&#$DD+G&<9!' 7/@8Y'\^%!
M!8]*$A9Y8B31079 /]/?ZUXHU?2A/E2S^:CR?<UY'\ZXZU55.JMODD6-&R-T
MA^QQA6 PN>"%P,GC<QSTJ]/<*1&DMO(^;\QJR/*_Y>:XZ)!G$I(4D,"%.QI/
M'L-H-'Z>]U].D6[\:=MFK>U.O[-<J"&[4]=IB\Q)2R <R-;YP#&QY252048$
M$'!...I5V-F3Z9W-IK1%XQ'EQL\B@BN;()^@ X]N>B\U \GIO&X9FA6-A]"U
ML%'! %DD&JYOJHWI7TL=P=9UVI:F74%+;:"UW/\ *[710552TL-/ U06^J!A
M!68[HR0^7)W,[$GC2O>_Q1S=%U&#$T+26R,;T/4?(G N5W(8;239V@_,3S9K
MQ75E:1\,LK.B?-[AU2;;/L_LR#!DECBQ\) P564.H$C H7\G<"2Q)OJ=+2W>
M+6M^EOULLM:LT575U]/<;C2,\7NTU+4SAXT*';'%\F,@4G<05!P1U8.=I\,"
MQM-&T9"(Z1-7EP""W!W$5YKZ^W1^!I>DE\67UH\RFC2Q3,'0 /M%"K\57\[/
M237_ %=#IZLO-ZU)75!M]'',E0L*F:67W0(Z:*-,D9DE< +C"AL>0<&X^$<Y
M(<6!4::8JJ!B  0?G)OVVUY/Z<GJ:DOIR/EQ8[+BX2S9$DM&S&@W40#1  ]@
M38KZ]9-&^A34?<"&V=TM,.D]HOJ"XI0UL+)4Q-(0Y64*&PP)+-\B5!QSD#IT
MR.Y1H\4VE9"J&@_A"6)@58 5XX!OQP//T]Z_S?B+IFL9&/D.DD1B-ON46]&D
M*\V:H "JJO?RW#UB]C^[W:W3\]>^F9I=-(^R6OHJ9YY*20AMOO,$=H:7 ^+C
M:N3\R,#I#H_=^EIEQ13%H<EV(0R$1^I'>UF3_F8FN2QX\'ZS#)UB+7.W=2@[
M>F>;5&QN<,BV4%-S>E'XW \<*&(LBR3TD7HCM%/J'N%8SJR%4LXN=*L\M0X2
M9YP6>$1&3],8<!9"" %;!\'%D=WY2MH22XC;LF3&=U"<@@BB6%W9!X!'GV\=
M4?VSD=R8K:A^-AF7'26-)6R5E4(0QLH?(Y%6.>*^HZ5'U@WG45R]3M@T[8J.
MOG2RPT5#9(J*.6=I'J)MY>F2!6:29@L:[54$! Q'(/46^&:8QTK5<C)D(:4R
M_B5G&R.,1M2JN^@P%FS5 $WSQU+?B?DZ@F@=M0XD,OIR^OEIDHI6/UV:)020
M%Y1$X)Y(>R>>K ';#1-UM7=#L_<1ISW;PELIQ=HS!MJ_9DHXS[]2J@;9!(I+
MR%?B,9 &<U)E31%]:BCF/HEF,?/\-3O(I?K]@#R?'/2#4]3FR^QX$S\LAR\:
MK\UECLHK9!X'D7=_J>I+>XD]/1Z><3T:4\\M.V]?U.I(.%#@8)Q@GG:#_JZK
MOT5>:ED#JM$%:IA1!!YLG]0?VYZ@W:,<CYF[U6VHZ&RQ.XAE%\^+''@"O;I
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MNR!G^0'W']1D8R,\$?;KH1-N 8>*%6/W\$W_ +\]=JAJV\77^ZY_W_/,KC@
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M8 1E2&H@6P(\GI!G[YUUDI;EHO1U-6PWFLV4/UE$2M;]:S^TT*1)_%DWU#%
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MP(MR<@NP')]Q7L ?I7 \]&W&$HV2HM;_ /#0_7W^O_0I.VY,X"'GDL3M&/B
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M*H_10/\  =#>X\.W_P!Q_P!>A^36<_\ W*MO_<:7_P KH;%_Y5_D/].AO?\
MYF_^X_Z]8IM/V"HC>&>R6B>&12LD4UMHI(W4C!5T>%E92"00000<'KT*%-J
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M?_G&_P!>OO\ 8S1__533?_P*U_\ I>A^'Q[OT(;^OI)?_P"'KWUYO_G2\?\
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CZ'0Z'0Z'0Z'0Z'0Z'0Z'0Z'0Z'0Z'0Z'0Z'0Z'0Z'0Z__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g626950g34x60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g34x60.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2+.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $P< 5H  QLE1QP"   "   < E  "')R,CDS-S0Y' (% "M-:6-R;W-O
M9G0@4&]W97)0;VEN=" M(#8R-CDU,"!'<F%P:&EC<RYP<'1X.$))300E
M   0D'# SK0\]09X"7NS4.*4TCA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  (#P
M  $  CA"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8             !#H   8+          $
M                 0             &"P  !#H
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P  !#H     4F=H=&QO;F<   8+
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   0Z     %)G:'1L;VYG   &"P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      84P
M  $   "@    <    >   -(    8-P 8  '_V/_M  Q!9&]B95]#30 "_^X
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M(AR_#B($N(ROCE6O%)YVWZL=0K98]]K<H/(:]E+!5::R1ZWIW/?L]79]'?\
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M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@    @
M" $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !
M  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0
M   !    O    .@ +<;    G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q.#HQ,#HP.2 Q,CHT,CHQ.0!R<C(Y,S<T.0
M Z !  ,    !__\  * "  0    !   &"Z #  0    !   $.@         &
M 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $
M @   @$ !     $   %& @( !     $              $@    !    2
M  $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P    $
M     1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
MZ    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$X.C$P.C Y(#$R.C0R.C$Y ')R,CDS-S0Y       #H $  P    '_
M_P  H ( !     $   8+H , !     $   0Z          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
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M 0$! 0$! 0'_P  1" %: >\# 1$  A$! Q$!_\0 'P !  $$ P$! 0
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M%%9S_/!ZD]&FMI%'8);4M/:HTIB6577V",.!EK#6(8)"0C3*V=73UY3?<\$
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M=<Y^?RTT]3?MZD\_UIUQD?4?MTUQZFKX^K?X?5/X_;^SS_?TR/J/VZ:>IO\
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M33IIITTTZ::=--.FFG333IIITTTZ::=--?+_ *,<O_5=]OZEZZN<(Y^BL?V
MZ#^OG^[5IM+E1J(CGI]/^D<G]R?X_P"'6$KN+KC$K#Q\G;^ .-2!B7/IX^G
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MJU&%B&+C%/E)N<B-+[S9$@E:1?O_ ,'?^V[[_OZ[>^CYMX]?4G^7[=9;Q/\
MF^O_ "T_EKAQ"_?PJ?\ \2_\/'3WP?XOV$_P^>N G_5YQZHOR]-4P;05)L[Q
M@K.N-(B_\9 )8#E2QJBJW^DBAFD>SPK7(OJ:GCTN3[M5$[&R1@\F^[&?/X'S
MZ^G@^,8]1@THYZTC-''8A=U\,BM$S+\OB53X],><$?AJI^^JKY]/U^R_F7]/
MT\?PZZ^^^N2?P+G/CZ^#JMQ&/0D?+X!Z?CZ_U]-/?^OCQX7Z_3U*J^?W?3PO
M]B?RZ"X2?4^GJ"<_(8]<_377C]/ \>JH!CY>?X'.?OSK'FIY>XTQ@%C9ZK=Y
M>F#JJRTN3W$W(CYAZVDH;34697PD$DQ<K1,]1W-T^.&"2:2OJSR88Y6"S>BH
MLSD9!;C@L6\XXJ"Q)(.,!0S?]*DC.-1=W?=FVZ.66[N=.ND,4UB3G+$76*"M
M-<F?MJS2'A5KSS\50L8X9&4$(V/%K.1V18/1:K /!VI=,2?5-AJ#HCH8;>M.
M=5VPI#PU)53J$QLS;"J9'(?\8&^K=!&8_P ,Z/<95?R2RYP,Y&?0YP3Z9Y%?
M+, 4P"P(IWMS"[9:O;5VMQ>%I8>-=U91/#(8IXR4#9DKR!@\.#)S4P\0YP,2
M8/N&/,F'"V 0)#2S@P8+O-NG?[1-B1$,*RPH)_58#1/GGCCB<*\V;RYD$D+I
M42<KJMR0J6+B1,A2Z$C!9@J\T!) .0O@MC^\=8_M75;RR)!N$,?*21(A+6!\
M/*XC19*S?I$4LP52H=O1>)/%WE6DZIY^B_5?KX>J?W_K]?K]_OUS[X/\1S]Y
M^?ZCX^FLYX_/SZ?)%(^O]?SUYB[04&"0@TD<,:%CI9IRR6#P1,8GE\DL\SHX
MXV-;]7/>]$:GU5?'06RW]X^/IDCY#R3Z?(?L^[71FCA4O)(L:*"S-)P15 'E
MB20  /4GT'GTU3:G6YZ^E,@I+ZFN9ZYT++""KMP["8%Y(\)8S3(Q")GC+.-/
M 1 DR,]R&:.6/RUZ*O8VR!GD?IG)\> <'!/$X(.#\B#\]=()Z]D.U:Q%86-Q
M'(T)BE".424(W#/%NW)')Q.#Q=&QAE)K2$*Q?R^6KY\^4<[SY^WGZ?JOV\^.
MN%N\2&5B"/0JY'GYD8&?GY\ZKE1CR/!\>47[S]?QT0[W_P WK][QX3U))ZO"
MN:DB(J_5/*L>QZ)]U8YC_'AS57M)==R"[,WTYEC@8'I\AX\^@\8/SUU54]$.
M/3/$+] 1DY/R(^_R/KK65WK]M/*'*^ZSV_R((.YH*O,/SQ6$L[RWK9ZDPW04
MKK#3YV26U,KX#IJQJ$G"TV?K3RQLLWQ:65R74 ,H23J[([!)."%1%(S*%/-#
MSCQS!D/$Y C!(C7]('/$Z8]I?1&_]0;C3W/:V6W!7JFJVW/8GK]MYK$)EN0R
MK.T:2"+#.D-=)#'5&)I)C!&,*]O%=W#XOFW 9./-<MYVD=;VL^Z9J[\NZPA=
M,MAK_F:PVUD_2D/T)UY5:"USC3):JFLJ@J^LJ]PUI?XVS=V$X3BJ=Y%5LOW)
M5DA9#WU+ EY6+F0-P&0&!=E4,4D&,]&UNM]NZCVVC+4WB"IWIVOM<LR6:$D(
MEN]WA/)[S(;+V(K$U<S&&O+7>S)&$FLT9#N@][][?_O*B_S\=<FVGR(_7KT?
MQ^A;_P  /\<ZX6=$_P";X_K>Y?[O'E>GO2_+'[],'YEL?]"_Z#.M?6__ !'.
M'\O=6V=R53H.2[6H-C"F3)QO- )D]C,FR,@LPH+ $$AD%IIZ@D/1ST!M/KL:
M31: 6J&MJVVD[FPN>(#2GX<]A2X'+MG!D([2MP9\AV4JR<6 !Y#4^[^U[IW;
M[$]6JDVYSUY!&144.DA*59"$DB66.-@);<#I;:M)7NTGKV4A6:*4VGF._F]E
MW>+H=UQPR@H]:<'0OEH23=]I1;B.LW!\ZU.5X[CVEY>_.IP,=" +"%#'G@Y-
M.?HK"&,0%LO=I98^ =1&'P/#!R&XR'!2(,1R*QA?B8@L>?JI6.V[VKM/NM"E
M=VSL0W72 FL6W"VLZQ;@[=FGMGOUFSWS%2"@1JM6,VGLR*$C#;,6S_9?'G^*
M.5/T_5%\_P OTZH^^ 8P0#]<G]WC6Z2I/^(?@BZ^U(5WCRCE\?;R]5_X=<F[
MR^TW+\68_P =<!,9QR&?\BZX]_\ ZG_WO^SKK[VOU7/Z_P"OW:<3]7_\(UQ[
MR?[*_P#MK_AT][3ZKKG!^K?_ *M?Y:@[W>]T6FX%L,!29BISLQ6N(+G,MM7:
M- IAZ^MCDF)JX9X5)*$T5BV%74J%ULU=8!#:">.=I% X<CN+(8JJ=L%N7F21
M47"A1Q!XLW,EOT9X\2!(<$H0=8^T/K>[TB^UQ4ZD$K7I6,LUJ18H$AB#,\09
M2[1V9./Z /"T<J"PX8-6*R61Q-W[WQLN/I.4^.I*X_2'T>?=HN/3GZJDCO[2
M)X$3)<Y&A.L!!M-#$.+5%N ("@AT%4VU.$B M;)EVENW75?MH"0N8RLT8+'"
M@+@RCDQ4*1$ 695+  MJ$Z>]J0OOM]7>MJ,=BX]:J;.VO[W MJ5>W\59#)=C
MBELJJPRLK1JEB/O2(L<THV-.(>]5<_RYWE?S*]WZ*O\ '[?N\>$_@GVZM'O<
MW)=LMG'(MD^/3&#\ONP/IK= 7  7(&!X"*1Y'U(R==WS GT^GUKX\>/O]?'_
M *7CU?W]5_SO-QX";"^F?'+'XXSG[\Y/UUU[*9SQ.?\ I\?LSC]VNCW_ *^5
M;Y5?JJ^I?JO]7A>K<W$)R6R?J?)_CKOQ/I\0'W(O_K^_3WD_V5_]M?\ #KCW
MM/J/Z_7I@_5O_P!6G\M/?_ZJ_P#MJO\ O3KCWM/D5_A_/3B?JW_@4?P&O?6S
M.<4UGU1JL>OCU>4\HB?S_M3Z>?OU*[18[EO@K?#VW8@$X../DCT\?(ZHSJ.W
MDYSR \J!^/IX^GIC5-T/(63S)S:JQ/+*NG"L.^09ZDO=;HF5\LDD,5C+GLK6
M7-U#7230S0QV$P+ WS120MG61CFI(7M]VS;IA5GGDDN&,3>XT*ES=+XA9F59
MVH[;7MVT@9E95G>%82RL ^5;%]M_3^Z[G ;=:"&*D)3![_N-ZAM&W-855=JR
M;ANMFE2>RJ.CM72=IE1U<QA6!/NS>QS>M86M#:1ESUTD45K6SP%UMW3S3L66
M""ZH;2 *YIYYXD66"&S $EFB3W8FOC_-U6V_=MOW1932L"5X&5+-=XY:URJ[
MCDB6Z5F.&W4=U^)$LP1,R_$H(\ZH;EL^Y;28??ZK11V5=ZMF.2&S2N)&W"1Z
M5^K)-2N)&YX2/5GE5'^!B&\:N;J1U&:=--.FFG333IIITTTZ::=--.FFG333
MIIITTTZ::=--=<O_ (J3S]O;?_\ RKU3F.(93](W/_E.N1ZC\1K':3)X3Z_I
M^J+Y_M\=:=6\0H^)?0>N/I_U:G00/'S'W'^7[_GKGWD_A_)>N??S_B3]W_VM
M<Y'W_L/\M/>3^"?V+_PZZF\?\7[!D?M!QK@D?1OU9'^HUY3;0*M&E-L#! 0X
M4:LQ1D\0HT*.<C&K+/.^.*-'/<UC5<]/+G(U/JJ)UW2S+*P2(/(Y\!%5BQ_
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MPRW%D*/*HT5A9B32-8<=$#%71>X\]+NB2'X!''@*%6)>,?EBS%QX+,,JH./
MYXXY.;OH3H+<>E+MF_=W:.T;5;L-0IP-7I1NLQ<3A>8$LXB54,TJ,[*S(@C5
M<O,K1#GVE!=5M4?\KL["IL J^S:TISJ\TH2: 4UJ"&UQ2N$FD9.U!CPIU=&B
M1%0/\2-I)>PZECXSGX1Y\9^(#()QZ@9'D>H/D;)O12V:=F""4P32P2QQ38D_
M12/&RI)^C>)\HS!O@D1O&0X]1I%3)=V':V:KJQF_.M+)GRL*^SQL_(F#U]^.
M"45&3H<Y>S^_FXB& O-FN'355;54,#F61@0]=+3AWZV:KQMGNPR1ICG$6E@D
M**7 9)1R4OQ]<((U'E@ 4UY=.V>T?H6TS5SN5SWDF&.>O)^<:%JPJ.5>U3L-
MRJ1_!W#862&&*LI[K(D301[G"=/=U/'Z:6QH9IM")FX+2PSH:^N5MHT&.8RN
MC?&LZO; 2LL3I(&DR.CC<\>&=ZQQOL&MX9@2/7YG !&,CR3X!!.1GQ]G.1KT
MPUNU!M'ODU1WMQU%GDJ1@LW>$09X5*AL\7RN5#$@?"#XUC7'\VVF@T%71'Y5
MHB6$\XLI D]M*X!T,$TK9BXBZ06&.!9!W"2>LN.6,E\3?:5$D5O,ER-0I]Y@
MD'+CA)&)P0?DRC.",8!SY&H7:^H;=RY%6FVB> R,X>4+8(C(5R#)W*T2!259
M22X*L5\$9Q('WD_3QX_J7_O_ '=4_?S_ (EQZ9./X\O767<A^OZ8/\M=4RI-
M#+%ZY(_=C?'[D+ECF9ZVJWUQ2>%6.1OGU,>B>6/1')]NN/?_ ""64X\X^'U_
M:?X'760!T*Y=>0(Y)E67((R#CP1G(^_6I*V_#ZY&7D_2V6?Y2=7\>:O73:PR
M"P((T&NCB+V&/^? 'Z_1PW-M:7VERLG(&ACMIJ]XE+J)<_1LD(I8)25DH]XC
M1<+,P!<N045I#R=7=>;9!+DR-GM.%?B.1!+KYXM^QC<9M\MV(=W:/;+UTW)4
MDEDLW C7J GCEOVQ/8FLVJ1W.R)2O;@MFK7!>!"3ECBO\/+#Y*YS&NY!U^@Y
M"UF>^#+82XVZIA!KE,?C*JQLZ*0&Z@.H#$V><T&NICZ:2M, JMUHL,8ZRSDS
M(4H/NG,'/)V^1DD;"DKQ8J%**"6^-650R^5;EZZR38/8[M&UV*=W<+DVXW:W
M!^YSL0*)A2H1225V6?NU6%^I8NPO"8G2+<;=!C)5?AK*W=9W4E=N;L..)F*N
MU=L"[)LU[I]!^RN4J!:<9"BQ);9X92$7YL2^]5U<#9)) @[@\E!X0(FF\U9/
M>&P)%3'(LTK\(QQP?+8P6/($(ISQ!)XC!,W[0>O'Z)7;!'MRVOSC),IL69Q5
MIPK73FZ-,4<^\RJ2T$:J<I'/(W$1JLF+^V?NXY$Y?Y47%W-+36U 9F['1RZ'
M-4&DK:?-)',*^G"2Y/0\.]99C$OABGD?6?$/@:=') A(=:55LO%"BE+"6#CD
MS1!NVH."OQY*MRSXQQ]!C.=0O0OM!W?J3>)-NN;:ON\E=KBW:\5F"M6C'E(N
M4T<@M=]714E:2!3VV? [T46MAI!B#CSSJQ7^S#++Z$5&J[VV.?Z4555$\^GQ
M]?MY\]6*W2Q5<KEF"CY>2?7(/H/GZ:W$\@1'< MP1G('S"C./Q^FM<6 _$.'
MTFAL1--Q-H:+.LT5O3CG5=C7WVBH(:T\X)S-UDQ9/F-1=!RB-&NZJI?=)63O
M]U"28(C_ )=(^[VGC$T2F:-O3M-SE09\B2/ ;NJ,<D0, >0SD8UI+:O;/7M;
ME/4W'9+=&NEN:LDJ2PV)ZZPRO&PW*HC]ZO/&R<9XXO>!"?B[CIW>S-=1^+>=
M<907DP>:Y#Q=Z&VYH"R(![6MG&L YPI9Q5<CO;DG")-J;&'\DJC$652=&D<Y
MHSXX7S&64L""02K8() \'!]?'@X^60?!(UM,P;'U1M]:T\53==OM1B>K(R)8
MB9)49&9?!XYC=X9%.&XM+#(,,Z&/]1V(]M]#I:/0UF1*8/GR1C LR;9D7&3F
M+%KTJFD6%!<_'U]D]X#6JKS8)B([5/VAA(CT"NLW<_G)0 !@ 8P.Y\'+.>1B
MSVL\B2/@RIXD$,H.L1K^R?HZK>K7X=NX^Z.LD55Y'FJ%UA[ ,T$XE28]L YD
M#,)\VE86B93,WWOXI_)>NGOY_P 2G[SC/_U:V4, 8 ./P/\ +3WD_A_)>GOY
M_P 2?N_^UKG(^_\ 8?Y:>\G\/Y+T]_/^)/W?_:TR/O\ V'^6GO)_#^2]/?S_
M (D_=_\ :TR/O_8?Y:>\G\/Y+T]_/^)/W?\ VM,C[_V'^6JK33(IS6_JL4JI
M]_T1O]:_K^Y?[.I_IFT9=TX@J3[M,1Y^^,>F<?KS]=6EPYB\ ^&!)]/KX\_C
MJ,^C+NZWM*VG)>;U!F4W5MQ[J>5[_0U8U7+;%:M,O9W+Z*6>W".^''HC( <N
M+'[*V%714 ],%,"^%D\$7N$MRO[+]WZAV_<9=LWJUL6Y=37;U=*[6I-S_-UF
MV:+/9BEX)3E2+;D 03UZ=):L)@90Z;0VV*E9]K6R]-;EMD6Z[%4ZAVOI.AM]
MJ6TM2+:?SI6I"\J5)H.X]Z%Y]TE;F*]J]?DNSI,KM')FW?1#@:SBS45KX8+T
MO7MQTSXFM6;09BYHK\^RHYGL15F'K9JN#7CJOEPLM!.L3XH"SVSYCO:I!N?3
M>XUBBW)=U7:I&7'*[MUNG=FL5'8?;CKO73=(\Y,;4G*%4EF#X3L#26-IZIVR
MRKO1BV@[RBN3PV_<Z=ZA7K7D5OL264M/M$F,"5-P3F'>&OPBUR#N!:+?[8O:
M%S6&SJ^4<A4X'$&\NZ[C R7CFRK\;!5WO&^<ST<P7(9A.HLM"_2*0,]Q#@K#
M/VEC'7UHU8NM-_WF.EO>\S;O(T^[UNH]LJ['LTW5.Z].2R=/V*^TI7N=/4*"
MO#OTTNY6+QW#N1L6:*:C9L+#6BKZVET_L<M[I_9(MFB2OLMKI;>+F_[Y!TCM
M'5$*=1UK&\R6J/4FY;@RS].PQ[76VY=M$<BB/O5MPJUS8LRVM8A+W&RK;7E6
M7-ZDTZSFC[J:ZY#RG(^KU^NSD-+RZ<^ETFEP9ONUG'D6;Q]99U6&-SK7&F3'
MU4<;%CF2*'%I=WW:M9ZFDV[<I9K+CVDU[D&U]0;GNVZT5J]42FIN&X;).7K[
M"-OVFO/6V:7;QWI9)ZP4%7"IF$6Q[-9J=*IN6UPP54;V56:4V[=-[3L^S[E)
M=Z0@6[MFV;]#PM=1-N6\6:MO?8-Q(@ACKVV8\D+29%;?XANN?63<B'L[99M^
M5$/JG<FZ!N6DTT?$M<:W/Q<D?M$A3\\ML^QM$#9I'5J[@=X3&K9Q/$;.B]LX
MW5J[[],/9P^^2B/<SU%?&VG<%Z7@F]Q3J'W\2FC[V9[(B&XM7_/$;0 >\+VE
MQT[?O9VA;*=.P-[35Z?B:3:ATQMYW5=M;JVS =Q;IH;=VEW#W,5JIF.VBR-C
MD$Y/NSB;7CR&RY>,T_:=-LJOE(6NAL,YFF$S>T.!N5T'"^\N+?3;*-UN*<98
M 219USZR[JF$516<UMQ[<QIM?!UUVG=NJ)=P]F4F[P=1QP)8I;<KL"L.\"_T
MGO5NQN6[ 64EFFA*[>#!<K]VM+1W2V5,LT*ZJ[QLO2,.V>UA-EM=+2V'K[CN
M31)RDGV(;=UIL52IMFRN*<M>&O85MP"V:5HQ6XMRVBER2&"P^MD_7H+7FS3I
MIITTTZ::=--.FFG333IIITTTZ::ZI_\ Q,W_ .ZD_P#Y%ZH6CBO.?3$4G_TG
M79?M+_U#^.L0H4J-:BHU?")^GG[IY_<OWZ\Y+9;BOQ?(?,#]VLB,39]/X_Z#
M7/Q?\&_R_P"SKM[RW^+_ ,P_EIVG^G\?Y:Y^,7^'\O\ LZ>\M_B_\P_EIVG^
MG\?Y:C#W:5/[2<9YR$G#6/(U/4\S<(:749&IRO[;&6.4SG)V;M]!+^RB#E/O
M(*^M%G/("A%*G= .]\,$LC&MZE-IME;#@RI&S02JCNX4<N!(!)^$<L8^+ .<
M$X.-4IH6X E<CEY &?EXSZ8\G/ZM0A.M>6^-KN*KX6K+KA[.]R_+=[QMQ7PQ
M9#9&GN.-*K18'!DW/<F#QV8TXK(U>-L./.4]$["#1-KY2-@!<:+-@7%X1"-,
M"2O-&[6G2Q)3KI-/8CSP+H[<8.XC .TBLBLYPR\,(Y"KJAQ8$!05[A(">"3G
MYC(_#'\/.K]N*WNZB)UMCG3N0:*'+6B7N)RF>J,$!GM=9V_>;R>VZ;H!6T+C
M;@<KM]GS-B;"MD"TD"PBTDZSZQ76# M[0S1#]&PF#AR7G+)\'-%&0Q/$^ !C
M(QG*>#R(I0#D'P?)P,^, XQ_FS\CYR,C!Q;O9+SWR1RUSCIHN0-YKH0),CO[
M6BQ%P;36N?W,5?RRE,'R-EH*3& P8"HSF-FRM"W"&;6]LR++0F61PY!M89?W
M'3=XX:].!H8>*=R$//RR0&B!*X.">1+9." 5#!P'$:<PAG?'(,Q4GB!Z-@G!
M/W_(#&<@_+QQH]!W=+C8EKCN? -<W95T/.+IN/0[K/5 RQ<CHQO;Z-FX ==>
MYYUQ#QT,>7F)KH"'))7GERKI#-\K*D,NVF5 YJB-HLP-W3W#@1',P. C$&3"
M^,OR&>'#0I)@XY9!^+P<#Z9.,?MQY^>-5/BWB'EVWYNJM%R[FKFU@N3;@S;Z
MZ>DK<L):V5MVF=MF2.M_DE1H- /0//WF3TU:E77V]L)6VU0:$,>6&..41UM[
MI4&WO'7F0$*HBB#LQ3^U2LH$A1.38 ;EA0<DX'@"WEHK;5Z]B,R0SJ8Y005R
MA7/RQCU!!^[.I_4?%62S]P#> I<2EUKIGA,.N#3A(99Q_A73(/,YT;YF1.E2
M.5_K>QTTCD7U>/&-/N-F1.#S,PR#\3Y\C/$_J!/[3C&K2ITMMM&S':@CF[L7
M/@))I944N@0GBY8<@O+!.2"3@^2-7U>UE;I:>QH+@5AE9:"3!&#O1/+X9F.8
MKF.>QZ1SQJ[W8)D;[D$S&2QJV1C53B&X4;R01Z8)!^7CU^GR\>#YU*VJ$=VO
M-5L1B2&>-HY$/C*L"#@D8!'JI^1P1Y U&*/M+P]-HTTF3T>EH992Y"7 2FOM
MQ(DF-A(?"!\T4EP(XXRFC""C^U'&V0%'.5@3V$S3;T3#VUED QCCS#J,GS@N
M&( &0H!\>,><DZ__ .S':*U_\XT9;51^X79!(TJ ,X;C&)681HB]Q41 JA60
M'(CPTM*JO"$H8*22)A(,->RO?'(LCFR0-A2%[6J][Y6-]/E(T65SXF^$;(JL
M1R75&^(XCE R@?7Y#R?.#Z_(#T &LX%1%A2N!RC6,1X\X*\2O'R2<8] 22/
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MQ!E\$#+?$%S]Y'P@><G.L2V_JK8MVGDK4-PAELQ>6K,W:G^9_P"4_%B"H+>
M?&&(X^=4H?E'9R[&OIR,(4'2F&""R$$C&*2)'*$Y3CWGM:ZK]H4ISQ/9D= Z
M>%KGQ2/?*R*2JNXPPQG-J-6!_P"66 8KC!8-G&?)XJ .0'KYQJW3<=XGW*&
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M"K&+0#H503",80[WH;V!S7TLK56.U]2, <0]4;T_XGZ<][K41OFUM;N+5:K
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M2.-KGJC45RHGA$5?'60606KSJ/5HI ,>?/ X_;Z:Q=2 RD^@8$_@#K4?QO\
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MEZ;3YJNH1\@T/<9Z3!V-M6\AVFLSEO;5JUE;A):4QUXT4RQLRG2@"Y^ON3;
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MO[/+8JP0V*Y:/>*[&O&I#/+$Z9((4GBS(RNJY\J?\7@X9ON'^.<)R+BY*?E
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M!J]]#WU]NU'PQJ^>!=9::K$9':V/&YP65S5Y8[&PY K"4AFR-+D31*ZV/LR
MU;H YGQCUA60>S81V'[-.;9K:P[-?DNQ43&L4\T,=A&DE18EAD7(E:4,R*OJ
MGJ6$@:/CW5XZLJVWV[UJMM]2A//N5[M^Z4U0)/,DU87(95#\0(9*9%E92W;,
M!$G+CKKLN\WA*LY3X1XR$'T%M:<\Y7.;/(ZNJH!$R]13;L2U)X_74G&F W=8
M7NWT%F'1C"4UDX<P4>*_6G8=7R$<KM-TU+EINVBU)7CEB+#O.T3!)NVJ@JXA
M+H7RX/%OT8;X@*=7:I[5&WN]:CSV[;GIQ7KH$2"M+N#%*R%"PE?N$ 2=M&[6
M4,F%(.KJQ?=MQ'ON?N0.VS-F:.?D;C<.0F[G*SIX>1LB069UV@ILWJ)$4*XN
M\JNMSD6A 8V!19[)T DATE9<I7TIMHN04:VX2*G8M-QC575IAR9U1GB'Q*DA
MCD",1@E#G&5S5?;K4=*ON<M.2+;+DUJO4O,D?9L3TB!:C3XBX[9S@NBB3A)P
M+=M^,6+S\6WMOITNW#9WEZ]93Z"4(62JS-%Z-'B:[YQ\^Y9SJ&:P64O#5#J(
MZ-HQL5=LKJ0BG6ARMB/<!$.DTZ6O.4'=JHS1!RC2ME)6QPK.1$P$S\E/@F)?
MBY2#B<2$73'45CW;L;0[>^;'8ZEK SU TNRU<"2SP,O))&+QB*JX6Q)WHB$"
MMD2S*[L>"Q1^<YW[F.1W;C"'/RR'#4W;K"DBM*=+JF?4@OKHY]6R\9[M52R9
MAMM#9:04W-#2ONPR0HHK\U7^5)3 0=P+"J>2<9"KF-LL&(3B1EN97BA#MA2#
MJ&2)I!7,=:5VN\/<4$!Y7C)8-1!5! [O*TKUAQ])D9&P1K#U]^(IP+GN,^%>
M5R!>0ILQSA8VPU0*W,0!:#&5.6OX\ON]/R'3VEN ^FI,%?SCUFD;5S7EJ^:=
MLU'67(D<\\5ZO3]UK%RMF%9*2Y=NZ&29V0R11P,BL&:9!RB+<%/HS*2-7R[/
MNDD^ZU(MND-O8JEV]O5<M K4:NW2+#==BSA9C#(V.$!D9P&:(.JDZRIH^[KA
M_+=QF7[7;<_0,Y/UE&-= 2C9X\S' 36,&C+H\]>ZJ!' U.ET0&1T=A2UI#/;
MG%KQVD%"EW5 -:VB;3;DVZ3=$5#6BD,; NHF;';#.D1(=XT,T0=P/'<! (5R
MM%-OM2TY]RBIROMM6S7I6KRI&88+5M#)7A?)YY=0,N%**TD:,P>2-6K_ !!W
M<\:;KN@V7;90@Z^37X6DO"K+3$5 4.$L+7/NRZ:;+TULMJ^U+O,XFMJ&V3I:
M(:F>4VVKP;8RPH[04?-NA]ILP;C7OR&+M35+*]L,W?5'*=J1DXX".T4@7#%P
M "RJ&4ZCMZVN_%L5;>7IF/:KNX34:=PO"!8LTPWO"+"'[RHA#*LKH$=TE56)
M74_>MOZPG3IIJ,]UVUTEQM]+R"RVAK]1HMM#?/N0Z2&.WCQQ7%]-QAH\ 1:,
M-84;66HE<1H02'.B@I]"^M/CK"I:Q[SM=W/9[3M;SN&_+:2#<[^\)=:Y%2C%
MI=IDZ<J].W]C>QW1)-7LQ0/>A=BL=6\:\ZUI6KDR[,I>TJ]3V/;.GFIO9VO;
MMDDH+2FO.U-MXBZHN=4;=U!'4,!BAM59;$6W3Q@.]S;ULP-9B2RJP6L!VO6%
M?C9,ZS49J;01C96NK=M-1\D/T%:'D:Z_!J#ZX_\ RS?,Z*\"FORRP9<M9T-.
M-$7=U;Z><"[DC$C(/9M-!M+45W+;VOA-L@K[P]3J%[U>+:Z]Z&K/7F;JXV*=
MR%[TDL+;=8IU(UDMUFJ207&6*5G]J->QO*[B^U[DFWM)NMBSLB7NFAM]F;=[
M.WV+<%F#_@OW:_1F3;X89UW2M?N2M#1M"XEBBK2W+-P+IX;\S1UG(5>^R;R)
MFN4JJ6]QTUDY=75<2B\.WC;_ . U-/!9U=YG8);,6"M'HS*:_(^+::<' P!T
MB_1&XK=EW"OOM=K"[]M_4E5KVU/8/YSJ],1]*W%O=G<JJ6:URBCV(E@CIS5+
MLG<$TT<:Q&,3KW:WH1;=:Z=L"L>G=RZ6M)0WE*H&U6NKI>LJ)V_WC:KKU;5'
M<9%JRO9DOPW=OC[1@@FD:<=U)V_V= !M'5?()%=J-C@[O-+IZR@8#-2:;1[K
MD3D*VT],(EO*\0)M[R#.RLHHSFD@!U8J?/IS7(;#VI="6*,.[M7WV2#<MVV.
MWMQW&M1$+T]QO[WOV_VMQJ1BTS10^^[[(M>DLPD@BK1_VUY2)4IW>OZU^QLP
ML]/QV-KV??J6Y#:[-\S)>VS;=BZ=Z>J;9=E]S599S0Z?1K5]H#'8FM2GW!(1
MV7\F&[?+K$WP.EAVX)UDFVU&EM8S*32V4!-/K<CALM8TH1V@W]YH&60ZX4$T
M&^N+J[CC:80&^G=!$/[5/9>A+FSW8-Q7>89[ WG<MRLK+3W&PDE7=-JV;;+%
M.&>]OEV^L\?YFAFANVKEQ0)7B-0HD?&MOOM!I;W0GVQ]CF@K'9-KVVJ\-W;*
MTD5S:-WWW=*UV:#;^GZ.WM6D&_6(+%"I2I,QBCF%T2-(6IN<[9[+.5%'E1]X
M$1E(H>#I]2//DYOGUK<<'!Y06J(H;EFG07.UE^N+HI+&O(J+PD'_ )4=7641
M-BTD2UV_V<V-NJ4MLCWN*3;%CZ,;<T?:V%VU:Z+@VR&K)1MC<>W0KWCM%)[$
M$E6[+!_:#7LJ\XDBN=Q]I=;<;=[=)-AFCW9GZX3:I(]V3W"I3ZYFW:6W'?I-
MM9EW&U0&]7UK6([E"*?^RBS5>.N8ILA\>\,LP9^'-;?-L?V-X_U6%6-M2T);
M/]IM7G].MHYZ'DJ+\&^C>+\'X)^(<:\GXF%8UBFR#8>D1L<VS3"\+!VG8]RV
M8J*HA]X_..YTMR]YSWY.WVC4,7:P_<,ID[B<2C8]U#UFV_0;Y :!KC>>H-JW
MP,;9F%;\V;5N&U^ZA37C[G>6ZLO>S'VQ (NTX8.F.['MFL[;.76-.W@7[-MR
MG,V:QB#Y*:*[IW\QN.^,L-+9OT\L&G^006!(XHP=?G/FCUC.LYY#HHYFX_:]
MG-BYMMS9YM[B&WC;.K]NVGM[6RW*IZM[XEGW"P=Q,>X^X1V)$BBB@H"R2LUA
MS,BN,AK^TRM5W&EO,.PS_G([KT9N6\F3=T:E<7HT0=FOMM4;6LFV?G!Z\<DL
MDUC<O= &@JH('9#E#EOBF?DEV+.K[Y:&VQ-X=;A22IH5 /BLZ&RH30C/V5U.
M-O8'>U8,*&*!OQ_;E&^')@+#*(@=DO573#=1?FF:&Z:5G9[D]N$L=P$,ZV:5
MBE+%*=KW/:+J?#.)(Y(;J -'PDCEBD==8QTCU6G30WF"Q0]_J;W1@ISA/S<)
MX&JWZU^&:'\Z[5O5!QSKF*6*>A)E).Y%)#-%%(,2U' .F'T1E-#9Y_.\:5Y7
M 9L-=79N:4RYGX;6KN@Q\Z?/L#"\O5.OJ4 0L2]$TAJU39(@;/XF>:R=BM3H
M7<8]PFJ+8HT.G89NAYD@@HN\UQ^DO=KD249I-VFFVVL;U."*6.['?F-8.(;!
MDD:QK++G7^UR[=%<>MN&X]36(^O87L6-R1(:4?67O=*:3<((]GAAW2W[A=GE
MBFH3;; +15YZW;1*P]2]LAT>;M<N-N FU^@X7&XBNI2<I,04]*RWUEO4WM>Y
MFF'@%:R77GPV-65 ?\;&.*H]@"[W?76_[.9EH6MNCWF(07^D4Z6N-)MC/(P@
MN;K<K78,;BB18;=ITGK2)/W5CBX3PGF6I?\ :;"VXU-TDV.8V-OZT?JZDD>[
M)'"OO%/::=JA8!VN228LNSP/7M1R5^RTDO.O../&J;#MSFT.NM]I6ZYM=:6.
MTFU$(<X>E@KHP3N-\=Q_8514N1V^.NB9W.QH-R+816XD,:3359-:7$Y2NKG=
M^@&W#=+6[0;H(+%C=FW%87CW*.!89NG]KV*>M*^T[SM-R1B=JAMQS+9C1>;U
MY*\JGN:MMF]HR;=M-/9;.T&S5K;*FUO-'-MCV&G@ZEWGJ&O;B3=]CWFE$@&\
MSTI:[U)G8HEJ*S"X$6OE>V]XCHY,YL_V2F!*B*H7T6?\-S4@G ,_!U7\F98W
M1_I2G=)!J*Y#GF^GX2&F)4GR^T=U_P"SUH7#[?O'YK:&02433HX_-YBZ%DZ+
MK>Z]^Y,1[H63<H.\9C^B2I(9#RLGC_M'$P9=RV7\[I/$T5];^X9_.2R^T"/K
MFT+C5J5?/O@1]KL&!8,]Y[D0BPM4=W'W;T=CM !I;+:?.CAM\=NB8_@M'.D\
MAG%$'%R5J6>MVVQOY/0R!ETXT^W.5TCGUPX@HR0OB[;#T%-M-^#<;&\>^3Q[
MY/O4JB&^XD:;I>/IKW<6-TWC=KQXB,7#+-:FR28$CBC"E>.H?:%!O-"?;:VR
M^Y02=/P;%$W>VV,QK#U8_5'O)J[1LFS;>O(R-2$,%2# "V))9I>8?.>X=Z<5
ML'>//IR^@5$3[JJ5):HB?Q7[)_'K8DO_ "I?_P!&_P#])UK'7X;VZ >PXH'X
M3?7'R'\E87AG55=LSX9]&,+C.%N:LK=PV3U):</8*7OLM+4(. 2PR!Q\CIAG
M5KDDUXL#B075*]NO/,DBG/(F2>!DXCT8'#AU)P!C/AM>V-RZ6N[OU-TSN"0Q
MR;9_P)9VFU,TB85KFT7ZD:F-CW9!(+L>"D;#CS8D<2-2#T_>/G4YMW?=KELY
MJK&NT-'>9NMJK &"NO MYINTRDP8Z6(YA<4,E16<C5(E9;6(I)4$E5\3>UBV
M L;$FL8=BL>Z0[7*T22(XD9E;*&!+[R\T*G +12,Z*3S_ND<VQK7J]"]26_9
MU#L?YO[&Z0]9O<:&Q/"H]RFVM:#7!+W.+Q+(2_ 'F\:L\:D<0U$IN0<QQUP;
MRUV^V4EI)HN: >T_.8B""IL9ZX^JXXY$]_=&6%C%#)75SJO+"#S>S8DCS6<M
M@&&$PERS>SS)3GL7ZM^-08ZC;C-.20"CR0,T"@$Y;E*0 5!/]X^@.LQZLZ6W
M"YU]T#-3IS3[7M\&T16KR1DUZT6S;C[RR6'^PCO"$$",<R2,5CR02/MW.T1'
M'3>UV2KM&WXW=4)S3!:?#+\B3CUG#D[BH''^IOIOF<DJQ$K7Q*Z:JL&V,<CF
M0S1Q/S:RV?SKR7M-MONI4$!_>/>BGH23V_=P"7X_+!/G5T>E=S/M?AZ@$ .S
M]LWY+7<3BEL;/^;/=RA(D,CR\95^ +V/BRI!Q 9MW94&+VUG7A,LCW[CD7"S
M!2%-%66NY)X9M.&+.=)B'1QHZHI]G+<1#/5$);4QB#N]<T+D<2V\*@8KF@DP
M('_YO:]XQG!(#M%V\@>KY/C6R]GZ.O\ 6?L)N[+M9KC==O\ ;!NFXP>\RB*(
MFKU;)[TS.?"LFU6[,T:MY=HUB7!=2,C[S:#ZS($\4"U-M%?\4TW/UB483\,V
M@NJ[>[O#\F9E*@KXEY$!49;;ZNMA2A1T$,'9:)+.+9BN;0AC=(]LN<AVK5FD
MBA3ET*I-"_)?D#Q4H<D%6XG#!@,E/LWZC/7WY0T@K0IMO7'1%BOL=XV*X@GW
M&QMP@%>>,.;-=X;#N97>'MLC+.CMW.(RC1]R4>=Y*M^[*\H+N,3<[#O#U$%!
M7C-M;,(SF;#<W5_'%!8?+97P,1EQ;8Z@N[.&6>NJR'SV,Y*UHLA[./<&DO6-
MN4KS2I0C+YPA,+4WF="Y!(4-(RJ<.0.(4MA3AG77LKZK;\F_V?='[?MWYSZB
MVGJ*.]N5.G-#+[J=T/48LGO%TCDKT9]TABL6$)B$:/8'*%>8Q=4;HKA[CK=<
M+LK[&P#Y\[9^.^$!BP&Q(+5WV5Y0P]C#;VS)"('LJ7XTW?L=,.PLGYH^J!^'
M2.SE(AJ4T%Q[MYF -3=+5PY]6CE@<L%\'XN4,:X) XLQ)P -9W[8/9;NG474
M_L2M;1'#-4Z;N;7MV^2]Z"(5MLIV]JMI;5)9(VG113LQ&.%7E$DT&$*L[1[O
MOPS,_D-_P[W1\>[&E%O*2VYQCGN*TIKVME#O^%>, (IH)XG1E EL;6%_"V($
MXYX<JI.&1 0QDJ8-O%B6)=I<'!6K,%)"D$^^6.>>600PXY!'U]-><ORH^GMO
MWGVJ=4[?NE>.W2W38.G.["P*GM-M\E5BDB$21RAHWXS1LDBL/A96&1G+E7MO
MX#Q4P<W^6*^X1=?6KHP(1] )\.CC[$8R<>CKK5A-?5>AL-Q#53Q ,@K&6#V0
M.:'1UH@?:AU#O,8S#)/,(P,@XE"\?F!*)%3'CRH4<@OHQP?#75WLB]F^W212
M6-\DZ3EO6.-?A<6%><\\<C)6@D(@C.!86)A%B%9&"$158ECG#QI69[)X7*9K
M+'1&T-%2 UE:5#9'V@TL T2-5PI-K:W9K!/<]?P84UF8VM%]FN@D0<6)C(":
M8R2N[@AG8D@XSD_B?.?)))^T?J=;SZ=VJAM>R[;0VYUL4J=2*&O)'-)/&T:*
M%'!Y9[#B,>>W&9G[2 1AB%&OSO\ XB^M+P/=WR=R$)7+=&8D/MRW0=.Z<43Y
MPF8:%8K41DD^!1UM4K#*UDY:^S%(3ZIE;"GE,VV)#9K[974A?>/SA7YX)"=P
M2#D0/+ '#$>I(^><:]9>RKIJSU7[!_;)TW1$)W#<=Y)HQS2B&)[T&U[%;I))
M,WPQ)+8K+$9&'%.19L!2=0#I;L0?B:A[;G!6*W\E]#R,EQ##$N<?3V/:Y7</
M6#)2EF^+BN8+K,5KVB*'*PRJ,C)BG20 N-)Z8NT$FX+Y1+30<2?C5TW S X\
M94F5CD#U!SC(&MI[1[.M^V[VV[=OLE2([-<]DT&Q7-SBFAX0[Q!1IT6BFA:0
M6',B5(WBECB:-H_#2(\;*V9N,>?ZA>7<1W/ZNGOJ+(9#FC@VWNJX4%E[H*O+
M<78;C3C*RGBK:*0U#YI8\^=:L"JWD3+7%>AD2$>X.VG<I2&[%MZ%7DDV^=.0
M<)&TDTUFP%#R"-<XX*.85>2X)XD'6$P>RWJ?9_R8NIND3MWOW5-WJ!=[.V4)
MHKDC]K?-G"+7E1A'/(=NH"P5C;.7:,98%=8WP?-)_"V<7;%T%J;/R[P+W)<;
MG5]:T20NOON><M->4Q!B2$#PN! VX](/<RC2R2B O*L((2F!NADJQ5?>]QO0
MAU IW=OD5G) :*BS5VX$#_X1)56 SX'@\<2/M4]D^^[_ .QGV2]-[94AGWKI
MQ-EJ;C";,,(@JV=ICJ[JZ22R+$XJVA%*RJY=XXW[2N5XGUU(7HU9><@1CS2>
M.'BBI(J,B?[.=U-1&LKU158Q9YXD>[TN]#'.7Q]$1>FURB2"1QX7WMW^A.9$
M;U_Z1D?,D^I/K?\ M;J,OMCV8(N5F]DFXTXO(PSQ]0JN"?3&95.?. V<>?,A
M)>Y;,6$O<)N"J?65E=W.\-F<6Y4)U3"38 [+/4G#--5BZ2$ TR,*M+/R.NA"
MN6DSAP-F&--:%#:O4:[.U6![E ICD?;+26)LR* T$DMAV9.6,LJ-&7498_94
M'!UY@;H/J"#8>B NVF6WMG46X2W88I8&FCI3[A0D@LMB0(8@M-G=%D+0AU)!
MY-QH^DY%GW>>I>WZNI31).)T[H+\VR)^%;7W=CSGM:B^RSZET4\DR-K:,NS$
MO&E0C)!8SQLA4F'^GZJ1T3"[;@S9%H[>B)YR@JP+'(&\G[3Q IX\J,?)@-@;
M/TIN-7V@]=[Y92-:.ZT[D&V.)$9IVW)Z\TI=%;E$*_:,3]U5+.^4R!G5[<X=
MQ]3RAR*3W!\8A6=C!Q3QWVQ5E7%:UIU";:Z3B&Q7E715'PUQ .0+[&BT).24
MTB-0I3JXDN&0JO;&3/:T]JG@J_F^WA/?+&Y/QR"(DN(*T;,4)'I&9/&#Q/H"
M3K&.ANC]Y7H'K/;[U&6A?W4""I7N*(I'?;:R=B1PPRD<UQ>"2-\+*O=4F,AF
MM7FSF*DYEY2Y8YNHA+43*<B:SE^'(1W0;ZVW2E$[5-9QU1FV-?(Y\E?),;G7
MV2AS.66$::-LR1RJ]C:D%!]OJU:3_%+"*7<",I +;K'.QY*2#QC=? ) (922
MH&J"['N.S^SKIV'<XA3NR=?[7N,T4AC8PB>XU>%9&1G3DV$)\G"R*" V1JDU
M_+J8W444DE)=R&]OO-]ASN1,!\OD9<Y*^M>UJ[4"AD>8QZZ-\/%_(5>2!90A
MC1>[4.^.</;(X6L]&2Q"X1DX[C6--.1\+-'%=CR^?2/,D+<P#Z$@94C4UU%T
M9O.X;][2+D%6.2'>>G:$>WN\\*]Z]5FVBQV54L61C^;IDYR\(T=HUY<7Y+6S
M^=: 2Q[A+>BK+ZRK>Z^PY:QV#L7US:UP=1L>ZL7=/L=,%8S#6%2.5Q[87<XX
MJBSF?-HQ:HD<=Y_OP]%VN9A325E1MK6"69<ALO%26,*N'()[B@$H6&6S\0!.
MH>/HK?+FU^RN*6I[N=EO73O44\L22U*S;S'N$;,H<E^[%!P5(^3+)*HD"Y)6
MYB>3Z).,*[M\5;)VY3NX(YU>&ZJL/E ^"&X#CHPK5MV\=*N0J?<%2 MJV$NL
M6R@&EO'8)'$1-3%*9;<M_ ]W.U+4#?"6[QN%F0+GD,0?/ 7&%SGQJ>CZ>W1O
M;--O9IS#:A56\FX!"*SROL<6V" 2_9:R+ D9X0>02,R$!6!U0[+FJOY%XKX<
MX%"JK<2Z[=\SW%9Z\+-%=%5$BZG:U@?'GRHOW'--<['B3LM&M1%K2H5%E8BO
M@>[L-ODJV[=]F!AORT)(\,.0XPO)85U!++B4D#(!8 %<@'7?I#I+<MJZXZTN
MR5C'MUJIN46UV2T96?\ .NX+<*JJL9 :Z*T4Q9%PWE3\2G4U^)+4@7B/M^=$
M$4;^V_#O"M8;*.L#&!F4VEX;Y,@L3TGG@>P2,&EUT:R#QSS+9V  R0*A2R0]
MK-=FLQNG$>Z6I68%R/T;1RQGCX.6[BQ #QX/J /.N8]KFLUNEK,* C;HJ;63
ME5*Q/33+ ''+BT97B#DE_OR,EB;WP/Q:1\MT1$O!>2X8I=?!\OE@4\KC#EY+
M:U3,$%N'!O6FYBL6SJ/AIT8[X@.K*>(>Z4>&,BVZ=8MZA)0>_P UJ2LW)>++
M-"Y7/$Y3#NJL& (\D J,FR@V"_'7W^J:P$EUD%(Y':LJ&:3"-E0,CB!SXG)
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M4?MW4*R6!'8@6-V(C$JGQR;"A75AR7S@9#, <9  !UK'X(R59HC^6*P@*$J
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MG2O;80L]13@E)]SX9$F5T#8T>JO>](O?>BLC67VD5BU(XF=3$S,(_MA /5O
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M%?7HV&-C&>$1J)X7Z(GW^_[_ .W]_P!O/5U!7!'@?0G[_P"O'CSK+9[)R1G
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M(FN20<^C5SZBS%*14^)&L R(G^E%:QCD1R7#QPVT[%R-+,;9&)%S("2""LP
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M0RN=/)HK"S+2T0A&N]J0%!)8H:J$5ZME$#KV0P#>AC8V,:W\V0JX52@4"/&
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MZ::2&* "H(8Z5+%\Q\R+'&-'Z]=]?;U1CBBZ>JLLUM9!<OM&P>*LT(>&*HS
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MU48!%L322)&&R,JC'@IP?+!02/GC)U4DV*M5I6TIH3+)$"O.1I&+1,) %S@
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M0,5YGXN!4@$>"%PH]3=*^V2';*46W=34+MJ2NB1)O6VK%8GLQ0QK#";]2:6
M]^.)%1IHI7$H'<[2R-(SVC%PMWB1IZ?\VWD#[)]M5PUX\)^]/\J"+]%^_A/'
MC[+Y^G5N=IE8Y[U?];N#^'_+_K[L:S(>VWHGYKOY_#:8_/@'YW0?W?=Y.OI_
M"_>*]JM7MMWR>45%_P#"GAM?T_7QR?\ K^Y/K^_QX7SQ^:9/'Z6O]_QO^O\
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MY>60^<\4/'!).O37Y/'1O377'4F_6^I8J^YITM5VZYMVP6/->Y9N2SJ=SM1
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MWB=#)'69HE.5![-!Q]S=-4;C"[G#[3BW19U)-R\ P2BL^0;#"9KB;ES>7O[
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M52Y4F08YG[0?_,WKA@/7.<DCTSDX1TWN(NI%LUB*205HC[K93R4B3BB0S(%
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MKQXZAMN+'#0Y":0B+*WX]==2F0V6@9JJPZ>_^84^(LHF5HG#1HN>TRCDR<E
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MYJLG@*UOGB.1B6^*W_&=OG;!OU;[U:5H]9C[_P!M_I]216^;J3&L<SW8&/\
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M'LFBT<G(HV2DT<UK<T*DX^MY/'(*YU#Y=!)TI<+<5$=0@51UI>/4#[0=D_\
MN7%)9T/8I^YL&8UVKL>!D2Z  _'E("5^)1"0=8C%TU9?=)Z$E/<HMW@V^"ZG
M6QO6WCGW)G#M72#OK&:BOFOV"J6U5'G,2PO#*U1U7"7=?^VL&3YTR]OSMRF$
M+5SU^IAU,=WAWYK1Z%U-EYQA/EM5!4,(L<I3CZM/V(K&R:(&'1V 7PCQ[&+#
MK54-=L=FI+)&TTDE;NO&P2O+,_95FSQ4HJJC8B#,5#,I\N=9=8;!UE?ZHO07
MH+.\LTD4]&3WHMM\%*[.$KI#30N*L'O=2)7B:)RIC@GL22!?>!(/A/M$[BM9
MR3QWR!R-59K$9#'6*:<7,E!6Q"VA#ZO)' @7  5QCK()I%7K-+!"K I(,]R%
M@5'T%'>4\P;Y^RT[,LD;SK&BQDNL8#/DM&%'+_D\1^DD\!3QEC',$>LWTC[/
MNJI-ZVO>-T->G4I2I9%26.8K,6CHS*DL4=BG*O*&W91<QA:^X[?BU7M5S&6V
MS<C[S'<29"QW&ZL'U6>K7CPSDQBE%S2&'2M%K@8!AHY)92[$Z2"O#9Z6LD,)
M@C?)&U_K2J]>.(%Y<*@QDX8DECA0!@DL6. !ZDCZ^/1&\]0;?L&WR[EN<QAJ
MP\>3A2^6D;A&@4#/*1V6./R%,CHN?.=>#C/E/CGEW,PZW!:,*WJ)B"!%];W@
M6 A0\SXE'L:LWV;"NGD1B3PP&00S.'DCD=&Q5<QO6.&.50T?%U/S],8.,$$Y
M4_4,%(R,_=3V7JG:.H*2W]LNQSP.649/;D!5BN)(I )(RV"0KA6*^<#.K*WG
M$&HY,?L8K:^HZ6M/ %RV0D I!;TL;+'GT9^S.LYSXH2([ZZAKSZ*MA!*;658
MLC#2H;.=_HAJI5(+<HU*Y^#'K@><DX/JWCB#C R" =9]MW46W;4FVM4K6;DJ
M--<W/OV#!!+=6&U6HP5UA9T:E")X;%EI4,UAPT2F%%!;73RYVL<O[Z;39#CC
M19[D?B+C/9ZF=V4)L18]E1;&&EQ13 AZ'6Y>7C[=[*NR[+ZBP8^ILP\!1:?4
M 7VA%,DIX_@9[8[5/;??9?=1->"B&D\L<3PU)CR,DQ61<-($*+$RY52'5BJN
MVH7VE_G3J3_A%Y!+L^WV]HCL[_7J6Y:K]04TOW!6AK-6D9JE&1HF65++K*6/
M= XQ1EL0]BW%G>'>7U1S)1 @4 5?<6=!K[[ELF^S&FVP;*?4"W6-DRX&#$,U
ME%DM$_#UM?H-<8!=Y[4X_3I0V,M#9F98&C!U+;ZCV64]1;19I[M%>F2K-.*P
ME$,,AB8/V57NUY%5S"<)S;C,JLBQ$ZHZ7IN;0WC;-BL]%;;-[S5L]*6K]W=%
M4Q-_9[M:U<E:6*8D\+#.ACE,<KU1[M-$YQCS[P%W8<69:F2^P#^4.8>8= ZL
M?:YNT3?XO6:T2AI2QJKD]ME@X;"UON0]V7K[FM?>AUG&7%O&V> J<RZEM(B[
M:IOMRZQO[4^U5NGMFDL;5+<@J7*JQTI'[)5Y)+5]GPSJ2"KR+*BH,MGN211"
M&W7I^=):,NYT-PZAW7=MPGAFW7;[UFK%TY R,U>2G 9 $CB(#KWXA7?MR03S
MI(U<V-WW;!Q]RIQ[Q+5X_EXFG*OJ:WO8J".EU%YM&U.*GL)"\OGSM7H*:BMK
MPK.AD24@YI@+Y_E -7"0?9%13G3Q&Z15+-Z>:C6]VK2/S2!B&$3,H,@!15''
MN%BH"X4$(,!0-;1V1;M7;:U;<;2W+<,?;EMJC)W^+$([!R[<S%P$C,S,\BM(
MQRQ&I"_!-_V5_F[_  ZC_=/\G[O]]2W> ]"1_7_3I\$W_97^;O\ #I[I_D_=
M_OKGO#YLQ_'_ /YT^!8OT]"_N^BN^W\NGNF//'&/N_WUP9E]22/Z^]=/@6?[
M*_S=_AT]S_R?N_WT[P'H3_7_ ,NGP3/I^5?/Z?5W]WTZ>Z>F5'ZP?W>O^FG>
M4#U_7^O_ *<:?!,_V5_F[_#I[H/3 S]ZL/Z_EYT$ZD>') \^",#_ ,NGP3?]
ME?YN_P .GNG^3]W^^N>^#_>;]OK_ .751JAFQ&L>C53Q'(GZK]T3]Z?P_P"_
MCZ7=*MVYPW' X,/QSCY>1^'G5G=D#0\<^K+Z_=G[A_KJZNIG43ITTTZ::=--
M.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=-->&>
M'U.\^%\+_6J>?O\ I_'Z^%_LZHR)YY D9\>/!.?Z.JBOA>)],Y'X_P!?CK!&
M)[B>%>1>1M?Q/C-[47NXQ"SMNZH-TSAY)@)VAWD%-:.C;6: C,'OAK-5#2EG
M29NTGBKKAHA:K$EA#9I6+-BG#;AEMT^/O59)%,T'-59>X@.1E70DD84LH)#,
M!JU@W>A9MVMOKW();E'C[W7CE#30<@".XH\CRRA@,F,NJR<20IS1/\*'&\@B
M8<:+U>9)IY(X(_5Z$1'222/:U7>B-K45RJJ,:C?LU$2\,9P 3@ 8!)]/U_3Y
MD?+'KJ\:=$RS,J@^I)X@>,YR<?0_O.L;S\T<1BE-#GY*Q4<SHRI?_C#6N@8P
M,?(E3>Z4TA1(54??8F:!LL['%QZNA>(D[;(59*1[0_[U/O/(8&..<^?HZ$?<
MRGSG42W46S*XC.ZTN;*[@>]1%>,:T68EPQ1?@W*@RY8<Q<K\.7=3E3.2^&:S
MD*<>VCLS*;1 U\U:&?%Z2!7"2R>_\*8#,CX98$)1DR^VC%5S?S(_U+UUEJ"3
M!RRR %488((/R<$X(!P?0'QG(SJVWC98-W99FD>&Q&AC253R4J26"/&PXLI8
M ^@/UU0^'>*=1@;/0%7EM4S!GC"!! 4D!8X;U%GFF6UE%EF0<,PA9I62##P/
M8D;XY'&3SN(ZX@JF'F'9?.,",$*<9^(J20I/IA1CT)\YU0Z?VJYM4ME[%B)X
MW")'' KK'Q0L1*T9/%'8L0512/1BY8G4@O9=^_Z_V?X]5>W]_P"[_?63]S_,
M?WZI-I;TU+&DUS<5=3%[<\R261X@+?:%B?.3*CB9HD6,:".2>9Z+XBB8Z1ZM
M:U7)R8\#)8+\\D@??\S\@"?P'W:I2VX( 6GFCB3#$M-(J)Q52SDEV48502Q/
M@*"3@#.O:*\8V"(H,@<L:9ON0DBS1SCS,55_/%-$]T<K%<B_F8YS?**GGST,
M1'DGU^[U^I]?_7.JW=^6<8P/3'R_#(_=]VO%;6M-0CM,O+:LIPWR+"PJT.%
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MI 8_0MC/CTSZ_(&:M17ZNTI7VQ^]:@2&$22D,[(G%)'!E<KW.() =N(/C
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M;8ANT;_=*5;,Y:<V$"&&P;.(,6/-=Q0_-C'E1VL.V5X)5E0RD)@K&TC,@<9
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M!DK&1<G'G%G'&UPO$^GUV.H[W2Y.A^#S]P>*OS&L"AOI+)E=&2R2*2:MCLP
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M2FN5H&XRRA7\80 LYSZ?"@8^?09 _9K9&\=8=/;%.M3<=P1+;<.-2)'GL'N
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MG333IIITTTZ::=--.FFG333IIITTTZ::=--<+^_]WU_N7IIK\FG?W^)[R/\
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M(PTDB)".:/.I"I/&3)&K8FR5 ;4>0W)KJ>1P>HL3X&/(9)67/GSD-\L:P;K
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MNV]R<8DE/(D>"TCA4!"1B26:01JH>61@6,ENI+4EK65^+W&V3L:U;7M:Y/\
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M[09@IK29[8E;N=H1IW) "3:>T[V4;?U9TS:W+IVF;>V[S5DW3:KK0K6L=/\
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M.4WZ:ZXJS:@AUI:15\[>-1.1AM1)K:T:*$.IN"Z$=T3<%)=#C-<_U_'/S_#
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M,/<#%"BW-&1#[I0A$#92XM#5;T^V7Y=@WM/=+L#%:\C96"W"2>W)$SX +#T
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M>*2<@B>1D, \$+'233SS2.;'%#%&USY99'-9&Q%<Y4:BJG?7?2*84X:.<>6
ML,N!DL,\+V3C$CSQH^.6*5BOBFAFB<U['L<Z.1CD<BJUR>6FL#?YJ7;8E'-F
M6\(\;,H"+MFBEJ8\M61AK;,!?5,(9&R!JQ0MJ99:AH$+F5Z5$TU4@OR^:49[
M362:3C/C[-7LVFS^,S=+H"([F&>XK*@(*PEAT)E587L3R8(62+';'45,4>SU
M>DB>K!D>BN'C5K35\=--=!)$ L$Q!4T8X\$<DTT\TC8H888FJ^6665ZM9'%&
MQKGR2/5&,8U7.5&HO336*^.L+PR-9W_+?&%#B'6'*S0;N[WF2CK"V[6%(&(%
M8?.JYTPQXLS40A90IOAS2WRV!'OFS2D/HQPP(TDT4<2O8*R2RQH@:<A B/(Z
MC,F$"JK$G"@ '&J$4%:-Y9X884DM%))YHHT5[!5 D;RR( 92L8"HS%L+X!QK
M+/I3RJ^/JJ(G\/I]4^GVZK:KZ\,\#Y)41B_7RB^?T1/X_3^7A/[^FFK'W_+G
M%'$0E65RKR9@>-Q+B:<6I+WFOS^1&M"A8VSE#U\U_85\1DP\4C)98AW221QO
M8][6HY%5IJZ,WI<QLZ"JU62O*349B]#AL:30T%B#<4EN 0GJ@.K+6OF(".$F
M3RL1(L\L3T15:]?'337NL[6IHP9K&WL0*JM'="V<ZR,'""A<3/&*.V4DJ2."
M-9RIH1X4>]ON3RQQ,]4CV-5IK5/W?_A/=K7>YHEYOR>BN.%.=G>]6R\Y\*%T
M\R:N2E))K) .1\J0PO'\@R5!@TU9(?8P"ZT#X-]/'HA!AE#9"[UT]L_4$ @W
M:E'9">8I@3%:@/KF"S&5EC\^2 Q4_-3K+ND^N^J>B;$LW3NZR58;.!=VZ=([
MFU;@H  %S;K*R5IF"C"3!%L1X!CE7 UJW*_ F[P<O?.(Q_-_9]N!4>Z.+3;_
M (5W.9T3AW2J]'F46?O]/0S$.]+)94B-@A=+Y^B?1RX2_LQ@7X:G4_4%6#SB
M$O6GXCY*)6C5\#.,GSZ'6Q6]MLEG#[AT7L4]G&&FJ;AN]!'S]HF!)Y@G(X)5
M)%48"J ,8SYG/P+>4.2(J^M[L>]2YM<! ]JV'$';5Q_!P[0VH[?2KZ\W<6MY
MI]'$"0U98"4HJC/'NA<CH;&"3PK+K;/9ATW1M)>N>^;Y<C8-')NLW=B0KZ$5
MD"Q,0?(,O<P?(QJRM^W#JE*LU3IFCLW1RV4,=B]LU>:;?)(R,%%WG<9K5JL&
MR>1I"LYR<.,G6\S@#MUX4[6^-:3B'@+CG.<9<?4+5<'0YT5T:E&2,8TNXO+,
MJ0BWT5_8N8V2SO[TZPN+&1&O,,F<UJIL55"J%5555  50%50/0*   !\@ -:
M<DDDFDDFFDDFFF=I)9IG:2661SR9Y)'+.[L3DLQ+'YDZS5USKIITTTZ::=--
M.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::TR?CT6
M=E5_A]V<HWJ^2S\_]L\&P\*](US3.9LH6]I'I<UJBR70M+'.V7S$Z-RH]%3Q
MXB][E>#9MTGC^W#0LR#'^6-B3]V%R<_=^O6P/91!6L^T[H""YQ]WEZMV-7YD
M!>7O\)A#$X&#.(P<^#GY^FOS*\=7(W.&W.T]HA)<"C$!-!GG<55NAKR4 %1(
M9W.2&>,49C61L8R)C%E]M/5^9-05;36:L4I(7F2S>2?CQZ?,X^6,D>?'@>/H
M/U=[I%O^XP3]RI#PF5UA4SH9(PW:YQR.,-,X'-@0(U?(#8U-<3/4-I"M-\##
M;M&D$C,KA2/"A*STO&:9'%*U8T5&>5BF\,>UJI*BHJ(Z\B1L#]HXX!!\Y.3Y
M'GSZYS^_7S;@F[4;.V7M^I[?2VS-R&K:0MW9_P!*>$9AXRN06/Z,M)_S!^B8
M#Q,]G=#H,-FS,]J,/F-KDXL\'6'4KJQV5DL)$B]H:YDOJT)'6MO$/6L98LCF
M^(F8P9\D@DKXR776&7 (#9\>3Z_3R?O'TQZYU@U%$NS5[-)]_J;QM=U=PL[W
M6LS;HM'9>;>\Q1[?<Y0+%!WR8N+B)&?#@I(RZL+OQQ!2]L^*WX]9DL;/)6"Z
M:BIZN)'#P27/HMJ&\+L+(@R88@FODA0X&<@L>&1GJCG?)ZFQZ^ZS"Q;AL(C1
MFORWH8X)&F[<2H6)D$D1_1R\HN2+D%D9PRLI !WW[$NK*5[JCJO;H+^[;W7F
MIV(WW3<G6)C'4IM%9J>Z11PPM%#8!:*?M1/P)$D83!>2'X HVLDQW>)=VSR)
MJ"RYQX]!#(]R-]81KJC@;CU-G)6^TJQ2>F [+PED0^8I)HFP*OO"SM;Z$Z<C
M[6P[:AR,1S$ _)6L2D?B/7!_<,:\$^VIHF]J/5HAQA;51)"I!'>3;ZJRCQXY
M!P>0'H?4 Z_09U-:U;HOC]?U_P#Q]--8XY0Y4XXX<S+]ER9J:7)4(Y408IEI
M*OQ)]J6R1@E/0UH\<]I>7U@U)8@*6E$-M3U1\8HLWAR=1^Z;MMNR4IMQW:[7
MV^E74O+9M2K%$@4$G+,0"< D*,D@' \'5[M^VWMULI3VZK-;LR?9BA0L0!ZN
MY^RB+GXG<JB_,C6OG4=[W+FJG(+X6[5IDIIX) 6;+GW1IQ^7:U_J<K9 L%GJ
M/8:E]40K_<B&TYV2._.[XBJA<J^KR]U?^5GTIL4DD&P=/;]U2Z>!9J0I5I,<
MD$I-;DA$J>A#Q%PP(.!@@;7VKV2F8(V]=14*#G!:M54W)$'S5Y>4<:N/1@BR
M@'^\?0X9([WN\W%DHZWX)[==%7CI$X>CS6EY$R-J,)"R:-D8IUG0Z*";TI),
MV"8>G9"QLLD*1)ZW^=:5_P N;;(;BU][Z(W7;%)! D>)'*'T<.TSQLOU901D
M$ CP-92?8=M]B RT.H+$H'P]T0UYTY@ E6C5H64^?LB1F^>,>=2Z[9_Q!N*^
MX+0P\<7M-=\-\Q2L)<'Q]N)Z^8?6- '^(L9N.]=72NIMDT"%DQ!E6UM5K A!
MYSK#,!@1J2OJCV<^V'HOVF5PVP[@BWE16FVRRP2Y'E0<JC<6D3[6'XCGQ+(&
M4%M:KZIZ WSI938G5+NW\@IO50_")B<*MJ)ASKL3@ MRCY$()"Y"ZR?W#<&E
M[- ^2..I7TW*N4]HRO+!<@TM_ "JR1A2R)Z6?,H$]25Q,R.9.Q5JS/4)-%()
MHS\I_P#)XO\ 7?N/M5]ET[[![9^B^U>VN]0=:LW4M;;^4D6V3RY6(;I O)=K
MM6 \4\9;9[_*C/%)2R;V9^T&#8^_TOU,BWNCMYYP689P94VV2Q\#V(UP6]VD
M.#:BCPR-BW!B9'6:Y. .<P^6Z2:OMHFT_(.<;\+J:&5BC2/D@>@\EJ"-*J3,
M$E(_HBAGM]VL-5PDWECAIR,J_)I_*'H>VSIZ?;MYA38O:;TL/<^L>F9E-68S
M5Y!5DWFA4FXV$HSV/T5NK(G>VG<"]&QR0U+%J,]I'L^GZ+W!+--VN]-;H>]M
M&XH1*H613*M.Q*OP&9(_BBD!X6H )D^(3)%E;D/_ .(&X_\ 4_3?_P!%-Z].
MZUGK6+D.X'D3C4/MQQ.6;2W@FB[5^S&GI,UICWU%"!J.4=@7A#=66?65=C>3
MJ'3A"^*V)$'-D#B'C>%)/.8QIK'&@[N^?M5O\>4'H,YALV!48R@T><S4B63;
M/=P?B,Y3M?VUQ"7=U\DLN;NLE0WXE( 3+$;3QZDQ)'DVXPEB.UQGQX_5_7_I
MG]^LDXC\175<DZ43'X;(<=WY^NUG%(.$U/[6VP./+Q_+#^7V5E_-"@!VN/6O
M'XHEM 9+#.XI^J&NXH@ZNI#%CN36@.?Z_KZC]OD Z]%'WY\P%YO)6UMQAQ6Z
MSY%J<[+B:VMY!TS (;.7NAP7;+?R:.U*R4D\->58;L;6TD575FE5\ #J*PEL
M2266$;7/]>?77O-[[.3,<#:6_)>5XAIZ,*^[B^.0K6LU6V)83O\ @7:@XP:Q
M-#9EBS1:#<61[*X#/5\-S>UEJ\"*:V+@L)GU;3S]Q_7\_P#3]N=86T7?]RU9
M"G[6%N3SN1S/"_<K+ILB+H 0-!?<@<-<QX3#BWN4O1G;*NJ6)57;#3*:0W2_
M)A#KH8^0TL,(R)C^OW?U^W3_ %/Z@//KZ_=K-UIW_:\*0WY?C^,[8J_M;:OQ
MN;BWMDW1XQU'W,\==N,XO-8\%(8_-6=R7R"W1UP=8&^2O.HK;(2-M"!W72M<
M>1Y/I^OY^G_KXS],:O +DV_Y1Y,[3C=574M=IL9W5]S7&%ZF<),)H3K#CSA7
MGK-.MJM+%J6 HUI ' 8ZO-?/. 1),*I14<;)Y&N=;&9%5&.5/X)^B_=43]?I
M^OZ_3]_334(>UGNSU/<'ON8\;?<*;#C83C>\G "L[N%[/A5@)8&S*;)L_LP5
M_($XWMZR.MSLM[2-R]K7S.ME1:\Z^A]LW67<+.Z5Y-MO4?S;;]V6:U%PANJ4
M#K-5DSB1>)!?AS1 \8,AD+QQP>S[Q+NLVZ12;5?VX;=>DII)=0(MQ8R5$\./
M!5^/=7@98S7EK2"4O(\<><.X_A>+N#X:VO$TFGML>[4A#1P7M3ZI4@*K[ 6T
M%%N:SWQH[_,6$X; --G)R!X;VC)/K5)%>0PF*\W&FNXT;5%Y9H%M0O"TL#F.
M:,.,%D8>A^H]'7*-\+'5[NFWKNNW7-N>>Q66W \)GJR&*>,-\T<>H.,21L"D
ML9>)P4=AKT]O?#HW G$..XJ%T-MJ69<,B*2YMWN1TY)YQ-F7!5@+-/#19P$D
MR4',YL25X>>HAZ^I'DF8)[TE2I7%2K7JK)+*M>)(A+.YDE<( .4CG[3']@&
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MI[E6QG^Q6,!O[-(W9RA@^4*GG[BK024"P!:,K/VE'<41$_YZFYL*HD:%7/\
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M!R'2S62QN5""(="7\0YRN<OT8B:^?V:V:WP;1U5>J5AD)7O4:^X]H'T5)^Y
M_ > %9"?'E\>-;='MRI7XP=]Z(KO;\%K.Q;Q-MD4CC(YFG>I[J(V/DLL5@19
M8A8U &I,\5?A-]\2Q-I-5R'VR]ON5,B='<6G$86WY5Y (@?$B/%A,TM!QR.Y
M\KU5C2+*^M18?0V9]25ZU@;V@]E\$\B2;]O^Y;PB'D::11T*K'(P'$<DS%<
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MBC7+&JQ\:P;S7P)P%WJV3M_Q3OQ>).?IZ\:OL8KZJBGI^00ZR-Z5=5R!CTL
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MGA<^*6-R?5KXWN:Y/JBKU[5I7:>Y5*]_;[=:_1MQ)/5N4YXK56S!(.4<U>Q
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MHI*R^*K[A;<FX&K[;B^SI0EM^-P;*Q?J:.P=7A<NDQ5N%*:$&QSS#5MY%!U
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M/DLQ9W=?0F"U5SPID^1;*L G%J+&QT%HP@^S(;"T$KT>Y)(2;5U ONCV,?M
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G*762:Q;3IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g626950g35s54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g35s54.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M-4-C<G:"AK+_Q  = 0$  04! 0$             !0,$!@<( 0()_\0 6Q$
M @$$ 0(#! ,)"0H,!00# 0(#  0%$1(&(0<3,10B05$5,F$(%B-457&3TM,D
M,T)2@9&2E:$7-$-68G64L>'P)34V<G-T@K*SM,'1&"938X,WM<+Q1$6B_]H
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M_6'_ 'XI3SK_ *97]8?]^*4\Z_Z97]8?]^*4\Z_Z97]8?]^*4\Z_Z97]8?\
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MNVY=*[(X_P![>:UVO",:[<F,5 3;F+C[14K@V+$VF&96*NOTIRDSMB@'*$Q
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M+?-#%)Y?LLMRENP=X8KAF5=N=1@N!L+@.4 0\9?)+"1-!O,,08KOFJ%QH,R
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MJOBW>UCW3<&VR6CG6>H8EMLU#>C>4:PS*Y(M89'?7$_7'$.PMX%-[<'ZJ#>
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MQ-<^9;6T'?<(;F2 .1Y'RQO9+"-"0"0/K$=P-U'[F159U^L/[,O_ "='!/\
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MW1Q]/X+\M8G^L;/]M3V6Y_%Y_P!%)^K3Y#7-CZGO*7[/NV?NCCZ?P7Y:Q/\
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M)^(46,GR)7$&2VLA<JYDNFL<I+<0=)7G5L0DQ-S8I/!;R6MC<6;7$\RRQ7/
MBVDB$[04NZ[PGJ[#WADG5H2#FH%E<X=N\C[&2;7C;[$Z7D-Q(//@CJL12;VL
M%B"HLEIM=P@Z7GU 8C JQ3A*76NL+T589&[PDS92\O;.^FP]Y)!<8\V2W&"N
M^LH.D)(?;(LE=-#DS=EYELHXWB2P4SB_6ZC:T2US/6U_CK3.0+BK*QO;&#,V
M<<UOD5OGML]:=&W'5Z3>Q28VU6;&"S6.%[V21)7R#"W-@UK(MV])=;PM<9<G
M@&C$Y" 9NY:N1D>@LJFN_L3[<&S:4V5F$H:AV6:2C&D9KP18*0:BCM=^X;I2
M4;+K217<-=Q]%8NYP\.KEH+^:*UR-Q.Z(R08Z#I'IK,RK:/>9S&V;7,MSU"/
M/6]41);Q.]M<VB6S17EI+UOEK;,3;MEN+"&:ZQUM;QNZR7&1GZPZGPL3WBV6
M!R5XMM#:=/'R&LB97N)$2YM[Q[D36=R26_G<= 3,ZXH;&.:1)H=@6-FIZ82F
MGU@?:M8;/DX1")KU#LZB1H6L.G:3E\Y,DT[(QVLX,R8IJJHQUMT'%<7]G8QY
MR>XENQ=SFYLK&T>S@Q\/4]QTS;7KW60SF,5A>9.*)HH(PTN[F%(_.G95>1N>
MOY;:PO+^3 PVT5HUG;BVO;Z\2]FR$_2\'4]S9):8_ Y-T-EC)95DGD*Q:MIG
ME,%NKNE(3WS8"OI"2F:I!!4V+RW+G/&3BKF6"KUX])?/I>>CGM=(DT=0]7GW
M5A7;Q\PZ3?JQQHM,I">[R9KENAK P6]O:92^.5GBQ2!;FQ2.U.2OQFH(+.QN
M8<@S2QW>4L(;!)+BTB:!9Q<L2?,MA;+UW?B>YN;O%6'T3!+EI&:UOGDN_HO'
MMA9Y[R_MIL<JQ26F+OY<B\=O=RBX:W-JJ@>7<F\*9N\EVM<?7XZC/DXATHW,
M$X8[U1-K'OH&3MM1GC)EKY84D1-5YM$'1*:QISC&;F?AB4([9QKV9+%9CHLX
M7%SW]QFH#=1*X]B A5I;B"^ML5EK%2;\WIN[*_DNPY&.:RGLK/VEKV*:YALS
M+8;K89O*V]A;X*=;29HV]N)G81V\]C<Y7$7Y QPLA:7N/CM"@.22^M[V\-LM
ME+#;2WE6C-[HMDVB[C*%4R0IR[)8TUK8Y%V\C45$V^QGE+LH%-)T"5BVTL]=
MQQA:>X-K<T1C7SIY)+,)E@C$NI:RZ.Q5E)#<9W*F\!Z<GS$N.MXH;EP9.G8<
MSCMBVSUK=/:PQ7 \[VB3$RO<010VR3V<[W<43?=99:]CFML#B19$=26^'BR-
MQ++;(RQ]1RX7) &YZ?N[2.ZFEMSY7L\>6BCMYY9KEX+VW2SEH=-Y'V!A46SZ
MV55]..H^B?AY:I*)<* TBTI"DSFP8YE&BG2H.!)!$C(QM!(+2<T2;:2CH6RQ
M)]I%O[&I>9?P\L+C+208K)P645QG/H+%V]VB^;=/;YJRP%Q-<@YF^OC?&YN9
M+Z1+:R-E+:Q"5#82W5OCELL/XC9"#$QS97%3WTMO@OIW*W-H[^3:K<86^Z@M
MX+8KA;&P%B+:VBL8WN;X7L5U+Y4@OXK:?(OG2I7BV3=]FJM,P]-8QT52ZS8?
M>H"W2%A=#*35DOD*NT1.XK,(W?,4F]20474%./=1;Q4[95&1!V4T=A.5PN*L
M\%992SO,O/<769R6/\J_Q5O81>RV6.P=XDKK'DKV2"=I,JZHO*XBN85$BO;F
M(BXSC$YS*WN>O<7>6>'@M[7"XS(>989:XR$OM=[DL[9/"C28VRCG@6/$HSMQ
MMY;69C&R7 F#6_>YGZ^U^-E,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K!_)O_ !;>0G^P_;'_  %/XI5QZ4_[
MFM2?[,J'_P *Q6*5DW%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I4 ^]?:7\Q*!LGFG'Z\U3KNSZRXT66YTI.SS6G]R,8*BOHC6''RYTBR7?;I
MMB1NNMJ2%WL^W[#67.F=?-:=?*E#5^)N4W,A"RR!W*OL*"!W]?M'V_#U'IZF
MJG9?:4<EH?;-PXN$+H/^-#6MSW8VLW(2OZKV7L355PJFF=+\<=P/ZSKO0$9O
M"KW!YNU5#D8VCK+13\@I-M3X765WM?OT^!DX&.4"C6SO7;ML ]R1O>CV&O77
MQU5CS/M5.3+^N\G-@Z^BM83M!U!4>&Z^NI4G&3=<O%W&9Y0:VX<WMU8)6W%Y
M UYJB\:EY(V)>JZ))6XNZ/HJ*KQI#8)7",H=\IQ'H=[[[&P3VY>@U]GK\_[)
M7>"6_;SR9XUUC;FQHFNPUJDKEM^J.VU:C9*N-7+36NW;QKB+E)2CS=CN,[K2
MT2L=56S^V:PG[=99_7MB<254FY=>3BW2:*OD]CV_W_U;_/KOZUN!BO*CTY:/
MWN[]G:RX=5ITN1A9'#78^\7[%0Q3Q.M:Z\(X90ZRJ?<"+BP2:*9D0.!56S\E
M:5.4S.0/UVST'%%TUA<UXA7J*9;-),1TS%*H(GS-W$4DN%5OK):0L0VO=>(W
MJ@B2(5I[Q!FEZHSF#\.+&1A%>O'FNJ9HF(-OA+.0-';,R_5>\G4%=Z9)18L0
M8YC6ZUIHD'9M=V#6AFB#*N3E.DZ45FV1*1NQB)"&6A$T6J)>A4R,VBI0;%)V
M^+Q)]@E$H"&N+')W-GE[3,B1I+RVR$.2,CL2\MQ%<+<EG8]R9)%)<GZW([WN
MMG7^*M;[#WF$,:16=UC9\8(T4!(K>:V:V547T CC8< -<>(UK0K5SV?]K?SG
M'*$JTX(ELVI+'9]56% YNJC9W6)(RL>U$H@!BE:0<C%LBB/H86IQ#IT$A,V\
M5;&*VZON;ZV'[BSUG99RT<#M)'>PA97!'8F2ZBGD/Q <;WV)P3PBR$MUT9:V
M%UVONGKR^P%XA/=)+&8M"FO4".UF@B'S,9U\AFWD!HVM<B=;O]8VR5G(:&D)
M*)DU7U>48)29%HAV5V@FF>28R+4$E%"@58#-3&$G4"&(;YV:%Z\Z)QWB#T[/
MTUE;J]L[.XN+6Y>?'M MR'M)1-&JFY@N(N+,-/N(G7H0>]=!] =<Y+P[ZDM^
MI\3:V-Y>6]M=VRP9%;A[5DO(3#(66VGMI>2J=IJ4#?U@P[5'M_(V<< !B'X9
M;,Z1:)6\:'6B=(YN0[14B#$/P*_FB)%6#%0J3?QD*=DT.!0,V1$FD?\ X5>C
M_P -_P#-76G[I<R7'[MQ?X>0K*IDF_X*_"N5GG4L_)BLTH)U(^]Z?_%GUG^
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M9**&;&$1$R0B.6Z?<L])QPQVT?5O6R6\5P+N*!+_ !JPQW2@!;F.)<6$2X4
M 3*HD   :KE_NK^KY)Y+F3I#H5[F:W-I+</C\FT\MJVRUM)*V6,CVY)),+,8
MSL[7O7\=>QBXSOFSQD]M6QGC.0*8C]HZ3H#AL^(9XO(F(\05I!TG)32#IR^,
M58IP%XX7="'G64.;V+[EKI2"2&:'J[K>&:W(:"6*_P ;')"1"EN#"Z8L-&1!
M'' "A4B&-(_J*JCR7[J[JZ>.:&?H_H2:&X!6>*7'9.2.=3,]P1,CY8K(#<2R
M3D.&!FD>4^^[,?6O[%[C&Z9A'.;-L)Q'E6:.2L5T-?+,RN(]!!JP7!JI1S(
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M0R8E,(#[_P#"YTL(IH!U?UQY-Q.+F>'Z0QWE3W*D,MQ-']&<))U9582N&D!
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M"IR[EO)TJG;"@Y8["(EI16,1DZO>H)P5G+ R>^?WE=BE(U]>$L$RJG_O_O\
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M4B2216\ E1-^X3&"O(@ ;.NX[ZUW^RXE'2Z*S,B/F I00["+ (%!RJ/1H82
M(BJ5$?,Y,!BE$QT!6#N!T %\"*0[,!\?0]R!W8?9OL.WH&]=BKSRU)9W&QK0
M/Q^T?F[[]/YZR'13/I"T1B)G)T6C(SETY$QP'WE5GXVY/()CCXTR+J$$YCB
M*.$W'4.ARE&VFCC2%F"CDQ7C\.()V?D.X[#T[:_/49DDBCL96$89I=JH[=]#
MWNVQQ]?_ &-;DV7E!=JPTB:_'RYFB#9(9$R@$2.[)$(B5!@F=4Q?*5%X'>Y#
MO,!A3152 !(!.VH+ZZ$4:K(RH#H$>N_36P-Z^&CV.P=?"M=VW1V-NI9[RYME
M);:D:+(7)XEBI)3E_E=C[O;N363J9S,>I* RLS%O(%1*1-RZ*)&KE)P =RZ)
MC$,*0BW,<K4_>GY!617$1'Z KPY>>/BLJB4$>I]TC6N_+7?>]@D$Z]?6HK(^
M',,G*6R>2W]3Q[/'\#]5CV]>X#@;]!\*WBH=XA=A5YO8H-4IFRJJK=9'RD54
M:N4>T3H+"GZ ?QG26+U HBDJF;M#NZ9D%M.MS$LJ#0)((]=$>HW\?@0>W8CM
M6K\MB[C$7KV5S]=51U;6A)&XVK ;.NX93W/O*>Y'>KRRO4;3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I6L?(KE%2./\81JZ ++?I-J+B!I+)T5%P= QCI)R\^]!
M-P$% @LFHF5VJ@N\D%4ED(EB^4;O!:U)FLL=8/F,U=>P8J.0PI(J++>9"Y55
M=K'$VC21>V72JZ-,S20VEDCQR7MS )H%FOL)A\UU3F8^G>F+$9++O&D]P9)&
M@QN'LG9D7(YN^6*865JS)(MM$D4]_D)(Y(L?:7)AN&@@YVMN+86Z;!^$.P)U
M21,W45-#P;0JC.M5Q)7J H0</YEDT#BF/B7DW:KR:>I@5-]).$TT4TM/=3=>
M9'.1R8VQC^A< S _1EM*7FO>!!CES-\$BDR<RD!UB*0XZWDV]G86SO(\G97A
MYX-=/=$-#EKUAU)U:(R'S]];JD=@9%*RP=.XTO-#A+5@S1O*DEQE;N(B/(Y.
M\C2%(L8Y@E;@JGRYCDB9,Z8F*<D>],0Q!$IRG*V5$HE$OJ!@$ $HAZ@/00]<
MRKH6*"?K?HZ"YCBEMINJNGHKB*=4>"2"3+V:2QS)(#&\3QEED5P49"0P*DBL
M$\4I[JU\,?$:YLI9X+VWZ$ZOGM)K5Y([F&ZAZ?R$EO+;R0E98YXY51X7B99$
MD"LA# &K1I$;,-@>R,N4H*R/A-W.04/)G\(=I#+'.?HDCVB( D8@K', &.)"
MD(!]Y_=$]7]!Y=L!TMT3)(]MTH]]$4Q/LEOTE![:XDN(["&*WYWEYYR*6O()
MTL(H^:0"YDGEDBY<^X]\/O%;I].K.NO$V*&.]Z]CQ4PESPO[OK^[&-B,-G+E
M;J>Z,>.QPMI&"8ZZMI,K/+Y<ETUG%:P13W]G,5=O4Q2K:M[(7M?D"D ?*V3!
MZB(?E%.T,"QA+_XA1*J0 ^GJ;T 3=,V[X%9].G_%'I>6<CV+*W4G3]\CZ\N6
M'-Q-80K+OMY27TMI,_+W=1>]I=FN>_NI>DY.K? WKB"U5OI+ V,75V+ECWYT
M%STQ.F5N'@X^]YTF,@R%M'P]_E/[FVT#5HMX$A&L7P=/YTU16, ?050Q \I/
MS?D*=Y!Z>G4OIZ9A/6F ?I;JWJ/IY@P&(S-_90EM[DM8KA_8YN_?4]J89EWW
MXN-ULWPUZKCZZ\/^C>KT96;J'IS$Y*Y":XQ7T]I%](V_;MRMK\7-NP'8-$0.
MU??F,5F]?P0 >T?SD.10A@$2F343."B2J9P$#$424*51-0@@=,Y2G(8#% 0O
M<?D;_$W<-_C+RYL+VW;E#=6DSP3QD@A@LD95N+*2KH25="R.&5B#&Y?#8G/X
MZYQ.;QMEEL9>)Y=U89"VBNK6900R\X9E="R.%>-P \4BK)&RNJL)%N.'.ZP4
MQ6/INZG;ZTT\3)-&5X.59_:JRGZ)I_'@(55U:X=(.T57P@K9V90455/804(D
MSW5T[UICNI"EEF#9X;/OI8+U1%9X3+N= 1W*;2WPF0D;?":,186X+*CQXHQF
M2ZX]\1?!3*]()-FNCUO^H.F(PTEYA':;(=1X&(=VFQTA\R[ZCQ<2]Y+68S=0
M6JHSQ39L2B&SF+BI:,G8QA-0L@REHB5:(/XV3CG*+Q@_9.DRK-G;-TW.H@X;
MKI&*HDJD<Q#D, E$0',FFAFMI9(+B*2&>%VCEBE1DDCD0Z9'1@&5E((((!!K
M2T$\-S#'<6\L<\$R+)%-$ZR1R1N-JZ.I*LK [!!(-5#*55:8I3%*8I3%*8I3
M%*8I3%*8I3%*8I3%*8I45/-/D\$P+[16LWB;I5V<S6\3;=X1!J#%(!^(Q7OP
M]6S>*0("A9Q\L<$CBBNU[5F325*>*O;M=-&A]U3J5@=$M\(DT06._K\>^O=!
M!.QNKP[Z(4^7U'FXOW/$!)8V4JZ,F_J74JL.Z@]X8QIF[2^G&N<OE;O6M4*$
ME)):34D:?43$2CB(=[4MMMH(*MFB4<FJ4ZJAC.#NTV8N!6+#1(*2"Q3.1DEW
MN<]%]-W.0N+>WAA_X0OS[K-LBVL@=L\NAM%4 ,QT"Y' ;VBCHK(Y[">'O2M[
MU?U(_E"UM^5K#L">?F&%EC;)'/OW=S+Q52W(QH'EE(CCD9>;J_7JP;)MDQ<K
M.Z%S*R[CR&* F\#)JF'C9QK(AO\ !,F#<"-T"!ZB!154$ZRBJA^Q<)B+7!8Z
M"PM0 L8Y22$!7GF8#S)I-?PG([ [X+Q0'2BORSZ[ZVS/B#U+D.ILW+RN+M^%
MO;*S&WQ]C&6]FL;56^K# I.R #+*TL[[DE<FSLE=:/KV)/;7KO[:P^NW'V,N
MO6U X T"6*R!E+;(L5OV!+*G\:IWA'5C<UR)5[D@Z@FI7JQ#"@D8!.F*R@&Z
M&$_7AGQ=R3W_ %WG.3\TL6M<= "2>"001EU'?XW$D[-K^$Q%=A>'MBMET5@$
M5 'EADR;D_X6:_N9NS#X@VL=LA^.D7U JJ[ZL(/+?:W#DQ1[7,=$(].GS"@S
M3?NE2=3&Z(,?=9&!* B(F2?('Z@!SE' [&/DRA3O;&1B>XUOB!\]]U?_ +'K
MVKI7I>V*6-M$ONAI7F;D.S1'LGRUM>3+_E?.LE\!JW+O^1U!?,(U\Y;183DS
M(KD#^;QT*G!2<<1Z].)0(F19^_:-40#M,LNY0*F!@(?I**S276@IX1G6SKU"
MD?V=_CW^6_2$\4[V"'I/*0SDQ^UO:P6*MK=Q*EU%*2HURTD4<C$GX#?Q[]%^
M2%<ETQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5I+R5Y*Q=38RU'JKL%Y=RV<QTY
M--' %^#BN0R2\9%K)CT/."B*A7#DJA$H3J!Q.9^04FT3?W_E[MX-/,RD,0>T
M8/;>P?K#?I\-CX]JV/T9T9-DY8<ED8VCL$=98(6'%[TH0P)V/=MNVRW^% *K
MI=M414VVC))N[FK0S1?0CA!:*;5U8"BSFDQ*9 \<LB=(R:T.DBJ9)X8P'*[.
MH+3L4%?PGB(0^A$CZD)+R2[V5#=]D]MR'7N_$#1]=D;ME>5P,78E59U*WMP2
M&BMH) 4\MP/=,TBCBJ>NCH:YEDH*BKARNR6?*IMTB()J U0(D1C',&A"F;,6
M#=+H1!LF(I)IHE_%@"*!/3URJ%"!EC&^W$'N"6/JY8[^WY^IU]DE:6D-E%[/
M;KI0JJS: YL![SD]_K>NMZ4#0TNM>'G.W,I)%1,JY[V[5@D*A1%U-N4O=B%$
M@>0X(PJ)$4S'[>B94S].O>;M]"\CP[ !2S,?01!M_/ZTC;[>O?[-&Z"[<@CL
ML8< @<6'Q 'KL=]^A['7;59_U=3D8N/0>.P6=*3KQ,QOF"91:)BD3NB()"<P
MB*DL]**ZXC^6HX.4_4"%RQN)3*X'8(@[ D>O+WOY.P4#Y ;^%8OE;[S99H4!
MU&@[>FF)T3\1Z;/ILC^6L:7>9-+6YW/E<',Q0=/5%6A0*5"2:192(LR"82@8
M&KV426]R0+V]S:43.J8 3Z#=0A5C:(J"S<2K=R8R_P!;^7B=GY&,ZWZU,8Z$
M6V.CA*GG(JRML=P">*JWQ$A')B-]M,0=Z!I57AY^Q3\#7(8RS^;L4@W;-T"*
M= D)%\L'4'*W=VI>1PJ=9=8X]J2?G54,!2&'/?)$[^6H"[= HUZ#OV)]==@/
MS=_SKZYMK"TN+N[D6*TM$-Q,=;!6,,>  T3)(_%8U[EG8+OO4_FF-8M-2T&)
MJ23H)"0)WR$]* F"024V\*F+U=), #QM4@329L4S=5",FS<%C'6\AS9);P);
MQ+$@  [G7Q8^I_W^&JY9Z@S$N=RMSD9$$2RMQ@A7TAMT[1)]K<?>=O1G+$:&
M@,JY6J%IBE,4IBE,4IBE,4IBE,4IBE,4IBE:E\JN3D7H*MIQT.#.6V=9&JIJ
MS"KB*K6*9]QT%+38$TE$U2Q358ITF#(%$7$](I'9-5$6C66D8SVYNL?A\=+F
M\R7]@AD,%M:Q.L=WF+\()%QUFS*XC5%9)<A?&.2+'6KH[)-=7%C:7<MTYTYF
M>M,]!TST\J+>21K=9+)3QM+8]/8HR&)LG?(KQF:65TD@Q.-66.?*WD<B+)!8
MVF2O[&!>=G9JT34I9+)*O9VP3;L[^7F)%7S/7[M0"E%14P%(FFFDF1-NU:MT
MT6;%HD@R8MVS-N@@GH/J'J+)=2WYO\BZ (GD65E;J8['&V:LS1V5C 6?RH(R
M[,S,TD]Q,\EU=S3W4TT\G>O1?16!Z#PL>%P5NRH7]HR%_<%9<EF,@R(DV2RE
MTJ1^T7<PC1 %2.WM;>.&RL8+6QM[>VBI>059;3%*8I3%*]Z35RN( @W76$?H
M\22A_P#_ "4<D+/$Y7(]L?C,A?'>M6=G<W7?Y?@(W[_94/D^H<!A1O,9S#XH
M:WO)9*RL>WS_ '5-%V^VOI&)E0#J,:^ /ZQ:K@'_ +1)DL_1?6$:>8_2O42I
MK?(X7(@:]=G]S=AKUWZ?&L?C\3?#>63RHNO^BY)"=!%ZGPI;?IK0O=[KX5FY
MP R3A$Y0.42F(J0Q.XI@$# (& !Z" B Y"E+_%W4,CQ7-C=VTL<\)EBD@FBE
MB</'(JR*K!D=0P.O45DJS8G/V%Q#%<6.5QU[!-:W'LUQ#=V\\%Q&T4T3/ [H
M5DC=E8!OJM]M672SF19/XA4PBK#2;IH #](MSG%5%3KT#J"AQ7$OI^2 =/3H
M ;R^Z#@BR'4/3775HBK:=?\ 2&&S3%!I5R4%K'9WMO\ 'W[>!+ 2]^0D=@PV
M-MS!]R+=7&)Z1ZU\+,A*[Y#PF\0NI.FHUD.W?#7=[-D,;=_ ^7=W4F5>$@<&
MB160\2%6\LT#765,4IBE;?<5>4\QHB;1KMC7>2NI9AX)I2-*"KMU3GCI03+6
M2NH%[U1:&5.*UA@6Q3 _(*LK&(_&B.&\WN;HSK*/)16W3?4=RD=Q&B6V SUS
M($$84!(,+F)W(!L2 L6,R,S;Q;<+2Z?Z),<F*Y2\8?"![5[[KGHFQ=R[2WO5
M?2]E$7-Z6)DN>H<#:Q@D993RGR^*@76<7S+VSC^G1+%FYY(R2CYF.82\2]:R
M45*,VTA&R+%=-RS?,7B)'#1XT<(F.DNW<H*$6163,8BB9RG*(@(#F;30RV\L
ML$\;PS0R/%+%(I22.2-BKQNK %61@592-@@@USA#-%<0Q7$$B303QI+#-&P>
M.6*10\<B.I*LCJ0RL"00017W93JI3%*8I3%*8I3%*8I3%*8I3%*8I3%*CFYG
M<J5J6B[U+K602-<WS<$;5,-E %2LL7:8'".:J=2IIR[UF*RSAP*Q#13(!5[T
M%3JO8N.O;K@&BC/OD ,R[)3?HHT#[Y_G4$$ L5!VGX?=$C,,<UDPRXZSEB,$
M!39OY0^R-$CE"I7CI0WFMR7T5@W/9M';<.DC)HQLBT1KL.59Y9+4[.<C*6=,
M$O>!$5E103-6(4"BX RIDQEY0&DBL5LQ:QC=O,XG!L3"9XV>XE91%;J.4D8<
MZ1. #-[1.Q*@ $HO)>[LQKK:RQEK:0_2.6DM[6TM(C>2-<,D=K86T49D#W!8
MK&ONJQ=I& B"GE\37/'MN_W;EKN&N476\'*335Q,!6=9U)@BJ=Y*O)%<"+33
MAN8A/=G4H) =NS. 30AXM'J[5)X'[M7K#IS$8_H3 769S<L-O<"W]JR5R^M6
ML"@%;.,@$MIN(XILS7)5(^06(5^>'C#XE9/QBZPM<+@!._3UA=-9]/V0Y1B\
MF8\)\Q<QG0B\U59HA)H65BOO\':X9I+5>'.C-!U-*@3,)#[/VL\CRH;#N\P
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M^Z)JBT0=)++@1(1.%18I6CDE6-VBB*"615)2,R%A&'8#2\RK!=D<B"!WKPL
M0I(!;>AON=:WH?'6QNJYE.O:8I3%*8I3%*8I3%*CYY+\JTX9)[2M</Q,Z[5F
M\S9V*HD,FHF*B:\;!K]OH)1+VO9I$PE1[O=XU0SD3N&T/>9 #E#;L.7H\OP3
MY@?Y7S/P_/6U>C.AC>%,IF8N-JH$EO9R;!G&MB6X .UB]"D;:,G<N @T\8[I
M>5/-Q9IUD4R#\RJRY5'(J*MHY!+WAV8[,$SG*(D,03=3JJ' RIECD.4 -#@1
M,'*2;D7YJ?>=CH>\?7OL[T.Y WW)K<5S);6UA<O X#16[1QB(<2K/^"C$>B
M C%>(76AV ^!I8N9FV.C.U@*=A'-7;U)H)&[5E%1Y5$R)+N3_-!NR9$4;"JN
M8YUW;P@$03.*221JA585*H&Y-Q#'9)9AL[[^I8\N^AQ'_.[?=K;08NW(4R/)
M<<//=FV9)P"4TOH%0DE6UV+;8L3LT>12;$5;)M2K 4YT4TUW!P[W"Q?G%6!C
MX4Q9M$A\K@C<YUE%4TFIEO$J91!+[BV%/+N>YUKY^NF^)WH;^'VCO5_!S"$2
M'TVWIWTWP/?Y#^;^:OJ9"S9.TD%/G+>[D08?C2G4]\?+I)+N#%$1$">,O3J
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M^'YNP)JR']JE[I8',[WI(1,C'FBHZ,%KU<QK(Z[H71U70K"19P^;] <&!'M
M7*OC.=%)MTNWABM8A 03/%*6DDW[K]AQ4+QV.)V22WR[ [J[^C+:WM8+23G)
M<VUQY\[['&9QLQJVQRXQL5<D%=E%V2 :^U@J!V8$5,5!JJ1-TL4#""SPB9SF
M8E<B8_8G'L?$5XDD"?:HZ,+E917W1L1*U=2&[ DD\0?X/?LX4?%CO1)]% T-
M'M]21 RAW4GN G+^,?K:!UW4:9@>X&M$&OD%@_2<QZZB+DQ7BRID'+T621S$
M$#.3',T14!PB -2IH( JU2-XP QR^83":J)(R' 91P4;5>?;6A]8C1[G;$-]
M8GX=JK"1&VO)257ZGIZ$#?RT#W/<D'X? WC,*H1=)IY&C(WQ*P6Y^X<*-S *
MBWP6650#N*8  RARKQK=+N#QD1;"/01]!I*A>25V/NK;A=L?J\X]@C7R[GMZ
M[/?OLQL8=[^[#,WE):P+V;83VB(MS ]"5*<5WVT3H&LTVM\<NO'S) 0 Y%F;
M)Z8WS"';A(M&ABE .H=RSA\B"91Z@/C-U ?3I:0=Y$7?NJ6;?QV$9@-;^8]?
MEK6Z@[).68C=^X?S2H_-&[#?K\5'??\ ;NM9.WXN_;%:"DX,X=OHMJ!3CT66
M3^"H&)T^CT>J'0ZB(=0 Q>\.O49)4*J$8?7\LL"/3D7(T3V[@@_^U98[BWAD
MDE ")&TLF_3@B%F_D]T@_9]M=&&MZ6PUY1*M2XX ]WK\.T8J*]A2&=/ 3!20
M>JE)\WS/GRCAVKZC^,6-\X?IS(XUX(J#^" *Y#RN1GRV1O,C<-RENYWE/<D(
MI.HXUWWX1QA8T!]%45>V?=1],4IBE,4IBE,4IBE,4IBE,4IBE,4J"7G)NM39
MVUEZ?$.A4INKW#V#:E24 S>3MX&]WM$N8"CVG^'+)?@RP\A1.W%A,KME!;3)
MP'#/$C,&PLK/I2V?4]TMMF.H&4Z8"6,387%,?7C#:RC+7*@E)9KZQ21!/C5(
MZ)^YXZ.%Y<9#Q%R$7*.-[SI_I)7&PL<$QM^HLVBGMYEU>PG"6<A EAML;D7A
M=K;,,#I3FFJZOIBE>1"'4.5-,ICG.8"$(4!$QC&'H4I0#U$1$0  #Z1RK!!-
M<S16]O%)///(D,,,2-)+++(P2..-%!9W=B%55!+$@ ;JA=75M96UQ>7D\-K:
M6D,MS=7-Q(L4%O;P(TDTTTKE4CBBC5GD=R%55+$@"MW.-/%F:VA(EDY %(RO
M,%B!*SATP.5%0 *?X7#IG#QO)8Q#%,LL/<UCDS$56[CG;H.^J^D^A\1X:V=K
MF^HX(,KUI<QK/88MRLEK@PP]V67197ND.PUQWXR Q67[W)=G\Z?%3QFS_C#?
MWO2O15U<X/PXM)GM<IFHP\%_U0RDAXXR>,D6.D'>.S]PRPL)\G^^Q6"3/4;7
MM2US#)PE2B&\:V*4@N7 %!20D5B%[1=23TP>9VX-ZCU.()I (IMTD40*F6EE
M,QD,S<FZR%P\S]^"?5AA4G?"&(>[&H^P<FUMV9MDX?B,+C<':K:8ZV2! !YC
MZY33N!KS)Y3[TCGN>YXKOBBJH"B],C*E:8I3%*8I6@'.@IJ,]X[<AFY1(.GM
MPQ32QN$P$IDZ)>2IQEF%10/Z)P8,V"0&[@(>3.8 $#'*?:OAD?I./JWI)SO[
MX>GYWLT/H<IC.4UEH$^H\V25M:V( ">P(U'XJ;Q4G1W6*#7WN=1P1WKC8(Q6
M5"P7W(CX$0QQ+O8!G/8[(;/VY^/5+W#'+N5$&\1:A;F!E8FJ"9@=?,_%-II
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MPU*P.ZXDTE3MFMPK@+N4U7;@C2DO56+>#+7"^T&/#SK!<_@D!E#W+VBSVVY
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M!H.!ORI=!9E'PD#H,RQV12\3BVEN%'OIZ!O\M/L^8]5_-WJ;7,%J3IBE,4K
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M]-<6;<H(S\HT4_/8+$[_ )P/AH[&JV)XSW9DR>!L^X%MB#+\>[75RX)U\]0
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MJJ-?BJQS"5NX7*4QA,_LD@W(5,B0>\,HYB9<"E5B@5>Q#&2^NXH(_P#".$0
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MD[GJ/*QAB"UKCD]DM591ZHZ395N_;G A'==CHA  * %* %*4  I0     .@
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MU^SC;7MO<+_/[<2#\1]E27?P>^6%24Y7U;R]IWU:UM+-RB F*!FSF[1JQQ*
M_D]TDT X@'Y(=/SAF#?=$P<K;IFX ^I<92 MV'>2.TD4?$'M"Y^?J?LK4?@=
M,%N\Y"3W:.Q=1OMI7N%<Z_,R_'X:]2*Z;?9\/PC-A;RJH]2%?.$)U!(RGY"<
M;+OF)032Z ':5M+LTQ. >@$3 WY09S]BY.1=>W[W&=?9W(/S[\ZWWXKQ"7&]
M,WV^3!9[=VT?2:"VN8O7Y@2 #U' @U*GDQ6DZ8I3%*8I3%*Q]9M4ZZN=TU[L
M.UU&&L%RU0K9'.N)R5;>^.*<_MK!I$S\I!I+&,U:3#Z*9EBRRY4!DFD<YD63
M)TW;2DBFYN(KNY@@N;:&9XX;L1"YC0\1,L+%XTD([E%=N7#?$L%9@2JZ^&1&
M9'906CV4)[\2PT2/D2.V_76_F:R#EO7W3%*8I4.W.SES#$L,MH^MS3=O(5Q^
MR;6%DN*[1=W/*M4))KY 6*D@[BXQJY;N&2)#K%>S?8NHF"<:W.K1N+"_NA&$
MMY?8R#)),HV) K,OEC6R &4\M@#7QU70'AAT!<R6UMU+=VAFCO YL- .L-ND
MCQ/.>QU-+)'(B?%(T8_X0\=)M81+&$BIS;]M4<J0M8CI*8:)+?/<22S0JQ5W
M8@L( H4'21FC(3'ZKR2@F[@\/<>,N6-S/#B[5=.\B(W;2@L0%3?\7^$[=^(&
MOLK9N4N/:IX,%8%O,EEC25FV JDA2!VTJIK;,?0#OZ@U:T;)6[:%H;*HJ.)5
M\HU*DX!)1(C=DV[2%<-TB(&]V;IH+*D;@5$1,NY-Y3B983F+]3008^"1' #\
MM+V)9F!V" ='WO7N-:/PV-W4T-E@K26.4JCJY4DC;/(NF.M\=@G1[Z&B"?@:
MSLIK*JT.K2&P]A&7!A4DD)9XQ15,^;**-WK<[!J,<DFU56,BN=DH1%-^4[IV
MHD!C)I) 96/@-Y>SI:VW$-<,8T&@&8R#BP))T 03L_!=UC2Y.[R=[#BK!0!>
M.R!F]T$..,@[#OVV?S'7?U-[WEPO>M0@]9D?)*V%"*LJB*+A5C)2$,*3>8:-
M3G9*D,T3<NQC&+U-B^\K=HX<I>1%50RP4(C[%>B-^.XI'B9M<XP03$SKR!5N
M +,.2D<AL@Z(-C81IC\Z8Y9"[6TLD!;?N)Q;B2&].[$@?#0]-5IJG6[18+-7
M*BU8/$9&?DHV!KS)9N9HW67D7:,<T;M6X% B+5F[>$!=/L R?>=RY[U%CKGR
M.T>*17>,I*PY-)Q;DVV[ D^NVUZ[UVTN@-5GKY&SM;&_R/-'CLH;J]NN)!VD
M,+'OZ:T1K7;O\S74+4*U'4VJURI1*2:$;6H2,A&::1"IE!"-9HM"&[2^@&4\
M7D./TF.<QC")A$1NE&@!\@!_MKB>\NI+V[N;R8EI;J>6=RQV>4KLY&_LWH?
M  #M4"VU)(EGVML5\W,!DY&\NTDA  'J0[\#)#VG#KV=CL@B(&[?4WY@S%[G
M?G2$^ADE8?FY,-]CK?N'X;[>FNU=2X"!K;IS%PMV(QUH2I]0?9HR=C8(T ?4
M'TJS^5:"4G9ZO&**'3,T31DCJ="B51H%N.9NBCU,!S>(S,@..@=J9'"(>OD
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M'/%5Q@*3FP3)R]P #)@*B?8W Y>Q61>*-8Y _1-5T54Z:9[.\O[6PC\VZEX
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M_BV E4;[F-HS\N0)?_4FQZ?'YUU-U]$MWT)9W*:)L[ZT>0^I (N+<]_D#<Q
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M@CX5V9]SRX?PHPWIM,]U\C ? CQ!ZI*[^TH5;[0P/QK$^:]K=E,4J3_V=:Q
MMDTD(AWFIDF!0_./CL<,8P!_J Y1'_U?V]>K>FB'\&NF2O\ @L]DD?T^L;C*
M,-_:58?R?R5^;'BTIC^Z-ZSY_P"&Z;P3Q[[;5<=AD.OF.2,-_8>_PJ7'(JHZ
MF*4Q2F*4Q2J5-SL-6HI[.6"480L/'(F</I.2=),V35$O0.]9PN8B9>IA A"]
M>Y10Q4R 8YBE'QF5%9W941069W8*JJ/5F9B%51\22 /B:J112SR)##')--*P
M2.*)&DED=NRI'&@9W9CV"J"2?05SH<ZN4>DF<N^N<?#6>=:.I0T<-N<1P)&=
M.5$7*C9K!0S<L4NBT\+?HA,7:4D':OC(T;,XMN1LD;'LC<6^8G>SQOL-S<PP
MKYEQ-<NUG"HTGF1P689;Z522H:Z5K>)G/%)4</6S<#:WW2&/@R74+92RLKBY
M98K"SL8SD;AW5I1#<7F096Q4+J@=H\<\-S,(P7FBEC,=:#7S=%:;Z53OTE4I
M1_#7%HI&-*[(H%!5RG*$?(MB2[E%95&/8/6C<[GWI)5<XHKH%:@JX4)T@K#"
MS193V8Y)^=GY5R3;O%;IQ/EEC';@2B732"%PRQA2&$HXE%DR[,]66<W3(R38
M-7@R@GL1%>QS74C%O.6,3WO*%K=7BA-S&R23,RO$T&W\UX?FUOI6_/>.5<ON
MI./0/G$TX1EC2MG2=&J\-)/%E8M"R-Y>U&%J]_%MT#1+1&0*X*W=%%([@#.0
M<Y1'C<[ELY)CQ=WEOC %N+>&VYVL<P,*2LLMXG C09D9^9>15X((B\9.NY\_
MT?TUT;;YH8[$7.=)>WO);]H\A/:,+F6W2:#'3&4MS,<<D48C6*)I!)(T_ES"
MMBYLL)I?7<+9-U75NV6:LXB)DWD7&.'BDS93L0,Y)'-FS<AE%G:S5XX( ,4T
M4D2'4/[LB0W2:N/#G&V[SW>1S%S!;32%/(L8@DAB8L1;)<2FX?RB-[B2W13W
M,K2Z4KA]GX_9N^CM,9@.EK.]O[:!9&OLO=;@,\857OWL;5;1!-S((EDO)&4D
M+"D.W#Y6U#*42\049>H"$DI&)6=*E:MK[ *HMY1)N)2J'6@Y%$C.2B78',F1
M845FS@ 5*F<%$C"3),/T1TA#"MQ;8DRL3[EQ?O<23[76I$21Q$A!]Y9(HD]X
M>Z=#5:^ZI\8O%&>[>RONH(+5%&Y+/#0V<5MQ?D&@FFCC>Z=2NUDAFN6]TCD-
MG=-H+I.9I)PW8,(M!<':Z$9%-B,HN.15=G.DPC62?4C2/9D$K=FV)\Q!NFFD
M7T(&85]T,JQ9#HV $DP].E3R.VXB944L>VR2C;.AL@UTK]Q4[S]/^(EVP4"Y
MZKMWT@(0.UD\KA 2=*/-70V2!K9-8TSG6NV:8I4TGLV$C)Z5O)A^A;<$PJ3^
MTH4'7"(__,D8/_5G1F#4CH[HDG^%A<FP_-]^/5*__P :_/OQ0D#^*WB,H_P6
M:P,9_/\ >!T=)_8) #]H_DJ0S+RL+IBE,4IBE,4IBE<N/M%=:N-=<XK,_0:'
M:Q.]:.WME<=IID, 7&,C31[XK$3=A D5I6![%2F,!S!9@'N*+@ALR".02X+9
M/_%UZKR#O[UI*P,H;B-\!R9^_;\$-]M@]L^#><&0\-(+9I?PW3F4GMY1W9_9
M7;VM/=!!"".;BI^J6C*COV$<NU^)UKW?-P&DK0>2KZ:$M!V:2BV"K1W+J>2.
MD546<DZ!=TSBG;M%^>9D7+KSJLF+<0%N#MRB)Y;"]:V_3*7&<L8H[JY>UFLK
M=IP\<22220-(R(.+RJOE^6B\D4LP);@KK7QXK=,8'Q+Z9QEM=Y>ZLL/CLM#D
M+T6T*I<Y&6"UNX#803S!H[=FGGY-<M#. BGC'R8,LY'$GAMI_B[38^#H5+A&
MMBD#(/9:P+1R;B?\(I(E3;J2COS/3=>T156,J5585EC=B:0))IZQSG4N9ZJO
M9+W-7DUVQY")"Q$$"D':00CC'$@]=(JDD LS-W.E8[7#82$X_IK&6^(QL:@M
M'""T]RZ^[YUY=L3<74A'?G-(S#T0*NE$7>]&PM^4M_@O?7"D8T2,+P"JG62.
M+!Z9-(R;9'M0<+'\@-6I@2,X,JY\2?43#URG$HB=)PR*BF8WTR(_$<R&/U>0
M][A[O)OAI>1T*ZAZ8:-.A+2[?M-,><LLFO,"K&-[XC7E#RRS,=E5T2>S:Z4N
M#G'P^C-1MGE@CDV6P[\5I/6IOV%\D$Q*FH-<IY3E$W4*^P<G-("!C%6GW\PN
M011.B4D=\2=[)]6/Q^W7;6_EZ@:!]*XR\1^KI.J\_-)$X.,L&DM<<B#BCH&
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M_>UH ;()UVV!L_&MG-3/Z<TC&%7@K?%3?N< \@W,PT>-S/&Z$"61=+2#L!4
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M(09.:T>_Z?NIL5* 8(9X6\B)C;'B2^P83RV/@#5+.=-G&PM/;.7D@R,UL\B
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M4U,4IBE,4IBE,4IBE,4IBE0L\\O9L/MD3DSN?0Z"1K7*++R=SU\*S9F6POE
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MUSB>I+R60333]8YJ2YD4:#\1"58#0(5N9.CWUK=-+42RLEJ[.NT_<6D/KYM
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MZLK#L58%6'YP=$5YY4KYIBE,4IBE,4IBE,4K23GQKL]ST8ZL;)#RRFM99O;
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MC;6L$:NJ6UG8VJP@R.?+0 @O*S-L*J>9P[C2!MDU76F_-8[=E9N)U]-/IY2
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M'V1RAU''7NF/[=];]16DECD;Q2.,<X-U%(&]?-+%H_D/+<.H]#K1/SK.>G>
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M[D'L-=OB3\/S[K)_L>:L\@>'4=-/$#(!>+_;[*Q Q1**D>@:/K:*WKZF!5>
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MJ[3],93/]'W!)?6$R<WL+R>H,^-O#<VLL8/^#58AKL"HU4NO4-U( E_!9Y-
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MCJ/1F#Q)Z=Z=L,5(O#(7Q3-YH$:>.XN80,9CY/MQN-<2NC 2V]_D\E:RCE"
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M'N1<O43 (_U"FY+T_L /0/IZ9#R>$'ATY)7IN&!C_"M;W)VQ'YO)O4 _D%7
MZCS0];YV'R>*!P?SAHCL_:>X^=>D==P)?_-W$XS_ *@:S3\@!_: **J=.F4#
MX0]*I_>=UU-C>^P+'J7*Q@?+0EGF]/AO?\U??WQY C4B6,_VRV-NQ/\ *J+_
M +Z^5/P'.G_YK;K@@(?D@:7*X3 /S!XUFX@(!_:(B/YQP/#*2'^\NO\ Q#MB
M/02=0"[C&O@([BT8:^PD]NU/IQ7WYN'PLF_BMFT3>GKRCE!'S[:'V=Z?@M9$
MPZ-KW+%Z>I?>H^/=^O\ XA,5,3!_8';_ %]<^3T-UE%_>7BGGD ^J+[$8C('
M_M,R0EO[-T^E<:W[Y@+0_/R[FYA_F"D@'[='\U/@]\2Z>.XL'/I_Z57D$O7I
MT >J"XC^8!'J(^HC_8&/O=\4X/WGQ#Q5Z/@+[I*UA_D+6EUO\Y_LI[9@&'O8
M:XB/_P!K(R/_ .)'_P"E:3<T./EVV744+Y'I0LM;-?,7BIV\.T>HR]BJ@B+J
M1BTT/QI'KZ*4!28AFQ0.NH896-8)BYFLF\=A.N\];7/3G5=_TE=V<RO=X*_L
M8;_'WMCU"BHD*S&Y:6T&-R\"MC;\<[=89SC<E+*T6+,$TOTQUCC^@NI+/JK&
MP97V1D7&=58_<=RM]T[)(TC7-O%$HFFR6 N6^D\>H266>V.6Q=NBS982QPQ%
M,4Q2G*(&*<I3%,40$IBF #%,40]!*8! 2B B @("'IFI;BWGM+B>UNH9+>YM
MII+>X@F1HYH)X7,<L,L; ,DD<BLCHP#*P((!%=]VEW:Y"TM;^QN(;NRO;>&[
ML[NVD2:WN;6XC6:WN()HRR2PS1.DD4B,5=&5E)!!K^Y1JXIBE9 HFQ)^B2S&
M3B7[MFJQ7!=JX:*BFZ9G$#%.9 WY)TE2&,FY:+ 9NY1.HBJ02**%-MKP]\4K
MOI-&PF8MSF^D[IB+C'2$--8F1MO<8UI"%0A_PK6Q9(WD'F126\[&8\Z>-'W/
M^+\26'4F N8^FNO[*,>S9B-"MKEEB3C%:9J.(%G 0>1%?HDEQ#$1#-'=VJ);
MKN$6U:VW Q0<J!"Z]O8>KF5:H+(4JT+"3H!I-BV[_P #I550!.JZ09+1#E4R
MBS@&!3=Y>F<6UGE[(Y3I/))U#B)%4O;B1?IC%D^\;>>&0I-+H?X.<1W7%1Y?
MM*L&;\ZNK>G<MTUE'PG6V$DZ0ZAC+\+IH7^@<XBD(+JTN80]M&KGN;BT,MH7
M9A/[)(K(NO&Y>.47LYLPJNQ:]/2D?'.5)IFV@IF52BI0B28I&?D=UUY[A-QZ
M1.\4GJ:SE)J(K"@N@<RW6E<6=MD%6*Y#^7&^W0M- R/KZLL1\MUD WQCE4."
M>P&^\'87N6P4\CV2()9HM"40PW:/""3YEO,%E1HCZM+"Y0@>\3Q[4KX(GK'7
M2D+JRE-9 :W%JIU>F-9)"&;OG)E3*^!26DC*IH'<.%UGCQ\\467<*F654.JX
M6[C?97V:W*6EN"(4(@M@XC!T=A>;[ ))+.S;+,2QY,>]D)CDL@)LI>M'[3*#
M=7C1M,R+H#D(H@"W%5"(B *H"@ *O:BZEEMR3,3(.]PU2IU!^9TD$-%UJ77E
MG)&78<5_BZ@JO&!5BG\0-S,9!?RE%454&XD3\OME+>3!Y+^&""7EN-(G+JW;
MUE))52#HCBQ5M$%8QHFKEH<1!+&F'NKJ[B"'SI;F(1#GL<1" $<C6]\T4J>.
MF?9U=6Q8&Z3=3DH:D6E.A69XFU]QL;J"3G!8-SJ(K+&0C73AJB*KID)DVSI0
M52H J5=-(YP3.1=)<212)#,+>9NPF,8EX^][VE+ $GN QWHG8&P-4+"6TM[N
M.6_M&O;==EK83-;\R5W&2ZJ3Q!*L5[!U[;T>]$U92;'0:XI%VS8]@V9,.'AW
MJ\[8$6S04>]%)+W*-9(&74:L2F2,L5)P^?* JLJ)52)]J1*F+QMZR^2DEQ?S
M%N32LH4)O0 V/=C0:W[[GN3H^@'UF,E97,XGAL;7%0*G!8(69N>B3S=B!YDF
MB >$:C0'8]S5QSEG8PZ9@.<%7(@/C:)F+Y1_S14'J/@3_K$P"80'YA!Z"&6_
M576/2_A_!SRL\>6Z@\OE:X.TD1IA(1R22^<<EMH=D:EG0NR[,$%PRG6?^%_@
MQUQXMW<9Q5I)A.EUDXWW5.1@D6T$:MQDBQL9\MLG=@ CR+9Q'&^A=75JK*6P
MI*RSR7<F<NS]?I!)(HCXD2?YB91'T_M,/SC#ZF$1SCOJ_K'-]:Y5\IF9^1')
M+2SBY+:6%N6V(+6(D\1Z&25BTLS#G*['6OU*\./#3I?PNP$>!Z9M. ;A+D<E
M<<'R.7NU7B;J^G55Y$;800(%M[6-C'!&@+<J9F*UL"F*5G#CSI64WOLN+I[<
MKA"NL_%,WF80$R?PJL(+E*NW1<%_P,O/J :(A0 15364=2I4EFT.] NRO#OI
MN.^NI.HLG LN&PLR>5!,H:++9KCYMECN#=IK6WTM]EQW06:1V<C12Y.T9M">
M.OB$_3>'CZ3P=TT/5/5%O*GM%N_&? =/<O(R6:+K[T%Y< OC<"Q*NV1DEOX5
MFAP]ZB]&<;&L(>.81$4T;Q\7%,FL;&L&B946K)@Q03:LVC9$@ 1)NV;I)HHI
ME "D3(4I0  #-I332W$TL\\C2S3R/--*Y+/)+(Q>21V/=F=V+,3W)))KCZ&&
M*WABMX(UB@@CCAAB0!4BBB4)'&BCLJHBA5 [  "OMRG52F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2J5-P<+9HF0@+%$QL[!RK91E)Q$NR;R,;(-%B]JK9
MXR=IJMW"*@>ADU4S%'Z>G4 ST$@@@D$=P02"#\P1W!^T56M[B>TGBN;6:6WN
M(7$D,\$C131.O=7CD0JZ,/@5(-1Y/_9.<))"U+V4^MI5LU<*E<*U%A<;&RJ0
M."G[S*(L&[XCYLDH/Y3)M)HL" ':BU2)\W)5<YE5B\D7;\0-;*QM)KY>:R&0
M_G+%OMK;$/CIXE08]<<N<1T50JW4UA9RWNAZ;G>(\F[#WW1G)&V8G9K=[6FI
M=9:<KZ=5U;1JS1(!,P'-'5N*;1Q'*P (>\OEDB>\R+LW4>]V^6<.3]1[E1R,
MDDDE=I)9'E=CMGD9G8_G9B3^8>@^%:TRN9RV<NGO<QD+O(W3DDS74SRD<CLA
M QX1KO\ @1JJCX"LB9\5&4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2M;.0'$S27)9LQ#9U94<3$4@HVBK1"O58>QL6RACG%H#]N!BO6)5CF738
MR2#QHBN8ZR*2:BBACW5M>7-H28)2@;7)>Q5M>FU.QL?/U^'I67=+=<=2='R2
M-A+]H8)V5[BRE436<[)Z,\+:T^O=\R-D?CV+$ :BQFO8MJ!,=:UO-L-?4=]0
M1L%*6/+M&1A#J45HNP-F4DZ3*)P*86\8B<0*)DR@8Q2SJ]2R^7I[96DUKDLA
M5#_V>!(^?U_L]*WA:?='2+9\+SIA9;X(?PD.1*6LDFCQ9H3;>8B[T2!+(?4;
MJ8?2>EJ+H+7L+KF@1I&45%I%.]?*$(,G8)<Z29'T[,N2E SJ1?'3*8YA_%MT
M2HLFI$6;9!%/'IYY;F5IIFY._K\@!Z*H^"CX#_UW7/O47464ZHRUSF,M.9KJ
MX;W5[B*WA4GRK>!/1(8E/%5'<]V8EV9CEK*-0=,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE0O\ -KBXK0I60V_08T1HDT[,ZM\2S2^;3)MZOU5ED44P_%U>:=*]
MZ_:7QP,LL<O4L0_;)1&/]8=+MU3;ME\;&7ZELK?]WVB F3J"QMHP%N[=1W?,
MV-NG&YB7;92SB6=%.0MYSD=R^#GB>G1=S%TCU'<"/I'(71&#R<S 1=,9&\E)
M;%WDC$"+I_)7,A>PN'/##Y"9[25QB[NU&*COS0]=ITQ2F*5]+5XZ9*@LT75;
MJA_23,)>O]A@_),']93 (#^<,E,1FLM@;Q+_  V1N\;=IV$UI,\3,N]^7*H/
M":(GZT4JO&WHR$5 ]1=,=/=6XZ3$=38;'YO'2]S:Y"V2=$?6A+"S#S+>=1]2
M>!XYD/=)%/>LPTG?%^HJX+0DY)QIQ'\8:+>JM"+@(E[O>F/XR/=]>TOS5FPE
M'M#J&;LQGCQ>S11VO673F,ZDC7BOML*KCL@ !HN2L<MNS_$"W2R'<C??MRKU
M']R!A!/+?>'75V9Z-F<L_P!&7?/,X@DG:Q(7GM[Z./X$W4^2;ZIUV(:O36XF
MMK>?$IA!NUDU>X7CQE"LXWWY0W0?.[:0X(QXK]0,)UV[%!9P8YE'1EE![R["
MQ_B[X77"!9DZCQ'^1<P>UI']B2P7%_,T?P4.-J!I50:%:'SOW*/C5#,\MLW1
M^>)V?,QU_P#1TDW^5+!>V6*MDE^+%&(8G;.YV1<D#N6D0"13*4RJV%Z4"]'4
M^G;W92F#IU'X>TFXZ,4 P_T5VJX!] >G7K>W'B-X5,"R=6Y=1Z^3;8>\#GY#
MS+G#-HCYK(F_F14+9?<Y>.43<'\/L'(WH+B^ZDQ4D:_-C%:]0@,#ZZ:!B.W;
M?8_W97)B1V-\/"5BH8GPM!-LP+#5Z.B#(MDD_$BT%^87,F9HBF  DT%<S5/H
M IHE,'7,>;QB\.L&LOT/B.HLY<.QD!R,L5M:-(226)>>5E9C[S-]'LQWW/P&
M?0?<H^+/4TEL>IL[T9TW:Q!8RN,BN<AD(XU4 *J16EO$ZJ/=6/Z65%(V%';>
M I&ZR[T#$0,1@D;T_$=17$/S *YOG!_K3!,?_5U#-=]2>.O6&9CDM,4+7IBP
M<%?+Q:DWI0[[/?R .C=_KV<5FWV^N]\]#?<E^&72LL-]G$O.M\K$0XDSA6/%
M)(IV&CPUN?)E7YQ9*XR49))X@\>-HF,8YA,<QC&,/4QC")C"(_G$1ZB(_P!H
MYIB662:1YII'EED9GDEE=I))'8[9W=B6=F))9F))/<FNGH((+6&*WMH8K>W@
MC6*&""-(H88D 5(XHHPJ1QHH"JB*%4   "O'/BJM,4JY*?4+)?[/#4RGQ:LS
M9)YS[K&L$A["?-#O</7K@2F(QBX] #.Y*06 4FC5,Z@E44%)%7)NENF+SJC(
M&WA<6MA:HMQELI*C/;XVSY!3(X!7SKF9OP-C9JPEO+EDB4HGF2Q8%XA^(&)\
M/,&<G?*;S(W;M:8'!PRI'>9K)<"ZV\)8-Y%K O[HR5^Z-#C[-7GD#OY,$W0I
MQXT3 :"H+:KQRB<E/R*B<I<K+X?$M/3ID2)',D0W51M#QR9?<H2/$YO=6A!6
M7,O)/)!XZWS(;2&"TQV,@:TQ.-B-OC[9F#R\6<O-=W<BA5GR%]*3/>SA54N4
M@@2&SM[6WAX)O+[*9G)Y'/YVZ6^SF9G%SD+E%9+>,(OEVN.Q\+,S6V+QL&K:
MPMRS/P#W-S)/?W5Y=3YXRA5*F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2OG=-6KYJY8OFS=XR>-UFKQFZ13
M<-735PF9%PV<MUBG27;KI'.DLBJ0R:J9C$.4Q3" _2.\3I+$[1R1LKQR(Q1T
M="&1T=2&5E8!E92"I (((KXDCCEC>*5$EBD1HY(Y%5XY$<%71T8%71E)5E8$
M,"000:ABY3\*977RTC?]11KN:H!A5>S%3:%6>S=**(B=9>*0*"KJ9JB?J84D
M_-*U],.JA'L.15U$8[U/T=;]4F3)8=8+/J5R7N\?N.WLNH'/=KBS8E(++-2'
MWI;5C'9Y1R7MFM\B1;Y'='AAXR7'1:6_3G5\MS?](QA(,7G2);O(=,1#W8[/
M+* ]QD.GX@ EOD$$U_ADXQWJ7.*5KS%1Y%,4Y2G(8IR'*!B'(8#$,4P=2F*8
MHB!BB'J @(@(>H#TS1L]O/:SS6UU#-;7-O(\,]O/&\,\$T;%)(IHI%62.1&!
M5T=596!# $:KLNTN[6_M;>]L;FWO+.[ACN;6[M9H[BVN;>9!)#/;SQ,\4T,L
M;*\<L;,CHP96((->64:N*8I3%*8I3%*8I3%*8I3%*O?7>M[KM>T-:?0H->;F
MG %57$!,A%PS$3^,\M8),4U$8F*2,!@%PJ51PZ4*+.,:2$B=!DKF'2W1N0ZE
M=KAG&-P=M($O\U<1LT$; !S:V47)&R.3="/*L8'!7DLUY-9V8DNH]8^(OBG@
M/#VV6&8'+]2WD)DQ/3-G,BWMTI8QK>7\I61,1AHY%87&4ND*G@]O809#(&&Q
MFGAXV\9ZIQ]KZGA.E/WV;;HEM5P5;^(ZY2&!4L+!H'%0\776BP =-KY#N9!P
M0KZ4677(V3:;L1+&PL8</AK9K+$VS^:L<C"2[OKKAY;Y+)SJJBXO9%VJ*JK;
M64+&WLXHXS(TO$.8S&:ZHS-QU)U->+?9FYC\A!"K18[$6'/S$Q.%MG9VMK&-
M]/+)(\EYD+@>U7TTL@B6'9C*=6=,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K0[D!P6I&SUG]JUX
MLSUY>W)EG3M%-L/X&65XH(J**S$6U)Y8>1=*"8RTY!D[E%55GDK$3CD2"7XR
MMAB.I8EAZAMY'N(XUBM<[9!%S-I&B\(HYC(5AS%G$H55M+]EGCBC2"QR./BY
M!LCZ/ZTZI\/IS)TO=Q/BY9FGO>E,HTK8&[DD<R32V31![CI^_G=G9[W&I):3
M32/<Y+$928(4B,V;IS9FG9 6&Q*G(021U_ RG"%]_J\J<1_%_"[&U T:NJL4
M/(2/<*-)E),0%Y%M##V!JC-^'6=QB2W>."=0XJ,&1K[$K))/;1#1+9+%L/I#
M'B/862XDADQQDVEO?W(',]8='>.7175#6]AD+ANDL_,RQ+A^H9(K:*[G;L(\
M/F0WT3ES*06@MH+B/+>4!)=8NT)X#&>8#6Y:8I3%*8I3%*8I7DD11=PW:-TE
MG+MXL1LS9MDE'+MXY5'M2;-&J!5'#IPJ80*D@@FHJH80*0AA$ R4Q.$R^=N?
M8\/CKO(W 7F\=K"\HAB'UIKB0#R[:W3UDN)WCAC4%I)%4$U!=0=3]/=*6!R?
M4F9QV%L0W!)\A=16_GS$;6WM8V;S;RZD](;2UCFN9F(2*)W(!WJTGP,V;L)5
MG,[&!UJ^GG$BIFKM%(]]ED!Z#XV<(X(JWK95"]Q1=V4@R+90H%-6'":A5R;7
MPWAWB\64N>IKF++WBZ9<%BKDG'QOZ\<KFK=A[2 >SVN"D>.5&Y+G+=T:)N8>
ML_N@\IE5EQWA]938BS?E&_5F=LPF0=#L<\%TY=(3;L0=QWW4L<3P2(5?IRZC
M=9UF!UGJJA:@KB57U_7VL'&@8JSQ4G>XDYAZ! 3-(S<HX,H^E7YRE OG=K*>
M%("-FI4&B2*">;7%U)<"&,K%#;VL?DV=G:PQVUE90;+>3:6L*I#!&6)=^"\I
M96>:9I)G>1N?EC/GW5W--<7E_?S>T9#)7UQ+>9'(7'$+Y][>3L\\[J@6.(._
MEP0I';VZ16\<<29#RVJI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*^1\P8RC-S'2;)I(Q[
MQ$[=XQ?-T7;-T@H'11%RV<$4071.'H=-4AB&#T$HAE2*66&1)89)(I8V#1RQ
M.T<B,/1D="&5A\"I!%4Y8HIXWAGBCFAE4I)%*BR1R(W8JZ."KJ1V*L"#\16G
M&P>!>@;J==W"Q,IK:45[A\]%>I,XH3]1,0HUB4;2E=:MP,(]Z4-'Q"JA1$H.
M"#VG+Y?IC,SLY["8S+RMLM>R126.5+-]:63)XR6SN[V;^*V4?((I[F)AL&;P
M'4O5G281.E^J<SA[6/07%--%EL&J+]6"'$9F+(6F.M]_63"KBY&&]3*3NM2+
M/[-._M%%3TS9=/GDAZB@A9XF9JBJ8?F35=Q1KDFX, ?2L1DT*<P^B"89BMSX
M?=(7.VM+_J+#'UX318[J&,GY*ROTV\2;[*&-RZCU>0^NU<9]T/U[9@)E^G^D
M^H1Z>=8W>6Z4E _C/'-'U=%-)KNW VB.WU5B7L,.2' WDLP.<B56KLR!>O16
M%N4-XE.G^;\>/ *AU_-WHD_M[<B'\+8W[VO5^'4?+(X_-VKC_G"PL,NH^W4C
M?9NLNM_NF+%>V0Z ZH5M=SB<CTUD(R?\ELEEL"Y'R+1(?F!5-2X/<G%#@4VN
M4D $.OD7N5$%,/[!]WLSA7K_ *DA#^W*:^%4^_?ZPZ4X[[^7'U6[Z^85^EX5
M/\KBKEONFL!Q/E]!>(!?782_>/&F_DSQ];3./SB)JOB"]GAR DSD-+/-=5IL
M/3R>^626DGY '\Z;.)KCEDL)?Z13R[<!] *H/41"]A\,L-&1[;U5=2:]4Q>
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MJ@2["%[C@C&RT8_9-_(9)I))$=F;J2&(Y.3-8+E=VDC9+&>LEM=\II[/[1<
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E2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g626950g37g52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g37g52.jpg
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M=YBVN!HB55G6V",QTB5!_\0 &0$! 0$! 0$               $$ P(%_\0
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M2F :CJ@)L"S!03QL+D:V!/8">:9OQSQSQQSQSQSQSQ\/'/'Y>.>.?_7/'/\
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MB,!Q\4/!AAK;C;AN/$B6B+ <Q0XWVVWX1:,VZ*"7&VVVW&B>OE;<\_#SB:
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M2,1&(C$1B)K#[:>&J3[86.ZG;GOGWPI$$MO!'K2IJ.M>'Q>K1$@KHJ+D$<E
MJ/EZZD#M"0(2<()E&Q!8HX4T/L&SYKZ-YA!))/0:W^*GCJ0;Z]A$M]UIHTIU
MVJH;61B\[N[$OAY4T3WLSL)*14QLE]H7>[.TQ;TX' 1MJN+$:[>BB4=QW*[9
MM_XMW"NG">J:0FYO8#J'#]R9/V)(Q$8B,1&(C$1B(Q$8B,1&(C$2F_3#\Q=B
M/MD=G/O'?93Q[AY"9MF^&M^IK_R&7(R33&(C$1B(Q$8B0CV+ATRG]/2J(P1E
M%2YTNZB>KF/S;9@G%Y7%&<SCQ&?0PLY*1&=L&2<S@K21Q5N1<1,SJ.=EV[[1
M)LJWT>MDY5E9Z;*H4DXW5K8LH92Z&ZN!F@9;E3:]^N1KTNI6?4!4CNMYVZBB
MV@Z3:NHNUAK ()!LAKF'0[25K,Q$?BD0%A6$CMAO8\T QY!@[]6XQ)@<>Y(<
M\"]6# =9XV:D]&G@V.C<G$  #%<M J@95,W UQ5@+Z6%N,31&(C$1B)K2\(3
M]G_47[]]F_[JKLQ*>/</(39;B2,1&(C$3!9TE82C</ZA*17R-2NFTK:21(WJ
M](QKA%7TQA%208F/U!R1SOY"8\P23(CV.W/GU6"W.G'P)Y?/3#'CRKWO;\I'
M!N@FX'09HU?]:9^^,J\@J5GD"ZQKR6JB4MK)M3<(DTH1DH6HK^CQ!H9J^4FI
MA&;V?1B9EJJUEUZR -)W=BG#HR2--W*=4"+&BUT_;MZ.%N'L&_-\H[.Q.E)D
MH9(604U+7%*LI#4R66J5<T\JI#%R0P_XPZSAUEICL+&.Q$!FUKUXNE.%W$?3
MFA9,*-(PN"5$EU"C<>X PVY5Y*:L ^0"W^-VAJU6GY,?BY!NL?MMS#W<JY'V
MV6&W-T?WZ>EYUH4JRUE>HG+N YT*I3^S*++4R+M:L,<"Q4B]0KE:H=RF2?2C
M$1B(Q$8B,1&(C$1B(Q$8B,1*;],/S%V(^V1V<^\=]E/'N'D)FV;X:WZFO_(9
M<C)-,8B,1&(C$1B)5+N7"U)C2^ZC8599Q[%I]54J3&57-;:B4F^+1-EQ-23E
MTV%-3&%2Z;\1>*;&Y2UA;4KRZ,$0K/4'PTDB8<BSH-O^KS/M*Y4N%0XO3:U-
MZBM8.N1^Z96;%;MA?6VG*L9B/1)I.6%9SAG8T9(1F8)62BL;3+2BW9>4=D2%
M4U64)M7IN[K(M*<DO4LJ^?UBR/<2-K&9J,@K&P(> "QJ6#6V#[T \IYV3/=L
M'4JV>MVJ,=:=,VO5>HYQ)*7N%;'-5"L)<LL]<#11,BS$D#SM@/>O6H(2H+1*
MFG#5LHN@)&*G"08*D0(JZ:LV2A@P)%Z.5D]B!)BTX6=)2:2; D D@$V%KGJ%
MR!<\!<@=) FH>].T=[PFSI@=CSA\F30AC\1 .J6M@U<_M4?8GR?9S90=]/ZA
MCM:SDA,XZ[D+%IJ0DU<]EM H]D-3W;L"*H:2CW'H6_WKTCW<CJM/G5J]579E
M-C@<-GWE/>"ING<9TPCEA<"Y2N%TX'E"8,5[,2UJ4/QAGW)(JT2+"2V2@>UG
MP4LNX,VD)H>#SH32^QS2"_B])-EG!R0VU\0,@"4F=(CO4?5_S'&#D'LMU:GF
MU];COT-YYWYN5^TG=6)%?[K6H**L*66.&MVJV"WTQX B7 M"_>]<7C=.$:7Z
M*Q_L$\F%81V368L8[.Q3KZK7\[(,&BY.'(QZ60*9/RZ;955;?E_J\;<-=M?0
M5D5%D]E>?,^G3.2*7Y+%5)%KV) )'<=)R_AJT_:=$=+ZEK*ZXPPAEH"BMO'Y
M7%!DD&R]B <3Z[;'L$<-0DP?C4:9]'#2D=JH\:Z):;J^<UW004UW1T3T>.G4
M/ 6EZL21B(Q$8B,1,"M*R8O3U<S6TYLX=M8C7\;*RN1N6+-4@\0#AFN[Q\JV
M8H?^9VMH@GMRF@E_G4VXXUU_+S@:Z3Q4=::-4;X44LUA<V''29[B>XQ$8B,1
M&(C$1B(Q$8B,1&(C$1B)3?IA^8NQ'VR.SGWCOLIX]P\A,VS?#6_4U_Y#+D9)
MIC$1B(Q$8B,1*M=S6<7)=?)$-F I:0!B4WI(:E&=1<:-,99(']XURSB,/D0N
M8E@47>PV72Q8+&IND;+CV/$0*&]]W.F^NGPIPVD*:+!A<%J8QLI#$U4"J0Q"
ME6:RL"0,29 /A=Q^&Q?K_( \*;M1[!.;1=\Y#CX+&( /%\&.OE%F(YMP+B4M
MF(HK(#\%?Q*76%)O31+@[9\BFSO:+1E'E .UIX^S[_?MG'8 BTF":#-38(J
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M1U_^G.G?:;"O?>(WU+YM/ZU]8^41U_\ ISIWVFPKWWB-]2^;3^M?6/E$=?\
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MG9%:<_"QTY A,9C-DQ&YY[4A8?*71HZ\C%&VK$JLDFL]#KQX4QCQ@YO/X7*
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M.K![MNZ..X8I$>9HI%PD%?QRPQ+^%P^/N;"EKP3"8TY&Q-D[?CUD ^O,9BG
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$]S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g626950g48b31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g48b31.jpg
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M$DTO -L]8%Z$FV6(W6A9#UM+1IM\U7#M?$V"8(, 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & :^G#]*K$?W?5B_U&U;@NY<WZ(V"X(, 8 P!@# & , \_;LU:=0L6W-
MOT]B;QNP6;:U-ZU$U%J0(QN86_Q/2]MX%9A:4:W1/HP5)@"-F:-$$.Q+5U:N
MKK?7&N!Z&"GDI7YC7+U#4B>6E8Z)2!*E3:E<4:A>F3 <%K2-0H1DG#4$D!=6
MQR;!&F%A+"X-ZU%L6E*0\LL2TW5J^%Z[6O5-<TSX(Y1&7%X<HZWR)B7R!FZ>
MN&)&[MZIX:N\4D/#ZR;"% UJ'J0X(#M>E$%=2EJ0S7U%).Q@I1;:33:VI-6N
M:VH]W!1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , U@\[."%-6]';G
MY R&8\DF"PH_3DI7-(:YY2W_ %M#T2V%0YX6L2I/ H58++#TYH5*<D]PVG9B
M0.Q^C%+D%2I4*3CAN,FFDJIM;D_-JS-.(G BD^/BZ+7!"97R->Y>\UXC;UY%
MF\HK]M2*&ER)"T.#DHW"Y]8#]%A+M*4H!(EAC4,]NT,S:$9 Q=_0CE)JG7@E
MZ(V%8,C & , 8 P!@# & , 8 P#7TX?I58C^[ZL7^HVK<%W+F_1&P7!!@# &
M , \E];ECNRNK6WOSM%ES@@5(TDD8B6-0],2A02,LIU:B),S2*.G+T(Q:4)2
MWMA>&L9P !6MJPC8R!B--II-Q;32DJM=JS*4;6ZTUQ3-0/:-]FER'YETDQ5I
M ^>-P,#FSV R2Y4EL)GJYMB3VA;D3FC$G6&T/5-32@3@W*%Y#RT!='%^8=K4
M =',Q#@)O?F=]^_?W^;^=^#C_E8*PX?F8L6IJ3SK#46DGI_)P\*5J[5MJUJK
MIJ]%.\>;0K.-UDR2/F'R LP<$CL297LF2L/'<#5.#HXTH6Y>:\K2J+,L729]
M-2&*%:@RQE<KWI0(:N6KW/9SH>/7AX.)!04OR<:>2,4U)8-2RI)V^ASZ_P#/
M-QDWJ>!>W':96M;41ES6^HVN'HF.(1V7H4\IE<7?WED:K78IM(V8"F,)B3E#
M0]QYL5-2M :\)4SOM0-J<R?5:I2;EO1=^WM2)BX,L3$C).HJ,5+K2BVEB*4E
MU=:<4TU=/8]&RG4KX3<N":N;8-!K31;=CZGBI#M(G2^;D*?&_D.U5<NB[O9;
M<^O4;F85+$NE9B1X. >P@D AH&=RC1D'=4RI88M;]O)56G+MV>)YI_B_D=&H
M0Q->CBFWC8MK&6'E<U)J=K-KJKV-97J2I%^&5IE6$F'(9"WMU/K;ILZQ9E#X
MQ;-H)%,H9IZ_<HY>E3GIVYNCY9*LAZM^K$3PT =P-3F7 5SB>I4Z+;VY8O3M
MU]$OOCM.D?QL135M+#Z7$G.*G/K1F\>254OZIX>96D\K>I@<<X:<J$4QB\KE
M4ZC\GDB:/T\R'6"&ZK62/L,<8<W47N>2!#'PQ$MKGQ<E<H'90BF61.#8C==R
M\1+R AOFDT+25M4DNW;O5W[(S'\;'N+E)2DHX:S]+B)Q<5A9FDHU*W">CI/-
M353D;>,R?0& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"$N2_YN/(#
M[$K6_@1^P5;5S7J9S6_Y.X%_DN+?Z&AP0S3 & , 8 P"">0= L/(R%M\(D%A
M7C6J-MD:.3%/U W//Z-F*A2B;G5M"UN$JKIY9'AQCIY3L:I5L"Q0<V*7%&UN
M!B?:ML1FE"IUP[TGZIFLFBNSJB<S/MDZ0<N>TE5_0F]IU"6,L':"\G4Y08]&
M]LPVU*K"3/@;5&ZVK/">H&+1QP1:T(6MAUO0KD_\=B_HAO7_ !-UF#(P!@%#
M>;$]O.$#KP=3ER@IB,9+/>WTV&(3E4DD,[C:2)'5?6C8:&LK41D+)YZPF?JP
MI[8VB/K7QA:4SU(=(A&1J3OO<>3\F>+%PZ/-ERXDI..USBH]'#]&)6>Y5:2M
M*W75EZ7%B9W!)IS8R.PG*;N21(P-2R0-\MB (VS06T3K)MEM=X5 '(,98=2&
M-)(0TP@T@T+C)BA,A<4EVG=6?/53H[OOW?XEP)8DIS4W)TDVI1I0GGQ$XQ>5
M6LJC6W3+*^O;K74DOOB7=J2E-O2E(C3"UOX'3]-&$<3N7[L14C:1\B*R$>YK
MU?W.:[^CR@DT)106ST=W\8)HC?32_#[@QZWL5<7[=K-NF"# & , 8!TG)>0U
M-ZUR4EK34Z!,<K/*;6UQ>' PH@ C!@1-30E6NCBI$$.]$HV]&I5J!]TH@@PP
M00[&9S6'"4Y*34(N34(3Q)M)6\N'AQEB3EPC",I2>D4WH4-Y3\^HSQLC<8D"
M>LYY,12-\4,PDC]')Y4Y*/1" Q;I00YS:OP(W4T6R_#$@1;VI+!O:@>O"#O-
M1CFWT?D_]>_]6X'^BX.!BQ_!_*_)>-BRP\N-@_E_Z>HY89LRQ/ROP\N(]V2/
M62U>A8.J>0<:M&(5U)"(U8;*LL"+Q60EH3ZRL]2QM1\F9T+II&*;B@Z*++6]
M$)9X 9(!:G95I)87 D\"0X LR]&UP/L?@?ZQ@?G?C?AXZP/S,*7Y>!^/C*#_
M  ?SI86&\?#A/+_%?PL?QY0CFKI\\<.45G346B".3%_7W K20US2$699<[&T
MV^6,VQI75<UG*V92M#)T["R0Q3-&"QH3&JA97P9@49\]F#;(VMF-4[=#V]2E
M;%"%75V_4>S&Q<6$U#"BI/HY347AREFDI)*&=3C'#4K_ %24DM76E/"%':+1
MR&>DEV+!GY6F:UE\A?Y' R"71K9 5&/D1)6UH<41SBI]5/;O75 ."S8)*\QT
MUW?G]G-C36NCQCXX1=7HGXU\F'^9&'ZXMT\6W#51Z/II4U>C<,)O5JVUE35M
M9](.;?T4FS56DAI&R$\UTJBI4S31[3=/66#(+"FGT%@;XY/<--=$8F]R<P+7
M9\(>1Q=>P1QC?'$9"P\#*C?%;>PU+\K+)0>%//<<RC4E!3EDBVUNNVUHU%-[
MTG@,([058XP.)J9=2TC*M!;0L?Y%R2+L$@AP&,-5*8$DF#[+61Z<9,<W@<"E
M@E+$UP!<['/>UXT1ZQXU&!*I<0KPNMOWQT7H9C^9<(YL*72/!6,XIQKH\F9R
M3<JN[2@W=[7EZQL=;7!*[-R!T0C$8B<D25P2&#*-(&-*L(+4)QC). 6<2(11
M@!"*-  TO>]@, $6MZU#VIVD^.IW< 8 P!@# & 80ELJOELLE4$232-*)E!V
MYB=IC&BWA$)WC#=)B5ZA@5/:/QO$;BW9,V+52/2G18S$A057=TG.(,-&<\'*
M4,T<T<KE&]8YKRWSIT>Y)9*P0Z//<LE3N@8(U&VM<]OSVZ*"TC<U-+:F,5KU
MZU2;O0"4Z9,48:8/>_8$.^FM[WK6Q9244Y2:48IMM[$EM;(_'>U3EU^3: I@
MEW##W<<<)7 ;GHQT-E!3Z=%SXD"*EMHI6*8)9&F5,:N):9/I&D=4BM"I;"E"
M5066,=+AY,^99;RWK>:\N7+6;,I)IQJTTU6A](M>543B0)(S#9FW2ET7,35)
M4AC G<G5F.9'UA;)2S+0R5$B.C>O6L;>6A]0)Q.P5:II=&Y>20-,L3F&!'%P
MYNH24FTGI;5-*2=I5JFFM=C)7P=!@# & , TR7E1':-Q&70,Z,=K!/&MBM>\
M"(,@CX^'7$E>&%L#^T3*2(B$CHM@YJ][,9"(^D:"E#D("A>4(:Q6;Z1UT,:T
MUT6B[>*7$V&<:JKOBJ(N_M-_<I9!RKD;F_:<6:6O]2U74)L;9=-Z5-]'DS)5
M+,SM;D6):4I<ANCH%0OV-7I* 1:<@ 1"/E7C[EC\$& , 8 P"$N2_P";CR ^
MQ*UOX$?L%6U<UZF<UO\ D[@7^2XM_H:'!#-, 8 P!@# & 5=XP_AY$?M16Q_
MV1W!7M[EZ(M%@@P!@# & :^G#]*K$?W?5B_U&U;@NY<WZ(V"X(, 8 P!@# ,
M?D$2BLM(3I95&8_)DR0T1Z5/(&9N>B$QX@;+$<G)<DRDLDT1>]@$86$(]@WL
M.]]W?3!QQOQ\#\A*./@8..HNXK&PX8BB]EI3C))UI:/71(D;:C2-S<D3(&]
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M>K[%L2PNU*1'V%0$^H4]HX&6 B:$,\EE02L^5(C.1-8C,=VLVH[%L-*@2$#
M DQ._J&AQ$,T BD9A83!@'K>Q;]7Q[.*1MHP08 P!@# & , 8 P!@# & , 8
M P!@# & , 8!@-I3\BJZ\EUB*HG/ITGB#.H>38?5L1<I[8<A"GV#7JV(PYGT
M)RD+P?L>O1VY'KQ3-:&+J$(!"T!K(UVPU<BD)D2#P@[4;<J*9BI&9&]<%+1V
M^EQ\]<<V$/@VG1OIP6DYQ3*$!3B(C20Q80<F";LXL8-#65_X_P#[C\FSFKY\
M1:5>Q&PTT4GD&3R]E2O140M").,$L*/!5:%OU9+H>[ZTY1YZ3[#O2IM6:\8G
M>P]=[T+6]C)GF , 8 P",;CE5@0FN9%)JOKD5L3=L+1;98"7($<8.?C53@E1
M'!)>'$@Y GVA(4&.)P58DQ9B5(>$*D!WA ,'/$E.$)2A#I)*JAF4<UM+:]%6
MW7AM*X<M;,@D$<N(&[*FT%K]>_\ )R&@0HY-,6=E*7N (#8"9:C95#^:RG/&
MDJ]U;T6C"41)PS%[>$U(F.6D$;'6-M/36E:6M.UI>_P)TLSD52=0.")BGUB,
M;9+G9.)2PUZUZ72VTI.2$7=$*(U7#T;]8LMV$6]:$7&HPZF!WO7>!KKK!*O[
M[D8;N/D18OWNFN.RB',A_P#X-C<GI""NTIJ0WV%.T<I^'$36U'@XG?UCXS9Q
M-!N PA'K3B1]Z$:+W^'WTLX;XT3>???N0O(NRY\G-^LHK^H3EO&JI0&:ZZZ%
M)*]?UEVNR(\&_!<&.<7Y,XRY$]25#%X)JDH\+[/?]O(G>MJBJNFV0V-U-7,(
MK9B4*1+EC7"(PS1E*X.!G79[FY@:$:3;FZJ1B&:L='#:EP6'F&GJE)QQA@Q"
M$B8 P"$N2_YN/(#[$K6_@1^P5;5S7J9S6_Y.X%_DN+?Z&AP0S3 & , 8 P"J
M%Q\'^*]XLLT03.D:Z32&<1E_BSC9$9B$=C=I($DB;%;6K5M%@-38GDJ1:46L
M,/)V-><D,4 +VL2JBN^4,5-K8_O(T\=AQV/D0[.ZR>5=H);KD-LR%SEL@X^,
MJ=3$DT+:FN&0Y]:)&<YN2(B1R3UU)'E=ZI+TK :V)&E,WK2DJ0_UN:)*.F)/
M/2JJU[VC8:9S!DH+,]7_ '4*' 7YBB:-#QO'$Y-]VP3(9=I=)BF^Y]JR]-P5
M8DPQ7$4UZI\39N"^&P"=='#W-P/OWDSYG\1+I*SX5=-T70Y)=)72]%GSYZO_
M ,E='632[ZQ8&_+GGM:OT;8HNUQ@>I"@<W) )1$[QM>6NQ<?-;2Y#M)7%'US
M*71IC;2)^CJ5;.WI]*0)'=\;F@;$:<O;C5M2^Z5XM_?([8N+.#BHJ/6MKJXN
M))U6;J84)-15I.3:5M*M43]"G21O48:'26LC='GY:FT>L:FES=W9O("8(0TH
MR%<@C,-?0"/2;(.4(7F+LSDVJAGMRI*(Q+L\Z':+DXIR23WI-M=UJ+[G%-;&
MC*NG_P#/;@T, U].'Z56(_N^K%_J-JW!=RYOT1L%P08 P!@# & , 8 P!@#
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M;-JLYN7QGCZT(YNVLSJF'L"EGE]J+W6/T?7CRFWK8C&2P[/BKR:#0MHV]4(
M@:%K?L7'[J>?ICY@6K[9%+H/Q8B9_P#\GK$A#=%V')Q?7)-.L.P8XCJ*#K]
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M)*Z25ZNEM?%\2ACA^E5B/[OJQ?ZC:MP:W+F_1&P7!!@# & , 8 P!@# & ,
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M8B(<2FYP$GWWDRDU"I)5%!, '1I0][+$+8!Z# TXNFJ?:3]@@P!@# & , 8
MP!@# & , B:XZ%H_D1&44*ORGJPNN'MSTFDC=%K7@D8L&/H)$C1KVY(^HFB5
M-CJ@2/"9O=71 0Y)R"UA2)R7I0':(6*"S!4VM4VGV:%;"^R[[-8HPLTOL_\
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M.H>J"J$5;=1BK>UTEJ^U[7VF48-# -?3A^E5B/[OJQ?ZC:MP7<N;]$;!<$&
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M)R1(E0)4R%"F3HD*).2D1HTA):9*D2IBPDITR9.2$!)"<@D "B22@ +*+ $
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M3 7,/'YD=4HRS$4WN)L&%=-ST)OK>$TH:J5]Z/2&T:ODI0JTU\.?'[M?'4N
M@0(6I"B;&Q$D;6UM2)T#<W($Y*-"@0HR0)TB)$D3@+3I4B5.660G3D%@)()
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MNXMEI,$& , 8 P""-?G-F?803_, _+N7-^B)O?)>K)WR%& , 8 P!@# & ,
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MKD"A,M3)SRQ+K5:,IIV5?%GC]Q>X?UJAH:L6.NP64PL\]GJMO/=W1WEDK6H
M$&.CV^2!Q=WI;I.0#P&QO,7^K&<@9Q+2B1%'G ,%;<M6[9LAP08 P!@# ,4G
M(IP"(OXJU)BBB>:;S=Q8F<J7=)$3'7O!\$+^I8$JUY);^[W]FB;DAZGO:#H
M.F][TY[ [W;>TH9J+=I1JPA6'ZMX.>L!0T,,] ^E=]^A^A@>QOFEG?\ H1XW
MI.SA[)[O?\+PM:WW>_[<UU?\J[NSXX&>MMZOGV_)?2$"FXXDP"L@J*D3O;<3
MN4DPA0[JXD6[?6]("P*7Y*B>#F[^SX(W%*0I_M:&#V:WO)KGM,JP!@# & ,
M8 P!@# & , 8 P!@# & , 8 P"*+A,O(N,HQ4 DJA9,MO2;2\JX7&7ML9#'?
M0U^U@T9\*:W9U$]:<-->DQ1R<"':,2\1IP3@)P#JK??<1WNKO*=PF+=I)#39
M-X3;P?5DRN;/,S7^)*KYT8E/?-I-*D:3082$(B2 I=>CB.WL>Q"WX@MZR]7_
M "TY<6_<G6U_3KSY&QO,FA@# & 0+6'(>%VH[2EK:FN31\J.M!$I;WF5IV)
MRS.$*9',(JFG$55-L@=S]1XUVA#UU!)4L;?2&\QH=53*0VO3:I4#EAXT<1M)
M25)23DDE.+<HJ4:;=7%_J4953JFC2=>?:G\8J6[3X$G>3I-*X7#N-@Z'=IQ
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MNSW"((G!(IG<HHNMM/TA$N>W-W H<=*6AW/\1*4X ;RO$<5._1TA/00 ]"@
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M<=MJXRBI1E32:NZ::3337!N3L'08 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , C^4UA#)F^)9'(6TY
M8[HH%85:)U!;@O2A!#[150U9-&W9"5040,US40&+C)7C+VN;](# H%"<*U9H
M\8E",GF:U4)PNW^G$<7)=^2.NU5IM9&R#BK2#:VLK0FBJCU='W$QT;$Q[^^J
M0%K#;J9>09@C_'<#-JRAVG'FM]&G4[-($D),8]E[93ST)C[X&%@822671:K5
MO_RK&UUU_F)/RV:&.(N*-/5Y1]IU+#&U\98C-86Y1]87N1NCLN9FI%%CF!A3
M1Q2^FNA38*-( $C:#Q)U*@QP)"Z/)KLXF*%)UO9V??O[D7X^'#"GAQ3491R_
MJ;:2C2RMMUE6Q[;U=L^+/QLI.SDB:V99!DJF;6>_T%>4L<DSM($H%%A5!'VG
M[GRY&0%V$%"ULJ8![>H8B-Z:GUO<GE)(4KJ6\NFE<(L#"Q*Q)0Z^)+!QI-.2
MN>'%9-^BBM*V-6I7;OIKN"_')>>^*A15X3*7F7JYVE-22N0% C,H<UTN<7=R
MBR02XQ U"=U,]F1:\K:524)M?3&-.!.QMK(VMEOX^^G(?PN#KU7K)S76?5DW
M)MQ5TKSROL=;$DO0/X5<?^CN)KCK_'%;^UMK*_.#!-Y:B72%K96Z#-#(BE1I
MKNI!,DS,V5ZQ(&XB7E/Q1"1;*TVP#(FDL+>(/X;!U:4DY))M2DFTE%1S:];*
MH)+-?]7]TK]KCK7$2KH5EM$2;S&UJ8I'$*V8$)BM2N"S06K*K@L6A<<2JEQJ
MAP4)6U(%<O,4N:Q>XJG5Y=5)ZP11R=,E&L&$89U%4HN.&M]0P\.$8JWJZUU;
B;MO4LI@[# & , 8 P!@# & , 8 P!@# & , 8 P!@'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g626950g59i87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g59i87.jpg
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M<7)W&#AC@H23LK7"_\0 ' $!  ,! 0$! 0            (#! $%!@<(_\0
M31$  @$"! ,%! 8'! @#"0   0(# !$$$B$Q$R)!!3)187$C0E*!!A0S8G*1
M0W."H;&RP14T4_ D8X.2H[/1X1:BPT149'1U=I/"TO_:  P# 0 "$0,1 #\
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M;&I\-:UJ(B?9.968L2S$LQ-RS$DD^))U)]:VJJHH5%554 *J@*J@;  6  Z
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M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M G]HWKE7Y%Q]J-:G]U]R>/Y/<OV5'
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MD+G]XCO0S#[V@).W%1K"PJHA?> 9.OI1-CLPBY#QX&.\(I/J2+6Y!4M5[D\
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ME.*4XI3BE.*5Y3S1#0S$3/2.&"*2:61WV9%$Q7R/7_!K&JJ_X)SH!8A0+DD
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M;#4(G\5[[<&>)#-"=2 I4=<KOPV(\!&LLI]9/*O-[0'!Q&'G&@8NK'P*)Q5
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M2[P9VSH.F:UL]KQ'937RM"L@]6[V-S#,<"'BOA$=9X"C,IGJ?86P$<BWL0&
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M64!1X 6%3#BNU3NV>GW26\@F"[9U1KO84X@TP]199CAM!D-K0NE1_C/1V=F
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M0Q7!X>;$3,!8%CF5;CW0\C.Z#91#86"BLRK(BC L<B+=Z4-@Z:U\WHOY-0-
MD=>O9?QL1]>.P^2!4[Q%&$M\4553D)%.=(5U*6CMXR%KOX#1R4!ZJJZVJ<;
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MD?M6"+R1(#8M[J@W:1[7YF/0$W)6-;V058/8HSOSS2,+A=V<Z)%'>W*@T%[
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MN&I,!J((^[GQK@558RN[*C55DKB!8F/7[^3AI?Y*U>43S-AR,TN,D)V/UR1
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8I3BE.*4XI3BE.*4XI3BE.*4XI3BE?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g626950g66h20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g66h20.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M+/IUO#;7$.NW?1W5()9DO9HHKV<7UFSPRPBW%IE1)&R,DMK==7;3;89&E!#
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MHUC->3L5WE%Q!;H3CK;J=L16\0[WE903V5W.54[EC87FHSK;V<#SR-C.T=A
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M!EE=W("B-4^4.GG3*3I=J2/"CP:58B2/3X'X2/O*];=SJ"0)I]B 1@D0Q(B
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MM)@R&1E)7[Y. $?82((=T6]FFE5/A_[;?M;@Z7LG1KHY*[='[2<37E[M>/\
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M1<.,/'PV<9SG#46'$;9C1V\9SG.&VFT)QG.>V/OSN(         X  #  '<
M. '<*Z426)8DEF)9F)R68G)))XDD\23Q)YU(<FHIQ2G%*<4IQ2G%*<4IQ2G%
M*<4K^*2E:5)4G"DJQE*DJQC*5)SCME*L9[XSC.,]LXS]LX^V>*5SCZN^D/IC
M.5^%<".C]>?4DV[U:"0,00,<1,F0R9#V"#<E8GX*7ERD9_GKZT*D97_/,.X<
M[KYPE[T6Z-ZM,9M2T'2;V<\6GN+"VDG;_.G,?6D<>1<CS5V/3NFG2[0X%M](
MZ3:YIULO!;:UU.\BMEY^3;K+U*GSK&#YZV;U9TI].&DY*9VK=,4*GDT?9LO
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MB(A24DVG[[*>D,X9;3EE$63!6ASNI;CB>R,2" ",'CY_[J@L20?"KT\YM/\
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MCY5.\^;W_.GG-I_LDH7[WY_^4SCAX'VCY4WGS>_YT\YM/]DE"_>_/_RF<</
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M#)F!T Q:IH<7(-EH=;&2I+4TY*%A8<LN1CC&)3L(7%D3Y*&HC#KJ5064%02
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MW!S$AK.'8<JR3I30]+Z?;=\-%L2X4B,18B268'CX<O3_ '?+NJ7.!CQ^%65
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M^X6DK#&P8<$?&?+62W6L^0<BP8C+,=B66-F)[T:'$CMOR'EQXC'9N"<UKLP
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MMC'B<F*W//GR3S(X*'BJ=(E9SK<2#&?D.);RJ"RKC<P7)"C) RS'"J,\RQX
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M(E-'=4!</2 NQ@._MCV)FS=)YK7IF+L9 *FT6GT/J2B7?9@?<50=WE:15CN
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M58.[],]4=GVJZ6H@#;:ML@-N]1]PH^V2.S(^=#5ZE6;HTZA-<: 0#HA.[S1
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MD3=@;G9<L2H\CJ""_37CT#BYC_;()599R!5:+%)&"?,<5'WH#.4=V"LY"!0
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M<?2/@:NG/U?B*HKGTK]/NPKH_L"XZQ"&[,0D )9]QV49BA+C,JGQ\5>;?ZE
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M_F1O(_%[]OD_"]SY/Q^_V][VO;[_ &]7(QW]U*H?JJK^.\Q]2 ?$_(^)Y3S
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M*5ZL)6GU)[*QWN@P>/A^(I6OFN>H:VU*?7(MID3[A5*^P2A08C[R'#PB(43
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MU?7E(/QJR''!8,*?8Y;^'B *6(PM6Q;O-(_YQAM$,38"8#,[2@MD@$=E$;:
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M"@5=KP^9K\Q/HTB+!INS=>;?ICS:J\Y#1DC3[[K&L%ZR06VJ4(:6<'17$P+
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MJ ,#.;'7T*Z,0B7$%2=I5D*3HL+6!NNU#;5\J84YKL7:]DV\/323-?,CY?A
MLW;5Y%AVH<R'(&5TFP#B2&H(^$AE5?NL7'&]04$9"R.H*!G8+V2. ,C@8QA3
M@< *R#'Z5]'PZXNLPJ:S"B9V@$W P1B2I$<]!O%9N86[5N6/.-K22A"P,RN
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M46&)&5E&&'68XD_X1][<">X\%_LJ2JX4XJ1N_2WJJ_WE%].IMK,YVU:VO1D
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M*4XI3BE.*4XI6N=:3EE%CC+QE+\>_;$4^TK[+;P0O!\O$RK'ZF) XC#EM?\
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M$[3G0;7KGI+_ "=\:MV;: )NZ$E[0ZK]A=1XO6T8==:^L+(%WF^Z^MDQJM+
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M1_W3W\7QV/VO=38?-[_E3Z3V3^N:/^Z>_B^.Q^U[J;#YO?\ *GTGLG]<T?\
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MX\]&A1&4J?G2XS&,N<Z_TDZ3:1T5T]M2UBX,46[JX88UZRYNIB"PAMHLKO?
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M+/XO_P!(Y(_E!6!X#HS=^O4H1_\ Q#6;K/-[_P"ZJE/X0@"KO_\ 5D7QV_\
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M^G_N6Y_\PI_LPU4_J&V'_P ;C?\ 5WC\JW2_U,O_ -\6_P# 4_)#U7]=]/\
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M A)5'DI9]IZ+=+=%Z8:=_.6C7#2(CB*YMIE$5W9S%0W57,(9PI*G*21O)#*
MW5ROM?;X#TRZ$Z_T$U7^:=>MDCD=#-:7=NYFL;^ -M,UI.4C9@K=F2*6.*XA
M)7K84#H6L&W=9%=K%VOU:':=W?>JEJ*WUBA[@VW1PM"*4;6MJM%?IUL9'% 9
M#8HG;=G:!U>_T\_:B.N=8W0:!'FTYDRER!5@8#]EKI+7(5W412NL;*DDBA-J
M,RHP!!<2-A74L41@ ?,V,\3-SZ>'62S4TAM?6L&WTNO/6VXU69>JO&LE3JD>
M.W+?LUF!O%$% ->8BO,R7C12+%&MQW6WER4MN)5E68RQ@LID0,HW,I=<JO\
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M#D&(2E>.?>;F-K9PHDT4C,J.I9&9&4$9!7;NX<R!N&2. )QSK*P<P(L(H<=
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M 89RB-B0,8SQSYO&MF]9;"JNUZ'4-CTDI%,U6XA8!P-/ARH<UIR/*1CW(ZY
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MBLB!&->9?:/I6I:QT;:STWH]HG2K_E]E-?Z#K;M NH:;&[&ZBTR]%Q;1Z=K
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A/OVIK');1B"&94F2WLHI;E.LFCC>>:=]L:Q0QRS_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g626950g80k69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g80k69.jpg
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M P # 0$            %!@0'" (#"0$*_\0 11   04  @$# P(#! 0)#0
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MA57PP7GPBSC30\@+J=0X[1CZH?O%SY,A7YQQU7)RJ63Q,TQ;2Z.,]Y6!FO\
M"(U$\0;VVS3 ^V0$4.GFE7ZJ_/;(_P!WDLBZJJR"]WC[-)266>1R>%\-14IV
M,=Y54<J*J\N8Z=!Z8A'798Y'<"Q_71S&[[?66._(&4JNID/JG:4\\M-%&A^!
MADTW'4540!JB>3F4R@TS5<60REKP>WP%28JGTXC$3]O<?/MKI(PJB)Y(2N"U
MC?NKE7[)'SX" %,KM?/^M2P&O@)2ZD]J#DD]AWGY&J'/U,:]BVCBU(;\]/Y3
M!: Y,:_/C) %?HOIDD1X.!LT:Y6?5YZD,)X_9X]_S20W\6=%.S[>0P8<TR?9
MOQH]$18,\.XJSZR/]V:4-8/2E,+*1\7917>N1-8]05W*F@E -;H(&!Z<DL-0
MKJPX]*([=JS+B6U\!SQB^1I -0DAGUMC9!;Y54:LFJM(4W3QA.;]T><U)$3[
M.=)1BH]8M'$>31!/I]*1D^X62-ET[$'B@)6ZTO09-99U- D$<L-TDBCK1:*1
M'U*@CW,*]/563\?;!CC86^B$KX;_ +#O *R;1N1'>Q'RIL(LR/6*]Z._ TN0
M$*-7YY;'>$6DZ4L:A8.W^R;T2^]*C;2_%&PH)[+EZZT* 9U,:?[=:>#YLZ%U
MCLWP68#[S#IEX&09AL*(C"B*QI!D&YKQD&]$<Q['M56O8YJHYKFJJ.145%5%
MYD(()!%$<$'@@CJ",V@@@$$$'D$&P1[@CKGGQG<<8QQC'&,<8QQC'&,<8QQC
M'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,CIMD*&X8&#)+G':KH\",C7'(U
MJHCC/5[F"C11JJ(25)((#7*T37/.00235"W)(5!U=N@^ [LWLJ@GOP 2*WD"
M$* 7=N5C6MQ ZDW051W9B!V!+$ TO06X8(WK=R12S^\8TI8ABBJ0%.GNCQ[
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MQC/%[&D:YCVM>Q[58]CT1S7M<BHYKFJBHYKD545%145%5%3QP#7(X(Y!';!
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MR=CO\7 VV<S77>>K3%LKJWD5TP[)(I X,6LCU5Q?6\RNS5397,3H4FOC9OV
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MK@TX^YIHX(AP@RS^@V4RO],V#ZLEN06H].Z3_3GLZUZHDNNO.G)*Y"">2/\
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M[*_G_/"?TDWS3_D&=9<CEN<G:S_CS=!?]U+U;_\ BYZ*N=['YC^1RH_TZ_\
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M#FZ:JS]'6 2-6TU'71*FIKXS556QX-= #'AQ -5RJ@HX1C1554;Y5>1R8 '
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MFDLR/][N&9CSSRR(HL+<CM<FQEP0))K9Q/*-L$5>7%]V^&50...%>1B 7J)
M%C$BO=2237-BGT1'-1P2!KY#/"_1UI'_ !S] BJBL0]@\3J[/*YK_D&*19!^
MI@&F#9E $:>H7S;KTW.!:0^])]N;I1*H0'"D["S32#9P""(V%'9&;$FH^!DK
MR]/UL!I!N0N!)D"&64-##8UE76MCI9(SRH_8)@WPJ9JJJ^[Y6(*3/:Y7^(""
MCF&]EHT@X E09F-R2;MGO9)#RGVHVJ'CUVP-Q\VE0Y$" "*.O,KIP 4A'SX9
M^OH 4BI+%CY1FC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8R
MJ:?.MN0?-'5PK$'PO"4;VA*]\0JR(;Q&<PC 38,A72*V4\9&!*\\>0(]?-GQ
MCZ()O*--10DV"+ W *P(L$HZ@+(MBP 5(=49<NITXF4E>)!1!!VDE"60@] \
M;$M&Y!"DE6#1NZM6,UIP--,I+9C([Q/<R=#,/XAPRR'*CY P%<16T=F0BN4+
MR'2DL#$KRG/6GK)2WSP&EECL@BT8&]P'0$BOK8P*OCSD D $@D7,NFU(MX)@
M%()\Q"*"%NK ,3]3*23MMO(<F,LT;1-D_)K@B>*NG/>P+T?%I+=R-*\8Y*>U
M]!:?,CQ2XYF^T4=DQ'AL1-$$JMMXT>9*J60FY%J^&ECZ617UT=5M8'EBE,AL
MCZIF5=#1**CD)VFUAEZD!N/(DNPZG@*'L2"@:E57;P@VTRA.RITC?BB/<T55
MH/>\E<7W*C!5\^25SBPI:JK&0B6+_P#&*YL+ZV?/$DNQ/&LH,D!MNLD-4X]W
M11PR]V"?8^UM5#M3B3- PBU VH:6+4<F-CT$;L;,;]D,A]?";Y)!NDFEK9,!
MSB4KPL$Y5<2HE.>RO>Y5\N=#*-A2U9'+X<]H@R(3U1SOH6',23RK>'_I;)[2
M+6_^\#0D^%E6Z>N@%R[RVCLPD4>?*8U'\T(!,9/4T&0\^@,2V>P=W$1[ 3VE
MJ9+W(QH;%&!85[OY619C7D@3'N3\D%&DD.QJI\P1.\M3AB:K2I%'4I9('NRD
M!U'Q*A?8G.B9> X,3'@+)0!/LK@E'/P5BU=0,F.5Y=CC&.,9Z),J-#$X\N0"
M*!OA'&D%&$357[(CB$<UB*J_9$5?NOV3G55F-*"Q/0*"3^@YR+,J#<[*JCNQ
M"C]30RHW>RBUD9IF)\+#/:&-)FQY/NF'(]HQQZ>F$U+F^EE(021P0P BR4(G
MLLF_UTQ:5I#1Y(!+*A'I ZF64_50J!>XL2RURF9)]8D2[N@/"LZM;L:"K#"!
MYT[,2 JHH5KXDRCU^;M=!/+*T#GOL3O":1".Z-*'21&N0]?&M7A:L"5.CL5L
MF%FXJ%J(TXQ;VX?:N)6C;K>>.% L-; " X#+YK])&BLAU1B*>=JE90(HQ'3G
M,4>FEU$A?4?TC$%HVVOY*@W&LI4^6SJ/4FG3=$DA,TIF)CVW"7)8?VYB@'\P
M1(\<\GRD5CT4KTD#D2T5Q?B)(^;]8G*]TJ7(^HKH;C6+[&5495!'^L2FB:*"
MOAP57IP*\I.%4;78"/8LFQF!_P!6@%A?Z1K//)W!GZT6OS7O<YW(EN7:.4$Q
MT3Y*FJ(A[4RL+:VA!,44)7C8UIC#;_"^= (,=74L7VACM I49$;\A:R=U22<
M1BQ'&#RU=AWHM9DD[M=6W L *7%$=TIHRR$"DL#D@<;MM"*(<!:ND%F?AQ P
M8[(P$=[&*]SGO<KRF*1[B&.<B_D4YRN>4Q7?D0CW.7]^5,Q=BQZ^PX  %  =
M@!0 [ 9H1%10J]![\DDFRQ/=F)))[DWF5R.2QQC'&,<8QQC'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8RH:;(0K]P9PG_07<-KFP[,;%=[AN16OASQ-<
M-9<$K7.8\?R#,-KW_3G$A"M)I@U+PVA]<3?:C)_XD)O:XZ@T0>-P-"LFITB3
ME9 ?+G2]DH%\$44D6QO0]"+!%G:PLW2(6EF4I39O3UI#QD&X;XKT;((V(J*B
MGKR.8(-O4^WR_P#A-$:$(<A\F-4M;#I0ZGA64"?3N UV&Y4;AR XLF.3YV')
M6FD.Z5L2:EXB=/J8[6B"A]1"=-T9H":*N>-K( Q=8O1"+I#G@/!?\!6:?.F&
MX!?:U9ME# 5GAT6PAE1Q[./\+E:]I!_JR#]C#QK)Y2R69G0AQ8^CS@[A]R-B
M#89&!J-KJJ/EW9#1@!3L1PR':1JM.PH_?E0$<K(A!:5:ZV/-K@K(26R/BU<B
MK"DG)V)I=*JK[*QAQSQPE8OM<&(&85J$BA=[O?6AG5$P#_E_Q<I6@@#DT@D.
MW4(%E[R$;2W'5BHX8\4Y613QZ5!9S!8VC4-I)"\/:($.$KC:@<BU7O&'B=>?
M4W""9BVTN:(S'0H5L(:?#*%"/]-/:YZ?ZN927+(WT*N;]U!)L7D5OY(CFJG*
MFC52#N:,GE=PW+7NLL1;?\U0#Y9<LK."-B3 <.$;:XOL\,H798^ZTA/Y9CH&
ML!^U1H*7Q]VBK6SFQFN\?S?29Z5,KWN7^JO"_P!R_P WE>2MSSYD,ON7V;B/
M[4RJ_':B".W&0J,?U6HA^$?F;1\=D#/&?T/RQ]0J_85QL5_Z+/[.,;_\$^67
MEF__ )%,J_;\G?OY5[Q:;Y^>??V74?R'3IG;XXFU?P'T<7^KZ;^9[?KXO;8D
M:[Y6Z4PD1SOEGV%'21&L:BJKC'I4#:!8B?=5^F<Y$3RJ(G[]M ;'D*>E(DLK
M'Y"6XS_O#.$2&[^DD4?4\D,* =R3#4@^>SIS['*U,EAAA=:-+ BB&K1_K+5-
M-5CRK[&1X^GNA2YMRZ2JJ./#HZ@A2'1(R3(A'(_ERH6/ED.Q//E<+8 LEH(R
MJ1;>I>64 #G:U5F=W"+YEQJ!QYPW/R305=3,'>8MT5(8B2WIWJ><PZRD1A2Z
MN\,M,,(W*RUNB(.?#CD11N=&9.-(6#*.TKH_UMB>5-B1G.K8:2D>RV+.26Q]
M'B'F$GU1P@[&8<\[  ZJ1NVHJJS#S&VFXQ".$ G5SGR0H)$LQ =%/%J'+;&8
M';OD9W13Y:;OZ5IETR58P_@K6OR>38JM+=V2/AV=JAGJK_TZ-*<V8'ZM[G.6
MQL?CG3#&20$15]RR*@JHVZ0_2=0>D*>I(Z'WV6U.T?<2U4+1([6EVD3;&#I=
M(.LTH*22W_LT>G&X]9)*=R=R@_>G:V"]L5L*FCEI:S\5+/D!]EM.]K&C18\6
M0SW1$^-K!,D6 FDCA$V+$JQ1VQCAI=P6+RL)9.R _5KWY93ZN>:0TQ.YI"VY
M3HC0[=D*F&+N["I7[>E6'H%  &06JC:L2J%(LL2)'@@;'BC00FJYR_DY[R$>
MJN(8Q2.<4YRO52&.9[S&(YQ"O>]RN6EF+&V-G^  Z  <!1T"@  <  9H5%0;
M5%#\R23R22;)8GDL223R23F3R.2QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,C+6GKKJ-]+8QF'8UWO$Y41"@(G[$"3QY8[^CD^X
MRL\B,P@G/&Z<<CQ-N1B#W]B/8CO\.X/(((!RN6&.9=LBAAU'N#[@]OCV(X((
ML9K2=B9U?(69 D3".3RJ3Z\Q(]JUGN5[VR4$OR'4OW=)EM9<$*JL#"HHHF)S
M<NJ5QM=5'[C@-'?8B^!715^KKDO,UUGFOHY$;>C.:Z/&2LE=]]$%K^\P\XMT
M2% !D<.1HDD$>.4"5/8QJR)@(9PW#58GL$ \*G:Z3*1C/'L=I\_'"QWN=\#?
M/GEFV @6I1#]E2P,5FRQ#2^E>?\ ]/,QKOQE8;4;C3AY !N<(1**L*K+$-S?
M_N8% ZT+Y\W:*VDG&VRJ**6437#CRO[0.J=%';Y\N3W4D:PG-<5?L4 XU8-R
M+X>QR>6J\B)03'+,H-%E\GS(3[?TK(I[T29*HB\Z=1,S 210.1PK_2/)G O_
M +%97LGJH$8/<$9F!U&T"5C0T$^5%]WY.LHTV2Y6_LC03:VFA.0?C]GR:^69
MWCW/(JNY Z?3$&YD5O9&5?F6625_T5T'L.,F-5K 1MT[LOO(KN?D'CA0@?%H
MV/QSTV._T5:A"7-'+K87M<J2J^/#:@T\_BCK#4V-*$3W?YG/ICC9_3W\ZFCA
M>O*E5WZ;7+G_ (-.DI-?]X+^&0DU^HC!,T#1K^*-4%<<?6:N6 7[_4M7QRN?
MVQM[L##U60O[HSC(Q)4K].NP@=^[)HX[K*MJ()Q^6J$L:G-'.B.\S1M7Y%O^
MC1Q$B340Q  ^E2\1(/52WEO(ZGD490P_ >F4?3)IE!BT>HF):M[>5.H]G"F:
M.*-AV*PE#UWUSEA@0-^62R6M#%!9^'+^O:RUB6\F*A6^"BJ*BF*VNHAN8OQN
M6*IWD]K/K6V/Q-]U#/HPI43,8^/J=/&T8:NADDE&^:CT#;0+.SR[.71QZ]F#
M^0JR57GZN5)G4'J(HH3Y<((H$KN)KUAZ%VZ+EK IPS;:P%)G!=[A2Y#&VTR(
M3Q[?FJU/'@45696_PW%B9EIR#_$YSN\O7.VH0 K&A"G@JOU2L/PR;6>:1;YI
MIR >@&;%TKE@\LF^0='>I60]+BW+'!$2."4TP9APS-URS1JB'',V4]"3)K?=
MXG3BNE26>]%0B1U)_#A#)Y7W@@"BQW?^R3E#2,PV\*OX$ 5373=7+D=BY9OC
MFI8D4[B"[_C<[F^.V^$![A J_#)3E>68XQCC&.,8XQCC&.,8XQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9B3(,*<Q&38<68QGES&RHX9#6
M.\?S-:9CT:[_ 'HB+R2NR<JS*3P=I(O]",A(B.I#HK@60&4, :ZBP<YNO+6T
M#82H8;*>*(PBM9%',D,C,:C_  C6@:1!-:B?9$1J)SW(HXS'O*(6HG=M7=T]
MZO\ CGST\LH=T$D@0=%#L%'J[*#0_3*PYSGE_)RN]SF^[W*J^?/CSY\^?/G^
MOGFAA2FN.G3CN,S$^NNQ(OX],Z1R=!10Z^)-B4M3%FE&CBRX]=#!*(Y?W<20
M(+2O<OC[JYZKSP9YI7=E:61E#$!6=BH^0)(&?0Z2"!(TD6&)9&!+.L:!SZCU
I8 $_F<N7,^;,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g626950g91g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g626950g91g01.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ [0(D P$1  (1 0,1 ?_$ !X
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MTV>U:S=M),P:6S<$AODT#[9-[I&Q\,QC1?@93C:!/Y TF T>PKV,229SZ&,
MI8-N;CQK+JSORRKOTWT6A\?<LLN3:2'YVR&U).+_ "&=93DV>6HC)M2(+MK(
M&UK[=H(6+TE+1JI'FL>3'5*X?5[&-$('!"A=T/BXX5P\(L$!BBN^Z[,JE[1S
MMOVDC_;*G>NG8/K#5->16_$+K5K6QJY[)&;2+[<TX!82A7YTP@M0]<H!=3@4
MBV]GEC+3.S AMLV]EX@GRZV%14S$S<5<3%:[3<^4-)<,F P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
M P& P&!_+#T-['=JY)<O4%B:K6R38(-3?F-.UV_+7K'2#7ME((WVCKI2/A'H
MUX:66@KNOG^K2NX\8M1--DP;'MGX%5N ;/L.LQAZ.*<M<&\5<3]MKTGJE]/%
MSV)[76%VEZ;QBTZRLJ/PPC3?E9</9-)+UCLW'RW=CW>ACA0T3C3$R\);N*;/
MH#*/#\ED%'CID>T.Q'9.%M'G/!,41&&:F-<'"?AG/OUKAI.:T/C4[3]['O43
MKHQUZ*6!<L9<#GS':_#7:RDFCV3A]IW(&JLK>1R8'E)UKJ.:>VGJ,)\;%%4!
MVB+?7V=V^N2-(O6DF,-S[59Z5*&^L/:;M>.JKPWPO>.SAO6=OWZ^CEC=B3%F
M121*VEPI7O;T[O3)R&E7!&R4>&SJ'1V5:2UQJ@)](BS%(/N-ETFRM68CV^J(
MJ-L\,7XS#^EW#F8# 8# 8# 8&:79S^L;\7G]R[P?Y,0_#4>[B[O-I;ADP& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P*1^/.YI=V,ZJ0&Y+$;1[B:F9CV  .EH\&1##TAT+["
MV; 1>C1GHHORV4= X<$5+[Z+>A(HDJ_6UX44UUT+BBI[L,\\,3/C*Z23!BAN
MFJ@S:HJ):N]$E$FZ*>Z6C]PF[?:I[Z:<;::O7223EWKKSQPY<))K+<;J::[<
M$?5!!!LEH@V12;H):^RDB@GHDDGK^?V=$T^-=--?7GGGTUXXX^O S0[^H(-;
M;\5:#9%)N@EY&@^J:*">B22>OT/>X7/IHFGQKIIQZ\\\^FO'''KSSS_SPUAT
MQ_+'[\+33#)@,!@,!@0G.NQ-1UM. 5=S"1$F$H/_ #0Y3390Z:G@H).P9:K
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M571=/ T4'O3"NSY35X9<$'J2;9)QHU1+,5/=AGGAB?NNAA# S0\@GZ8/%?\
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MZ8/%?_B-A_\ 1[W!PUATQ_+'[\+2_#)@,!@,!@9J]J^U=QU!?<-AE?Q]D;@
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MCXM%,XW0_G,MU"(HDSTX4_.NR<:?G3YPU$3&'%,Q,1/1J9C7/@V\PP8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M\*D!:ZOPOX5PES'TF^G#_@AMOQRWV;:ZEBNCBJ_^>-\>R&WV&# 8# 8# 8#
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M!3GW1),8H^::.]DOJ2V<)<;?\7&6XW*G:7F3^0?I)"ZDKV^I7V>I\!35L/S
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MWSDLW>>V'ET8KPI=+"&!FAY!/TP>*_\ Q&P_^CWN#AK#IC^6/WX6E^&3 8#
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M-V44CTO/B)-*0.IUPH>X0=&'"3(F68ID4^-423-WG-6NSA# 8# 8# 8# 8#
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M9L: ,^OS)Y6,A1L)JUE;NP;"ZK,"16%)U5<<T?MX*LXLZT(ZL?;&(&#5(M3
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M&I9FYTK+#'+#$7WZKH80P,T/()^F#Q7_ .(V'_T>]P<-8=,?RQ^_"TOPR8#
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MM]'YB[C;M#=5B8B;XTZC!X6NZ$FQ! 8Z<-%2W.G!.6$1])[:JN$R:*0J9V5
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MC>!5/7A1FBMH_3'K<2 M)-^6 X?IIOHXT<N71;O!,5$5T<XNY[<VW^&# 8#
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M\'R>0L7 1F^# GK8VJV*$F3V3QEB[:,U556SZ21]FMKHZ-C$G0J=DS@9 %E
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M(VH.16C!)J^ FM=8Z=9STRV<INM6)!LN(F:RO*](WW_.$4KT+2JQ*IV,#/\
MDDZDR5@EU]2J(M7Q+L5/=8W('Z=+\5FZ1?RT7VN$"$ I8MQL4=&V5((GVS)?
M=VFS<2Q/YPK#VMIZ_9C>]O#[.FRPM'I9 )G!%^X'1A(?.9*6=QAS)._LDLF<
M=?X_R,J347'VEJ3@*2D?92LC$UB$ZLR:T/9XR%P\N].QV ;21>)"&SH46OTS
M]-7KMIPJ5Z^LW:CJS$X)+.9'VGZXAU)?=]_6,% O;UJU%P&B]@W%,Y7'/E#;
M:5\+,7L@%%&\Q*C'::+X27DA 6_02>,U]."3$[3PX3PBEA_IJ=-_UM.LW[>*
ML_W5A*G:>4JL7UY'V :SNOE)],PW7_N1:M\%K*:? &':^,P,3"!=;0=2<O3!
MPS$H!=;OE,JQ:OF0Y%P$&);O6^J>KQ7E3;5(L8<IG%<1%<+N^^/-R7Y=_*C]
MG7UG^\6,_@GP5@^+%],?S/R[^5'[.OK/]XL9_!/@K!\6+Z8_FI[T,[5^52P>
MKT)E>_4"E;JV?RZ[&G-CSKO:3A<F,?!+ULH%\+>1QOU)E2+)G$.!GS,".-#;
MGXJ"CXTOLV&;/]A3(LQ@O7%P_P"8V^:/)7GJ?47:?R0DNM=A=TJ,IJ5T32-K
M>2V/GY-,K8&W5)Y&7F=N6;6$>B[*L)+2(("+8T<8B;>'0B6*G2BQ2/QH))4
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MS](3RB?9L49]X@U_"9@RWGE'JAZ6]]?(5"[DIZBC?C<J+6=WD$M,_!4VO?\
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M1/7[HF18+'GBY)XX22:%O+AE%=N<?>;:%]?NK<8Z\2&S3\;E\K-ZV:\%O'H
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"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
